Modulators of dnm2 expression

ABSTRACT

The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0322WOSEQ_ST25.txt created Jan. 10, 2019 which is 784 kb in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

FIELD

The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which can be useful for treating, preventing, or ameliorating a disease associated with DNM2.

BACKGROUND

Dynamin 2 (DNM2) is a large GTPase that is involved in membrane trafficking and microtubule dynamics (See, e.g., Durieux et al. J Mol Med, 88, 339 (2010)). Mutations in DNM2 are associated with several diseases, including centronuclear myopathy (CNM) and Charcot-Marie-Tooth disease. DNM2 is also associated with Duchenne's Muscular Dystrophy (See, e.g., WO 2015/055859 and WO 2016/170162). CNM and CNM-like myopathy are also associated with mutations in MTM1, BIN1, RYR1, TTN, CCDC78, and MTMR14

SUMMARY

Certain embodiments provided herein are directed to potent and tolerable compounds and compositions useful for inhibiting DNM2 expression, which can be useful for treating, preventing, ameliorating, or slowing progression of diseases, such as centronuclear myopathy (CNM), Charcot-Marie-Tooth disease (CMT), and Duchenne's Muscular Dystrophy (DMD). Certain embodiments provided herein comprise modified oligonucleotides complementary to a DNM2 nucleic acid that potently reduce DNM2 expression in animals.

One object of the present invention is a compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide 9 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 9 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide 10 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 10 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide 11 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 11 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide 12 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 12, at least 13, at least 14, or at least 15 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of any of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 7-3134. Another object of the present invention is a compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length complementary within nucleobases 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1, wherein said modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1. Another object of the present invention is a compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1. Another object of the present invention is a compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length complementary within nucleobases 83,573-87,287 or 87,359-90,915 of SEQ ID NO: 1, wherein said modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to intron 1 of a human DNM2 pre-mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to intron 11 of a human DNM2 pre-mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to intron 12 of a human DNM2 pre-mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to intron 13 of a human DNM2 pre-mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to intron 14 of a human DNM2 pre-mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to exon 10 of a human DNM2 pre-mRNA or human DNM2 mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide complementary to the 3′-UTR of a human DNM2 pre-mRNA or human DNM2 mRNA. Another object of the present invention is a compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. Another object of the present invention is a compound comprising a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. Another object of the present invention is a compound comprising a modified oligonucleotide having a nucleobase sequence comprising SEQ ID NO: 2879.

Another object of the present invention is a compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of 8-12 linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of 1-7 linked nucleosides; and     -   a 3′ wing segment consisting of 1-7 linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each terminal wing nucleoside comprises a modified sugar.

Another object of the present invention is a compound comprising a modified oligonucleotide 16 linked nucleosides in length having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises

-   -   a gap segment consisting of 10 linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of 3 linked nucleosides; and     -   a 3′ wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein each nucleoside of each wing segment comprises a cEt sugar moiety; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

In one embodiment, the oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of SEQ ID NO: 1, 2, 3, or 3135. In one embodiment, the modified oligonucleotide comprises at least one modified internucleoside linkage. In one embodiment, the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage. In one embodiment, the modified oligonucleotide comprises at least one bicyclic sugar. In one embodiment, the at least one bicyclic sugar is selected from the group consisting of LNA, ENA, and cEt. In one embodiment, the at least one bicyclic sugar moiety is a cEt sugar moiety.

In one embodiment, the modified oligonucleotide comprises at least one 5-methylcytosine. In one embodiment, the modified oligonucleotide comprises:

a gap segment consisting of linked 2′-deoxynucleosides;

a 5′ wing segment consisting of linked nucleosides; and

a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar moiety.

In one embodiment, the compound is single-stranded. In one embodiment, the compound is double-stranded.

In one embodiment, the compound comprises at least one unmodified ribosyl sugar moiety. In one embodiment, the compound comprises at least one unmodified 2′-deoxyribosyl sugar moiety.

In one embodiment, the modified oligonucleotide consists of 10 to 30 linked nucleosides. In one embodiment, the modified oligonucleotide consists of 12 to 30 linked nucleosides. In one embodiment, the modified oligonucleotide consists of 15 to 30 linked nucleosides. In one embodiment, the modified oligonucleotide consists of 16 to 20 linked nucleosides.

Another object of the present invention is a compound comprising a modified oligonucleotide according to the following formula: Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; wherein,

-   -   A=an adenine,     -   mC=a 5-methylcytosine     -   G=a guanine,     -   T=a thymine,     -   k=a cEt sugar moiety,     -   d=a 2′-deoxyribosyl sugar moiety, and     -   s=a phosphorothioate internucleoside linkage.

In one embodiment, the compound of the invention comprises a conjugate group. In one embodiment, the compound of the invention consists of the modified oligonucleotide and the conjugate group.

Another object of the present invention is a compound according to the following formula:

In one embodiment, the compound consists of the modified oligonucleotide.

The present invention further relates to a compound consisting of a pharmaceutically acceptable salt form of any one of the compounds described herein. In one embodiment, the pharmaceutically acceptable salt is a sodium salt. In one embodiment, the pharmaceutically acceptable salt is a potassium salt.

The present invention also relates to a pharmaceutical composition comprising a compound as described herein and at least one pharmaceutically acceptable carrier or diluent.

The present invention further relates to a chirally enriched population of the compounds described herein, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration. In one embodiment, the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having the (Sp) configuration. In one embodiment, the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having the (Rp) configuration. In one embodiment, the population is enriched for modified oligonucleotides having a particular, independently selected stereochemical configuration at each phosphorothioate internucleoside linkage. In one embodiment, the population is enriched for modified oligonucleotides having the (Sp) configuration at each phosphorothioate internucleoside linkage. In one embodiment, the population is enriched for modified oligonucleotides having the (Rp) configuration at each phosphorothioate internucleoside linkage. In one embodiment, the population is enriched for modified oligonucleotides having the (Rp) configuration at one particular phosphorothioate internucleoside linkage and the (Sp) configuration at each of the remaining phosphorothioate internucleoside linkages. In one embodiment, the population is enriched for modified oligonucleotides having at least 3 contiguous phosphorothioate internucleoside linkages in the Sp, Sp, and Rp configurations, in the 5′ to 3′ direction. In one embodiment, all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

The present invention further relates to a pharmaceutical composition comprising the population of compounds described herein and at least one pharmaceutically acceptable diluent or carrier.

The present invention further relates to a compound described herein, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable carrier or diluent, or a pharmaceutical composition comprising the population of compounds described herein and at least one pharmaceutically acceptable carrier or diluent, for use in therapy.

The present invention further relates to a compound described herein, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable carrier or diluent, or a pharmaceutical composition comprising the population of compounds described herein and at least one pharmaceutically acceptable carrier or diluent, for use in treating, preventing, or ameliorating centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

The present invention also relates to a method of treating, preventing, or ameliorating a disease associated with DNM2 in an individual comprising administering to the individual a compound or composition described herein, thereby treating, preventing, or ameliorating the disease.

The present invention also relates to a method of treating, preventing, or ameliorating a disease associated with DNM2 in an individual comprising administering to the individual a compound comprising a modified oligonucleotide 100% complementary to an exon 10, an intron, or the 3′-UTR of a DNM2 nucleic acid transcript, thereby treating, preventing, or ameliorating the disease.

In one embodiment, the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease. In one embodiment, the compound is single-stranded. In one embodiment, the DNM2 nucleic acid transcript is a pre-mRNA. In one embodiment, the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy. In one embodiment, the individual has at least one mutation in at least one gene selected from among MTM1, BIN1, and DNM2. In one embodiment, the administering increases body weight or muscle strength.

The present invention further relates to a method of inhibiting expression of DNM2 in a cell comprising contacting the cell with a single-stranded compound comprising a modified oligonucleotide 100% complementary to exon 10, an intron, or the 3′-UTR of a DNM2 nucleic acid transcript, thereby inhibiting expression of DNM2 in the cell. In one embodiment, the method is an in vitro method. In one embodiment, the cell is in the muscle of an individual. In one embodiment, the individual has, or is at risk of having, a centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

The present invention further relates to a method of increasing body weight or muscle strength in an individual having, or at risk of having, a disease associated with DNM2 comprising administering a single-stranded compound comprising a modified oligonucleotide 100% complementary to a DNM2 nucleic acid transcript to the individual, thereby increasing body weight or muscle strength in the individual. In one embodiment, the individual has, or is at risk of having, centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

In one embodiment, the compound is a compound as described herein. In one embodiment, the compound is a member of the chirally enriched population described herein. In one embodiment, the compound is a component of the pharmaceutical composition described herein.

In one embodiment, the compound is administered to the individual via subcutaneous injection. In one embodiment, the compound is administered to the individual via intramuscular injection. In one embodiment, the compound is administered to the individual via intravenous injection.

The present invention further relates to the use of a single-stranded compound comprising a modified oligonucleotide 100% complementary to exon 10, intron 1, intron 11, intron, 12, intron 13, intron 14, or the 3′-UTR of a DNM2 nucleic acid transcript for treating, preventing, or ameliorating a disease associated with DNM2. In one embodiment, the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

The present invention further relates to the use of the compound described herein or the composition described herein for treating, preventing, or ameliorating a disease associated with DNM2.

The present invention further relates to the use of the compound described herein or the composition described herein in the manufacture of a medicament for treating, preventing, or ameliorating a disease associated with DNM2.

In one embodiment, the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease. In one embodiment, the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy. In one embodiment, the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2. The present invention further relates to the use of the compound described herein or the composition described herein in the preparation of a medicament for treating, preventing, or ameliorating a disease associated with DNM2. In one embodiment, the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease. In one embodiment, the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy. In one embodiment, the the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

DETAILED DESCRIPTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the embodiments, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including” as well as other forms, such as “includes” and “included”, is not limiting.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and GenBank and NCBI reference sequence records are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

It is understood that the sequence set forth in each SEQ ID NO contained herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase.

As used herein, “2′-deoxynucleoside” means a nucleoside comprising 2′-H(H) ribosyl sugar moiety, as found in naturally occurring deoxyribonucleic acids (DNA). In certain embodiments, a 2′-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (uracil).

As used herein, “2′-substituted nucleoside” or “2-modified nucleoside” means a nucleoside comprising a 2′-substituted or 2′-modified sugar moiety. As used herein, “2′-substituted” or “2-modified” in reference to a furanosyl sugar moiety means a sugar moiety comprising at least one 2′-substituent group other than H or OH.

As used herein, “administration” or “administering” refers to routes of introducing a compound or composition provided herein to an individual to perform its intended function. An example of a route of administration that can be used includes, but is not limited to, administration by inhalation.

As used herein, “administered concomitantly” or “co-administration” means administration of two or more compounds in any manner in which the pharmacological effects of both are manifest in the patient. Concomitant administration does not require that both compounds be administered in a single pharmaceutical composition, in the same dosage form, by the same route of administration, or at the same time. The effects of both compounds need not manifest themselves at the same time. The effects need only be overlapping for a period of time and need not be coextensive. Concomitant administration or co-administration encompasses administration in parallel or sequentially.

As used herein, “animal” refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

As used herein, “antisense activity” means any detectable and/or measurable change attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments, antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid compared to target nucleic acid levels or target protein levels in the absence of the antisense compound.

As used herein, “antisense compound” means a compound comprising an antisense oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group.

As used herein, “antisense oligonucleotide” means an oligonucleotide having a nucleobase sequence that is at least partially complementary to a target nucleic acid.

As used herein, “ameliorate” in reference to a treatment means improvement in at least one symptom relative to the same symptom in the absence of the treatment. In certain embodiments, amelioration is the reduction in the severity or frequency of a symptom or the delayed onset or slowing of progression in the severity or frequency of a symptom.

As used herein, “bicyclic nucleoside” or “BNA” means a nucleoside comprising a bicyclic sugar moiety. As used herein, “bicyclic sugar” or “bicyclic sugar moiety” means a modified sugar moiety comprising two rings, wherein the second ring is formed via a bridge connecting two of the atoms in the first ring thereby forming a bicyclic structure. In certain embodiments, the first ring of the bicyclic sugar moiety is a furanosyl moiety. In certain embodiments, the bicyclic sugar moiety does not comprise a furanosyl moiety.

As used herein, “cEt” or “constrained ethyl” means a bicyclic sugar moiety, wherein the first ring of the bicyclic sugar moiety is a ribosyl sugar moiety, the second ring of the bicyclic sugar is formed via a bridge connecting the 4′-carbon and the 2′-carbon, the bridge has the formula 4′-CH(CH₃)—O-2′, and the methyl group of the bridge is in the S configuration. A cEt bicyclic sugar moiety is in the β-D configuration.

As used herein, “chirally enriched population” means a plurality of molecules of identical molecular formula, wherein the number or percentage of molecules within the population that contain a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules expected to contain the same particular stereochemical configuration at the same particular chiral center within the population if the particular chiral center were stereorandom. Chirally enriched populations of molecules having multiple chiral centers within each molecule may contain one or more sterorandom chiral centers. In certain embodiments, the molecules are modified oligonucleotides. In certain embodiments, the molecules are compounds comprising modified oligonucleotides.

As used herein, “complementary” in reference to an oligonucleotide means that at least 70% of the nucleobases of such oligonucleotide or one or more regions thereof and the nucleobases of another nucleic acid or one or more regions thereof are capable of hydrogen bonding with one another when the nucleobase sequence of the oligonucleotide and the other nucleic acid are aligned in opposing directions. Complementary nucleobases are nucleobase pairs that are capable of forming hydrogen bonds with one another. Complementary nucleobase pairs include adenine (A) and thymine (T), adenine (A) and uracil (U), cytosine (C) and guanine (G), 5-methyl cytosine (^(m)C) and guanine (G). Complementary oligonucleotides and/or nucleic acids need not have nucleobase complementarity at each nucleoside. Rather, some mismatches are tolerated. As used herein, “fully complementary” or “100% complementary” in reference to oligonucleotides means that such oligonucleotides are complementary to another oligonucleotide or nucleic acid at each nucleoside of the oligonucleotide.

As used herein, “conjugate group” means a group of atoms that is directly or indirectly attached to an oligonucleotide. Conjugate groups include a conjugate moiety and a conjugate linker that attaches the conjugate moiety to the oligonucleotide.

As used herein, “conjugate linker” means a group of atoms comprising at least one bond that connects a conjugate moiety to an oligonucleotide.

As used herein, “conjugate moiety” means a group of atoms that is attached to an oligonucleotide via a conjugate linker.

As used herein, “contiguous” in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, “contiguous nucleobases” means nucleobases that are immediately adjacent to each other in a sequence.

As used herein, “double-stranded antisense compound” means an antisense compound comprising two oligomeric compounds that are complementary to each other and form a duplex, and wherein one of the two said oligomeric compounds comprises an antisense oligonucleotide.

As used herein, “effective amount” means the amount of compound sufficient to effectuate a desired physiological outcome in an individual in need of the compound. The effective amount may vary among individuals depending on the health and physical condition of the individual to be treated, the taxonomic group of the individuals to be treated, the formulation of the composition, assessment of the individual's medical condition, and other relevant factors.

As used herein, “efficacy” means the ability to produce a desired effect.

As used herein “DNM2” means any Dynamin 2 nucleic acid or protein. “DNM2 nucleic acid” means any nucleic acid encoding DNM2. For example, in certain embodiments, a DNM2 nucleic acid includes a DNA chromosomal region encoding DNM2, an RNA transcribed from DNA encoding DNM2 (e.g., a pre-mRNA transcript), and an mRNA transcript encoding DNM2.

As used herein, “expression” includes all the functions by which a gene's coded information is converted into structures present and operating in a cell. Such structures include, but are not limited to, the products of transcription and translation. Methods for measuring expression levels (such as a transcription level or a translation level) are well-known in the field and include, but are not limited to, RT-PCR, RT-qPCR, Northern Blot, hybridization techniques such as, for example, use of microarrays, and combinations thereof including but not limited to, hybridization of amplicons obtained by RT-PCR, sequencing such as, for example, next-generation DNA sequencing (NGS) or RNA-seq (also known as “Whole Transcriptome Shotgun Sequencing”) and the like, immunohistochemistry, Multiplex methods (Luminex), western blot, enzyme-linked immunosorbent assay (ELISA), sandwich ELISA, multiplex ELISA, electrochemiluminescence (ECL) (Elecsys®, Roche Diagnostics), enzyme-linked fluorescent assay (ELFA) (such as VIDAS®, Biomdrieux), fluorescent-linked immunosorbent assay (FLISA), enzyme immunoassay (EIA), radioimmunoassay (RIA), flow cytometry (FACS), surface plasmon resonance (SPR), biolayer interferometry (BLI), immunochromatographic assay (ICA) (such as NEXUS IB10, Sphingotech) and mass spectrometry-based approaches.

As used herein, “gapmer” means an oligonucleotide, such as an antisense oligonucleotide, comprising an internal segment having a plurality of nucleosides that support RNase H cleavage positioned between external segments, each having one or more nucleosides, wherein the nucleosides comprising the internal segment are chemically distinct from the immediately adjacent nucleoside or nucleosides comprising the external segments. The internal segment may be referred to as the “gap” or “gap segment” and the external segments may be referred to as the “wings” or “wing segments”.

As used herein, “hybridization” means the pairing or annealing of complementary oligonucleotides and/or nucleic acids. While not limited to a particular mechanism, the most common mechanism of hybridization involves hydrogen bonding, which may be, for example, Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.

As used herein, “individual” means a human or non-human animal selected for treatment or therapy.

As used herein, “inhibiting the expression or activity” refers to a reduction or blockade of the expression or activity relative to the expression or activity in an untreated or control sample and does not necessarily indicate a total elimination of expression or activity. In one embodiment, inhibiting the expression or activity refers to a reduction or blockade of the expression or activity relative to the expression or activity in an untreated or control sample of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In one embodiment, inhibiting the expression or activity refers to a reduction or blockade of the expression or activity relative to the expression or activity in an untreated or control sample of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.

As used herein, the term “about” preceding a figure means plus or less 10% of the value of said figure.

As used herein, the terms “internucleoside linkage” means a group or bond that forms a covalent linkage between adjacent nucleosides in an oligonucleotide. As used herein “modified internucleoside linkage” means any internucleoside linkage other than a naturally occurring, phosphate internucleoside linkage. Non-phosphate linkages are referred to herein as modified internucleoside linkages. “Phosphorothioate linkage” means a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom. A phosphorothioate internucleoside linkage is a modified internucleoside linkage. Modified internucleoside linkages include linkages that comprise abasic nucleosides. As used herein, “abasic nucleoside” means a sugar moiety in an oligonucleotide or oligomeric compound that is not directly connected to a nucleobase. In certain embodiments, an abasic nucleoside is adjacent to one or two nucleosides in an oligonucleotide.

As used herein, “linker-nucleoside” means a nucleoside that links, either directly or indirectly, an oligonucleotide to a conjugate moiety. Linker-nucleosides are located within the conjugate linker of an oligomeric compound. Linker-nucleosides are not considered part of the oligonucleotide portion of an oligomeric compound even if they are contiguous with the oligonucleotide.

As used herein, “non-bicyclic modified sugar” or “non-bicyclic modified sugar moiety” means a modified sugar moiety that comprises a modification, such as a substituent, that does not form a bridge between two atoms of the sugar to form a second ring.

As used herein, “linked nucleosides” are nucleosides that are connected in a continuous sequence (i.e. no additional nucleosides are present between those that are linked).

As used herein, “mismatch” or “non-complementary” means a nucleobase of a first oligonucleotide that is not complementary with the corresponding nucleobase of a second oligonucleotide or target nucleic acid when the first and second oligomeric compound are aligned.

As used herein, “modulating” refers to changing or adjusting a feature in a cell, tissue, organ or organism. For example, modulating DNM2 expression can mean to increase or decrease the level of an DNM2 RNA and/or a DNM2 protein in a cell, tissue, organ or organism. A “modulator” effects the change in the cell, tissue, organ or organism. For example, a compound that modulates DNM2 expression can be a modulator that decreases the amount of a DNM2 RNA and/or a DNM2 protein in a cell, tissue, organ or organism.

As used herein, “MOE” means methoxyethyl. “2′-MOE” or “2′-O-methoxyethyl” means a 2′-OCH₂CH₂OCH₃ group in place of the 2′OH group of a ribosyl ring.

As used herein, “motif” means the pattern of unmodified and/or modified sugar moieties, nucleobases, and/or internucleoside linkages, in an oligonucleotide.

As used herein, “naturally occurring” means found in nature.

As used herein, “nucleobase” means an unmodified nucleobase or a modified nucleobase. As used herein an “unmodified nucleobase” is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). As used herein, a modified nucleobase is a group of atoms capable of pairing with at least one unmodified nucleobase. A universal base is a nucleobase that can pair with any one of the five unmodified nucleobases.

As used herein, “nucleobase sequence” means the order of contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or internucleoside linkage modification.

As used herein, “nucleoside” means a moiety comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each, independently, unmodified or modified. As used herein, “modified nucleoside” means a nucleoside comprising a modified nucleobase and/or a modified sugar moiety.

As used herein, “oligomeric compound” means a compound consisting of an oligonucleotide and optionally one or more additional features, such as a conjugate group or terminal group.

As used herein, “oligonucleotide” means a strand of linked nucleosides connected via internucleoside linkages, wherein each nucleoside and internucleoside linkage may be modified or unmodified. Unless otherwise indicated, oligonucleotides consist of 8-50 linked nucleosides. As used herein, “modified oligonucleotide” means an oligonucleotide, wherein at least one nucleoside or internucleoside linkage is modified. As used herein, “unmodified oligonucleotide” means an oligonucleotide that does not comprise any nucleoside modifications or internucleoside modifications.

As used herein, “pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to an animal. Certain such carriers enable pharmaceutical compositions to be formulated as, for example, liquids, powders, or suspensions that can be aerosolized or otherwise dispersed for inhalation by a subject. In certain embodiments, a pharmaceutically acceptable carrier or diluent is sterile water; sterile saline; or sterile buffer solution. In one embodiment, the pharmaceutically acceptable carrier or diluent does not produce an adverse, allergic or other untoward reaction when administered to an animal, preferably a human. It includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. For human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by regulatory offices, such as, for example, FDA Office or EMA.

As used herein “pharmaceutically acceptable salts” means physiologically and pharmaceutically acceptable salts of compounds, such as oligomeric compounds, i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

As used herein “pharmaceutical composition” means a mixture of substances suitable for administering to a subject. For example, a pharmaceutical composition may comprise an antisense compound and an aqueous solution.

As used herein, “phosphorus moiety” means a group of atoms comprising a phosphorus atom. In certain embodiments, a phosphorus moiety comprises a mono-, di-, or tri-phosphate, or phosphorothioate.

As used herein “prodrug” means a therapeutic agent in a form outside the body that is converted to a differentform within the body or cells thereof. Typically conversion of a prodrug within the body is facilitated by the action of an enzymes (e.g., endogenous or viral enzyme) or chemicals present in cells or tissues and/or by physiologic conditions.

As used herein, “RNAi compound” means an antisense compound that acts, at least in part, through RISC or Ago2 to modulate a target nucleic acid and/or protein encoded by a target nucleic acid. RNAi compounds include, but are not limited to double-stranded siRNA, single-stranded RNA (ssRNA), and microRNA, including microRNA mimics. In certain embodiments, an RNAi compound modulates the amount, activity, and/or splicing of a target nucleic acid. The term RNAi compound excludes antisense oligonucleotides that act through RNase H.

As used herein, the term “single-stranded” in reference to an antisense compound means such a compound consisting of one oligomeric compound that is not paired with a second oligomeric compound to form a duplex. “Self-complementary” in reference to an oligonucleotide means an oligonucleotide that at least partially hybridizes to itself. A compound consisting of one oligomeric compound, wherein the oligonucleotide of the oligomeric compound is self-complementary, is a single-stranded compound. A single-stranded antisense or oligomeric compound may be capable of binding to a complementary oligomeric compound to form a duplex, in which case the compound would no longer be single-stranded.

As used herein, “standard cell assay” means any of the assays described in Examples 1-9, and reasonable variations thereof.

As used herein, “standard in vivo experiment” means the procedure described in Example 10 and reasonable variations thereof.

As used herein, “stereorandom chiral center” in the context of a population of molecules of identical molecular formula means a chiral center having a random stereochemical configuration. For example, in a population of molecules comprising a stereorandom chiral center, the number of molecules having the (S) configuration of the stereorandom chiral center may be but is not necessarily the same as the number of molecules having the (R) configuration of the stereorandom chiral center. The stereochemical configuration of a chiral center is considered random when it is the result of a synthetic method that is not designed to control the stereochemical configuration. In certain embodiments, a stereorandom chiral center is a stereorandom phosphorothioate internucleoside linkage.

As used herein, “sugar moiety” means an unmodified sugar moiety or a modified sugar moiety. As used herein, “unmodified sugar moiety” means a 2′-OH(H) ribosyl moiety, as found in RNA (an “unmodified RNA sugar moiety”), or a 2′-H(H) moiety, as found in DNA (an “unmodified DNA sugar moiety”). As used herein, “modified sugar moiety” or “modified sugar” means a modified furanosyl sugar moiety or a sugar surrogate. As used herein, modified furanosyl sugar moiety means a furanosyl sugar comprising a non-hydrogen substituent in place of at least one hydrogen of an unmodified sugar moiety. In certain embodiments, a modified furanosyl sugar moiety is a 2′-substituted sugar moiety. Such modified furanosyl sugar moieties include bicyclic sugars and non-bicyclic sugars. As used herein, “sugar surrogate” means a modified sugar moiety having other than a furanosyl moiety that can link a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide. Modified nucleosides comprising sugar surrogates can be incorporated into one or more positions within an oligonucleotide and such oligonucleotides are capable of hybridizing to complementary oligomeric compounds or nucleic acids.

As used herein, “target nucleic acid,” “target RNA,” “target RNA transcript” and “nucleic acid target” mean a nucleic acid that an antisense compound is designed to affect.

As used herein, “target region” means a portion of a target nucleic acid to which an antisense compound is designed to hybridize.

As used herein, “terminal group” means a chemical group or group of atoms that is covalently linked to a terminus of an oligonucleotide.

As used herein, “terminal wing nucleoside” means a nucleoside that is located at the terminus of a wing segment of a gapmer. Any wing segment that comprises or consists of at least two nucleosides has two termini: one that is immediately adjacent to the gap segment; and one that is at the end opposite the gap segment. Thus, any wing segment that comprises or consists of at least two nucleosides has two terminal nucleosides, one at each terminus.

As used herein, “therapeutically effective amount” means an amount of a compound, pharmaceutical agent, or composition that provides a therapeutic benefit to an individual. In certain embodiments, the therapeutically effective amount refers to the level or amount of a compound that treats or ameliorates symptoms of a disease associated with DNM2. In certain embodiments, the therapeutically effective amount may be administered prior to the onset of the disease associated with DNM2 or may be administered after initiation of the disease associated with DNM2.

As used herein, “treat” refers to administering a compound or pharmaceutical composition to an animal in order to effect an alteration or improvement of a disease, disorder, or condition in the animal. In one embodiment, a subject is successfully treated if, after receiving a therapeutically effective amount of a compound according to the present invention, the subject shows observable and/or measurable reduction or relief to some extent of one or more of the symptoms associated with the specific disease associated with DNM2, such as but not limited to reduced morbidity and mortality, improvement in quality of life issues, increased body weight, preservation or increase in muscle strength, decrease in time taken to rise from the floor, decrease in nine-meter walking time, decrease in time taken to climb four stairs, increased ability to lift weight, increased distance of a 6 minute walk, increased leg function grade, improved pulmonary function and/or cardiac function. Parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician.

Certain Embodiments

Certain embodiments provide methods, compounds and compositions for inhibiting DNM2 expression.

Certain embodiments provide methods, compounds and compositions for inhibiting DNM2 expression as compared to an untreated or control sample. In one embodiment, said inhibition is an inhibition of DNM2 expression of at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In one embodiment, inhibiting the expression or activity refers to a reduction or blockade of the expression or activity relative to the expression or activity in an untreated or control sample of at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% as compared to an untreated or control sample.

Certain embodiments provide compounds comprising or consisting of oligonucleotides complementary to a DNM2 nucleic acid. In certain embodiments, the DNM2 nucleic acid has the sequence set forth in RefSeq or GenBank Accession No. NC_000019.10 truncated from nucleosides 10715001 to Ser. No. 10/835,000 (disclosed herein as SEQ ID NO: 1), NM_004945.3 (disclosed herein as SEQ ID NO: 2), NM_001005361.2 (disclosed herein as SEQ ID NO: 3), or NM_001005360.2 (disclosed herein as SEQ ID NO: 3135). In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded.

Certain embodiments provide a compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134.

As used herein, the term “identity” refers to the subunit sequence identity between two nucleic acid molecules, such as, two DNA molecules or two RNA molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit; e.g., if a position in each of two DNA molecules is occupied by adenine, then they are identical (or homologous) at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; e.g., if half (e.g., five positions in a polymer ten subunits in length) of the positions in two sequences are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 of 10), are matched or homologous, the two sequences are 90% homologous. Thus, the term “homologous” or “identical”, when used in a relationship between the sequences of two or more nucleic acid molecules, refers to the degree of sequence relatedness between nucleic acid molecules, as determined by the number of matches between strings of two or more nucleotide residues. “Identity” measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (i.e., “algorithms”). Identity of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988). Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods of determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al., Nucl. Acid. Res. 2, 387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. MoI. Biol. 215, 403-410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB/NLM/NIH Bethesda, Md. 20894; Altschul et al., supra). The well-known Smith Waterman algorithm may also be used to determine identity.

In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 or at least 8 contiguous nucleobases of a sequence having at least 70% identity with any of the nucleobase sequences of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2879 or a sequence having at least 70% identity with SEQ ID NO: 2879. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 3056 or a sequence having at least 70% identity with SEQ ID NO: 3056. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2123 or a sequence having at least 70% identity with SEQ ID NO: 2123. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2189 or a sequence having at least 70% identity with SEQ ID NO: 2189. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2453 or a sequence having at least 70% identity with SEQ ID NO: 2453. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2160 or a sequence having at least 70% identity with SEQ ID NO: 2160. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2232 or a sequence having at least 70% identity with SEQ ID NO: 2232. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide has a nucleobase sequence comprising at least 12 contiguous nucleobases of any of SEQ ID Numbers from 7 to 3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134.

Certain embodiments provide a compound comprising a modified oligonucleotide 10 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 10 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 11 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 11 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 11 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 12 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 12 to 30 linked nucleosides in length.

In certain embodiments, the compound comprises a modified oligonucleotide 16 linked nucleosides in length. In certain embodiments, the compound is an antisense compound or oligomeric compound.

Certain embodiments provide a compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded. In certain embodiments, the modified oligonucleotide is 16 to 30 linked nucleosides in length.

Certain embodiments provide a compound comprising a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134 or of any sequence having at least about 70% identity with any of the nucleobase sequences of SEQ ID NOs: 7-3134, such as, for example, at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity or more with any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound is an antisense compound or oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded.

In certain embodiments, compounds comprise or consist of modified oligonucleotides complementary to an intron of a DNM2 nucleic acid transcript. In certain embodiments, modified oligonucleotides are complementary to intron 1, intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 9-10a, intron 10, intron 10a-11, intron 11, intron 12, intron 13, intron 14, intron 15, intron 16, intron 17, intron 18, intron 19, or intron 19-20a of a DNM2 nucleic acid transcript. In certain such embodiments, modified oligonucleotides are complementary to a sequence within nucleotides 3404-44,737; 44,812-57,478; 57,629-60,702; 60,907-62,117; 62,217-67,959; 68,121-71,563; 71,707-78,719; 78,856-80,371; 80,440-81,060; 80,440-82,379; 81,200-83,485; 82,519-83,485; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 105,090-108,787; 108,990-110,056; 110,222-114,035; 114,269-115,126; 115,379-115,977; or 115,379-115,980 of SEQ ID NO: 1. In certain embodiments, compounds comprise or consist of oligonucleotides having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion of intron 1, intron 2, intron 3, intron 4, intron 5, intron 6, intron 7, intron 8, intron 9, intron 9-10a, intron 10, intron 10a-11, intron 11, intron 12, intron 13, intron 14, intron 15, intron 16, intron 17, intron 18, intron 19, or intron 19-20a of a DNM2 nucleic acid transcript. In certain embodiments, such oligonucleotides have at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 3404-44,737; 44,812-57,478; 57,629-60,702; 60,907-62,117; 62,217-67,959; 68,121-71,563; 71,707-78,719; 78,856-80,371; 80,440-81,060; 80,440-82,379; 81,200-83,485; 82,519-83,485; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 105,090-108,787; 108,990-110,056; 110,222-114,035; 114,269-115,126; 115,379-115,977; or 115,379-115,980 of SEQ ID NO: 1. In certain embodiments, these compounds are antisense compounds or oligomeric compounds. Compounds comprising a modified oligonucleotide complementary to certain introns of a DNM2 nucleic acid transcript, e.g., intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 pre-mRNA, are generally especially potent and tolerable. Thus, such certain introns can be considered hot spot regions for targeting a DNM2 nucleic acid transcript.

In certain embodiments, compounds comprise or consist of modified oligonucleotides complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, modified oligonucleotides are complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, compounds comprise or consist of oligonucleotides having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion of intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript.

In certain embodiments, such oligonucleotides have at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, these compounds are antisense compounds or oligomeric compounds.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

In certain embodiments, compounds comprise or consist of modified oligonucleotides complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, modified oligonucleotides are complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, compounds comprise or consist of oligonucleotides having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion of intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, such oligonucleotides have at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, these compounds are antisense compounds or oligomeric compounds.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion complementary to an equal length portion within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979; of SEQ ID NO: 1. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and complementary within nucleotides 89,722-89,737; 83,880-83,895; 90,081-90,096; 94,450-94,465; 11,960-11,975; 93,322-93,337; or 97,855-97,870 of SEQ ID NO: 1. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobase portion of the nucleobase sequence of any one of compound numbers 951799, 949935, 950023, 950089, 951372, 950060, or 950132 (SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232). In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2879 or of a sequence having at least 70% identity with SEQ ID NO: 2879. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 3056 or of a sequence having at least 70% identity with SEQ ID NO: 3056. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2123 or of a sequence having at least 70% identity with SEQ ID NO: 2123. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2189 or of a sequence having at least 70% identity with SEQ ID NO: 2189. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2453 or of a sequence having at least 70% identity with SEQ ID NO: 2453. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2160 or of a sequence having at least 70% identity with SEQ ID NO: 2160. In certain embodiments, the nucleobase sequence of the modified oligonucleotide comprises or consists of SEQ ID NO: 2232 or of a sequence having at least 70% identity with SEQ ID NO: 2232.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of compound numbers 951799, 949935, 950023, 950089, 951372, 950060, or 950132 (SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232). In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide having a nucleobase sequence consisting of the nucleobase sequence of any one of compound numbers 951799, 949935, 950023, 950089, 951372, 950060, or 950132 (SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232). In certain embodiments, a compound comprises or consists of a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of the compound number 951799 (SEQ ID NO: 2879). In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length.

In certain embodiments, a compound comprising or consisting of a modified oligonucleotide complementary to DNM2 is compound number 951799. Out of the over 3,000 compounds that were screened as described in the Examples section below, compound numbers 951799, 949935, 950023, 950089, 951372, 950060, and 950132 emerged as the top lead compounds. In particular, compound number 951799 exhibited the best combination of properties in terms of potency and tolerability out of over 3,000 compounds.

In certain embodiments, any of the foregoing oligonucleotides is a modified oligonucleotide comprising at least one modified internucleoside linkage, at least one modified sugar, and/or at least one modified nucleobase.

In certain embodiments, any of the foregoing modified oligonucleotides comprises at least one modified sugar. In certain embodiments, at least one modified sugar is a bicyclic sugar, such as a cEt bicyclic sugar, an LNA bicyclic sugar, or an ENA bicyclic sugar.

In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, such as a phosphorothioate internucleoside linkage.

In certain embodiments, any of the foregoing modified oligonucleotides comprises at least one modified nucleobase, such as 5-methylcytosine.

In certain embodiments, any of the foregoing modified oligonucleotides comprises:

-   -   a gap segment consisting of linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, the modified oligonucleotide is 16 to 50 linked nucleosides in length having a nucleobase sequence comprising the sequence recited in anyone of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 or a sequence having at least 70% identity with any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the modified oligonucleotide is 16 to 50 linked nucleosides in length having a nucleobase sequence comprising the sequence recited in SEQ ID NO: 2879 or a sequence having at least 70% identity with SEQ ID NO: 2879. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 or a sequence having at least 70% identity with any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the modified oligonucleotide is 10 to 30 linked nucleosides in length having a nucleobase sequence comprising the sequence recited in SEQ ID NO: 2879 or a sequence having at least 70% identity with SEQ ID NO: 2879. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length having a nucleobase sequence consisting of the sequence recited in any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 or a sequence having at least 70% identity with any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 2879 or a sequence having at least 70% identity with SEQ ID NO: 2879.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide 20-50 linked nucleobases in length having a nucleobase sequence comprising the sequence recited in any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 or a sequence having at least 70% identity with any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises

a gap segment consisting often linked 2′-deoxynucleosides;

a 5′ wing segment consisting of three linked nucleosides; and

a 3′ wing segment consisting of three linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment; wherein the nucleosides of the 5′ wing segment each comprise a cEt bicyclic sugar; wherein the nucleosides of the 3′ wing segment each comprises a cEt bicyclic sugar; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide is 16-80 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16-30 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is 16 linked nucleosides in length.

In certain embodiments, a compound comprises or consists of a modified oligonucleotide according to one of the following formulas:

(SEQ ID NO: 2879) Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; (SEQ ID NO: 3056) Gks Gks Aks Tds Tds Tds Tds Ads Gds Gds Ads Gds Gds Tks Gks Ak; (SEQ ID NO: 2123) Gks mCks Aks Tds Ads Gds Ads mCds Ads Ads Ads Tds mCds mCks mCks Ak; (SEQ ID NO: 2189) Gks mCks Aks Ads Ads Tds Ads Tds Gds Ads Tds Tds mCds Aks Tks mCk; (SEQ ID NO: 2453) Gks Gks Tks mCds Ads Tds Tds Ads Ads Ads Gds Ads Tds Tks mCks Tk; (SEQ ID NO: 2160) Aks Tks Gks Tds Ads Tds Tds Ads mCds mCds Tds Ads mCds Gks Gks mCk; or (SEQ ID NO: 2232) Gks Tks Aks mCds Ads Ads Tds Gds Tds Ads Ads Gds mCds mCks Tks Tk wherein A=an adenine, mC=a 5-methylcytosine, G=a guanine, T=a thymine, k=a cEt sugar moiety, d=a 2′-deoxyribosyl sugar moiety, and s=a phosphorothioate internucleoside linkage.

In certain embodiments, a compound comprises or consists of compound 951799, or salt thereof, a modified oligonucleotide having the following chemical structure:

In certain embodiments, a compound comprises or consists of the sodium salt of compound 951799 having the following chemical structure:

In any of the foregoing embodiments, the compound or oligonucleotide can be at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% complementary to a nucleic acid encoding DNM2.

In any of the foregoing embodiments, the compound can be single-stranded. In certain embodiments, the compound comprises 2′-deoxyribonucleosides. In certain embodiments, the compound is double-stranded. In certain embodiments, the compound is double-stranded and comprises ribonucleosides. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

In any of the foregoing embodiments, the compound can be 8 to 80, 10 to 30, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to 30 linked nucleosides in length. In certain embodiments, the compound comprises or consists of an oligonucleotide.

The present invention thus relates to a modified oligonucleotide or compounds comprising modified oligonucleotides complementary to a DNM2 nucleic acid as described hereinabove.

In certain embodiments, a compound comprises a modified oligonucleotide described herein and a conjugate group. In certain embodiments, the conjugate group is linked to the modified oligonucleotide at the 5′ end of the modified oligonucleotide. In certain embodiments, the conjugate group is linked to the modified oligonucleotide at the 3′ end of the modified oligonucleotide.

In certain embodiments, compounds or compositions provided herein comprise a salt of the modified oligonucleotide. In certain embodiments, the salt is a sodium salt. In certain embodiments, the salt is a potassium salt.

In certain embodiments, the compounds or compositions as described herein are active by virtue of having at least one of an in vitro IC₅₀ of less than 300 nM, 200 nM, 100 nM, 80 nM, 50 nM, or 30 nM in a standard cell assay. Standard cell assays are described in the Examples.

In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having at least one of an increase an alanine transaminase (ALT) or aspartate transaminase (AST) value of no more than 4 fold, 3 fold, 2 fold, or 1.5 fold over saline treated animals or an increase in liver, spleen, or kidney weight of no more than 30%, 20%, 15%, 12%, 10%, 5%, or 2% compared to control treated animals. In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having no increase of ALT or AST over control treated animals. In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having no increase in liver, spleen, or kidney weight over control animals.

Certain embodiments provide a composition comprising or consisting essentially of the compound of any of the aforementioned embodiments or salt thereof.

Certain embodiments provide a composition comprising or consisting essentially of the compound of any of the aforementioned embodiments or salt thereof and at least one of a pharmaceutically acceptable carrier or diluent. Therefore, in one embodiment, the composition of the invention is a pharmaceutical composition.

Certain embodiments provide a medicament comprising or consisting essentially of the compound of any of the aforementioned embodiments or salt thereof. Therefore, in one embodiment, the composition of the invention is a medicament.

As used herein, the term “consists essentially of”, with reference to a composition, pharmaceutical composition or medicament, means that the compound of the invention is the only active ingredient, therapeutic agent or agent with a biologic activity within said pharmaceutical composition or medicament.

In certain embodiments, the composition has a viscosity less than about 40 centipoise (cP), less than about 30 cP, less than about 20 cP, less than about 15 cP, less than about 10 cP, less than about 5 cP, or less than about 3 cP, or less than about 1.5 cP. In certain embodiments, the composition having any of the aforementioned viscosities comprises a compound provided herein at a concentration of about 15 mg/mL, 20 mg/mL, 25 mg/mL, 50 mg/mL, 100 mg/mL, 150 mg/mL, or about 200 mg/mL. In certain embodiments, the composition having any of the aforementioned viscosities and/or compound concentrations has a temperature of room temperature or about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., about 25° C., about 26° C., about 27° C., about 28° C., about 29° C., or about 30° C.

Embodiment 1. A compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134.

Embodiment 2. A compound comprising a modified oligonucleotide 9 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 9 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134.

Embodiment 3. A compound comprising a modified oligonucleotide 10 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 10 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134.

Embodiment 4. A compound comprising a modified oligonucleotide 11 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 11 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134.

Embodiment 5. A compound comprising a modified oligonucleotide 12 to 50 linked nucleosides in length having a nucleobase sequence comprising at least 12, at least 13, at least 14, or at least 15 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134.

Embodiment 6. A compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of any of SEQ ID NOs: 7-3134.

Embodiment 7. A compound comprising a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 7-3134.

Embodiment 8. A compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length complementary within nucleobases 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1, wherein said modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1.

Embodiment 9. A compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1.

Embodiment 10. A compound comprising a modified oligonucleotide 8 to 50 linked nucleosides in length complementary within nucleobases 83,573-87,287 or 87,359-90,915 of SEQ ID NO: 1, wherein said modified oligonucleotide is at least 85%, 90%, 95%, or 100% complementary to SEQ ID NO: 1.

Embodiment 11. A compound comprising a modified oligonucleotide complementary to intron 1 of a human DNM2 pre-mRNA.

Embodiment 12. A compound comprising a modified oligonucleotide complementary to intron 11 of a human DNM2 pre-mRNA.

Embodiment 13. A compound comprising a modified oligonucleotide complementary to intron 12 of a human DNM2 pre-mRNA.

Embodiment 14. A compound comprising a modified oligonucleotide complementary to intron 13 of a human DNM2 pre-mRNA.

Embodiment 15. A compound comprising a modified oligonucleotide complementary to intron 14 of a human DNM2 pre-mRNA.

Embodiment 16. A compound comprising a modified oligonucleotide complementary to exon 10 of a human DNM2 pre-mRNA or human DNM2 mRNA.

Embodiment 17. A compound comprising a modified oligonucleotide complementary to the 3′-UTR of a human DNM2 pre-mRNA or human DNM2 mRNA.

Embodiment 18. A compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232.

Embodiment 19. A compound comprising a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232.

Embodiment 20. A compound comprising a modified oligonucleotide having a nucleobase sequence comprising SEQ ID NO: 2879.

Embodiment 21. A compound comprising a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises: a gap segment consisting of 8-12 linked 2′-deoxynucleosides; a 5′ wing segment consisting of 1-7 linked nucleosides; and a 3′ wing segment consisting of 1-7 linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each terminal wing nucleoside comprises a modified sugar.

Embodiment 22. A compound comprising a modified oligonucleotide 16 linked nucleosides in length having a nucleobase sequence consisting of the sequence recited in SEQ ID NO: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises

-   -   a gap segment consisting of 10 linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of 3 linked nucleosides; and     -   a 3′ wing segment consisting of 3 linked nucleosides;     -   wherein the gap segment is positioned between the 5′ wing         segment and the 3′ wing segment; wherein each nucleoside of each         wing segment comprises a cEt sugar moiety; wherein each         internucleoside linkage is a phosphorothioate linkage; and         wherein each cytosine is a 5-methylcytosine.

Embodiment 23. The compound of any one of embodiments 1-22, wherein the oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of SEQ ID NO: 1, 2, 3, or 3135.

Embodiment 24. The compound of any one of embodiments 1-23, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

Embodiment 25. The compound of embodiments 24, wherein the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.

Embodiment 26. The compound of any one of embodiments 1-21 or 23-25, wherein the modified oligonucleotide comprises at least one bicyclic sugar.

Embodiment 27. The compound of Embodiments 26, wherein the at least one bicyclic sugar is selected from the group consisting of LNA, ENA, and cEt.

Embodiment 28. The compound of embodiment 27, wherein the at least one bicyclic sugar moiety is a cEt sugar moiety.

Embodiment 29. The compound of any one of embodiments 1-28, wherein the modified oligonucleotide comprises at least one 5-methylcytosine.

Embodiment 30. The compound of any one of embodiments 1-29, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked 2′-deoxynucleosides;

a 5′ wing segment consisting of linked nucleosides; and

a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar moiety.

Embodiment 31. The compound of any one of embodiments 1-30, wherein the compound is single-stranded.

Embodiment 32. The compound of any one of embodiments 1-30, wherein the compound is double-stranded.

Embodiment 33. The compound of any one of embodiments 1-32, wherein the compound comprises at least one unmodified ribosyl sugar moiety.

Embodiment 34. The compound of any one of embodiments 1-33, wherein the compound comprises at least one unmodified 2′-deoxyribosyl sugar moiety.

Embodiment 35. The compound of any one of embodiments 1-34, wherein the modified oligonucleotide consists of 10 to 30 linked nucleosides.

Embodiment 36. The compound of any one of embodiments 1-34, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides.

Embodiment 37. The compound of any one of embodiments 1-34, wherein the modified oligonucleotide consists of 15 to 30 linked nucleosides.

Embodiment 38. The compound of any one of embodiments 1-34, wherein the modified oligonucleotide consists of 16 to 20 linked nucleosides.

Embodiment 39. A compound comprising a modified oligonucleotide according to the following formula: Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; wherein,

-   -   A=an adenine,     -   mC=a 5-methylcytosine     -   G=a guanine,     -   T=a thymine,     -   k=a cEt sugar moiety,     -   d=a 2′-deoxyribosyl sugar moiety, and     -   s=a phosphorothioate internucleoside linkage.

Embodiment 40. The compound of any one of embodiments 1-39 comprising a conjugate group.

Embodiment 41. The compound of embodiment 40, wherein the compound consists of the modified oligonucleotide and the conjugate group.

Embodiment 42. A compound according to the following formula:

Embodiment 43. The compound of any one of embodiments 1-39 or 42, wherein the compound

consists of the

modified oligonucleotide.

Embodiment 44. A compound consisting of a pharmaceutically acceptable salt form of any one of the compounds of embodiments 1-43.

Embodiment 45. The compound of embodiment 44, wherein the pharmaceutically acceptable salt is a sodium salt.

Embodiment 46. The compound of embodiment 44, wherein the pharmaceutically acceptable salt is a potassium salt.

Embodiment 47. A pharmaceutical composition comprising the compound of any one of embodiments 1-44 and at least one pharmaceutically acceptable carrier or diluent.

Embodiment 48. A chirally enriched population of the compounds of any one of embodiments 1-46, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.

Embodiment 49. The chirally enriched population of embodiment 48, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having the (Sp) configuration.

Embodiment 50. The chirally enriched population of embodiment 48, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having the (Rp) configuration.

Embodiment 51. The chirally enriched population of embodiment 48, wherein the population is enriched for modified oligonucleotides having a particular, independently selected stereochemical configuration at each phosphorothioate internucleoside linkage

Embodiment 52. The chirally enriched population of embodiment 51, wherein the population is enriched for modified oligonucleotides having the (Sp) configuration at each phosphorothioate internucleoside linkage.

Embodiment 53. The chirally enriched population of embodiment 51, wherein the population is enriched for modified oligonucleotides having the (Rp) configuration at each phosphorothioate internucleoside linkage.

Embodiment 54. The chirally enriched population of embodiment 51, wherein the population is enriched for modified oligonucleotides having the (Rp) configuration at one particular phosphorothioate internucleoside linkage and the (Sp) configuration at each of the remaining phosphorothioate internucleoside linkages.

Embodiment 55. The chirally enriched population of embodiment 48 or embodiment 51, wherein the population is enriched for modified oligonucleotides having at least 3 contiguous phosphorothioate internucleoside linkages in the Sp, Sp, and Rp configurations, in the 5′ to 3′ direction.

Embodiment 56. A chirally enriched population of the compounds of any one of embodiments 1-46, wherein all of the phosphorothioate internucleoside linkages of the modified oligonucleotide are stereorandom.

Embodiment 57. A pharmaceutical composition comprising the population of compounds of any one of embodiments 48-56 and at least one pharmaceutically acceptable diluent or carrier.

Embodiment 58. The compound of any one of embodiments 1-46, a pharmaceutical composition comprising the compound of any one of embodiments 1-46 and at least one pharmaceutically acceptable carrier or diluent, or a pharmaceutical composition comprising the population of compounds of any one of embodiments 48-56 and at least one pharmaceutically acceptable carrier or diluent, for use in therapy.

Embodiment 59. The compound or composition of embodiment 58, for use in treating, preventing, or ameliorating centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 60. A method of treating, preventing, or ameliorating a disease associated with DNM2 in an individual comprising administering to the individual any of the compounds or compositions of embodiment 1-59, thereby treating, preventing, or ameliorating the disease.

Embodiment 61. A method of treating, preventing, or ameliorating a disease associated with DNM2 in an individual comprising administering to the individual a compound comprising a modified oligonucleotide 100% complementary to an exon 10, an intron, or the 3′-UTR of a DNM2 nucleic acid transcript, thereby treating, preventing, or ameliorating the disease.

Embodiment 62. The method of embodiment 60 or 61, wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 63. The method of any one of embodiments 60-62, wherein the compound is single-stranded.

Embodiment 64. The method of any one of embodiments 60-63, wherein the DNM2 nucleic acid transcript is a pre-mRNA.

Embodiment 65. The method of any one of embodiments 60-64, wherein the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy.

Embodiment 66. The method of embodiment 65, wherein the individual has at least one mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

Embodiment 67. The method of any one of embodiments 60-66, wherein the administering increases body weight or muscle strength.

Embodiment 68. A method of inhibiting expression of DNM2 in a cell comprising contacting the cell with a single-stranded compound comprising a modified oligonucleotide 100% complementary to exon 10, an intron, or the 3′-UTR of a DNM2 nucleic acid transcript, thereby inhibiting expression of DNM2 in the cell.

Embodiment 69. The method of embodiment 68, wherein the cell is in the muscle of an individual.

Embodiment 70. The method of embodiment 69, wherein the individual has, or is at risk of having, a centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 71. A method of increasing body weight or muscle strength in an individual having, or at risk of having, a disease associated with DNM2 comprising administering a single-stranded compound comprising a modified oligonucleotide 100% complementary to a DNM2 nucleic acid transcript to the individual, thereby increasing body weight or muscle strength in the individual.

Embodiment 72. The method of embodiment 71, wherein the individual has, or is at risk of having, centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 73. The method of any one of embodiments 60-72, wherein the compound is the compound of any one of embodiments 1-46.

Embodiment 74. The method of any one of embodiments 60-72, wherein the compound is a member of the chirally enriched population of any one of embodiments 48-56.

Embodiment 75. The method of any one of embodiments 60-72, wherein the compound is a component of the pharmaceutical composition of embodiment 57.

Embodiment 76. The method any one of embodiments 60-67 or 69-75, wherein the compound is administered to the individual via subcutaneous injection.

Embodiment 77. The method any one of embodiments 60-67 or 69-75, wherein the compound is administered to the individual via intramuscular injection.

Embodiment 78. The method of any one of embodiments 60-67 or 69-77, wherein the compound is administered to the individual via intravenous injection.

Embodiment 79. Use of a single-stranded compound comprising a modified oligonucleotide 100% complementary to exon 10, intron 1, intron 11, intron, 12, intron 13, intron 14, or the 3′-UTR of a DNM2 nucleic acid transcript for treating, preventing, or ameliorating a disease associated with DNM2.

Embodiment 80. The use of embodiment 79, wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 81. Use of the compound of any one of embodiments 1-46 or the composition of embodiment 57 for treating, preventing, or ameliorating a disease associated with DNM2.

Embodiment 82. Use of the compound of any one of embodiments 1-46 or the composition of embodiment 57 in the manufacture of a medicament for treating, preventing, or ameliorating a disease associated with DNM2.

Embodiment 83. The use of embodiment 81 or 82, wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 84. The use of embodiment 80 or 83, wherein the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy.

Embodiment 85. The use of embodiment 84, wherein the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

Embodiment 86. Use of the compound of any one of embodiments 1-46 or the composition of embodiment 57 in the preparation of a medicament for treating, preventing, or ameliorating a disease associated with DNM2.

Embodiment 87. The use of embodiment 86, wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, or Charcot-Marie Tooth disease.

Embodiment 88. The use of embodiment 87, wherein the disease is X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy.

Embodiment 89. The use of embodiment 88, wherein the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

Certain Indications

Certain embodiments provided herein relate to methods of inhibiting DNM2 expression, which can be useful for treating, preventing, or ameliorating a disease associated with DNM2 in an individual, by administration of a compound that targets DNM2, such as the compound described herein. In certain diseases associated with DNM2, modest or partial inhibition of DNM2 expression is sufficient to treat, prevent, or ameliorate the disease (See, e.g., Cowling et al. J Clin. Invest. 124, 1350-1363 (2014) and Tasfaout et al. Nat. Commun. June 7; 8:15661 (2017).) In certain embodiments, the compound can be an antisense compound, oligomeric compound, or oligonucleotide complementary to DNM2, such as the ones described herein.

Examples of diseases associated with DNM2 that are treatable, preventable, and/or ameliorable with the methods provided herein include centronuclear myopathy (CNM), Charcot-Marie-Tooth disease (CMT), and Duchenne's Muscular Dystrophy (DMD). Centronuclear myopathy includes X-linked CNM (XLCNM), autosomal dominant CNM (ADCNM) and autosomal recessive CNM (ARCNM). Mutations in several genes are associated with CNM, including mutations in MTM1, BIN1, and DNM2. Other genes have been linked to a CNM-like myopathy: RYR1 encoding for the ryanodine receptor, TTN encoding Titin, CCDC78 (OMIM 614807) and the phosphoinositides phosphatase MTMR14 (called hJUMPY; OMIM 160150).

In certain embodiments, a method of treating, preventing, or ameliorating a disease associated with DNM2 in an individual comprises administering to the individual a compound comprising an antisense compound targeted to DNM2, thereby treating, preventing, or ameliorating the disease. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual subcutaneously, intradermally, intranodally, intramedullary, intramuscularly, intrasternally, by intravenous (i.v.) injection, by infusion techniques or intraperitoneally. In certain embodiments, the compound is administered to the individual via subcutaneous injection. In certain embodiments, administering the compound increases or preserves body weight or muscle strength.

In certain embodiments, a method of treating, preventing, or ameliorating CNM, DMD, or CMT comprises administering to the individual a compound comprising a modified oligonucleotide complementary to a DNM2 nucleic acid, thereby treating, preventing, or ameliorating CNM, DMD, or CMT. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound is an antisense compound targeted to DNM2. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intrasternally, by intravenous (i.v.) injection, by infusion techniques or intraperitoneally. In certain embodiments, the compound is administered to the individual systemically, e.g., via subcutaneous or intramuscular injection. In certain embodiments, administering the compound increases or preserves body weight or muscle strength. In certain such embodiments, time taken to rise from the floor, nine-meter walking time, or time taken to climb four stairs is decreased. In certain embodiments, ability to lift weight, distance of a 6 minute walk, or leg function grade is increased. In certain embodiments, pulmonary function or cardiac function is improved. In certain embodiments, the individual is identified as having or at risk of having a disease associated with DNM2. Examples of factors of risk of having a disease associated with DNM2 include, but are not limited to, genetic predisposition, such as, for example, a mutation in at least one gene selected from among MTM1, BIN1, and DNM2.

In certain embodiments, a method of inhibiting expression of DNM2 in an individual having, or at risk of having, a disease associated with DNM2 comprises administering to the individual a compound comprising a modified oligonucleotide complementary to a DNM2 nucleic acid, thereby inhibiting expression of DNM2 in the individual. In certain embodiments, administering the compound inhibits expression of DNM2 in skeletal muscle. In certain embodiments, the individual has, or is at risk of having CNM, DMD, or CMT. In certain embodiments, the compound comprises an antisense compound targeted to DNM2. In certain embodiments, the antisense compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual subcutaneously, intradermally, intranodally, intramedullary, intramuscularly, intrasternally, by intravenous (i.v.) injection, by infusion techniques or intraperitoneally. In certain embodiments, the compound is administered to the individual systemically, e.g., via subcutaneous or intramuscular injection. In certain embodiments, administering the compound increases or preserves body weight or muscle strength. In certain embodiments, the individual is identified as having or at risk of having a disease associated with DNM2.

In certain embodiments, a method of inhibiting expression of DNM2 in a cell comprises contacting the cell with a compound comprising an antisense compound targeted to DNM2, thereby inhibiting expression of DNM2 in the cell. In one embodiment, the expression of DNM2 is inhibited by at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In one embodiment, the expression of DNM2 is inhibited by at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% as compared to an untreated or control sample. In one embodiment, the method is an in vitro method. In certain embodiments, the cell is a muscle cell. In certain embodiments, the cell is a skeletal muscle cell. In certain embodiments, the muscle cell is in an individual who has, or is at risk of having CNM, DMD, or CMT. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

In certain embodiments, a method of increasing or preserving body weight or muscle strength of an individual having, or at risk of having, a disease associated with DNM2 comprises administering to the individual a compound comprising an antisense compound targeted to DNM2, increasing or preserving body weight or muscle strength of the individual. In certain such embodiments, time taken to rise from the floor, nine-meter walking time, or time taken to climb four stairs is decreased. In certain embodiments, ability to lift weight, distance of a 6 minute walk, or leg function grade is increased. In certain embodiments, pulmonary function or cardiac function is improved. In certain embodiments, the individual has, or is at risk of having, CNM, DMD, or CMT. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual subcutaneously, intradermally, intranodally, intramedullary, intramuscularly, intrasternally, by intravenous (i.v.) injection, by infusion techniques or intraperitoneally. In certain embodiments, the compound is administered to the individual systemically, e.g., via subcutaneous or intramuscular injection. In certain embodiments, the individual is identified as having or at risk of having a disease associated with DNM2.

Certain embodiments are drawn to a compound comprising an antisense compound targeted to DNM2 for use in treating a disease associated with DNM2. In certain embodiments, the disease is CNM, DMD, or CMT. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound. In certain embodiments, the compound is administered to the individual subcutaneously, intradermally, intranodally, intramedullary, intramuscularly, intrasternally, by intravenous (i.v.) injection, by infusion techniques or intraperitoneally. In certain embodiments, the compound is to be administered to the individual systemically, e.g., via subcutaneous or intramuscular injection.

Certain embodiments are drawn to a compound comprising an antisense compound targeted to DNM2 for use in increasing or preserving body weight or muscle strength of an individual having or at risk of having CNM, DMD, or CMT. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

Certain embodiments are drawn to use of the compound comprising an antisense compound targeted to DNM2 for the manufacture or preparation of a medicament for treating a disease associated with DNM2. Certain embodiments are drawn to use of the compound comprising an antisense compound targeted to DNM2 for the preparation of a medicament for treating a disease associated with DNM2. In certain embodiments, the disease is CNM, DMD, or CMT. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

Certain embodiments are drawn to use of a compound comprising an antisense compound targeted to DNM2 for the manufacture or preparation of a medicament for increasing or preserving body weight or muscle strength of an individual having or at risk of having CNM, DMD, or CMT. In certain embodiments, the compound comprises an oligonucleotide complementary to a DNM2 nucleic acid transcript. In certain embodiments, the compound is a compound as described herein. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, intron 14, exon 10, or the 3′-UTR of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1. In certain embodiments, the compound comprises or consists of a modified oligonucleotide complementary to intron 1, intron 11, intron 12, intron 13, or intron 14 of a DNM2 nucleic acid transcript. In certain embodiments, the modified oligonucleotide is complementary to a sequence within nucleotides 3,404-44,737; 83,573-87,287; 87,359-90,915; 90,968-97,263; or 97,378-104,979 of SEQ ID NO: 1. In certain embodiments, the compound comprises a modified oligonucleotide 8 to 50 linked nucleosides in length and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 12 to 50 linked nucleosides in length and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a modified oligonucleotide 16 to 50 linked nucleosides in length having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises a modified oligonucleotide having a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In any of the foregoing embodiments, the modified oligonucleotide can be 10 to 30 linked nucleosides in length. In certain embodiments, the compound is compound number 951799, 949935, 950023, 950089, 951372, 950060, or 950132. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense compound or oligomeric compound.

In any of the foregoing methods or uses, the compound can be targeted to a DNM2 nucleic acid transcript. In certain embodiments, the compound comprises or consists of a modified oligonucleotide, for example a modified oligonucleotide 8 to 50 linked nucleosides in length, 10 to 30 linked nucleosides in length, 12 to 30 linked nucleosides in length, or 20 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of the nucleobase sequences recited in SEQ ID NOs: 1, 2, 3, or 3135. In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar, and at least one modified nucleobase. In certain such embodiments, the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage, the at least one modified sugar is a bicyclic sugar, and the at least one modified nucleobase is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide comprises a gap segment consisting of linked 2′-deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides, wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each terminal wing nucleoside comprises a modified sugar.

In any of the foregoing embodiments, the modified oligonucleotide may be 12 to 30, 15 to 30, 15 to 25, 15 to 24, 16 to 24, 17 to 24, 18 to 24, 19 to 24, 20 to 24, 19 to 22, 20 to 22, 16 to 20, or 17 or 20 linked nucleosides in length. In certain embodiments, the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of the nucleobase sequences recited in SEQ ID NOs: 1, 2, 3, or 3135. In certain embodiments, the modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar, and at least one modified nucleobase. In certain embodiments, the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage, the at least one modified sugar is a bicyclic sugar, and the at least one modified nucleobase is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide comprises a gap segment consisting of linked 2′-deoxynucleosides; a 5′ wing segment consisting of linked nucleosides; and a 3′ wing segment consisting of linked nucleosides, wherein the gap segment is positioned immediately adjacent to and between the 5′ wing segment and the 3′ wing segment and wherein each terminal wing nucleoside comprises a modified sugar.

In any of the foregoing methods or uses, the compound may comprise or consist of a modified oligonucleotide 16 to 30 linked nucleosides in length and having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

In any of the foregoing methods or uses, the compound may comprise or consist of a modified oligonucleotide 16 to 30 linked nucleosides in length and having a nucleobase sequence comprising any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of linked nucleosides; and     -   a 3′ wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each terminal wing nucleoside comprises a modified sugar.

In any of the foregoing methods or uses, the compound may comprise or consist of a modified oligonucleotide 16 to 50 linked nucleobases in length having a nucleobase sequence comprising or consisting of the sequence recited in any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232, wherein the modified oligonucleotide comprises:

-   -   a gap segment consisting of 10 linked 2′-deoxynucleosides;     -   a 5′ wing segment consisting of 3 linked nucleosides; and     -   a 3′ wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a cEt sugar; wherein each internucleoside linkage is a phosphorothioate linkage and wherein each cytosine is a 5-methylcytosine. In certain embodiments, the modified oligonucleotide consists of 16-30 linked nucleosides. In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides.

In one embodiment, in any of the foregoing methods or uses, the compound has the following chemical structure:

In one embodiment, in any of the foregoing methods or uses, the compound can be administered systemically. In certain embodiments, the compound of any of the foregoing methods or uses can be administered through injection or infusion. In certain embodiments, the compound of any of the foregoing methods or uses can be administered via subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g. intrathecal or intracerebroventricular administration. In certain embodiments, the compound is administered to the individual intradermally, intranodally, intramedullary or intrasternally. In certain embodiments, the compound of any of the foregoing methods or uses can be administered orally.

Certain Combinations and Combination Therapies

In certain embodiments, a first agent comprising the compound described herein is co-administered with one or more secondary agents. In certain embodiments, such second agents are designed to treat the same disease, disorder, or condition as the first agent described herein. In certain embodiments, such second agents are designed to treat a different disease, disorder, or condition as the first agent described herein. In certain embodiments, a first agent is designed to treat an undesired side effect of a second agent. In certain embodiments, second agents are co-administered with the first agent to treat an undesired effect of the first agent. In certain embodiments, such second agents are designed to treat an undesired side effect of one or more pharmaceutical compositions as described herein. In certain embodiments, second agents are co-administered with the first agent to produce a combinational effect. In certain embodiments, second agents are co-administered with the first agent to produce a synergistic effect. In certain embodiments, the co-administration of the first and second agents permits use of lower dosages than would be required to achieve a therapeutic or prophylactic effect if the agents were administered as independent therapy.

In certain embodiments, one or more compounds or compositions provided herein are co-administered with one or more secondary agents. In certain embodiments, one or more compounds or compositions provided herein and one or more secondary agents, are administered at different times. In certain embodiments, one or more compounds or compositions provided herein and one or more secondary agents, are prepared together in a single formulation. In certain embodiments, one or more compounds or compositions provided herein and one or more secondary agents, are prepared separately.

Certain embodiments are directed to the use of a compound comprising a modified oligonucleotide complementary to a DNM2 nucleic acid transcript as described herein in combination with a secondary agent. In particular embodiments such use is in a method of treating a patient suffering from CNM, DMD, or CMT, or in the preparation or manufacture of a medicament for treating CNM, DMD, or CMT.

In certain embodiments the compound comprising a modified oligonucleotide complementary to a DNM2 nucleic acid transcript as described herein and the secondary agent are used in combination treatment by administering the two agents simultaneously, separately or sequentially. In certain embodiments the two agents are formulated as a fixed dose combination product. In other embodiments the two agents are provided to the patient as separate units which can then either be taken simultaneously or serially (sequentially).

Certain Compounds

In certain embodiments, compounds described herein can be antisense compounds. In certain embodiments, the antisense compound comprises or consists of an oligomeric compound. In certain embodiments, the oligomeric compound comprises or consists of a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a nucleobase sequence complementary to that of a target nucleic acid.

In certain embodiments, a compound described herein comprises or consists of a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a nucleobase sequence complementary to that of a target nucleic acid.

In certain embodiments, a compound or antisense compound is single-stranded. Such a single-stranded compound or antisense compound comprises or consists of an oligomeric compound. In certain embodiments, such an oligomeric compound comprises or consists of an oligonucleotide and optionally a conjugate group. In certain embodiments, the oligonucleotide is an antisense oligonucleotide. In certain embodiments, the oligonucleotide is modified. In certain embodiments, the oligonucleotide of a single-stranded antisense compound or oligomeric compound comprises a self-complementary nucleobase sequence.

In certain embodiments, a compound or antisense compound is double-stranded. Such double-stranded compounds comprise a first oligomeric compound comprising or consisting of a first modified oligonucleotide having a region complementary to a target nucleic acid and a second oligomeric compound comprising or consisting of a second oligonucleotide having a region complementary to the first modified oligonucleotide. In certain embodiments, the first oligonucleotide is 100% complementary to the second oligonucleotide. In certain embodiments, the first and second oligonucleotides include non-complementary, overhanging nucleosides. In certain embodiments, the first modified oligonucleotide comprises unmodified ribosyl sugar moieties as those found in RNA. In such embodiments, thymine nucleobases in the first and/or second oligonucleotide are replaced by uracil nucleobases. In certain embodiments, the first and/or second oligomeric compound comprises a conjugate group. In certain embodiments, the first modified oligonucleotide is 12-30 linked nucleosides in length and the second oligonucleotide is 12-30 linked nucleosides in length. In certain embodiments, the second oligonucleotide is modified. In certain embodiments, the first modified oligonucleotide has a nucleobase sequence comprising at least 8 contiguous nucleobases of any of SEQ ID NOs: 7-3134.

Examples of single-stranded and double-stranded compounds include but are not limited to oligonucleotides, siRNAs, microRNA targeting oligonucleotides, and single-stranded RNAi compounds, such as small hairpin RNAs (shRNAs), single-stranded siRNAs (ssRNAs), and microRNA mimics.

In certain embodiments, a compound described herein has a nucleobase sequence that, when written in the 5′ to 3′ direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

In certain embodiments, a compound described herein comprises an oligonucleotide 10 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 12 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 12 to 22 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 14 to 30 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 14 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 15 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 15 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 21 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 20 to 30 linked subunits in length. In other words, such oligonucleotides are 12 to 30 linked subunits, 14 to 30 linked subunits, 14 to 20 subunits, 15 to 30 subunits, 15 to 20 subunits, 16 to 30 subunits, 16 to 20 subunits, 17 to 30 subunits, 17 to 20 subunits, 18 to 30 subunits, 18 to 20 subunits, 18 to 21 subunits, 20 to 30 subunits, or 12 to 22 linked subunits in length, respectively. In certain embodiments, a compound described herein comprises an oligonucleotide 14 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 18 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 19 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 20 linked subunits in length. In other embodiments, a compound described herein comprises an oligonucleotide 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to 30 linked subunits. In certain such embodiments, the compound described herein comprises an oligonucleotide 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 linked subunits in length, or a range defined by any two of the above values. In some embodiments the linked subunits are nucleotides, nucleosides, or nucleobases.

In certain embodiments, the compound may further comprise additional features or elements, such as a conjugate group, that are attached to the oligonucleotide. In certain embodiments, such compounds are antisense compounds. In certain embodiments, such compounds are oligomeric compounds. In embodiments where a conjugate group comprises a nucleoside (i.e. a nucleoside that links the conjugate group to the oligonucleotide), the nucleoside of the conjugate group is not counted in the length of the oligonucleotide.

In certain embodiments, compounds may be shortened or truncated. For example, a single subunit may be deleted from the 5′ end (5′ truncation), or alternatively from the 3′ end (3′ truncation). A shortened or truncated compound targeted to a DNM2 nucleic acid may have two subunits deleted from the 5′ end, or alternatively may have two subunits deleted from the 3′ end, of the compound. Alternatively, the deleted nucleosides may be dispersed throughout the compound.

When a single additional subunit is present in a lengthened compound, the additional subunit may be located at the 5′ or 3′ end of the compound. When two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in a compound having two subunits added to the 5′ end (5′ addition), or alternatively to the 3′ end (3′ addition), of the compound. Alternatively, the added subunits may be dispersed throughout the compound.

It is possible to increase or decrease the length of a compound, such as an oligonucleotide, and/or introduce mismatch bases without eliminating activity (Woolf et al. Proc. Nat. Acad. Sci. USA 1992, 89:7305-7309; Gautschi et al. J Nat. Cancer Inst. March 2001, 93:463-471; Maher and Dolnick Nuc. Acid. Res. 1998, 16:3341-3358). However, seemingly small changes in oligonucleotide sequence, chemistry and motif can make large differences in one or more of the many properties required for clinical development (Seth et al. J Med. Chem. 2009, 52, 10; Egli et al. J. Am. Chem. Soc. 2011, 133, 16642).

In certain embodiments, compounds described herein are interfering RNA compounds (RNAi), which include double-stranded RNA compounds (also referred to as short-interfering RNA or siRNA) and single-stranded RNAi compounds (or ssRNA). Such compounds work at least in part through the RISC pathway to degrade and/or sequester a target nucleic acid (thus, include microRNA/microRNA-mimic compounds). As used herein, the term siRNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term “RNAi” is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics.

In certain embodiments, a compound described herein can comprise any of the oligonucleotide sequences targeted to a DNM2 nucleic acid transcript described herein. In certain embodiments, the compound can be double-stranded. In certain embodiments, the compound comprises a first strand comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of any one of SEQ ID NOs: 7-3134 and a second strand. In certain embodiments, the compound can be double-stranded. In certain embodiments, the compound comprises a first strand comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 and a second strand. In certain embodiments, the compound can be double-stranded. In certain embodiments, the compound comprises a first strand comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of SEQ ID NO: 2879 and a second strand. In certain embodiments, the compound comprises a first strand comprising the nucleobase sequence of any one of SEQ ID NOs: 7-3134 and a second strand. In certain embodiments, the compound comprises a first strand comprising the nucleobase sequence of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232 and a second strand. In certain embodiments, the compound comprises a first strand comprising the nucleobase sequence of SEQ ID NO: 2879 and a second strand. In certain embodiments, the compound comprises ribonucleotides in which the first strand has uracil (U) in place of thymine (T) in any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises (i) a first strand comprising a nucleobase sequence complementary to the site on a DNM2 nucleic acid to which any of SEQ ID NOs: 7-3134 is complementary, and (ii) a second strand. In certain embodiments, the compound comprises one or more modified nucleotides in which the 2′ position in the sugar contains a halogen (such as fluorine group; 2′-F) or contains an alkoxy group (such as a methoxy group; 2′-OMe). In certain embodiments, the compound comprises at least one 2′-F sugar modification and at least one 2′-OMe sugar modification. In certain embodiments, the at least one 2′-F sugar modification and at least one 2′-OMe sugar modification are arranged in an alternating pattern for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases along a strand of the dsRNA compound. In certain embodiments, the compound comprises one or more linkages between adjacent nucleotides other than a naturally-occurring phosphodiester linkage. Examples of such linkages include phosphoramide, phosphorothioate, and phosphorodithioate linkages. The compounds may also be chemically modified nucleic acid molecules as taught in U.S. Pat. No. 6,673,661. In other embodiments, the compound contains one or two capped strands, as disclosed, for example, by WO 00/63364, filed Apr. 19, 2000.

In certain embodiments, the first strand of the compound is an siRNA guide strand and the second strand of the compound is an siRNA passenger strand. In certain embodiments, the second strand of the compound is complementary to the first strand. In certain embodiments, each strand of the compound is 16, 17, 18, 19, 20, 21, 22, or 23 linked nucleosides in length. In certain embodiments, the first or second strand of the compound can comprise a conjugate group.

In certain embodiments, a compound described herein can comprise any of the oligonucleotide sequences targeted to a DNM2 nucleic acid described herein. In certain embodiments, the compound is single-stranded. In certain embodiments, such a compound is a single-stranded RNAi (ssRNAi) compound. In certain embodiments, the compound comprises at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobase portion of SEQ ID NO: 2879. In certain embodiments, the compound comprises the nucleobase sequence of any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises the nucleobase sequence of any one of SEQ ID NOs: 2879, 3056, 2123, 2189, 2453, 2160, or 2232. In certain embodiments, the compound comprises the nucleobase sequence of SEQ ID NO: 2879. In certain embodiments, the compound comprises ribonucleotides in which uracil (U) is in place of thymine (T) in any one of SEQ ID NOs: 7-3134. In certain embodiments, the compound comprises a nucleobase sequence complementary to the site on DNM2 to which any of SEQ ID NOs: 7-3134 is targeted. In certain embodiments, the compound comprises one or more modified nucleotides in which the 2′ position in the sugar contains a halogen (such as fluorine group; 2′-F) or contains an alkoxy group (such as a methoxy group; 2′-OMe). In certain embodiments, the compound comprises at least one 2′-F sugar modification and at least one 2′-OMe sugar modification. In certain embodiments, the at least one 2′-F sugar modification and at least one 2′-OMe sugar modification are arranged in an alternating pattern for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases along a strand of the compound. In certain embodiments, the compound comprises one or more linkages between adjacent nucleotides other than a naturally-occurring phosphodiester linkage. Examples of such linkages include phosphoramide, phosphorothioate, and phosphorodithioate linkages. The compounds may also be chemically modified nucleic acid molecules as taught in U.S. Pat. No. 6,673,661. In other embodiments, the compound contains a capped strand, as disclosed, for example, by WO 00/63364, filed Apr. 19, 2000. In certain embodiments, the compound consists of 16, 17, 18, 19, 20, 21, 22, or 23 linked nucleosides. In certain embodiments, the compound can comprise a conjugate group.

Certain compounds described herein (e.g., modified oligonucleotides) have one or more asymmetric center and thus give rise to enantiomers, diastereomers, and other stereoisomeric configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), as α or β, such as for sugar anomers, or as (D) or (L), such as for amino acids, etc. Compounds provided herein that are drawn or described as having certain stereoisomeric configurations include only the indicated compounds. Compounds provided herein that are drawn or described with undefined stereochemistry include all such possible isomers, including their stereorandom and optically pure forms. All tautomeric forms of the compounds provided herein are included unless otherwise indicated.

The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the ¹H hydrogen atoms. Isotopic substitutions encompassed by the compounds herein include but are not limited to: ²H or ³H in place of ¹H, ¹³C or ¹⁴C in place of ¹²C, ¹⁵N in place of ¹⁴N, ¹⁷O or ¹⁸O in place of ¹⁶O, and ³³S, ³⁴S, ³⁵S, or ³⁶S in place of ³²S. In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the oligomeric compound that are beneficial for use as a therapeutic or research tool. In certain embodiments, radioactive isotopic substitutions may make the compound suitable for research or diagnostic purposes such as imaging.

Certain Mechanisms

In certain embodiments, compounds described herein comprise or consist of modified oligonucleotides. In certain embodiments, compounds described herein are antisense compounds. In certain embodiments, compounds comprise oligomeric compounds. In certain embodiments, compounds described herein are capable of hybridizing to a DNM2 target nucleic acid, resulting in at least one antisense activity. In certain embodiments, compounds described herein selectively affect one or more target nucleic acid. Such compounds comprise a nucleobase sequence that hybridizes to one or more target nucleic acid, resulting in one or more desired antisense activity and does not hybridize to one or more non-target nucleic acid or does not hybridize to one or more non-target nucleic acid in such a way that results in a significant undesired antisense activity.

In certain antisense activities, hybridization of a compound described herein to a target nucleic acid results in recruitment of a protein that cleaves the target nucleic acid. For example, certain compounds described herein result in RNase H mediated cleavage of the target nucleic acid. RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. The DNA in such an RNA:DNA duplex need not be unmodified DNA. In certain embodiments, compounds described herein are sufficiently “DNA-like” to elicit RNase H activity. Further, in certain embodiments, one or more non-DNA-like nucleoside in the gap of a gapmer is tolerated.

In certain antisense activities, compounds described herein or a portion of the compound is loaded into an RNA-induced silencing complex (RISC), ultimately resulting in cleavage of the target nucleic acid. For example, certain compounds described herein result in cleavage of the target nucleic acid by Argonaute. Compounds that are loaded into RISC are RNAi compounds. RNAi compounds may be double-stranded (siRNA) or single-stranded (ssRNA).

Antisense activities may be observed directly or indirectly. In certain embodiments, observation or detection of an antisense activity involves observation or detection of a change in an amount of a target nucleic acid or protein encoded by such target nucleic acid, a change in the ratio of splice variants of a nucleic acid or protein, and/or a phenotypic change in a cell or animal.

Target Nucleic Acids, Target Regions and Nucleotide Sequences

In certain embodiments, compounds described herein comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain such embodiments, the target nucleic acid is selected from: an mRNA and a pre-mRNA, including intronic, exonic and untranslated regions. In certain embodiments, the target RNA is an mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain embodiments, a pre-mRNA and corresponding mRNA are both target nucleic acids of a single compound. In certain such embodiments, the target region is entirely within an intron of a target pre-mRNA. In certain embodiments, the target region spans an intron/exon junction. In certain embodiments, the target region is at least 50% within an intron. Target nucleic acid sequences that encode DNM2 include, without limitation, the following: RefSeq or GenBank Accession No. NC_000019.10 truncated from nucleosides 10715001 to Ser. No. 10/835,000, NM_004945.3, NM_001005361.2, or NM_001005360.2 (SEQ ID Nos: 1, 2, 3, and 3135, respectively).

Hybridization

In some embodiments, hybridization occurs between a compound disclosed herein and a DNM2 nucleic acid. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Hybridization conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.

Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In certain embodiments, the compounds provided herein are specifically hybridizable with a DNM2 nucleic acid.

Complementarity

In certain embodiments, compounds described herein comprise or consist of modified oligonucleotides. In certain embodiments, compounds described herein are antisense compounds. In certain embodiments, compounds comprise oligomeric compounds. In certain embodiments, oligonucleotides complementary to a DNM2 nucleic acid comprise nucleobase that are non-complementary with the DNM2 nucleic acid, yet may be tolerated provided that the compound remains able to specifically hybridize to a target nucleic acid. Moreover, a compound may hybridize over one or more segments of a DNM2 nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).

In certain embodiments, the compounds provided herein, or a specified portion thereof, are, are at least, or are up to 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a DNM2 nucleic acid, a target region, target segment, or specified portion thereof. In certain embodiments, the compounds provided herein, or a specified portion thereof, are 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to 95%, 95% to 100%, or any number in between these ranges, complementary to a DNM2 nucleic acid, a target region, target segment, or specified portion thereof. Percent complementarity of a compound with a target nucleic acid can be determined using routine methods.

For example, a compound in which 18 of 20 nucleobases of the compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining non-complementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, a compound which is 18 nucleobases in length having four non-complementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid. Percent complementarity of a compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J Mol. Biol., 1990, 215, 403 410; Zhang and Madden, Genome Res., 1997, 7, 649 656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482 489).

In certain embodiments, compounds described herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof. For example, a compound may be 100% complementary to a DNM2 nucleic acid, or a target region, or a target segment or target sequence thereof. As used herein, “fully complementary” means each nucleobase of a compound is complementary to the corresponding nucleobase of a target nucleic acid. For example, a 20 nucleobase compound is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the compound. Fully complementary can also be used in reference to a specified portion of the first and/or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase compound can be “fully complementary” to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase compound is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the compound. At the same time, the entire 30 nucleobase compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the compound are also complementary to the target sequence.

In certain embodiments, compounds described herein comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain such embodiments, antisense activity against the target is reduced by such mismatch, but activity against a non-target is reduced by a greater amount. Thus, in certain such embodiments selectivity of the compound is improved. In certain embodiments, the mismatch is specifically positioned within an oligonucleotide having a gapmer motif. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, or 8 from the 5′-end of the gap segment. In certain such embodiments, the mismatch is at position 9, 8, 7, 6, 5, 4, 3, 2, 1 from the 3′-end of the gap segment. In certain such embodiments, the mismatch is at position 1, 2, 3, or 4 from the 5′-end of the wing segment. In certain such embodiments, the mismatch is at position 4, 3, 2, or 1 from the 3′-end of the wing segment. In certain embodiments, the mismatch is specifically positioned within an oligonucleotide not having a gapmer motif. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 from the 5′-end of the oligonucleotide. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 from the 3′-end of the oligonucleotide.

The location of a non-complementary nucleobase may be at the 5′ end or 3′ end of the compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e., linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer oligonucleotide.

In certain embodiments, compounds described herein that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a DNM2 nucleic acid, or specified portion thereof.

In certain embodiments, compounds described herein that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as a DNM2 nucleic acid, or specified portion thereof.

In certain embodiments, compounds described herein also include those which are complementary to a portion (a defined number of contiguous nucleobases within a region or segment) of a target nucleic acid. In certain embodiments, the compounds, are complementary to at least an 8 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 9 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 10 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least an 11 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 12 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 13 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 14 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 15 nucleobase portion of a target segment. In certain embodiments, the compounds are complementary to at least a 16 nucleobase portion of a target segment. Also contemplated are compounds that are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase portion of a target segment, or a range defined by any two of these values.

Certain Compounds

In certain embodiments, compounds described herein comprise or consist of oligonucleotides consisting of linked nucleosides. Oligonucleotides may be unmodified oligonucleotides (RNA or DNA) or may be modified oligonucleotides. Modified oligonucleotides comprise at least one modification relative to unmodified RNA or DNA (i.e., comprise at least one modified nucleoside (comprising a modified sugar moiety and/or a modified nucleobase) and/or at least one modified internucleoside linkage).

I. Modifications

A. Modified Nucleosides

Modified nucleosides comprise a modified sugar moiety or a modified nucleobase or both a modified sugar moiety and a modified nucleobase.

1. Modified Sugar Moieties

In certain embodiments, sugar moieties are non-bicyclic modified sugar moieties. In certain embodiments, modified sugar moieties are bicyclic or tricyclic sugar moieties. In certain embodiments, modified sugar moieties are sugar surrogates. Such sugar surrogates may comprise one or more substitutions corresponding to those of other types of modified sugar moieties.

In certain embodiments, modified sugar moieties are non-bicyclic modified furanosyl sugar moieties comprising one or more acyclic substituent, including but not limited to substituents at the 2′, 4′, and/or 5′ positions. In certain embodiments, the furanosyl sugar moiety is a ribosyl sugar moiety. In certain embodiments one or more acyclic substituent of non-bicyclic modified sugar moieties is branched. Examples of 2′-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 2′-F, 2′-OCH₃ (“OMe” or “O-methyl”), and 2′-O(CH₂)₂OCH₃ (“MOE”). In certain embodiments, 2′-substituent groups are selected from among: halo, allyl, amino, azido, SH, CN, OCN, CF₃, OCF₃, O—C₁-C₁₀ alkoxy, O—C₁-C₁₀ substituted alkoxy, C₁-C₁₀ alkyl, O—C₁-C₁₀ substituted alkyl, S-alkyl, N(R_(m))-alkyl, O-alkenyl, S-alkenyl, N(R_(m))-alkenyl, O-alkynyl, S-alkynyl, N(R_(m))-alkynyl, O-alkylenyl-O-alkyl, alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃, O(CH₂)₂N(R_(m))(R_(n)) or OCH₂C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is, independently, H, an amino protecting group, or substituted or unsubstituted C₁-C₁₀ alkyl, and the 2′-substituent groups described in Cook et al., U.S. Pat. No. 6,531,584; Cook et al., U.S. Pat. No. 5,859,221; and Cook et al., U.S. Pat. No. 6,005,087. Certain embodiments of these 2′-substituent groups can be further substituted with one or more substituent groups independently selected from among: hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl and alkynyl. Examples of 4′-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128. Examples of 5′-substituent groups suitable for non-bicyclic modified sugar moieties include but are not limited to: 5′-methyl (R or S), 5′-vinyl, and 5′-methoxy. In certain embodiments, non-bicyclic modified sugars comprise more than one non-bridging sugar substituent, for example, 2′-F-5′-methyl sugar moieties and the modified sugar moieties and modified nucleosides described in Migawa et al., WO 2008/101157 and Rajeev et al., US2013/0203836).

In certain embodiments, a 2′-substituted nucleoside or 2′-non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2′-substituent group selected from: F, NH₂, N₃, OCF₃, OCH₃, O(CH₂)₃NH₂, CH₂CH═CH₂, OCH₂CH═CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O(CH₂)₂₀N(R_(m))(R_(n)), O(CH₂)₂O(CH₂)₂N(CH₃)₂, and N-substituted acetamide (OCH₂C(═O)—N(R_(m))(R_(n))), where each R_(m) and R_(n) is, independently, H, an amino protecting group, or substituted or unsubstituted C₁-C₁₀ alkyl.

In certain embodiments, a 2′-substituted nucleoside or 2′-non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2′-substituent group selected from: F, OCF₃, OCH₃, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O(CH₂)₂₀N(CH₃)₂, O(CH₂)₂O(CH₂)₂N(CH₃)₂, and OCH₂C(═O)—N(H)CH₃ (“NMA”).

In certain embodiments, a 2′-substituted nucleoside or 2′-non-bicyclic modified nucleoside comprises a sugar moiety comprising a non-bridging 2′-substituent group selected from: F, OCH₃, and OCH₂CH₂OCH₃.

Nucleosides comprising modified sugar moieties, such as non-bicyclic modified sugar moieties, may be referred to by the position(s) of the substitution(s) on the sugar moiety of the nucleoside. For example, nucleosides comprising 2′-substituted or 2-modified sugar moieties are referred to as 2′-substituted nucleosides or 2-modified nucleosides.

Certain modified sugar moieties comprise a bridging sugar substituent that forms a second ring resulting in a bicyclic sugar moiety. In certain such embodiments, the bicyclic sugar moiety comprises a bridge between the 4′ and the 2′ furanose ring atoms. In certain such embodiments, the furanose ring is a ribose ring. Examples of such 4′ to 2′ bridging sugar substituents include but are not limited to: 4′-CH₂-2′, 4′-(CH₂)₂-2′, 4′-(CH₂)_(3-2′, 4)′-CH₂—O-2′ (“LNA”), 4′-CH₂—S-2′, 4′-(CH₂)₂—O-2′ (“ENA”), 4′- CH(CH₃)—O-2′ (referred to as “constrained ethyl” or “cEt” when in the S configuration), 4′-CH₂—O—CH₂-2′, 4′-CH₂—N(R)-2′, 4′-C—H(CH₂OCH₃)—O-2′ (“constrained MOE” or “cMOE”) and analogs thereof (see, e.g., Seth et al., U.S. Pat. No. 7,399,845, Bhat et al., U.S. Pat. No. 7,569,686, Swayze et al., U.S. Pat. No. 7,741,457, and Swayze et al., U.S. Pat. No. 8,022,193), 4′-C(CH₃)(CH₃)—O-2′ and analogs thereof (see, e.g., Seth et al., U.S. Pat. No. 8,278,283), 4′-CH₂—N(OCH₃)-2′ and analogs thereof (see, e.g., Prakash et al., U.S. Pat. No. 8,278,425), 4′-CH₂—O—N(CH₃)-2′ (see, e.g., Allerson et al., U.S. Pat. No. 7,696,345 and Allerson et al., U.S. Pat. No. 8,124,745), 4′-CH₂—C(H)(CH₃)-2′ (see, e.g., Zhou, et al., J Org. Chem., 2009, 74, 118-134), 4′-CH₂—C(═CH₂)-2′ and analogs thereof (see e.g., Seth et al., U.S. Pat. No. 8,278,426), 4′-C(R_(a)R_(b))—N(R)—O-2′, 4′-C(R_(a)R_(b))—O—N(R)-2′, 4′-CH₂—N(R)-2′, and 4′-CH₂—N(R)—O-2′, wherein each R, R_(a), and R_(b) is, independently, H, a protecting group, or C₁-C₁₂ alkyl (see, e.g. Imanishi et al., U.S. Pat. No. 7,427,672).

In certain embodiments, such 4′ to 2′ bridges independently comprise from 1 to 4 linked groups independently selected from: —[C(R_(a))(R_(b))]_(n)—, —[C(R_(a))(R_(b))]_(n)—O—, —C(R_(a))═C(R_(b))—, —C(R_(a))═N—, —C(═NR_(a))—, —C(═O)—, —C(═S)—, —O—, —Si(R_(a))₂—, —S(═O)_(x)—, and —N(R_(a))—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_(a) and R_(b) is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O)₂-J₁), or sulfoxyl (S(═O)-J₁); and

each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(═O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl, or a protecting group.

Additional bicyclic sugar moieties are known in the art, see, for example: Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443, Albaek et al., J Org. Chem., 2006, 71, 7731-7740, Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J Am. Chem. Soc., 20017, 129, 8362-8379; Elayadi et al., Wengel et a., U.S. Pat. No. 7,053,207; Imanishi et al., U.S. Pat. No. 6,268,490; Imanishi et al. U.S. Pat. No. 6,770,748; Imanishi et al., U.S. RE44,779; Wengel et al., U.S. Pat. No. 6,794,499; Wengel et al., U.S. Pat. No. 6,670,461; Wengel et al., U.S. Pat. No. 7,034,133; Wengel et al., U.S. Pat. No. 8,080,644; Wengel et al., U.S. Pat. No. 8,034,909; Wengel et al., U.S. Pat. No. 8,153,365; Wengel et al., U.S. Pat. No. 7,572,582; and Ramasamy et al., U.S. Pat. No. 6,525,191; Torsten et al., WO 2004/106356; Wengel et al., WO 1999/014226; Seth et al., WO 2007/134181; Seth et al., U.S. Pat. No. 7,547,684; Seth et al., U.S. Pat. No. 7,666,854; Seth et al., U.S. Pat. No. 8,088,746; Seth et al., U.S. Pat. No. 7,750,131; Seth et al., U.S. Pat. No. 8,030,467; Seth et al., U.S. Pat. No. 8,268,980; Seth et al., U.S. Pat. No. 8,546,556; Seth et al., U.S. Pat. No. 8,530,640; Migawa et al., U.S. Pat. No. 9,012,421; Seth et al., U.S. Pat. No. 8,501,805; and U.S. Patent Publication Nos. Allerson et al., US2008/0039618 and Migawa et al., US2015/0191727.

In certain embodiments, bicyclic sugar moieties and nucleosides incorporating such bicyclic sugar moieties are further defined by isomeric configuration. For example, an LNA nucleoside (described herein) may be in the α-L configuration or in the β-D configuration.

α-L-methyleneoxy (4′-CH₂—O-2′) or α-L-LNA bicyclic nucleosides have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372). Herein, general descriptions of bicyclic nucleosides include both isomeric configurations. When the positions of specific bicyclic nucleosides (e.g., LNA) are identified in exemplified embodiments herein, they are in the f-D configuration, unless otherwise specified.

In certain embodiments, modified sugar moieties comprise one or more non-bridging sugar substituent and one or more bridging sugar substituent (e.g., 5′-substituted and 4′-2′ bridged sugars).

In certain embodiments, modified sugar moieties are sugar surrogates. In certain such embodiments, the oxygen atom of the sugar moiety is replaced, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, such modified sugar moieties also comprise bridging and/or non-bridging substituents as described herein. For example, certain sugar surrogates comprise a 4′-sulfur atom and a substitution at the 2′-position (see, e.g., Bhat et al., U.S. Pat. No. 7,875,733 and Bhat et al., U.S. Pat. No. 7,939,677) and/or the 5′ position.

In certain embodiments, sugar surrogates comprise rings having other than 5 atoms. For example, in certain embodiments, a sugar surrogate comprises a six-membered tetrahydropyran (“THP”). Such tetrahydropyrans may be further modified or substituted. Nucleosides comprising such modified tetrahydropyrans include but are not limited to hexitol nucleic acid (“HNA”), anitol nucleic acid (“ANA”), mannitol nucleic acid (“MNA”) (see, e.g., Leumann, C J. Bioorg. & Med. Chem. 2002, 10, 841-854), fluoro HNA:

(“F-HNA”, see e.g. Swayze et al., U.S. Pat. No. 8,088,904; Swayze et al., U.S. Pat. No. 8,440,803; Swayze et al., U.S. Pat. No. 8,796,437; and Swayze et al., U.S. Pat. No. 9,005,906; F-HNA can also be referred to as a F-THP or 3′-fluoro tetrahydropyran), and nucleosides comprising additional modified THP compounds having the formula:

wherein, independently, for each of said modified THP nucleoside:

Bx is a nucleobase moiety;

T₃ and T₄ are each, independently, an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide or one of T₃ and T₄ is an internucleoside linking group linking the modified THP nucleoside to the remainder of an oligonucleotide and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugate group, or a 5′ or 3-terminal group; q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, or substituted C₂-C₆ alkynyl; and

each of R₁ and R₂ is independently selected from among: hydrogen, halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(═X)J₁, OC(═X)NJ₁J₂, NJ₃C(═X)NJ₁J₂, and CN, wherein X is O, S or NJ₁, and each J₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, modified THP nucleosides are provided wherein q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is other than H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is methyl. In certain embodiments, modified THP nucleosides are provided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ is F and R₂ is H, in certain embodiments, R₁ is methoxy and R₂ is H, and in certain embodiments, R₁ is methoxyethoxy and R₂ is H.

In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example, nucleosides comprising morpholino sugar moieties and their use in oligonucleotides have been reported (see, e.g., Braasch et al., Biochemistry, 2002, 41, 4503-4510 and Summerton et al., U.S. Pat. No. 5,698,685; Summerton et al., U.S. Pat. No. 5,166,315; Summerton et al., U.S. Pat. No. 5,185,444; and Summerton et al., U.S. Pat. No. 5,034,506). As used here, the term “morpholino” means a sugar surrogate having the following structure:

In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as “modified morpholinos.”

In certain embodiments, sugar surrogates comprise acyclic moieties. Examples of nucleosides and oligonucleotides comprising such acyclic sugar surrogates include but are not limited to: peptide nucleic acid (“PNA”), acyclic butyl nucleic acid (see, e.g., Kumar et al., Org. Biomol. Chem., 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., WO2011/133876.

Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used in modified nucleosides).

2. Modified Nucleobases

In certain embodiments, modified nucleobases are selected from: 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and O-6 substituted purines. In certain embodiments, modified nucleobases are selected from: 2-aminopropyladenine, 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl (—C≡C—CH₃) uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8-substituted purines, 5-halo, particularly 5-bromo, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, 1,3-diazaphenothiazine-2-one and 9-(2-aminoethoxy)-1,3-diazaphenoxazine-2-one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in Merigan et al., U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz, J. I., Ed., John Wiley & Sons, 1990, 858-859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, Crooke, S. T. and Lebleu, B., Eds., CRC Press, 1993, 273-288; and those disclosed in Chapters 6 and 15, Antisense Drug Technology, Crooke S. T., Ed., CRC Press, 2008, 163-166 and 442-443.

Publications that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include without limitation, Manohara et al., US2003/0158403; Manoharan et al., US2003/0175906; Dinh et al., U.S. Pat. No. 4,845,205; Spielvogel et al., U.S. Pat. No. 5,130,302; Rogers et al., U.S. Pat. No. 5,134,066; Bischofberger et al., U.S. Pat. No. 5,175,273; Urdea et al., U.S. Pat. No. 5,367,066; Benner et al., U.S. Pat. No. 5,432,272; Matteucci et al., U.S. Pat. No. 5,434,257; Gmeiner et al., U.S. Pat. No. 5,457,187; Cook et al., U.S. Pat. No. 5,459,255; Froehler et al., U.S. Pat. No. 5,484,908; Matteucci et al., U.S. Pat. No. 5,502,177; Hawkins et al., U.S. Pat. No. 5,525,711; Haralambidis et al., U.S. Pat. No. 5,552,540; Cook et al., U.S. Pat. No. 5,587,469; Froehler et al., U.S. Pat. No. 5,594,121; Switzer et al., U.S. Pat. No. 5,596,091; Cook et al., U.S. Pat. No. 5,614,617; Froehler et al., U.S. Pat. No. 5,645,985; Cook et al., U.S. Pat. No. 5,681,941; Cook et al., U.S. Pat. No. 5,811,534; Cook et al., U.S. Pat. No. 5,750,692; Cook et al., U.S. Pat. No. 5,948,903; Cook et al., U.S. Pat. No. 5,587,470; Cook et al., U.S. Pat. No. 5,457,191; Matteucci et al., U.S. Pat. No. 5,763,588; Froehler et al., U.S. Pat. No. 5,830,653; Cook et al., U.S. Pat. No. 5,808,027; Cook et al., 6,166,199; and Matteucci et al., U.S. Pat. No. 6,005,096.

In certain embodiments, compounds comprise or consist of a modified oligonucleotide complementary to an α-DNM2 nucleic acid comprising one or more modified nucleobases. In certain embodiments, the modified nucleobase is 5-methylcytosine. In certain embodiments, each cytosine is a 5-methylcytosine.

B. Modified Internucleoside Linkages

In certain embodiments, compounds described herein having one or more modified internucleoside linkages are selected over compounds having only phosphodiester internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

In certain embodiments, compounds comprise or consist of a modified oligonucleotide complementary to a DNM2 nucleic acid comprising one or more modified internucleoside linkages. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.

In certain embodiments, nucleosides of modified oligonucleotides may be linked together using any internucleoside linkage. The two main classes of internucleoside linking groups are defined by the presence or absence of a phosphorus atom. Representative phosphorus-containing internucleoside linkages include but are not limited to phosphates, which contain a phosphodiester bond (“P═O”) (also referred to as unmodified or naturally occurring linkages), phosphotriesters, methylphosphonates, phosphoramidates, and phosphorothioates (“P═S”), and phosphorodithioates (“HS—P=S”). Representative non-phosphorus containing internucleoside linking groups include but are not limited to methylenemethylimino (—CH₂—N(CH₃)—O—CH₂—), thiodiester, thionocarbamate (—O—C(═O)(NH)—S—); siloxane (—O—SiH₂—O—); and N,N′-dimethylhydrazine (—CH₂—N(CH₃)—N(CH₃)—). Modified internucleoside linkages, compared to naturally occurring phosphate linkages, can be used to alter, typically increase, nuclease resistance of the oligonucleotide. Methods of preparation of phosphorous-containing and non-phosphorous-containing internucleoside linkages are well known to those skilled in the art.

Representative internucleoside linkages having a chiral center include but are not limited to alkylphosphonates and phosphorothioates. Modified oligonucleotides comprising internucleoside linkages having a chiral center can be prepared as populations of modified oligonucleotides comprising stereorandom internucleoside linkages, or as populations of modified oligonucleotides comprising phosphorothioate linkages in particular stereochemical configurations. In certain embodiments, populations of modified oligonucleotides comprise phosphorothioate internucleoside linkages wherein all of the phosphorothioate internucleoside linkages are stereorandom. Such modified oligonucleotides can be generated using synthetic methods that result in random selection of the stereochemical configuration of each phosphorothioate linkage. Nonetheless, as is well understood by those of skill in the art, each individual phosphorothioate of each individual oligonucleotide molecule has a defined stereoconfiguration. In certain embodiments, populations of modified oligonucleotides are enriched for modified oligonucleotides comprising one or more particular phosphorothioate internucleoside linkages in a particular, independently selected stereochemical configuration. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 65% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 70% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 80% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 90% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 99% of the molecules in the population. Such chirally enriched populations of modified oligonucleotides can be generated using synthetic methods known in the art, e.g., methods described in Oka et al., JACS 125, 8307 (2003), Wan et al. Nuc. Acid. Res. 42, 13456 (2014), and WO 2017/015555. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration. In certain embodiments, modified oligonucleotides comprising (Rp) and/or (Sp) phosphorothioates comprise one or more of the following formulas, respectively, wherein “B” indicates a nucleobase:

Unless otherwise indicated, chiral internucleoside linkages of modified oligonucleotides described herein can be stereorandom or in a particular stereochemical configuration.

Neutral internucleoside linkages include, without limitation, phosphotriesters, methylphosphonates, MMI (3′-CH₂—N(CH₃)—O-5′), amide-3 (3′-CH₂—C(═O)—N(H)-5′), amide-4 (3′-CH₂—N(H)—C(═O)-5′), formacetal (3′-O—CH₂—O-5′), methoxypropyl, and thioformacetal (3′-S—CH₂—O-5′). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See for example: Carbohydrate Modifications in Antisense Research; Y. S. Sanghvi and P. D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH2 component parts.

II. Certain Motifs

In certain embodiments, compounds described herein comprise or consist of oligonucleotides. Oligonucleotides can have a motif, e.g. a pattern of unmodified and/or modified sugar moieties, nucleobases, and/or internucleoside linkages. In certain embodiments, modified oligonucleotides comprise one or more modified nucleoside comprising a modified sugar. In certain embodiments, modified oligonucleotides comprise one or more modified nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more modified internucleoside linkage. In such embodiments, the modified, unmodified, and differently modified sugar moieties, nucleobases, and/or internucleoside linkages of a modified oligonucleotide define a pattern or motif. In certain embodiments, the patterns or motifs of sugar moieties, nucleobases, and internucleoside linkages are each independent of one another. Thus, a modified oligonucleotide may be described by its sugar motif, nucleobase motif and/or internucleoside linkage motif (as used herein, nucleobase motif describes the modifications to the nucleobases independent of the sequence of nucleobases).

A. Certain Sugar Motifs

In certain embodiments, compounds described herein comprise or consist of oligonucleotides. In certain embodiments, oligonucleotides comprise one or more type of modified sugar and/or unmodified sugar moiety arranged along the oligonucleotide or region thereof in a defined pattern or sugar motif. In certain instances, such sugar motifs include but are not limited to any of the sugar modifications discussed herein.

In certain embodiments, modified oligonucleotides comprise or consist of a region having a gapmer motif, which comprises two external segments or “wings” and a central or internal segment or “gap.” The three segments of a gapmer motif (the 5′-wing, the gap, and the 3′-wing) form a contiguous sequence of nucleosides wherein at least some of the sugar moieties of the nucleosides of each of the wings differ from at least some of the sugar moieties of the nucleosides of the gap. Specifically, at least the sugar moieties of the nucleosides of each wing that are immediately adjacent to the gap (the 3′-terminal wing nucleoside of the 5′-wing and the 5′-terminal wing nucleoside of the 3′-wing) differ from the sugar moiety of the adjacent gap nucleosides. In certain embodiments, the sugar moieties within the gap are the same as one another. In certain embodiments, the gap includes one or more nucleoside having a sugar moiety that differs from the sugar moiety of one or more other nucleosides of the gap.

In certain embodiments, the wings of a gapmer each comprise 1-5 nucleosides. In certain embodiments, the wings of a gapmer each comprise 2-5 nucleosides. In certain embodiments, the wings of a gapmer each comprise 3-5 nucleosides. In certain embodiments, the nucleosides of the wings of a gapmer are all modified nucleosides. In certain such embodiments, the sugar moieties of the wings of a gapmer are all modified sugar moieties.

In certain embodiments, the gap of a gapmer comprises 7-12 nucleosides. In certain embodiments, the gap of a gapmer comprises 7-10 nucleosides. In certain embodiments, the gap of a gapmer comprises 8-10 nucleosides. In certain embodiments, the gap of a gapmer comprises 10 nucleosides. In certain embodiments, each nucleoside of the gap of a gapmer is a 2′-deoxynucleoside.

In certain embodiments, the gapmer is a deoxy gapmer. In such embodiments, the nucleosides on the gap side of each wing/gap junction are 2′-deoxynucleosides and the terminal wing nucleosides immediately adjacent to the gap comprise modified sugar moieties. In certain such embodiments, each nucleoside of the gap is a 2′-deoxynucleoside. In certain such embodiments, each nucleoside of each wing comprises a modified sugar moiety.

In certain embodiments, a modified oligonucleotide has a fully modified sugar motif wherein each nucleoside of the modified oligonucleotide comprises a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif wherein each nucleoside of the region comprises a modified sugar moiety. In certain embodiments, modified oligonucleotides comprise or consist of a region having a fully modified sugar motif, wherein each nucleoside within the fully modified region comprises the same modified sugar moiety, referred to herein as a uniformly modified sugar motif. In certain embodiments, a fully modified oligonucleotide is a uniformly modified oligonucleotide. In certain embodiments, each nucleoside of a uniformly modified oligonucleotide comprises the same 2′-modification.

B. Certain Nucleobase Motifs

In certain embodiments, compounds described herein comprise or consist of oligonucleotides. In certain embodiments, oligonucleotides comprise modified and/or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases in a modified oligonucleotide are 5-methylcytosines.

In certain embodiments, modified oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3′-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 3′-end of the oligonucleotide. In certain embodiments, the block is at the 5′-end of the oligonucleotide. In certain embodiments the block is within 3 nucleosides of the 5′-end of the oligonucleotide.

In certain embodiments, oligonucleotides having a gapmer motif comprise a nucleoside comprising a modified nucleobase. In certain such embodiments, one nucleoside comprising a modified nucleobase is in the gap of an oligonucleotide having a gapmer motif. In certain such embodiments, the sugar moiety of said nucleoside is a 2′-deoxyribosyl moiety. In certain embodiments, the modified nucleobase is selected from: a 2-thiopyrimidine and a 5-propynepyrimidine.

C. Certain Internucleoside Linkage Motifs

In certain embodiments, compounds described herein comprise or consist of oligonucleotides. In certain embodiments, oligonucleotides comprise modified and/or unmodified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each internucleoside linking group is a phosphodiester internucleoside linkage (P═O). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is a phosphorothioate internucleoside linkage (P═S). In certain embodiments, each internucleoside linkage of a modified oligonucleotide is independently selected from a phosphorothioate internucleoside linkage and phosphodiester internucleoside linkage. In certain embodiments, each phosphorothioate internucleoside linkage is independently selected from a stereorandom phosphorothioate, a (Sp) phosphorothioate, and a (Rp) phosphorothioate. In certain embodiments, the sugar motif of a modified oligonucleotide is a gapmer and the internucleoside linkages within the gap are all modified. In certain such embodiments, some or all of the internucleoside linkages in the wings are unmodified phosphate linkages. In certain embodiments, the terminal internucleoside linkages are modified. In certain embodiments, the sugar motif of a modified oligonucleotide is a gapmer, and the internucleoside linkage motif comprises at least one phosphodiester internucleoside linkage in at least one wing, wherein the at least one phosphodiester linkage is not a terminal internucleoside linkage, and the remaining internucleoside linkages are phosphorothioate internucleoside linkages. In certain such embodiments, all of the phosphorothioate linkages are stereorandom. In certain embodiments, all of the phosphorothioate linkages in the wings are (Sp) phosphorothioates, and the gap comprises at least one Sp, Sp, Rp motif. In certain embodiments, populations of modified oligonucleotides are enriched for modified oligonucleotides comprising such internucleoside linkage motifs.

In certain embodiments, oligonucleotides comprise a region having an alternating internucleoside linkage motif. In certain embodiments, oligonucleotides comprise a region of uniformly modified internucleoside linkages. In certain such embodiments, the internucleoside linkages are phosphorothioate internucleoside linkages. In certain embodiments, all of the internucleoside linkages of the oligonucleotide are phosphorothioate internucleoside linkages. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester or phosphate and phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester or phosphate and phosphorothioate and at least one internucleoside linkage is phosphorothioate.

In certain embodiments, the oligonucleotide comprises at least 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 10 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 6 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 8 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 10 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least block of at least one 12 consecutive phosphorothioate internucleoside linkages. In certain such embodiments, at least one such block is located at the 3′ end of the oligonucleotide. In certain such embodiments, at least one such block is located within 3 nucleosides of the 3′ end of the oligonucleotide.

In certain embodiments, oligonucleotides comprise one or more methylphosphonate linkages. In certain embodiments, oligonucleotides having a gapmer nucleoside motif comprise a linkage motif comprising all phosphorothioate linkages except for one or two methylphosphonate linkages. In certain embodiments, one methylphosphonate linkage is in the gap of an oligonucleotide having a gapmer sugar motif.

In certain embodiments, it is desirable to arrange the number of phosphorothioate internucleoside linkages and phosphodiester internucleoside linkages to maintain nuclease resistance. In certain embodiments, it is desirable to arrange the number and position of phosphorothioate internucleoside linkages and the number and position of phosphodiester internucleoside linkages to maintain nuclease resistance. In certain embodiments, the number of phosphorothioate internucleoside linkages may be decreased and the number of phosphodiester internucleoside linkages may be increased. In certain embodiments, the number of phosphorothioate internucleoside linkages may be decreased and the number of phosphodiester internucleoside linkages may be increased while still maintaining nuclease resistance. In certain embodiments it is desirable to decrease the number of phosphorothioate internucleoside linkages while retaining nuclease resistance. In certain embodiments it is desirable to increase the number of phosphodiester internucleoside linkages while retaining nuclease resistance.

III. Certain Modified Oligonucleotides

In certain embodiments, compounds described herein comprise or consist of modified oligonucleotides. In certain embodiments, the above modifications (sugar, nucleobase, internucleoside linkage) are incorporated into a modified oligonucleotide. In certain embodiments, modified oligonucleotides are characterized by their modifications, motifs, and overall lengths. In certain embodiments, such parameters are each independent of one another. Thus, unless otherwise indicated, each internucleoside linkage of an oligonucleotide having a gapmer sugar motif may be modified or unmodified and may or may not follow the gapmer modification pattern of the sugar modifications. Likewise, such gapmer oligonucleotides may comprise one or more modified nucleobase independent of the gapmer pattern of the sugar modifications. Furthermore, in certain instances, an oligonucleotide is described by an overall length or range and by lengths or length ranges of two or more regions (e.g., a region of nucleosides having specified sugar modifications), in such circumstances it may be possible to select numbers for each range that result in an oligonucleotide having an overall length falling outside the specified range. In such circumstances, both elements must be satisfied. For example, in certain embodiments, a modified oligonucleotide consists of 15-20 linked nucleosides and has a sugar motif consisting of three regions or segments, A, B, and C, wherein region or segment A consists of 2-6 linked nucleosides having a specified sugar motif, region or segment B consists of 6-10 linked nucleosides having a specified sugar motif, and region or segment C consists of 2-6 linked nucleosides having a specified sugar motif. Such embodiments do not include modified oligonucleotides where A and C each consist of 6 linked nucleosides and B consists of 10 linked nucleosides (even though those numbers of nucleosides are permitted within the requirements for A, B, and C) because the overall length of such oligonucleotide is 22, which exceeds the upper limit of 20 for the overall length of the modified oligonucleotide. Unless otherwise indicated, all modifications are independent of nucleobase sequence except that the modified nucleobase 5-methylcytosine is necessarily a “C” in an oligonucleotide sequence.

In certain embodiments, oligonucleotides consist of X to Y linked nucleosides, where X represents the fewest number of nucleosides in the range and Y represents the largest number nucleosides in the range. In certain such embodiments, X and Y are each independently selected from 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50; provided that X≤Y. For example, in certain embodiments, oligonucleotides consist of 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to 17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to 24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to 14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to 21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to 28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to 19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to 26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to 18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to 25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to 18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to 25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to 19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to 26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to 21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to 28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to 24, 19 to 25, 19 to 26, 19 to 29, 19 to 28, 19 to 29, 19 to 30, 20 to 21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to 28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to 26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to 25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to 25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to 26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to 28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to 28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linked nucleosides.

In certain embodiments oligonucleotides have a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain embodiments, a region of an oligonucleotide has a nucleobase sequence that is complementary to a second oligonucleotide or an identified reference nucleic acid, such as a target nucleic acid. In certain embodiments, the nucleobase sequence of a region or entire length of an oligonucleotide is at least 70%, at least 80%, at least 90%, at least 95%, or 100% complementary to the second oligonucleotide or nucleic acid, such as a target nucleic acid.

IV. Certain Conjugated Compounds

In certain embodiments, the compounds described herein comprise or consist of an oligonucleotide (modified or unmodified) and optionally one or more conjugate groups and/or terminal groups. Conjugate groups consist of one or more conjugate moiety and a conjugate linker that links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, conjugate groups are attached to the 2-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3′ and/or 5′-end of oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3′-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3′-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5′-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5′-end of oligonucleotides.

Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified.

A. Certain Conjugate Groups

In certain embodiments, oligonucleotides are covalently attached to one or more conjugate groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance. In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide.

Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic, a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J Pharmacol. Exp. Ther., 1996, i, 923-937), a tocopherol group (Nishina et al., Molecular Therapy Nucleic Acids, 2015, 4, e220; doi:10.1038/mtna.2014.72 and Nishina et al., Molecular Therapy, 2008, 16, 734-740), or a GalNAc cluster (e.g., WO2014/179620).

1. Conjugate Moieties

Conjugate moieties include, without limitation, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates (e.g., GalNAc), vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterols, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes.

In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

2. Conjugate Linkers

Conjugate moieties are attached to oligonucleotides through conjugate linkers. In certain compounds, a conjugate group is a single chemical bond (i.e. conjugate moiety is attached to an oligonucleotide via a conjugate linker through a single bond). In certain embodiments, the conjugate linker comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.

In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group.

In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moieties, e.g., those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀ alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, such linker-nucleosides are modified nucleosides. In certain embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methylcytosine, 4-N-benzoyl-5-methylcytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the compound through cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.

Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in embodiments in which a compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid. For example, a compound may comprise (1) a modified oligonucleotide consisting of 8-30 nucleosides and (2) a conjugate group comprising 1-10 linker-nucleosides that are contiguous with the nucleosides of the modified oligonucleotide. The total number of contiguous linked nucleosides in such a compound is more than 30. Alternatively, an compound may comprise a modified oligonucleotide consisting of 8-30 nucleosides and no conjugate group. The total number of contiguous linked nucleosides in such a compound is no more than 30. Unless otherwise indicated conjugate linkers comprise no more than 10 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 5 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 3 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 2 linker-nucleosides. In certain embodiments, conjugate linkers comprise no more than 1 linker-nucleoside.

In certain embodiments, it is desirable for a conjugate group to be cleaved from the oligonucleotide. For example, in certain circumstances compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate may comprise one or more cleavable moieties, typically within the conjugate linker. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.

In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a conjugate moiety or conjugate group.

In certain embodiments, a cleavable moiety comprises or consists of one or more linker-nucleosides. In certain such embodiments, one or more linker-nucleosides are linked to one another and/or to the remainder of the compound through cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, a cleavable moiety is 2′-deoxy nucleoside that is attached to either the 3′ or 5′-terminal nucleoside of an oligonucleotide by a phosphate internucleoside linkage and covalently attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2′-deoxyadenosine.

3. Certain Cell-Targeting Conjugate Moieties

In certain embodiments, a conjugate group comprises a cell-targeting conjugate moiety. In certain embodiments, a conjugate group has the general formula:

-   -   wherein n is from 1 to about 3, m is 0 when n is 1, m is 1 when         n is 2 or greater, j is 1 or 0, and k is 1 or 0.

In certain embodiments, n is 1, j is 1 and k is 0. In certain embodiments, n is 1, j is 0 and k is 1. In certain embodiments, n is 1, j is 1 and k is 1. In certain embodiments, n is 2, j is 1 and k is 0. In certain embodiments, n is 2, j is 0 and k is 1. In certain embodiments, n is 2, j is 1 and k is 1. In certain embodiments, n is 3, j is 1 and k is 0. In certain embodiments, n is 3, j is 0 and k is 1. In certain embodiments, n is 3, j is 1 and k is 1.

In certain embodiments, conjugate groups comprise cell-targeting moieties that have at least one tethered ligand. In certain embodiments, cell-targeting moieties comprise two tethered ligands covalently attached to a branching group. In certain embodiments, cell-targeting moieties comprise three tethered ligands covalently attached to a branching group.

In certain embodiments, the cell-targeting moiety comprises a branching group comprising one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether and hydroxylamino groups. In certain embodiments, the branching group comprises a branched aliphatic group comprising groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether and hydroxylamino groups. In certain such embodiments, the branched aliphatic group comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain such embodiments, the branched aliphatic group comprises groups selected from alkyl, amino and ether groups. In certain such embodiments, the branched aliphatic group comprises groups selected from alkyl and ether groups. In certain embodiments, the branching group comprises a mono or polycyclic ring system.

In certain embodiments, each tether of a cell-targeting moiety comprises one or more groups selected from alkyl, substituted alkyl, ether, thioether, disulfide, amino, oxo, amide, phosphodiester, and polyethylene glycol, in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, ether, thioether, disulfide, amino, oxo, amide, and polyethylene glycol, in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, phosphodiester, ether, amino, oxo, and amide, in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, ether, amino, oxo, and amid, in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl, amino, and oxo, in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl and oxo, in any combination. In certain embodiments, each tether is a linear aliphatic group comprising one or more groups selected from alkyl and phosphodiester, in any combination. In certain embodiments, each tether comprises at least one phosphorus linking group or neutral linking group. In certain embodiments, each tether comprises a chain from about 6 to about 20 atoms in length. In certain embodiments, each tether comprises a chain from about 10 to about 18 atoms in length. In certain embodiments, each tether comprises about 10 atoms in chain length.

In certain embodiments, each ligand of a cell-targeting moiety has an affinity for at least one type of receptor on a target cell. In certain embodiments, each ligand has an affinity for at least one type of receptor on the surface of a mammalian lung cell.

In certain embodiments, each ligand of a cell-targeting moiety is a carbohydrate, carbohydrate derivative, modified carbohydrate, polysaccharide, modified polysaccharide, or polysaccharide derivative. In certain such embodiments, the conjugate group comprises a carbohydrate cluster (see, e.g., Maier et al., “Synthesis of Antisense Oligonucleotides Conjugated to a Multivalent Carbohydrate Cluster for Cellular Targeting,” Bioconjugate Chemistry, 2003, 14, 18-29, or Rensen et al., “Design and Synthesis of Novel N-Acetylgalactosamine-Terminated Glycolipids for Targeting of Lipoproteins to the Hepatic Asiaglycoprotein Receptor,” J. Med. Chem. 2004, 47, 5798-5808, which are incorporated herein by reference in their entirety).

In certain such embodiments, each ligand is an amino sugar or a thio sugar. For example, amino sugars may be selected from any number of compounds known in the art, such as sialic acid, α-D-galactosamine, β-muramic acid, 2-deoxy-2-methylamino-L-glucopyranose, 4,6-dideoxy-4-formamido-2,3-di-O-methyl-D-mannopyranose, 2-deoxy-2-sulfoamino-D-glucopyranose and N-sulfo-D-glucosamine, and N-glycoloyl-α-neuraminic acid. For example, thio sugars may be selected from 5-Thio-β-D-glucopyranose, methyl 2,3,4-tri-O-acetyl-1-thio-6-O-trityl-α-D-glucopyranoside, 4-thio-β-D-galactopyranose, and ethyl 3,4,6,7-tetra-O-acetyl-2-deoxy-1,5-dithio-α-D-gluco-heptopyranoside.

In certain embodiments compounds described herein comprise a conjugate group found in any of the following references: Lee, Carbohydr Res, 1978, 67, 509-514; Connolly et al., J Biol Chem, 1982, 257, 939-945; Pavia et al., Int J Pep Protein Res, 1983, 22, 539-548; Lee et al., Biochem, 1984, 23, 4255-4261; Lee et al., Glycoconjugate J, 1987, 4, 317-328; Toyokuni et al., Tetrahedron Lett, 1990, 31, 2673-2676; Biessen et al., J Med Chem, 1995, 38, 1538-1546; Valentijn et al., Tetrahedron, 1997, 53, 759-770; Kim et al., Tetrahedron Lett, 1997, 38, 3487-3490; Lee et al., Bioconjug Chem, 1997, 8, 762-765; Kato et al., Glycobiol, 2001, 11, 821-829; Rensen et al., J Biol Chem, 2001, 276, 37577-37584; Lee et al., Methods Enzymol, 2003, 362, 38-43; Westerlind et al., Glycoconj J, 2004, 21, 227-241; Lee et al., Bioorg Med Chem Lett, 2006, 16(19), 5132-5135; Maierhofer et al., Bioorg Med Chem, 2007, 15, 7661-7676; Khorev et al., Bioorg Med Chem, 2008, 16, 5216-5231; Lee et al., Bioorg Med Chem, 2011, 19, 2494-2500; Korilova et al., Analyt Biochem, 2012, 425, 43-46; Pujol et al., Angew Chemie Int Ed Engl, 2012, 51, 7445-7448; Biessen et al., J Med Chem, 1995, 38, 1846-1852; Sliedregt et al., J Med Chem, 1999, 42, 609-618; Rensen et al., J Med Chem, 2004, 47, 5798-5808; Rensen et al., Arterioscler Thromb Vasc Biol, 2006, 26, 169-175; van Rossenberg et al., Gene Ther, 2004, 11, 457-464; Sato et al., J Am Chem Soc, 2004, 126, 14013-14022; Lee et al., J Org Chem, 2012, 77, 7564-7571; Biessen et al., FASEB J, 2000, 14, 1784-1792; Rajur et al., Bioconjug Chem, 1997, 8, 935-940; Duff et al., Methods Enzymol, 2000, 313, 297-321; Maier et al., Bioconjug Chem, 2003, 14, 18-29; Jayaprakash et al., Org Lett, 2010, 12, 5410-5413; Manoharan, Antisense Nucleic Acid Drug Dev, 2002, 12, 103-128; Merwin et al., Bioconjug Chem, 1994, 5, 612-620; Tomiya et al., Bioorg Med Chem, 2013, 21, 5275-5281; International applications WO1998/013381; WO2011/038356; WO1997/046098; WO2008/098788; WO2004/101619; WO2012/037254; WO2011/120053; WO2011/100131; WO2011/163121; WO2012/177947; WO2013/033230; WO2013/075035; WO2012/083185; WO2012/083046; WO2009/082607; WO2009/134487; WO2010/144740; WO2010/148013; WO1997/020563; WO2010/088537; WO2002/043771; WO2010/129709; WO2012/068187; WO2009/126933; WO2004/024757; WO2010/054406; WO2012/089352; WO2012/089602; WO2013/166121; WO2013/165816; U.S. Pat. Nos. 4,751,219; 8,552,163; 6,908,903; 7,262,177; 5,994,517; 6,300,319; 8,106,022; 7,491,805; 7,491,805; 7,582,744; 8,137,695; 6,383,812; 6,525,031; 6,660,720; 7,723,509; 8,541,548; 8,344,125; 8,313,772; 8,349,308; 8,450,467; 8,501,930; 8,158,601; 7,262,177; 6,906,182; 6,620,916; 8,435,491; 8,404,862; 7,851,615; Published U.S. Patent Application Publications US2011/0097264; US2011/0097265; US2013/0004427; US2005/0164235; US2006/0148740; US2008/0281044; US2010/0240730; US2003/0119724; US2006/0183886; US2008/0206869; US2011/0269814; US2009/0286973; US2011/0207799; US2012/0136042; US2012/0165393; US2008/0281041; US2009/0203135; US2012/0035115; US2012/0095075; US2012/0101148; US2012/0128760; US2012/0157509; US2012/0230938; US2013/0109817; US2013/0121954; US2013/0178512; US2013/0236968; US2011/0123520; US2003/0077829; US2008/0108801; and US2009/0203132.

Compositions and Methods for Formulating Pharmaceutical Compositions

Compounds described herein may be admixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

Certain embodiments provide pharmaceutical compositions comprising one or more compounds or a salt thereof. Certain embodiments provide pharmaceutical compositions comprising one or more compounds described herein or a salt thereof. In certain embodiments, the compounds are antisense compounds or oligomeric compounds. In certain embodiments, the compounds comprise or consist of a modified oligonucleotide. In certain such embodiments, the pharmaceutical composition comprises a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises a sterile saline solution and one or more compound. In certain embodiments, such pharmaceutical composition consists of a sterile saline solution and one or more compound. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one compound and sterile water. In certain embodiments, the sterile water is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises or consists of one or more compound and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one or more compound and sterile PBS. In certain embodiments, the sterile PBS is pharmaceutical grade PBS. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

A compound described herein complementary to a DNM2 nucleic acid can be utilized in pharmaceutical compositions by combining the compound with a suitable pharmaceutically acceptable diluent or carrier and/or additional components such that the pharmaceutical composition is suitable for injection. In certain embodiments, a pharmaceutically acceptable diluent is phosphate buffered saline. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising a compound complementary to a DNM2 nucleic acid and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is phosphate buffered saline. In certain embodiments, the compound comprises or consists of a modified oligonucleotide provided herein.

Pharmaceutical compositions comprising compounds provided herein encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. In certain embodiments, the compounds are antisense compounds or oligomeric compounds. In certain embodiments, the compound comprises or consists of a modified oligonucleotide. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

A prodrug can include the incorporation of additional nucleosides at one or both ends of a compound which are cleaved by endogenous nucleases within the body, to form the active compound.

In certain embodiments, the compounds or compositions further comprise a pharmaceutically acceptable carrier or diluent.

EXAMPLES

The Examples below describe the screening process used to identify lead compounds targeted to DNM2. Out of over 3,000 oligonucleotides that were screened, many potent and tolerable oligonucleotides were identified, and compounds 951799, 949935, 950023, 950089, 951372, 950060, and 950132 emerged as the top lead compounds. In particular, compound 951799 exhibited the best combination of properties in terms of potency and tolerability.

Non-Limiting Disclosure and Incorporation by Reference

Although the sequence listing accompanying this filing identifies each sequence as either “RNA” or “DNA” as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2′-OH sugar moiety and a thymine nucleobase could be described as a DNA having an RNA sugar, or as an RNA having a DNA nucleobase.

Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of unmodified or modified RNA and/or DNA, including, but not limited to such nucleic acids having modified nucleobases. By way of further example and without limitation, an oligonucleotide having the nucleobase sequence “ATCGATCG” encompasses any oligonucleotides having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as “AUCGATCG” and compounds having other modified nucleobases, such as “AT^(m)CGAUCG,” wherein ^(m)C indicates a cytosine base comprising a methyl group at the 5-position.

While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references recited in the present application is incorporated herein by reference in its entirety.

Example 1: Effect of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Modified oligonucleotides complementary to one or more dynamin 2 (DNM2) nucleic acids were designed and tested for their effect on dynamin 2 mRNA expression in vitro. The modified oligonucleotides were tested in a series of experiments that had similar culture conditions.

A431 cells were cultured at a density of 10,000 cells per well and treated with 4,000 nM modified oligonucleotide via free uptake or no modified oligonucleotide for untreated controls. After approximately 24 hours, RNA was isolated from the cells and DNM2 mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS36027 (forward sequence GACCTCATGCCAAAGACCAT, designated herein as SEQ ID NO: 4; reverse sequence GTCTGCCGAGGAGTATAGGTA, designated herein as SEQ ID NO: 5; probe sequence CCTTCATCCACCACGAGCTGCT, designated herein as SEQ ID: 6) was used to measure mRNA levels. DNM2 mRNA levels were normalized to total RNA content, as measured by RIBOGREEN®. Results are presented in the tables below as normalized DNM2 mRNA level, relative to untreated control cells.

The modified oligonucleotides in the tables below each have a 3-10-3 cEt gapmer motif, wherein the central gap segment contains ten 2′-deoxynucleosides and is flanked by wing segments on the 3′ and 5′ ends, each containing three cEt nucleosides. All cytosine residues throughout each modified oligonucleotide are 5-methyl cytosines. All internucleoside linkages are phosphorothioate internucleoside linkages.

Each modified oligonucleotide listed in the table below is 100% complementary to human DNM2 nucleic acid sequence GENBANK Number NC_000019.10, truncated from 10715001 to 1083500 (designated herein as SEQ ID NO: 1) and/or GENBANK Number NM_004945.3 (designated herein as SEQ ID NO: 2). “Start Site” indicates the 5′-most nucleoside of the DNM2 nucleic acid to which the oligonucleotide is complementary. “Stop Site” indicates the 3′-most nucleoside of the DNM2 nucleic acid to which the oligonucleotide is complementary. ‘N/A’ indicates that the modified oligonucleotide is not 10000 complementary to the particular nucleic acid. Several oligonucleotides match two or more sites on a nucleic acid, as shown in the table below. As shown below, modified oligonucleotides complementary to human DNM2 inhibited human DNM2 mRNA expression.

TABLE 1 DNM2 mRNA Expression SEQ SEQ SEQ ID: SEQ ID: ID: 2 ID 2: SEQ Compound 1 Start 1 Stop DNM2 Start Stop ID Number Site Site Sequence (%Control) Site Site NO 694793 3066 3081 CTCAGGCGACACCCGA 96 14 29 7 694833 60707 60722 GATGAGGGTCAAGTTC 20 580 595 8 694838 60773 60788 CTTGATCTGGTACTCG 5 646 661 9 694852 N/A N/A GTCCGTAGGCCTTGGG 46 774 789 10 694853 62119 62134 ACCGATGGTCCGTAGG 76 781 796 11 695014 115999 116014 AATGGTGGGCCGGCTG 99 N/A N/A 12 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 9 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 5 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 6 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 8 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 6 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 6 N/A N/A 13 907925 3055 3070 CCCGACCCGAGCGACC 96 3 18 14 907926 3057 3072 CACCCGACCCGAGCGA 77 5 20 15 907927 3059 3074 GACACCCGACCCGAGC 115 7 22 16 907928 3062 3077 GGCGACACCCGACCCG 96 10 25 17 907929 3069 3084 GTTCTCAGGCGACACC 101 17 32 18 907930 3072 3087 CCGGTTCTCAGGCGAC 95 20 35 19 907931 3075 3090 CATCCGGTTCTCAGGC 58 23 38 20 907932 3078 3093 CCTCATCCGGTTCTCA 47 26 41 21 907933 3083 3098 CGCCGCCTCATCCGGT 69 31 46 22 907934 3086 3101 GGTCGCCGCCTCATCC 65 34 49 23 907935 3089 3104 CACGGTCGCCGCCTCA 29 37 52 24 907936 3091 3106 CTCACGGTCGCCGCCT 42 39 54 25 907937 3093 3108 GCCTCACGGTCGCCGC 65 41 56 26 907938 3095 3110 CGGCCTCACGGTCGCC 106 43 58 27 907939 3098 3113 GCTCGGCCTCACGGTC 44 46 61 28 907940 3101 3116 CCGGCTCGGCCTCACG 87 49 64 29 907941 3111 3126 ACGCCCGCTCCCGGCT 100 59 74 30 907942 3123 3138 GGCCTCGGCAAGACGC 96 71 86 31 907943 3126 3141 CCGGGCCTCGGCAAGA 97 74 89 32 907944 3129 3144 CGCCCGGGCCTCGGCA 84 77 92 33 907945 3144 3159 CCGTTGCTCCCCGCCC 5 92 107 34 907946 3146 3161 AGCCGTTGCTCCCCGC 12 94 109 35 907947 3149 3164 TGTAGCCGTTGCTCCC 10 97 112 36 907948 3153 3168 CGTCTGTAGCCGTTGC 8 101 116 37 907949 3171 3186 AACGACCTGGCCCCGC 12 119 134 38 907950 3177 3192 ACCCTCAACGACCTGG 41 125 140 39 907951 3180 3195 CCGACCCTCAACGACC 26 128 143 40 907952 3182 3197 CGCCGACCCTCAACGA 54 130 145 41 907953 3186 3201 CCGCCGCCGACCCTCA 35 134 149 42 907954 3190 3205 TCGCCCGCCGCCGACC 61 138 153 43 907955 3196 3211 CGCTCCTCGCCCGCCG 52 144 159 44 907956 3198 3213 TGCGCTCCTCGCCCGC 120 146 161 45 907957 3201 3216 CCCTGCGCTCCTCGCC 32 149 164 46 907958 3204 3219 GCGCCCTGCGCTCCTC 105 152 167 47 907959 3220 3235 GCGGCCCCCGGCCCGA 90 168 183 48 907960 3302 3317 CTGGCCGATGGAGCTG 129 250 265 49 907961 3304 3319 CTCTGGCCGATGGAGC 70 252 267 50 907962 3308 3323 GCAGCTCTGGCCGATG 46 256 271 51 907963 N/A N/A GGGAAGGAAGTCCCGG 97 349 364 52 907964 44749 44764 ATTCCTGAACCGCGGG 89 363 378 53 907965 44751 44766 CGATTCCTGAACCGCG 47 365 380 54 907966 44753 44768 GACGATTCCTGAACCG 11 367 382 55 907967 57491 57506 GACTTGCAGTGCAAAA 6 438 453 56 907968 57493 57508 TGGACTTGCAGTGCAA 15 440 455 57 907969 57495 57510 TTTGGACTTGCAGTGC 2 442 457 58 907970 57499 57514 ACTTTTTGGACTTGCA 5 446 461 59 907971 57526 57541 CCTGCCGGACTTCATC 17 473 488 60 907972 57529 57544 TCTCCTGCCGGACTTC 13 476 491 61 907973 57532 57547 CAATCTCCTGCCGGAC 20 479 494 62 907974 57534 57549 TTCAATCTCCTGCCGG 25 481 496 63 907975 60711 60726 GGTCGATGAGGGTCAA 8 584 599 64 907976 60716 60731 CGGGAGGTCGATGAGG 66 589 604 65 907977 60718 60733 CCCGGGAGGTCGATGA 117 591 606 66 907978 60722 60737 GATACCCGGGAGGTCG 55 595 610 67 907979 60724 60739 GTGATACCCGGGAGGT 11 597 612 68 907980 60728 60743 CTTGGTGATACCCGGG 57 601 616 69 907981 60734 60749 AGGCACCTTGGTGATA 40 607 622 70 907982 60776 60791 GTCCTTGATCTGGTAC 28 649 664 71 907983 60778 60793 ATGTCCTTGATCTGGT 8 651 666 72 907984 60784 60799 AGGATCATGTCCTTGA 58 657 672 73 907985 60788 60803 CTGCAGGATCATGTCC 35 661 676 74 907986 60798 60813 GGCTGATGAACTGCAG 56 671 686 75 907987 60806 60821 GCTCTCCCGGCTGATG 40 679 694 76 907988 60809 60824 GCTGCTCTCCCGGCTG 68 682 697 77 907989 60826 60841 GTGACAGCCAGAATGA 26 699 714 78 907990 60842 60857 GTCCATGTTGGCGGGC 66 715 730 79 907991 60882 60897 CGACTTCCTTGGCCAG 68 755 770 80 907992 60884 60899 ATCGACTTCCTTGGCC 99 757 772 81 907993 N/A N/A TGGTCCGTAGGCCTTG 72 776 791 82 907994 62116 62131 GATGGTCCGTAGGCCT 68 778 793 83 907995 62195 62210 TCAACGGGAGCAACTT 18 857 872 84 907996 N/A N/A GCCTCTTCTCAACGGG 105 865 880 85 907997 N/A N/A TAGCCTCTTCTCAACG 17 867 882 86 907998 68005 68020 GCACGGATGTCCTTCT 8 924 939 87 907999 68008 68023 GCTGCACGGATGTCCT 25 927 942 88 908000 68013 68028 CCAGTGCTGCACGGAT 17 932 947 89 908001 68057 68072 GTGCCGGTAGGCCGGG 91 976 991 90 908002 68059 68074 ATGTGCCGGTAGGCCG 83 978 993 91 908003 68062 68077 GCCATGTGCCGGTAGG 77 981 996 92 908004 68064 68079 CGGCCATGTGCCGGTA 90 983 998 93 908005 68096 68111 CGTCTTCTGCAGATGT 26 1015 1030 94 908006 71583 71598 GCCGGCAGCGACTCCC 107 1059 1074 95 908007 71586 71601 AGGGCCGGCAGCGACT 64 1062 1077 96 908008 71589 71604 CGTAGGGCCGGCAGCG 67 1065 1080 97 908009 71603 71618 TCTGTAGTTTGCTACG 34 1079 1094 98 908010 71605 71620 GCTCTGTAGTTTGCTA 42 1081 1096 99 908011 71659 71674 GTCGGGCCGAAAGTTC 15 1135 1150 100 908012 71681 71696 CTTTGGTTTTGCGGGT 36 1157 1172 101 908013 78772 78787 GAGTGTCCACCTGATC 11 1235 1250 102 908014 78786 78801 CCCGGAGAGCTCCAGA 58 1249 1264 103 908015 78789 78804 GCCCCCGGAGAGCTCC 71 1252 1267 104 908016 78791 78806 GCGCCCCCGGAGAGCT 129 1254 1269 105 908017 78804 78819 GCGATTGATTCGGGCG 50 1267 1282 106 908018 78808 78823 AGATGCGATTGATTCG 14 1271 1286 107 908019 80422 80437 GACTCCATGGATGTTC 91 1369 1384 108 908020 N/A N/A GCCCGGTCCTGACTCC 54 1379 1394 109 908021 N/A N/A AAGCCCGGTCCTGACT 81 1381 1396 110 908022 81058 81073 GAAAAGCCCGGTCCTG 35 1384 1399 111 908023 81061 81076 GGTGAAAAGCCCGGTC 58 1387 1402 112 908024 81076 81091 GAATGCCAAGTCCGGG 43 1402 1417 113 908025 81079 81094 CTCGAATGCCAAGTCC 8 1405 1420 114 908026 81082 81097 GGCCTCGAATGCCAAG 169 1408 1423 115 908027 81103 81118 GACGACCTGCTTTTTC 4 1429 1444 116 908028 81106 81121 CTTGACGACCTGCTTT 13 1432 1447 117 908029 81107 81122 GCTTGACGACCTGCTT 14 1433 1448 118 908030 81109 81124 CAGCTTGACGACCTGC 33 1435 1450 119 908031 81111 81126 TTCAGCTTGACGACCT 5 1437 1452 120 908032 81113 81128 CTTTCAGCTTGACGAC 22 1439 1454 121 908033 81115 81130 CTCTTTCAGCTTGACG 7 1441 1456 122 908034 81137 81152 GGTCGACACATTTCAG 13 1463 1478 123 908035 81139 81154 CAGGTCGACACATTTC 2 1465 1480 124 908036 81147 81162 TGGATAACCAGGTCGA 14 1473 1488 125 908037 81160 81175 ATTGATTAGCTCCTGG 2 1486 1501 126 908038 81170 81185 GCCTAACTGTATTGAT 22 1496 1511 127 908039 81172 81187 CTGCCTAACTGTATTG 28 1498 1513 128 908040 81175 81190 ACACTGCCTAACTGTA 54 1501 1516 129 908041 81182 81197 TACTGGTACACTGCCT 4 1508 1523 130 908042 N/A N/A CTGAGCTTACTGGTAC 19 1515 1530 131 908043 N/A N/A GAACTGAGCTTACTGG 10 1518 1533 132 908044 N/A N/A GGTAGGAACTGAGCTT 8 1523 1538 133 908045 83499 83514 TCCTCTCGCAACCGGG 46 1539 1554 134 908046 83502 83517 GTCTCCTCTCGCAACC 34 1542 1557 135 908047 83505 83520 TCTGTCTCCTCTCGCA 11 1545 1560 136 908048 83517 83532 GTGACGATTCGCTCTG 48 1557 1572 137 908049 83522 83537 AAGTGGTGACGATTCG 5 1562 1577 138 908050 83524 83539 GTAAGTGGTGACGATT 17 1564 1579 139 908051 83536 83551 CCGTTCCCGGATGTAA 86 1576 1591 140 908052 83548 83563 CGTTCTCCCCTCCCGT 9 1588 1603 141 908053 N/A N/A CAGAAGAATCTGGTCC 33 1606 1621 142 908054 87290 87305 GTCGATCAGCAGAAGA 33 1615 1630 143 908055 87294 87309 CAATGTCGATCAGCAG 16 1619 1634 144 908056 87296 87311 CTCAATGTCGATCAGC 10 1621 1636 145 908057 87299 87314 CTGCTCAATGTCGATC 18 1624 1639 146 908058 87302 87317 GGACTGCTCAATGTCG 58 1627 1642 147 908059 87304 87319 TAGGACTGCTCAATGT 3 1629 1644 148 908060 87308 87323 GATGTAGGACTGCTCA 19 1633 1648 149 908061 87311 87326 GTTGATGTAGGACTGC 3 1636 1651 150 908062 97288 97303 GGCTGATGTTGTTGAT 31 1760 1775 151 908063 97290 97305 CAGGCTGATGTTGTTG 36 1762 1777 152 908064 97294 97309 TCATCAGGCTGATGTT 100 1766 1781 153 908065 97299 97314 GCCTTTCATCAGGCTG 89 1771 1786 154 908066 97338 97353 TGACTCGGCAGTCAGC 86 1810 1825 155 908067 97341 97356 CAGTGACTCGGCAGTC 24 1813 1828 156 908068 97345 97360 AGGACAGTGACTCGGC 17 1817 1832 157 908069 105015 105030 ATCACGGATCTTGAGG 40 1885 1900 158 908070 105019 105034 CCACATCACGGATCTT 12 1889 1904 159 908071 105020 105035 TCCACATCACGGATCT 31 1890 1905 160 908072 105022 105037 TCTCCACATCACGGAT 72 1892 1907 161 908073 105060 105075 GAAGATGGCGAAGACG 81 1930 1945 162 908074 108791 108806 CAGGTCCTTGTAGACG 60 1963 1978 163 908075 108804 108819 GCTCGATCTGCCGCAG 55 1976 1991 164 908076 108806 108821 CAGCTCGATCTGCCGC 54 1978 1993 165 908077 108857 108872 TCGGAGGAACGAGGCC 80 2029 2044 166 908078 108859 108874 GCTCGGAGGAACGAGG 67 2031 2046 167 908079 108861 108876 CAGCTCGGAGGAACGA 59 2033 2048 168 908080 108863 108878 GCCAGCTCGGAGGAAC 93 2035 2050 169 908081 N/A N/A GCCTGGTCCTTCTCGG 70 2058 2073 170 908082 110075 110090 AGGTGTTCTCCTGGGC 74 2090 2105 171 908083 110077 110092 GAAGGTGTTCTCCTGG 81 2092 2107 172 908084 110080 110095 GGAGAAGGTGTTCTCC 119 2095 2110 173 908085 110160 110175 ATGGACTTGTTGATGA 11 2175 2190 174 908086* 110166 110181 TCGCGGATGGACTTGT 36 2181 2196 175 908087* 110168 110183 GGTCGCGGATGGACTT 58 2183 2198 176 908088* 110171 110186 TGAGGTCGCGGATGGA 4 2186 2201 177 908089* 114042 114057 CGTGGTGGATGAAGGC 3 2243 2258 178 908090* 114069 114084 CCGAGGAGTATAGGTA 17 2270 2285 179 908091* 114072 114087 CTGCCGAGGAGTATAG 14 2273 2288 180 908092* 114074 114089 GTCTGCCGAGGAGTAT 11 2275 2290 181 908093* 114077 114092 CTGGTCTGCCGAGGAG 9 2278 2293 182 908094* 114080 114095 GCTCTGGTCTGCCGAG 39 2281 2296 183 908095 115141 115156 CTGGACACCGGTCGGC 39 2484 2499 184 908096 115144 115159 ATGCTGGACACCGGTC 47 2487 2502 185 908097 115146 115161 GTATGCTGGACACCGG 33 2489 2504 186 908098 115150 115165 GGGTGTATGCTGGACA 11 2493 2508 187 908099 115214 115229 CACGGGAACAGGAATC 25 2557 2572 188 908100 115221 115236 CTGCCCCCACGGGAAC 80 2564 2579 189 908101 115238 115253 CGCCGAGAAGGAGGCT 97 2581 2596 190 908102 115283 115298 GTTGGCAAACACGCTC 16 2626 2641 191 908103 115285 115300 CTGTTGGCAAACACGC 30 2628 2643 192 908104 115292 115307 GAGGTCACTGTTGGCA 9 2635 2650 193 908105 115324 115339 GGCCGAGATGGGATCT 73 2667 2682 194 908106 115326 115341 CTGGCCGAGATGGGAT 45 2669 2684 195 908107 115329 115344 GAACTGGCCGAGATGG 6 2672 2687 196 908108 115332 115347 TCCGAACTGGCCGAGA 33 2675 2690 197 908109 115336 115351 GGGATCCGAACTGGCC 82 2679 2694 198 908110 116010 116025 GCTGGGCGGATAATGG 45 2754 2769 199 908111 116015 116030 GCTCGGCTGGGCGGAT 101 2759 2774 200 908112 116017 116032 TGGCTCGGCTGGGCGG 89 2761 2776 201 908113 116022 116037 AGGGATGGCTCGGCTG 75 2766 2781 202 908114 116030 116045 AGTCGAGCAGGGATGG 53 2774 2789 203 908115 116035 116050 GGCCTAGTCGAGCAGG 104 2779 2794 204 908116 116038 116053 CGAGGCCTAGTCGAGC 79 2782 2797 205 908117 116042 116057 CCCTCGAGGCCTAGTC 87 2786 2801 206 908118 116045 116060 CCCCCCTCGAGGCCTA 69 2789 2804 207 908119 116047 116062 CGCCCCCCTCGAGGCC 89 2791 2806 208 908120 116057 116072 CCCGAGAGCACGCCCC 40 2801 2816 209 908121 116060 116075 CCCCCCGAGAGCACGC 38 2804 2819 210 908122 116063 116078 GGCCCCCCCGAGAGCA 95 2807 2822 211 908123 116068 116083 CGTGAGGCCCCCCCGA 67 2812 2827 212 908124 116088 116103 AAGCTCCTGCGCCGCG 55 2832 2847 213 908125 116096 116111 GACCACTGAAGCTCCT 32 2840 2855 214 908126 116098 116113 CAGACCACTGAAGCTC 38 2842 2857 215 908127 116108 116123 CGGAGGGCCCCAGACC 100 2852 2867 216 908128 116110 116125 GGCGGAGGGCCCCAGA 91 2854 2869 217 908129 116128 116143 TGGTCCCAGCATAGGG 88 2872 2887 218 908130 116130 116145 CCTGGTCCCAGCATAG 73 2874 2889 219 908131 116138 116153 ACTGGGAGCCTGGTCC 72 2882 2897 220 908132 116164 116179 CGTTAAGGAAGAGGCC 69 2908 2923 221 908133 116209 116224 GCGGTGTCCAGCCAGG 49 2953 2968 222 908134 116211 116226 GTGCGGTGTCCAGCCA 37 2955 2970 223 908135 116215 116230 CGCAGTGCGGTGTCCA 13 2959 2974 224 908136 116218 116233 TTGCGCAGTGCGGTGT 29 2962 2977 225 908137 116220 116235 CTTTGCGCAGTGCGGT 15 2964 2979 226 908138 116223 116238 CCCCTTTGCGCAGTGC 12 2967 2982 227 908139 116226 116241 GGGCCCCTTTGCGCAG 101 2970 2985 228 908140 116228 116243 CAGGGCCCCTTTGCGC 92 2972 2987 229 908141 116260 116275 TGCAACACCCCAGCGC 78 3004 3019 230 908142 116265 116280 CAAAGTGCAACACCCC 20 3009 3024 231 908143 116268 116283 CCCCAAAGTGCAACAC 47 3012 3027 232 908144 116300 116315 TGGTCCCCCCTCTGCC 64 3044 3059 233 908145 116309 116324 CAAGGGTTCTGGTCCC 45 3053 3068 234 908146 116312 116327 TGTCAAGGGTTCTGGT 15 3056 3071 235 908147 116314 116329 GGTGTCAAGGGTTCTG 8 3058 3073 236 908148 116318 116333 GGATGGTGTCAAGGGT 7 3062 3077 237 908149 116331 116346 GACCCCTCATTCAGGA 84 3075 3090 238 908150 116333 116348 TGGACCCCTCATTCAG 64 3077 3092 239 908151 116336 116351 GGCTGGACCCCTCATT 80 3080 3095 240 908152 116348 116363 GAGTCCCCCCCAGGCT 63 3092 3107 241 908153 116352 116367 GGTAGAGTCCCCCCCA 31 3096 3111 242 908154 116356 116371 CCTTGGTAGAGTCCCC 3 3100 3115 243 908155 116359 116374 AGACCTTGGTAGAGTC 73 3103 3118 244 908156 116385 116400 CCTACATGGGCTTTCC 37 3129 3144 245 908157 116389 116404 CTGCCCTACATGGGCT 115 3133 3148 246 908158 116398 116413 ATAGAAGGCCTGCCCT 71 3142 3157 247 908159 116400 116415 TTATAGAAGGCCTGCC 41 3144 3159 248 908160 116404 116419 GCACTTATAGAAGGCC 70 3148 3163 249 908161 116408 116423 GCCCGCACTTATAGAA 45 3152 3167 250 908162 116410 116425 GTGCCCGCACTTATAG 66 3154 3169 251 908163 116418 116433 CGCCCTTGGTGCCCGC 62 3162 3177 252 908164 116455 116470 TATACCCCTGCACCCC 11 3199 3214 253 908165 116464 116479 GGAAGTTGATATACCC 29 3208 3223 254 908166 116471 116486 GCTAATGGGAAGTTGA 13 3215 3230 255 908167 116474 116489 CCTGCTAATGGGAAGT 14 3218 3233 256 908168 116477 116492 GCTCCTGCTAATGGGA 139 3221 3236 257 908169 116481 116496 GGGAGCTCCTGCTAAT 102 3225 3240 258 908170 116497 116512 GCCAGGCTTGCCGCTG 80 3241 3256 259 908171 116499 116514 GGGCCAGGCTTGCCGC 87 3243 3258 260 908172 116511 116526 ACCGAGCCCACTGGGC 72 3255 3270 261 908173 116513 116528 CTACCGAGCCCACTGG 57 3257 3272 262 908174 116518 116533 GGGCACTACCGAGCCC 87 3262 3277 263 908175 116523 116538 CAGCTGGGCACTACCG 86 3267 3282 264 908176 116541 116556 TGTACACCTCAGGCCT 83 3285 3300 265 908177 116544 116559 CTATGTACACCTCAGG 10 3288 3303 266 908178 116547 116562 GGACTATGTACACCTC 7 3291 3306 267 908179 116550 116565 GAAGGACTATGTACAC 8 3294 3309 268 908180 116556 116571 GGCCGGGAAGGACTAT 51 3300 3315 269 908181 116558 116573 ATGGCCGGGAAGGACT 78 3302 3317 270 908182 116561 116576 AATATGGCCGGGAAGG 19 3305 3320 271 908183 116565 116580 GGTTAATATGGCCGGG 13 3309 3324 272 908184 116573 116588 GGCTGTGTGGTTAATA 8 3317 3332 273 908185 116603 116618 CCTCTGGCAGCCGAGG 100 3347 3362 274 908186 116606 116621 GCACCTCTGGCAGCCG 73 3350 3365 275 908187 116608 116623 AGGCACCTCTGGCAGC 61 3352 3367 276 908188 116614 116629 TAGCAAAGGCACCTCT 41 3358 3373 277 908189 116617 116632 GCCTAGCAAAGGCACC 146 3361 3376 278 908190 116621 116636 CCGGGCCTAGCAAAGG 60 3365 3380 279 908191 116624 116639 GCTCCGGGCCTAGCAA 123 3368 3383 280 908192 116626 116641 CGGCTCCGGGCCTAGC 97 3370 3385 281 908193 116630 116645 CCAACGGCTCCGGGCC 117 3374 3389 282 908194 116638 116653 GGCCCGGGCCAACGGC 109 3382 3397 283 908195 116640 116655 CCGGCCCGGGCCAACG 104 3384 3399 284 908196 116642 116657 GGCCGGCCCGGGCCAA 99 3386 3401 285 908197 116644 116659 AAGGCCGGCCCGGGCC 86 3388 3403 286 908198 116646 116661 GCAAGGCCGGCCCGGG 88 3390 3405 287 908199 116648 116663 GGGCAAGGCCGGCCCG 125 3392 3407 288 908200 116650 116665 TAGGGCAAGGCCGGCC 99 3394 3409 289 908201 116655 116670 AGGAATAGGGCAAGGC 6 3399 3414 290 908202 116712 116727 ACCACCCACATAGCCC 31 3456 3471 291 908203 116729 116744 CAAGACCCCCCGCCAC 64 3473 3488 292 908204 116732 116747 CCCCAAGACCCCCCGC 59 3476 3491 293 908205 116738 116753 AGAGGCCCCCAAGACC 86 3482 3497 294 908206 116772 116787 GGCCCACCCATCAGGG 110 3516 3531 295 908207 116774 116789 TGGGCCCACCCATCAG 127 3518 3533 296 908208 116789 116804 AGAGAGAGGCCGCCCT 37 3533 3548 297 908209 116791 116806 TCAGAGAGAGGCCGCC 70 3535 3550 298 908210 116808 116823 GAGTGGGTGAGGTCTC 77 3552 3567 299 908211 116815 116830 GAGCGAGGAGTGGGTG 59 3559 3574 300 908212 116819 116834 AACTGAGCGAGGAGTG 55 3563 3578 301 908213 116822 116837 TCAAACTGAGCGAGGA 5 3566 3581 302 908214 116826 116841 GTGGTCAAACTGAGCG 15 3570 3585 303 908215 116832 116847 CTTACAGTGGTCAAAC 10 3576 3591 304 908216 116843 116858 GAGTGCAGGCACTTAC 48 3587 3602 305 908217 116849 116864 AATACAGAGTGCAGGC 4 3593 3608 306 908221 82462 82477 CCACGAGATCAACACA 20 N/A N/A 307 908222 82464 82479 GACCACGAGATCAACA 88 N/A N/A 308 908223 82465 82480 AGACCACGAGATCAAC 82 N/A N/A 309 908224 82468 82483 CTGAGACCACGAGATC 34 N/A N/A 310 908225 82471 82486 GCTCTGAGACCACGAG 59 N/A N/A 311 908226 82482 82497 GACCGTGGCCAGCTCT 52 N/A N/A 312 908227 82484 82499 ATGACCGTGGCCAGCT 54 N/A N/A 313 908228 82485 82500 TATGACCGTGGCCAGC 31 N/A N/A 314 908229 82487 82502 TTTATGACCGTGGCCA 64 N/A N/A 315 908230 82488 82503 TTTTATGACCGTGGCC 102 N/A N/A 316 908231 82498 82513 CGGCACACTTTTTTAT 37 N/A N/A 317 908232 82502 82517 TTCTCGGCACACTTTT 4 N/A N/A 318 908236 N/A N/A CCCCGCCGCGGGCACG 103 3506 3521 319 908237 4387 4402 CCAAAGGAGGGCCCCC 88 N/A N/A 320 908238 4857 4872 CGCCAGCCTAGTGGCC 142 N/A N/A 321 908239 5585 5600 TGGGACTACCACCCTA 129 N/A N/A 322 908240 6095 6110 CTCCATACTGGCCGGC 91 N/A N/A 323 908241 6449 6464 CTTAACGAGGCCAGCC 56 N/A N/A 324 908242 7057 7072 ACCCATCTAGGCCCCA 23 N/A N/A 325 908243 7335 7350 TGGTGCACCGCAGACA 61 N/A N/A 326 908244 8045 8060 TCAGGAGGCGAGATTG 93 N/A N/A 327 908245 8318 8333 CGGGAAAACCCCGCCT 123 N/A N/A 328 908246 8813 8828 AGCCACTAAGTGGCCC 130 N/A N/A 329 908247 9601 9616 GCTAAACTGGCCTCCG 78 N/A N/A 330 908248 9989 10004 GCCAACGGGCATCCGA 104 N/A N/A 331 908249 10650 10665 GTCCACTCCCAGTAGG 77 N/A N/A 332 908250 11631 11646 GGTGATCCGATGCTGG 34 N/A N/A 333 908251 12300 12315 GGCCATCTTCCGCCCT 102 N/A N/A 334 908252 12662 12677 CTAACCTAGGCCGGGT 70 N/A N/A 335 908253 12991 13006 AGACGCAGGGCCACAT 66 N/A N/A 336 908254 13381 13396 GGCTCTAGAGGGCCCA 110 N/A N/A 337 908255 13954 13969 CCGCATACAGCCTTTT 12 N/A N/A 338 908256 14620 14635 GCATTCCACGGGCAGC 34 N/A N/A 339 908257 15396 15411 CACCGCTACCCTAGCT 63 N/A N/A 340 908258 15792 15807 GGGCACCCCGCAGGTT 102 N/A N/A 341 908259 16235 16250 TCTAGAAGGACCCTGT 64 N/A N/A 342 908260 16810 16825 AGCCGGGCTTCCGTCT 84 N/A N/A 343 908261 17238 17253 TTTAAGGGCGCGGTGG 99 N/A N/A 344 908262 17624 17639 TGCACTTCCGGACAGG 82 N/A N/A 345 908263 18173 18188 CACCAGCCCAGGCGCG 117 N/A N/A 346 908264 18617 18632 AGCTAGGTTAATTTCT 64 N/A N/A 347 908265 19070 19085 CAACATCCCGCCAGGC 80 N/A N/A 348 908266 19407 19422 AGCAATCTAGCCTCCC 39 N/A N/A 349 908267 19819 19834 TGCAATGTCCAGTCCT 11 N/A N/A 350 908268 20435 20450 ACCTAGCAAGCCTACC 64 N/A N/A 351 908269 21415 21430 GCTACAGCAATATAGA 67 N/A N/A 352 908270 21839 21854 TCTTAACAGGCTCCCT 63 N/A N/A 353 908271 22199 22214 CCTCAGGGACGACTTC 87 N/A N/A 354 908272 22636 22651 TATACGGGCATGTTGA 55 N/A N/A 355 908273 22916 22931 GTGCATCCCGAGAGGG 89 N/A N/A 356 908274 23292 23307 ATGAAAGTCTCCACTT 61 N/A N/A 357 908275 23543 23558 AACCGCTGGGATCCCC 71 N/A N/A 358 908276 24229 24244 GTACAGGAGTTCCCCA 90 N/A N/A 359 908277 25038 25053 AAATACACCCTAGATG 83 N/A N/A 360 908278 25670 25685 GAAGATTTTGGCCGGG 85 N/A N/A 361 908279 25997 26012 CTCCAGGACACACCGT 42 N/A N/A 362 908280 27088 27103 GGGAGTAGGCTCGACC 51 N/A N/A 363 908281 27400 27415 CCCTATTCCACAGGAC 85 N/A N/A 364 908282 27746 27761 GCTAAGAGCAGCCCTC 80 N/A N/A 365 908283 28198 28213 GGCATCACGGCCGGGC 76 N/A N/A 366 908284 29125 29140 TGTCACCCCAGCCGAA 67 N/A N/A 367 908285 29568 29583 AGCCGGGCACCACCCA 67 N/A N/A 368 908286 30330 30345 GGCAAGGACAGCCGAC 94 N/A N/A 369 908287 30334 30349 GTTTGGCAAGGACAGC 40 N/A N/A 370 908288 30337 30352 GTGGTTTGGCAAGGAC 14 N/A N/A 371 908289 30340 30355 GCAGTGGTTTGGCAAG 46 N/A N/A 372 908290 30342 30357 ATGCAGTGGTTTGGCA 86 N/A N/A 373 908291 30401 30416 TCAACACCTTGAGGGC 34 N/A N/A 374 908292 30498 30513 TGCCTAGGCGATCCTC 88 N/A N/A 375 908293 30928 30943 GACATTGCTGTCGCAG 78 N/A N/A 376 908294 31347 31362 TCCCAAGTGCCCCCCA 90 N/A N/A 377 908295 31703 31718 AGCCGGCACGGTTGCT 125 N/A N/A 378 908296 32187 32202 GAGAACATTCGCCCCA 27 N/A N/A 379 908297 32386 32401 TGACCTGTGGCAATTC 26 N/A N/A 380 908298 32388 32403 GGTGACCTGTGGCAAT 44 N/A N/A 381 908299 32689 32704 TCCCGTATCGGCCCCT 85 N/A N/A 382 908300 33343 33358 GTCCAGCCGCGAGTCC 59 N/A N/A 383 908301 33635 33650 GGCAGACCCGCAGTCA 73 N/A N/A 384 908302 34108 34123 GGGCAAGCCACCCCTC 93 N/A N/A 385 908303 34623 34638 AAGTCGAGCTCCGCCC 63 N/A N/A 386 908304 35031 35046 TGGTCCTAGCCCGTCC 78 N/A N/A 387 908305 35549 35564 GGGTACAGGCAAACCT 88 N/A N/A 388 908306 36028 36043 CCATACCCCCATCTGA 102 N/A N/A 389 908307 36712 36727 GCGCAGAGGGCCTCGC 123 N/A N/A 390 908308 37097 37112 CACTACAGACATCCCT 64 N/A N/A 391 908309 37538 37553 AGCCAGGGCCCGGCTT 93 N/A N/A 392 908310 38044 38059 CTCCAACTGTAGGGCT 87 N/A N/A 393 908311 39735 39750 GCGGATGGTGGCATTC 90 N/A N/A 394 908312 40399 40414 CAGCAGCGGCGGTGAC 84 N/A N/A 395 908313 41143 41158 CTCTTAGCATGGCCCC 73 N/A N/A 396 908314 41620 41635 GGCCTGGGATGCTACC 129 N/A N/A 397 908315 41957 41972 TTAAACCCCCCTCTGG 104 N/A N/A 398 908316 42239 42254 GCCCAAGCCCTCGGCG 147 N/A N/A 399 908317 42806 42821 ATGCACGCGCTACCAT 106 N/A N/A 400 908318 43841 43856 ACATATCCTGGCCGGG 112 N/A N/A 401 908319 44266 44281 CTGGATGTGGGAACGG 94 N/A N/A 402 908320 44817 44832 CCTCAGGCCGCCCCAT 57 N/A N/A 403 908321 45179 45194 GGCCATGGAGGGTCAC 111 N/A N/A 404 908322 45544 45559 GGGACAACTGGCGACA 39 N/A N/A 405 908323 45952 45967 TGGTAGAGGGCTGGTG 78 N/A N/A 406 908324 46827 46842 GCCCATCGGCTGCTGT 153 N/A N/A 407 908325 47604 47619 GGGTAGGCCTGCGCTC 119 N/A N/A 408 908326 48030 48045 TGCCATGATCAGGCGG 109 N/A N/A 409 908327 48530 48545 ACCAAGTGGGCACCTA 92 N/A N/A 410 908328 49088 49103 CCACAAGGCCCCGCCG 103 N/A N/A 411 908329 49883 49898 GTGACCAGGTGCGGGT 84 N/A N/A 412 908330 50310 50325 CTGGGCAGAGCCGATC 95 N/A N/A 413 908331 50840 50855 GACGAGGCTGGCCCTG 36 N/A N/A 414 908332 51504 51519 CCCCACTGTGCTAAAC 91 N/A N/A 415 908333 51765 51780 AGTCAGCCGTCCTCGC 58 N/A N/A 416 908334 52587 52602 CACCAGGCCGAGAGCA 111 N/A N/A 417 908335 53006 53021 GCCCAGGCACCGACCA 92 N/A N/A 418 908336 53680 53695 CCCCGGAACCTCAGGC 85 N/A N/A 419 908337 54271 54286 CAGCACGCTGTGTGCA 65 N/A N/A 420 908338 54667 54682 CACTCGGCCGCTCTTC 80 N/A N/A 421 908339 55325 55340 GCGCACTGCCCTGTCG 77 N/A N/A 422 908340 56452 56467 CAAGAGGGCCCCCTAC 110 N/A N/A 423 908341 56855 56870 TATGAATCCCCCTCCC 99 N/A N/A 424 908342 57413 57428 GCGCATGGACTGCGGG 150 N/A N/A 425 908343 57695 57710 TGGAAGTACACAGGCT 40 N/A N/A 426 908344 58949 58964 GTCTATGGCCCCGGGC 102 N/A N/A 427 908345 59713 59728 GCATAGGCCAACGCAG 88 N/A N/A 428 908346 60635 60650 AAACAGGCCCGCAGCC 95 N/A N/A 429 908347 61004 61019 CCTACAGCGGCCATGG 115 N/A N/A 430 908348 61545 61560 GTGCTAACCGTGTGTG 85 N/A N/A 431 908349 62025 62040 GTCCAGTTGGCCCTGA 84 N/A N/A 432 908350 62964 62979 AACCACCGAAGCTGGG 125 N/A N/A 433 908351 63324 63339 GGAAGATGGCCGGGTG 111 N/A N/A 434 908352 63675 63690 GCTACAATGCCTAGGA 85 N/A N/A 435 908353 64393 64408 GGTCAACGCAGGCTCA 48 N/A N/A 436 908354 64657 64672 AGCCAGGAGCAATCGC 78 N/A N/A 437 908355 65114 65129 GGCAACCAAGGTCTGA 15 N/A N/A 438 908356 65639 65654 CGCCTAGCCTGGGTTC 67 N/A N/A 439 908357 66042 66057 CACCATCACACACGGA 44 N/A N/A 440 908358 66433 66448 GGGAGAGGTGCCGGTC 99 N/A N/A 441 908359 66885 66900 CACCGAGAAGGAGGTA 99 N/A N/A 442 908360 67650 67665 AAAATCTCGGCCGGGA 101 N/A N/A 443 908361 67903 67918 GCCAAGTGGACCTGGC 84 N/A N/A 444 908362 68192 68207 GCCTGAAACAAGTGCC 75 N/A N/A 445 908363 68628 68643 CCCCAGGCAATGCATA 125 N/A N/A 446 908364 68993 69008 AGAACGATAGGCCAGG 52 N/A N/A 447 908365 69310 69325 TCTTTTCCCGGCCCCC 48 N/A N/A 448 908366 71364 71379 CGGCACGGAGCTGCCC 126 N/A N/A 449 908367 71557 71572 GGTCAGTTGCTGCAGG 40 N/A N/A 450 908368 72040 72055 GGCCGGCCAATGCTCA 118 N/A N/A 451 908369 73315 73330 TTGCACTGGCCGGGCT 75 N/A N/A 452 908370 73937 73952 CCCTTAGCCCACGACC 92 N/A N/A 453 908371 74402 74417 CTGCCAGTTTGTCCCC 25 N/A N/A 454 908372 74408 74423 TGTAATCTGCCAGTTT 53 N/A N/A 455 908373 74410 74425 CTTGTAATCTGCCAGT 55 N/A N/A 456 908374 74415 74430 GGCACCTTGTAATCTG 96 N/A N/A 457 908375 74908 74923 TGTGATGGGCATCCCC 56 N/A N/A 458 908376 75761 75776 ATACATGAGGTCCGGG 106 N/A N/A 459 908377 76583 76598 GCCCAACCCACGCTGC 79 N/A N/A 460 908378 77237 77252 CCCCAACTGGGAGAGG 107 N/A N/A 461 908379 77517 77532 TAGAACGGGCCTGGCC 93 N/A N/A 462 908380 78331 78346 TCCATAGGTTCCCGCC 89 N/A N/A 463 908381 78849 78864 GGGCACTACCTTCACC 138 N/A N/A 464 908382 79488 79503 TCCCACGGATTATAGG 140 N/A N/A 465 908383 80002 80017 GCCCAGGAAGGTCGAA 105 N/A N/A 466 908384 80333 80348 ATGCATGGAGGCACCC 93 N/A N/A 467 908385 80626 80641 TGCAATGGACGCAGGA 37 N/A N/A 468 908386 80968 80983 GGCCGGGTCCCCAACA 113 N/A N/A 469 908387 81643 81658 GGCCATTCCCGGAGCT 114 N/A N/A 470 908388 82021 82036 CCTTTTCTAATCGAAG 116 N/A N/A 471 908389 82046 82061 ACCTGTTTGGACTGTT 5 N/A N/A 472 908390 82049 82064 CCAACCTGTTTGGACT 74 N/A N/A 473 908391 82051 82066 TTCCAACCTGTTTGGA 54 N/A N/A 474 908392 82055 82070 CGTTTTCCAACCTGTT 3 N/A N/A 475 908393 82069 82084 GGCTCTAGGACGAGCG 55 N/A N/A 476 908394 82072 82087 CCTGGCTCTAGGACGA 41 N/A N/A 477 908395 82083 82098 TGTCCATGACACCTGG 66 N/A N/A 478 908396 82086 82101 TCATGTCCATGACACC 8 N/A N/A 479 908397 82088 82103 ATTCATGTCCATGACA 25 N/A N/A 480 908398 82704 82719 CCCCACGGGCAGCCAC 127 N/A N/A 481 908399 83290 83305 GGGCACCGTGGACCGG 112 N/A N/A 482 908400 83646 83661 CATATGCAGCTGTCAG 27 N/A N/A 483 83734 83749 N/A N/A 83822 83837 N/A N/A 908401 83647 83662 CCATATGCAGCTGTCA 2 N/A N/A 484 83735 83750 N/A N/A 83823 83838 N/A N/A 908402 83649 83664 TGCCATATGCAGCTGT 27 N/A N/A 485 83737 83752 N/A N/A 83825 83840 N/A N/A 908403 83650 83665 TTGCCATATGCAGCTG 18 N/A N/A 486 83738 83753 N/A N/A 83826 83841 N/A N/A 908404 83651 83666 TTTGCCATATGCAGCT 17 N/A N/A 487 83739 83754 N/A N/A 83827 83842 N/A N/A 908405 83658 83673 GGGTTACTTTGCCATA 7 N/A N/A 488 83746 83761 N/A N/A 83834 83849 N/A N/A 908406 83659 83674 AGGGTTACTTTGCCAT 74 N/A N/A 489 83747 83762 N/A N/A 83835 83850 N/A N/A 908407 83660 83675 AAGGGTTACTTTGCCA 7 N/A N/A 490 83748 83763 N/A N/A 83836 83851 N/A N/A 908408 83661 83676 TAAGGGTTACTTTGCC 2 N/A N/A 491 83749 83764 N/A N/A 83837 83852 N/A N/A 908409 83662 83677 GTAAGGGTTACTTTGC 8 N/A N/A 492 83750 83765 N/A N/A 83838 83853 N/A N/A 908410 83663 83678 GGTAAGGGTTACTTTG 12 N/A N/A 493 83751 83766 N/A N/A 83839 83854 N/A N/A 908411 83664 83679 AGGTAAGGGTTACTTT 17 N/A N/A 494 83752 83767 N/A N/A 83840 83855 N/A N/A 908412 83665 83680 GAGGTAAGGGTTACTT 12 N/A N/A 495 83753 83768 N/A N/A 83841 83856 N/A N/A 908413 83666 83681 TGAGGTAAGGGTTACT 3 N/A N/A 496 83754 83769 N/A N/A 83842 83857 N/A N/A 908414 83667 83682 TTGAGGTAAGGGTTAC 5 N/A N/A 497 83755 83770 N/A N/A 83843 83858 N/A N/A 908415 83669 83684 AACCCTTACCTCAATC 3 N/A N/A 498 83757 83772 N/A N/A 83845 83860 N/A N/A 908416 83670 83685 TGATTGAGGTAAGGGT 4 N/A N/A 499 83758 83773 N/A N/A 83846 83861 N/A N/A 908417 83671 83686 TTGATTGAGGTAAGGG 2 N/A N/A 500 83759 83774 N/A N/A 83847 83862 N/A N/A 908418 83672 83687 CTTGATTGAGGTAAGG 8 N/A N/A 501 83760 83775 N/A N/A 83848 83863 N/A N/A 908419 83673 83688 TCTTGATTGAGGTAAG 5 N/A N/A 502 83761 83776 N/A N/A 83849 83864 N/A N/A 908420 83674 83689 ATCTTGATTGAGGTAA 2 N/A N/A 503 83762 83777 N/A N/A 83850 83865 N/A N/A 908421 83684 83699 ACCGCTCTGTATCTTG 3 N/A N/A 504 83772 83787 N/A N/A 83860 83875 N/A N/A 908422 83685 83700 AACCGCTCTGTATCTT 3 N/A N/A 505 83773 83788 N/A N/A 83861 83876 N/A N/A 908423 83686 83701 AGATACAGAGCGGTTC 28 N/A N/A 506 83774 83789 N/A N/A 83862 83877 N/A N/A 908424 83687 83702 GGAACCGCTCTGTATC 8 N/A N/A 507 83775 83790 N/A N/A 83863 83878 N/A N/A 908425 83688 83703 CGGAACCGCTCTGTAT 13 N/A N/A 508 83776 83791 N/A N/A 83864 83879 N/A N/A 908426 83689 83704 ACGGAACCGCTCTGTA 47 N/A N/A 509 83777 83792 N/A N/A 83865 83880 N/A N/A 908427 83690 83705 GACGGAACCGCTCTGT 21 N/A N/A 510 83778 83793 N/A N/A 83866 83881 N/A N/A 908428 83691 83706 TGACGGAACCGCTCTG 33 N/A N/A 511 83779 83794 N/A N/A 83867 83882 N/A N/A 908429 83692 83707 GTGACGGAACCGCTCT 44 N/A N/A 512 83780 83795 N/A N/A 83868 83883 N/A N/A 908430 83693 83708 GGTGACGGAACCGCTC 27 N/A N/A 513 83781 83796 N/A N/A 83869 83884 N/A N/A 908431 83694 83709 AGCGGTTCCGTCACCT 67 N/A N/A 514 83782 83797 N/A N/A 83870 83885 N/A N/A 908432 83695 83710 GAGGTGACGGAACCGC 69 N/A N/A 515 83783 83798 N/A N/A 83871 83886 N/A N/A 908433 83696 83711 GGAGGTGACGGAACCG 62 N/A N/A 516 83784 83799 N/A N/A 83872 83887 N/A N/A 908434 83697 83712 AGGAGGTGACGGAACC 6 N/A N/A 517 83785 83800 N/A N/A 83873 83888 N/A N/A 908435 83698 83713 TAGGAGGTGACGGAAC 16 N/A N/A 518 83786 83801 N/A N/A 83874 83889 N/A N/A 908436 83699 83714 TTAGGAGGTGACGGAA 14 N/A N/A 519 83787 83802 N/A N/A 83875 83890 N/A N/A 908437 83709 83724 GACAGGGATTTTAGGA 29 N/A N/A 520 83885 83900 N/A N/A 908438 83710 83725 GGACAGGGATTTTAGG 49 N/A N/A 521 83886 83901 N/A N/A 908439 83719 83734 CCTGTCCCTATCATGC 3 N/A N/A 522 83807 83822 N/A N/A 908440 83720 83735 AGCATGATAGGGACAG 4 N/A N/A 523 83808 83823 N/A N/A 908441 83721 83736 CAGCATGATAGGGACA 2 N/A N/A 524 83809 83824 N/A N/A 908442 83722 83737 TCAGCATGATAGGGAC 4 N/A N/A 525 83810 83825 N/A N/A 908443 83723 83738 GTCAGCATGATAGGGA 4 N/A N/A 526 83811 83826 N/A N/A 908444 83724 83739 TGTCAGCATGATAGGG 4 N/A N/A 527 83812 83827 N/A N/A 908445 83725 83740 CTGTCAGCATGATAGG 44 N/A N/A 528 83813 83828 N/A N/A 908446 83726 83741 GCTGTCAGCATGATAG 70 N/A N/A 529 83814 83829 N/A N/A 908447 83727 83742 TATCATGCTGACAGCT 55 N/A N/A 530 83815 83830 N/A N/A 908448 83910 83925 GAGGTTGACTACAAAG 12 N/A N/A 531 908449 83913 83928 TGAGAGGTTGACTACA 6 N/A N/A 532 908450 83915 83930 TTTGAGAGGTTGACTA 17 N/A N/A 533 908451 83921 83936 TGGGTTTTTGAGAGGT 9 N/A N/A 534 908452 84177 84192 GGCGATGGCACGACCA 71 N/A N/A 535 908453 84938 84953 GTATAAGGACGGCCCA 45 N/A N/A 536 908454 85500 85515 TCAGATCCGGCCTGGC 191 N/A N/A 537 908455 86165 86180 GTGGTGTGGCGTGCGC 75 N/A N/A 538 908456 86583 86598 GAACTTACTGTCTCCC 14 N/A N/A 539 908457 87056 87071 AGGCAGGGCCGCTGTC 100 N/A N/A 540 908458 87386 87401 AGGATTGGTGCCGCCC 36 N/A N/A 541 908459 87906 87921 AATCAGCGGGTGATGC 118 N/A N/A 542 908460 88179 88194 GCCCAGTGGCCGCCCT 70 N/A N/A 543 908461 88831 88846 CTACAGCTGGTGCGGT 40 N/A N/A 544 908462 89400 89415 CGCCAGGCTTGGGCCC 100 N/A N/A 545 908463 89711 89726 GCCCAGATAAGAAGCC 38 N/A N/A 546 908464 90096 90111 GGCTAGTTCATGCCGG 63 N/A N/A 547 908465 90743 90758 ACGGCCTGGGCACACG 52 N/A N/A 548 908466 90747 90762 GGAAACGGCCTGGGCA 64 N/A N/A 549 908467 90750 90765 AAGGGAAACGGCCTGG 76 N/A N/A 550 908468 90753 90768 CGCAAGGGAAACGGCC 108 N/A N/A 551 908469 90755 90770 TGCGCAAGGGAAACGG 87 N/A N/A 552 908470 90757 90772 GCTGCGCAAGGGAAAC 124 N/A N/A 553 908471 90761 90776 CCCTTGCGCAGCTCTG 18 N/A N/A 554 908472 90765 90780 CACACAGAGCTGCGCA 57 N/A N/A 555 908473 90778 90793 GAAGCCCCCTGCACAC 37 N/A N/A 556 908474 90781 90796 AGAGAAGCCCCCTGCA 72 N/A N/A 557 908475 90809 90824 CCAAGTGAGCAGCCAC 9 N/A N/A 558 908476 90811 90826 GACCAAGTGAGCAGCC 27 N/A N/A 559 908477 90813 90828 GGGACCAAGTGAGCAG 63 N/A N/A 560 908478 91157 91172 CACTAGGCCCTGCCAG 128 N/A N/A 561 908479 91836 91851 GAGCGGGGGTCTGTGA 58 N/A N/A 562 908480 92802 92817 CAGCACTTTGTCCGGG 82 N/A N/A 563 908481 93315 93330 ACCTACGGCAAGCGCA 31 N/A N/A 564 908482 93568 93583 TACCAGGATCTCCCCC 19 N/A N/A 565 908483 94077 94092 GCTAGAGGAGCGGCAC 74 N/A N/A 566 908484 94531 94546 GCCCATCTCACGCCCC 71 N/A N/A 567 908485 95058 95073 CCAGAGGCCACGGCCA 94 N/A N/A 568 908486 95635 95650 CCGCACACCCCTCGGT 111 N/A N/A 569 908487 96522 96537 CAGGCCGCCCTGTGCG 93 N/A N/A 570 908488 97096 97111 CCCAAGCATTTCCAGC 37 N/A N/A 571 908489 97109 97124 AGTTCCACCCTGTCCC 23 N/A N/A 572 908490 97144 97159 TAGAGACACCTCCAGC 47 N/A N/A 573 908491 97147 97162 CAATAGAGACACCTCC 44 N/A N/A 574 908492 97150 97165 CCGCAATAGAGACACC 43 N/A N/A 575 908493 97152 97167 GACCGCAATAGAGACA 64 N/A N/A 576 908494 97154 97169 GGGACCGCAATAGAGA 94 N/A N/A 577 908495 97157 97172 CTATTGCGGTCCCTGG 31 N/A N/A 578 908496 97159 97174 AGCCAGGGACCGCAAT 85 N/A N/A 579 908497 97426 97441 GCCCACCCGCTCTTCC 80 N/A N/A 580 908498 98041 98056 TGGAACCCCGGTGCCC 119 N/A N/A 581 908499 98971 98986 CTTCACCGTTTGGCCA 45 N/A N/A 582 908500 100149 100164 CGCGGAGCCAGGCCCT 114 N/A N/A 583 908501 101337 101352 CCCCAGAGTCCCGCAG 72 N/A N/A 584 908502 101845 101860 ACACGAAGGGCCCCTC 52 N/A N/A 585 908503 102223 102238 GCAGACTGATAGGGCC 103 N/A N/A 586 908504 102495 102510 GGATAGCCGGCCCCGC 102 N/A N/A 587 908505 102955 102970 CGCGGCCGGAAGCTTC 93 N/A N/A 588 908506 103211 103226 CAGAGCATAGGAGAGG 7 N/A N/A 589 103249 103264 N/A N/A 908507 103213 103228 AGCAGAGCATAGGAGA 12 N/A N/A 590 103251 103266 N/A N/A 908508 103216 103231 GGGAGCAGAGCATAGG 16 N/A N/A 591 103254 103269 N/A N/A 908509 104082 104097 GCCAGCCACGGCTGTC 81 N/A N/A 592 908510 104495 104510 GCTGACGGCACGCACA 65 N/A N/A 593 908511 105108 105123 TGGGGATGGCTCGGGG 79 N/A N/A 594 908512 105526 105541 CACCAGGGCTCCGCCT 107 N/A N/A 595 908513 106268 106283 GGCACACGGCTCAGGG 93 N/A N/A 596 908514 106974 106989 CAGCAAGTGGCTGCCC 107 N/A N/A 597 908515 107645 107660 TGGGAGTGGTACTGCA 70 N/A N/A 598 908516 108733 108748 TGCCATGGGTCTGGCA 86 N/A N/A 599 908517 108893 108908 GCTCCTCACCTGGTCC 92 N/A N/A 600 908518 108899 108914 AGGACGGCTCCTCACC 111 N/A N/A 601 908519 108902 108917 GAGGAGCCGTCCTGCG 85 N/A N/A 602 908520 108906 108921 GCTGCGCAGGACGGCT 104 N/A N/A 603 908521 109226 109241 GGGCGAACCACCCACC 78 N/A N/A 604 908522 109577 109592 GCCCAAAGGATCTGCC 88 N/A N/A 605 908523 109968 109983 CCCTATTGTCCCACCA 43 N/A N/A 606 908524 110612 110627 GTGCACTCTAGGCTTA 100 N/A N/A 607 908525 111378 111393 GGACACAGCGGCTGCC 78 N/A N/A 608 908526 111925 111940 CCGCAGGTTTCTGTGG 122 N/A N/A 609 908527 112198 112213 ACCGATAGGATCGGAG 95 N/A N/A 610 908528 112578 112593 GGCCGTCACAACTTTT 116 N/A N/A 611 908529 112910 112925 CTGGAACCTCCTACTG 87 N/A N/A 612 908530 114292 114307 GGCCGAATGCTTGAGG 97 N/A N/A 613 908531 114921 114936 TCACAGGGCCCCCTCA 68 N/A N/A 614 908532 115371 115386 GGCCTTACCTGGGCAC 101 N/A N/A 615 908533 115837 115852 CCGCAAGCCACCAGGG 87 N/A N/A 616 *Oligos with an asterisk target an amplicon region.

Each modified oligonucleotide listed in the table below is 100% complementary to human DNM2 nucleic acid sequence GENBANK Number NM_001005361.2 (designated herein as SEQ ID NO:3). “Start Site” indicates the 5′-most nucleoside of SEQ ID No: 3 to which the oligonucleotide is complementary. “Stop Site” indicates the 3′-most nucleoside of SEQ ID No: 3 to which the oligonucleotide is complementary. ‘N/A’ indicates that the modified oligonucleotide is not 100% complementary to the particular nucleic acid. As shown below, modified oligonucleotides complementary to DNM2 reduced human DNM2 mRNA expression.

TABLE 2 DNM2 mRNA Expression SEQ SEQ ID: 3 ID: 3 SEQ Compound Start Stop Dynamin2 ID Number Site Site Sequence (%Control) NO 695118 1728 1743 ATCTCCCCCTGATTGG  60 617 908218 1732 1747 CAGGATCTCCCCCTGA 114 618 908219 1379 1394 GCCCCGTCCTGACTCC  61 619 908220 1381 1396 GAGCCCCGTCCTGACT  92 620 908233 1515 1530 CTGAGCTTCTCGGCAC  70 621 908234 1517 1532 AACTGAGCTTCTCGGC  85 622 908235 1519 1534 GGAACTGAGCTTCTCG  33 623

Example 2: Effect of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Modified oligonucleotides complementary to dynamin (DNM2) nucleic acid were designed and tested for their effect on dynamin 2 mRNA in vitro. The modified oligonucleotides were tested in a series of experiments that had similar culture conditions.

A431 cells cultured at a density of 10,000 cells per well were treated with 2,000 nM of modified oligonucleotide via free uptake or no oligonucleotide for untreated controls. After approximately 24 hours, RNA was isolated from the cells and DNM2 mRNA levels were measured by quantitative real-time PCR as described in Example 1.

The modified oligonucleotides in the tables below each have a 3-10-3 cEt gapmer motif, wherein the central gap segment contains ten 2′-deoxynucleosides and is flanked by wing segments on the 3′ and 5′ ends, each containing three cEt nucleosides. All cytosine residues throughout each modified oligonucleotide are 5-methyl cytosines. All internucleoside linkages are phosphorothioate internucleoside linkages.

Each modified oligonucleotide listed in the tables below is 100% complementary to human DNM2 nucleic acid sequence GENBANK Number NC_000019.10, truncated from 10715001 to 1083500 (SEQ ID NO: 1) and/or GENBANK Number NM_004945.3 (SEQ ID NO:2). As shown below, modified oligonucleotides complementary to human DNM2 inhibited human DNM2 mRNA expression.

TABLE 3 DNM2 mRNA Expression SEQ SEQ SEQ ID: SEQ ID: ID: 2 ID 2: SEQ Compound 1 Start 1 Stop Dunamin2 Start Stop ID Number Site Site Sequence (%Control) Site Site NO 694792 3060 3075 CGACACCCGACCCGAG 26 N/A N/A 624 694812 3317 3332 GTCCAGGTGGCAGCTC 37 265 280 625 694826 57522 57537 CCGGACTTCATCAAAG 82 469 484 626 694999 115263 115278 GTCCAGGCCGGGATGG 92 2606 N/A 627 695015 116005 116020 GCGGATAATGGTGGGC 12 2749 N/A 628 695016 116011 116026 GGCTGGGCGGATAATG 76 2755 N/A 629 695170 82446 82461 CTTCAAACTCGGCTCT 9 N/A N/A 630 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 12 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 9 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 8 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 11 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 121 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 14 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 8 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 6 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 31 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 8 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 6 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 10 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 8 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 12 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 11 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 11 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 5 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 12 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 120 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 6 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 8 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 9 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 10 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 9 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 9 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 9 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 10 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 7 N/A N/A 13 948484 82379 82394 GTGAAGAGCCCCGTCC 42 N/A N/A 631 948485 82380 82395 GGTGAAGAGCCCCGTC 103 N/A N/A 632 948486 82443 82458 CAAACTCGGCTCTTTG 99 N/A N/A 633 948487 82444 82459 TCAAACTCGGCTCTTT 15 N/A N/A 634 948488 82445 82460 TTCAAACTCGGCTCTT 5 N/A N/A 635 948489 82448 82463 CACTTCAAACTCGGCT 3 N/A N/A 636 948490 82449 82464 ACACTTCAAACTCGGC 1 N/A N/A 637 948491 82450 82465 CACACTTCAAACTCGG 25 N/A N/A 638 948492 82452 82467 AACACACTTCAAACTC 11 N/A N/A 639 948493 82453 82468 CAACACACTTCAAACT 51 N/A N/A 640 948494 82454 82469 TCAACACACTTCAAAC 30 N/A N/A 641 948495 82458 82473 GAGATCAACACACTTC 19 N/A N/A 642 948496 82460 82475 ACGAGATCAACACACT 5 N/A N/A 643 948497 82461 82476 CACGAGATCAACACAC 28 N/A N/A 644 948498 82463 82478 ACCACGAGATCAACAC 50 N/A N/A 645 948499 82467 82482 TGAGACCACGAGATCA 55 N/A N/A 646 948500 82469 82484 TCTGAGACCACGAGAT 107 N/A N/A 647 948501 82470 82485 CTCTGAGACCACGAGA 119 N/A N/A 648 948502 82490 82505 TTTTTTATGACCGTGG 18 N/A N/A 649 948503 82496 82511 GCACACTTTTTTATGA 17 N/A N/A 650 948504 82497 82512 GGCACACTTTTTTATG 54 N/A N/A 651 948505 82499 82514 TCGGCACACTTTTTTA 10 N/A N/A 652 948506 82500 82515 CTCGGCACACTTTTTT 3 N/A N/A 653 948507 82501 82516 TCTCGGCACACTTTTT 3 N/A N/A 654 948508 82503 82518 CTTCTCGGCACACTTT 3 N/A N/A 655 948514 3056 3071 ACCCGACCCGAGCGAC 81 4 19 656 948515 3067 3082 TCTCAGGCGACACCCG 88 15 30 657 948516 3092 3107 CCTCACGGTCGCCGCC 56 40 55 658 948517 3094 3109 GGCCTCACGGTCGCCG 98 42 57 659 948518 3103 3118 TCCCGGCTCGGCCTCA 48 51 66 660 948519 3139 3154 GCTCCCCGCCCGCCCG 71 87 102 661 948520 3141 3156 TTGCTCCCCGCCCGCC 23 89 104 662 948521 3142 3157 GTTGCTCCCCGCCCGC 10 90 105 663 948522 3143 3158 CGTTGCTCCCCGCCCG 50 91 106 664 948523 3145 3160 GCCGTTGCTCCCCGCC 53 93 108 665 948524 3147 3162 TAGCCGTTGCTCCCCG 17 95 110 666 948525 3148 3163 GTAGCCGTTGCTCCCC 14 96 111 667 948526 3150 3165 CTGTAGCCGTTGCTCC 10 98 113 668 948527 3151 3166 TCTGTAGCCGTTGCTC 9 99 114 669 948528 3152 3167 GTCTGTAGCCGTTGCT 13 100 115 670 948529 3168 3183 GACCTGGCCCCGCGGC 76 116 131 671 948530 3169 3184 CGACCTGGCCCCGCGG 83 117 132 672 948531 3170 3185 ACGACCTGGCCCCGCG 36 118 133 673 948532 3172 3187 CAACGACCTGGCCCCG 17 120 135 674 948533 3173 3188 TCAACGACCTGGCCCC 20 121 136 675 948534 3174 3189 CTCAACGACCTGGCCC 30 122 137 676 948535 3175 3190 CCTCAACGACCTGGCC 101 123 138 677 948536 3176 3191 CCCTCAACGACCTGGC 57 124 139 678 948537 3278 3293 CTGCAGTTTGTTGACC 45 226 241 679 948538 3299 3314 GCCGATGGAGCTGAAG 7 247 262 680 948539 3300 3315 GGCCGATGGAGCTGAA 104 248 263 681 948540 N/A N/A AAGGAAGTCCCGGCCC 81 346 361 682 948541 N/A N/A GAAGGAAGTCCCGGCC 101 347 362 683 948542 44750 44765 GATTCCTGAACCGCGG 106 364 379 684 948543 44752 44767 ACGATTCCTGAACCGC 38 366 381 685 948544 44754 44769 TGACGATTCCTGAACC 18 368 383 686 948545 44755 44770 GTGACGATTCCTGAAC 40 369 384 687 948546 44756 44771 GGTGACGATTCCTGAA 42 370 385 688 948547 44758 44773 CGGGTGACGATTCCTG 111 372 387 689 948548 44761 44776 CGCCGGGTGACGATTC 44 375 390 690 948549 44769 44784 TGAGAGGCCGCCGGGT 11 383 398 691 948550 44771 44786 AATGAGAGGCCGCCGG 76 385 400 692 948551 44772 44787 GAATGAGAGGCCGCCG 67 386 401 693 948552 44775 44790 GCAGAATGAGAGGCCG 99 389 404 694 948553 57480 57495 CAAAAACTCGGCATGT 20 427 442 695 948554 57481 57496 GCAAAAACTCGGCATG 15 428 443 696 948555 57490 57505 ACTTGCAGTGCAAAAA 15 437 452 697 948556 57492 57507 GGACTTGCAGTGCAAA 7 439 454 698 948557 57494 57509 TTGGACTTGCAGTGCA 3 441 456 699 948558 57497 57512 TTTTTGGACTTGCAGT 10 444 459 700 948559 57498 57513 CTTTTTGGACTTGCAG 6 445 460 701 948560 57500 57515 AACTTTTTGGACTTGC 3 447 462 702 948561 57501 57516 AAACTTTTTGGACTTG 92 448 463 703 948562 57502 57517 TAAACTTTTTGGACTT 8 449 464 704 948563 57503 57518 GTAAACTTTTTGGACT 26 450 465 705 948564 57504 57519 TGTAAACTTTTTGGAC 15 451 466 706 948565 57524 57539 TGCCGGACTTCATCAA 31 471 486 707 948566 57525 57540 CTGCCGGACTTCATCA 24 472 487 708 948567 57527 57542 TCCTGCCGGACTTCAT 26 474 489 709 948568 57530 57545 ATCTCCTGCCGGACTT 14 477 492 710 948569 57531 57546 AATCTCCTGCCGGACT 18 478 493 711 948570 57535 57550 CTTCAATCTCCTGCCG 29 482 497 712 948571 57597 57612 TCGAAGGTTGATGGGC 89 544 559 713 948572 57598 57613 CTCGAAGGTTGATGGG 88 545 560 714 948573 57599 57614 ACTCGAAGGTTGATGG 75 546 561 715 948574 60706 60721 ATGAGGGTCAAGTTCA 52 579 594 716 948575 60708 60723 CGATGAGGGTCAAGTT 15 581 596 717 948576 60709 60724 TCGATGAGGGTCAAGT 28 582 597 718 948577 60710 60725 GTCGATGAGGGTCAAG 22 583 598 719 948578 60712 60727 AGGTCGATGAGGGTCA 15 585 600 720 948579 60714 60729 GGAGGTCGATGAGGGT 53 587 602 721 948580 60717 60732 CCGGGAGGTCGATGAG 93 590 605 722 948581 60721 60736 ATACCCGGGAGGTCGA 32 594 609 723 948582 60723 60738 TGATACCCGGGAGGTC 34 596 611 724 948583 60725 60740 GGTGATACCCGGGAGG 32 598 613 725 948584 60726 60741 TGGTGATACCCGGGAG 79 599 614 726 948585 60727 60742 TTGGTGATACCCGGGA 27 600 615 727 948586 60729 60744 CCTTGGTGATACCCGG 44 602 617 728 948587 60774 60789 CCTTGATCTGGTACTC 6 647 662 729 948588 60775 60790 TCCTTGATCTGGTACT 20 648 663 730 948589 60777 60792 TGTCCTTGATCTGGTA 12 650 665 731 948590 60779 60794 CATGTCCTTGATCTGG 13 652 667 732 948591 60781 60796 ATCATGTCCTTGATCT 34 654 669 733 948592 60782 60797 GATCATGTCCTTGATC 57 655 670 734 948593 60783 60798 GGATCATGTCCTTGAT 38 656 671 735 948594 60815 60830 AATGAGGCTGCTCTCC 42 688 703 736 948595 60820 60835 GCCAGAATGAGGCTGC 92 693 708 737 948596 60848 60863 GGCCAGGTCCATGTTG 92 721 736 738 948597 N/A N/A GGTCCGTAGGCCTTGG 45 775 790 739 948598 62120 62135 CACCGATGGTCCGTAG 49 782 797 740 948599 62192 62207 ACGGGAGCAACTTGTT 76 854 869 741 948600 62196 62211 CTCAACGGGAGCAACT 48 858 873 742 948601 62197 62212 TCTCAACGGGAGCAAC 45 859 874 743 948602 68004 68019 CACGGATGTCCTTCTT 8 923 938 744 948603 68006 68021 TGCACGGATGTCCTTC 25 925 940 745 948604 68007 68022 CTGCACGGATGTCCTT 5 926 941 746 948605 68009 68024 TGCTGCACGGATGTCC 16 928 943 747 948606 68010 68025 GTGCTGCACGGATGTC 20 929 944 748 948607 68011 68026 AGTGCTGCACGGATGT 22 930 945 749 948608 68012 68027 CAGTGCTGCACGGATG 8 931 946 750 948609 68014 68029 GCCAGTGCTGCACGGA 37 933 948 751 948610 68015 68030 TGCCAGTGCTGCACGG 50 934 949 752 948611 68016 68031 CTGCCAGTGCTGCACG 27 935 950 753 948612 68018 68033 AGCTGCCAGTGCTGCA 107 937 952 754 948613 68056 68071 TGCCGGTAGGCCGGGT 122 975 990 755 948614 71653 71668 CCGAAAGTTCTTGTAC 31 1129 1144 756 948615 71656 71671 GGGCCGAAAGTTCTTG 88 1132 1147 757 948616 71657 71672 CGGGCCGAAAGTTCTT 75 1133 1148 758 948617 71658 71673 TCGGGCCGAAAGTTCT 42 1134 1149 759 948618 71660 71675 CGTCGGGCCGAAAGTT 20 1136 1151 760 948619 71683 71698 GGCTTTGGTTTTGCGG 80 1159 1174 761 948620 78729 78744 ATCCACCCCAAACTGC 45 1192 1207 762 948621 78771 78786 AGTGTCCACCTGATCT 27 1234 1249 763 948622 78773 78788 AGAGTGTCCACCTGAT 11 1236 1251 764 948623 78774 78789 CAGAGTGTCCACCTGA 88 1237 1252 765 948624 78775 78790 CCAGAGTGTCCACCTG 74 1238 1253 766 948625 78777 78792 CTCCAGAGTGTCCACC 51 1240 1255 767 948626 78785 78800 CCGGAGAGCTCCAGAG 98 1248 1263 768 948627 78787 78802 CCCCGGAGAGCTCCAG 44 1250 1265 769 948628 78805 78820 TGCGATTGATTCGGGC 11 1268 1283 770 948629 78806 78821 ATGCGATTGATTCGGG 3 1269 1284 771 948630 78810 78825 GAAGATGCGATTGATT 10 1273 1288 772 948631 78811 78826 GGAAGATGCGATTGAT 3 1274 1289 773 948632 78812 78827 TGGAAGATGCGATTGA 9 1275 1290 774 948633 78813 78828 GTGGAAGATGCGATTG 8 1276 1291 775 948634 78829 78844 CAAATGGGAACCGCTC 60 1292 1307 776 948335 78830 78845 TCAAATGGGAACCGCT 65 1293 1308 777 948636 78831 78846 CTCAAATGGGAACCGC 81 1294 1309 778 948637 78832 78847 GCTCAAATGGGAACCG 58 1295 1310 779 948638 78833 78848 AGCTCAAATGGGAACC 43 1296 1311 780 948639 78837 78852 CACCAGCTCAAATGGG 70 1300 1315 781 948640 80420 80435 CTCCATGGATGTTCTT 42 1367 1382 782 948641 81059 81074 TGAAAAGCCCGGTCCT 38 1385 1400 783 948642 81060 81075 GTGAAAAGCCCGGTCC 37 1386 1401 784 948643 81062 81077 GGGTGAAAAGCCCGGT 120 1388 1403 785 948644 81077 81092 CGAATGCCAAGTCCGG 84 1403 1418 786 948645 81078 81093 TCGAATGCCAAGTCCG 28 1404 1419 787 948646 81080 81095 CCTCGAATGCCAAGTC 13 1406 1421 788 948647 81081 81096 GCCTCGAATGCCAAGT 73 1407 1422 789 948648 81084 81099 ATGGCCTCGAATGCCA 94 1410 1425 790 948649 81088 81103 CACAATGGCCTCGAAT 35 1414 1429 791 948650 81104 81119 TGACGACCTGCTTTTT 15 1430 1445 792 948651 81105 81120 TTGACGACCTGCTTTT 21 1431 1446 793 948652 81108 81123 AGCTTGACGACCTGCT 84 1434 1449 794 948653 81110 81125 TCAGCTTGACGACCTG 61 1436 1451 795 948654 81112 81127 TTTCAGCTTGACGACC 11 1438 1453 796 948655 81114 81129 TCTTTCAGCTTGACGA 27 1440 1455 797 948656 81116 81131 GCTCTTTCAGCTTGAC 3 1442 1457 798 948657 81117 81132 GGCTCTTTCAGCTTGA 59 1443 1458 799 948658 81118 81133 GGGCTCTTTCAGCTTG 73 1444 1459 800 948659 81120 81135 CAGGGCTCTTTCAGCT 75 1446 1461 801 948660 81132 81147 ACACATTTCAGACAGG 3 1458 1473 802 948661 81134 81149 CGACACATTTCAGACA 7 1460 1475 803 948662 81135 81150 TCGACACATTTCAGAC 10 1461 1476 804 948663 81136 81151 GTCGACACATTTCAGA 51 1462 1477 805 948664 81138 81153 AGGTCGACACATTTCA 3 1464 1479 806 948665 81140 81155 CCAGGTCGACACATTT 6 1466 1481 807 948666 81141 81156 ACCAGGTCGACACATT 8 1467 1482 808 948667 81142 81157 AACCAGGTCGACACAT 34 1468 1483 809 948668 81146 81161 GGATAACCAGGTCGAC 34 1472 1487 810 948669 81148 81163 CTGGATAACCAGGTCG 43 1474 1489 811 948670 81149 81164 CCTGGATAACCAGGTC 111 1475 1490 812 948671 81150 81165 TCCTGGATAACCAGGT 100 1476 1491 813 948672 81152 81167 GCTCCTGGATAACCAG 51 1478 1493 814 948673 81159 81174 TTGATTAGCTCCTGGA 2 1485 1500 815 948674 81161 81176 TATTGATTAGCTCCTG 8 1487 1502 816 948675 81162 81177 GTATTGATTAGCTCCT 2 1488 1503 817 948676 81163 81178 TGTATTGATTAGCTCC 1 1489 1504 818 948677 81164 81179 CTGTATTGATTAGCTC 2 1490 1505 819 948678 81165 81180 ACTGTATTGATTAGCT 7 1491 1506 820 948679 81168 81183 CTAACTGTATTGATTA 56 1494 1509 821 948680 81169 81184 CCTAACTGTATTGATT 44 1495 1510 822 948681 81171 81186 TGCCTAACTGTATTGA 25 1497 1512 823 948682 81177 81192 GTACACTGCCTAACTG 23 1503 1518 824 948683 81180 81195 CTGGTACACTGCCTAA 14 1506 1521 825 948684 81181 81196 ACTGGTACACTGCCTA 8 1507 1522 826 948685 81183 81198 TTACTGGTACACTGCC 2 1509 1524 827 948686 81184 81199 CTTACTGGTACACTGC 1 1510 1525 828 948687 N/A N/A GCTTACTGGTACACTG 6 1511 1526 829 948688 N/A N/A AGCTTACTGGTACACT 26 1512 1527 830 948689 N/A N/A GAGCTTACTGGTACAC 12 1513 1528 831 948690 N/A N/A ACTGAGCTTACTGGTA 47 1516 1531 832 948691 N/A N/A AACTGAGCTTACTGGT 24 1517 1532 833 948692 N/A N/A GGAACTGAGCTTACTG 10 1519 1534 834 948693 N/A N/A AGGAACTGAGCTTACT 12 1520 1535 835 948694 N/A N/A TAGGAACTGAGCTTAC 17 1521 1536 836 948695 N/A N/A GTAGGAACTGAGCTTA 15 1522 1537 837 948696 83484 83499 GGGTAGGAACTGAGCT 28 1524 1539 838 948697 83500 83515 CTCCTCTCGCAACCGG 56 1540 1555 839 948698 83503 83518 TGTCTCCTCTCGCAAC 44 1543 1558 840 948699 83504 83519 CTGTCTCCTCTCGCAA 27 1544 1559 841 948700 83506 83521 CTCTGTCTCCTCTCGC 5 1546 1561 842 948701 83507 83522 GCTCTGTCTCCTCTCG 8 1547 1562 843 948702 83508 83523 CGCTCTGTCTCCTCTC 5 1548 1563 844 948703 83510 83525 TTCGCTCTGTCTCCTC 5 1550 1565 845 948704 83514 83529 ACGATTCGCTCTGTCT 69 1554 1569 846 948705 83515 83530 GACGATTCGCTCTGTC 91 1555 1570 847 948706 83516 83531 TGACGATTCGCTCTGT 37 1556 1571 848 948707 83521 83536 AGTGGTGACGATTCGC 5 1561 1576 849 948708 83523 83538 TAAGTGGTGACGATTC 25 1563 1578 850 948709 83525 83540 TGTAAGTGGTGACGAT 21 1565 1580 851 948710 83526 83541 ATGTAAGTGGTGACGA 27 1566 1581 852 948711 83527 83542 GATGTAAGTGGTGACG 37 1567 1582 853 948712 83530 83545 CCGGATGTAAGTGGTG 60 1570 1585 854 948713 83543 83558 TCCCCTCCCGTTCCCG 40 1583 1598 855 948714 83545 83560 TCTCCCCTCCCGTTCC 30 1585 1600 856 948715 83546 83561 TTCTCCCCTCCCGTTC 43 1586 1601 857 948716 83547 83562 GTTCTCCCCTCCCGTT 14 1587 1602 858 948717 N/A N/A GCAGAAGAATCTGGTC 27 1607 1622 859 948718 87287 87302 GATCAGCAGAAGAATC 126 1612 1627 860 948719 87289 87304 TCGATCAGCAGAAGAA 70 1614 1629 861 948720 87291 87306 TGTCGATCAGCAGAAG 27 1616 1631 862 948721 87292 87307 ATGTCGATCAGCAGAA 51 1617 1632 863 948722 87293 87308 AATGTCGATCAGCAGA 41 1618 1633 864 948723 87295 87310 TCAATGTCGATCAGCA 17 1620 1635 865 948724 87297 87312 GCTCAATGTCGATCAG 14 1622 1637 866 948725 87298 87313 TGCTCAATGTCGATCA 41 1623 1638 867 948726 87301 87316 GACTGCTCAATGTCGA 91 1626 1641 868 948727 87303 87318 AGGACTGCTCAATGTC 28 1628 1643 869 948728 87305 87320 GTAGGACTGCTCAATG 136 1630 1645 870 948729 87306 87321 TGTAGGACTGCTCAAT 2 1631 1646 871 948730 87307 87322 ATGTAGGACTGCTCAA 18 1632 1647 872 948731 87309 87324 TGATGTAGGACTGCTC 6 1634 1649 873 948732 87310 87325 TTGATGTAGGACTGCT 13 1635 1650 874 948733 87312 87327 TGTTGATGTAGGACTG 39 1637 1652 875 948734 87313 87328 GTGTTGATGTAGGACT 22 1638 1653 876 948735 87314 87329 CGTGTTGATGTAGGAC 3 1639 1654 877 948736 N/A N/A GGCATTGGCAAACCCG 106 1672 1687 878 948737 97293 97308 CATCAGGCTGATGTTG 43 1765 1780 879 948738 97296 97311 TTTCATCAGGCTGATG 90 1768 1783 880 948739 97340 97355 AGTGACTCGGCAGTCA 100 1812 1827 881 948740 97342 97357 ACAGTGACTCGGCAGT 25 1814 1829 882 948741 97343 97358 GACAGTGACTCGGCAG 13 1815 1830 883 948742 97344 97359 GGACAGTGACTCGGCA 33 1816 1831 884 948743 97346 97361 CAGGACAGTGACTCGG 23 1818 1833 885 948744 97347 97362 CCAGGACAGTGACTCG 36 1819 1834 886 948745 97348 97363 ACCAGGACAGTGACTC 23 1820 1835 887 948746 97349 97364 TACCAGGACAGTGACT 93 1821 1836 888 948747 105014 105029 TCACGGATCTTGAGGT 27 1884 1899 889 948748 105016 105031 CATCACGGATCTTGAG 52 1886 1901 890 948749 105017 105032 ACATCACGGATCTTGA 43 1887 1902 891 948750 105018 105033 CACATCACGGATCTTG 19 1888 1903 892 948751 105021 105036 CTCCACATCACGGATC 60 1891 1906 893 948752 105024 105039 CTTCTCCACATCACGG 4 1894 1909 894 948753 105061 105076 TGAAGATGGCGAAGAC 52 1931 1946 895 948754 105062 105077 TTGAAGATGGCGAAGA 101 1932 1947 896 948755 105063 105078 GTTGAAGATGGCGAAG 83 1933 1948 897 948756 108794 108809 CCGCAGGTCCTTGTAG 60 1966 1981 898 948757 108796 108811 TGCCGCAGGTCCTTGT 42 1968 1983 899 948758 108809 108824 GGCCAGCTCGATCTGC 85 1981 1996 900 948759 108855 108870 GGAGGAACGAGGCCTT 80 2027 2042 901 948760 108856 108871 CGGAGGAACGAGGCCT 107 2028 2043 902 948761 108858 108873 CTCGGAGGAACGAGGC 111 2030 2045 903 948762 108864 108879 CGCCAGCTCGGAGGAA 125 2036 2051 904 948763 110079 110094 GAGAAGGTGTTCTCCT 98 2094 2109 905 948764 110082 110097 ATGGAGAAGGTGTTCT 112 2097 2112 906 948765 110158 110173 GGACTTGTTGATGATG 9 2173 2188 907 948766 110159 110174 TGGACTTGTTGATGAT 10 2174 2189 908 948767 110161 110176 GATGGACTTGTTGATG 12 2176 2191 909 948768 110162 110177 GGATGGACTTGTTGAT 8 2177 2192 910 948769 110163 110178 CGGATGGACTTGTTGA 10 2178 2193 911 948770 110164 110179 GCGGATGGACTTGTTG 36 2179 2194 912 948771 110165 110180 CGCGGATGGACTTGTT 78 2180 2195 913 948772 110173 110188 CATGAGGTCGCGGATG 25 2188 2203 914 948773 110174 110189 GCATGAGGTCGCGGAT 4 2189 2204 915 948774 110176 110191 TGGCATGAGGTCGCGG 9 2191 2206 916 948775 114037 114052 TGGATGAAGGCCTTCG 6 2238 2253 917 948776 114065 114080 GGAGTATAGGTAGGCC 15 2266 2281 918 948777 114067 114082 GAGGAGTATAGGTAGG 7 2268 2283 919 948778 114070 114085 GCCGAGGAGTATAGGT 51 2271 2286 920 948779 114071 114086 TGCCGAGGAGTATAGG 17 2272 2287 921 948780 114152 114167 CTTGAGGGCATGGTAC 48 2353 2368 922 948781 114225 114240 TGTCATCGACAGGCGG 32 2426 2441 923 948782 115139 115154 GGACACCGGTCGGCGC 103 2482 2497 924 948783 115140 115155 TGGACACCGGTCGGCG 43 2483 2498 925 948784 115145 115160 TATGCTGGACACCGGT 33 2488 2503 926 948785 115147 115162 TGTATGCTGGACACCG 22 2490 2505 927 948786 115148 115163 GTGTATGCTGGACACC 78 2491 2506 928 948787 115149 115164 GGTGTATGCTGGACAC 79 2492 2507 929 948788 115212 115227 CGGGAACAGGAATCAG 13 2555 2570 930 948789 115213 115228 ACGGGAACAGGAATCA 19 2556 2571 931 948790 115217 115232 CCCCACGGGAACAGGA 101 2560 2575 932 948791 115235 115250 CGAGAAGGAGGCTGCT 45 2578 2593 933 948792 115236 115251 CCGAGAAGGAGGCTGC 37 2579 2594 934 948793 115237 115252 GCCGAGAAGGAGGCTG 124 2580 2595 935 948794 115279 115294 GCAAACACGCTCTGGG 6 2622 2637 936 948795 115280 115295 GGCAAACACGCTCTGG 11 2623 2638 937 948796 115281 115296 TGGCAAACACGCTCTG 31 2624 2639 938 948797 115282 115297 TTGGCAAACACGCTCT 23 2625 2640 939 948798 115284 115299 TGTTGGCAAACACGCT 15 2627 2642 940 948799 115286 115301 ACTGTTGGCAAACACG 66 2629 2644 941 948800 115287 115302 CACTGTTGGCAAACAC 39 2630 2645 942 948801 115288 115303 TCACTGTTGGCAAACA 28 2631 2646 943 948802 115289 115304 GTCACTGTTGGCAAAC 17 2632 2647 944 948803 115290 115305 GGTCACTGTTGGCAAA 16 2633 2648 945 948804 115291 115306 AGGTCACTGTTGGCAA 9 2634 2649 946 948805 115293 115308 AGAGGTCACTGTTGGC 3 2636 2651 947 948806 115294 115309 AAGAGGTCACTGTTGG 7 2637 2652 948 948807 115295 115310 GAAGAGGTCACTGTTG 19 2638 2653 949 948808 115297 115312 GGGAAGAGGTCACTGT 13 2640 2655 950 948809 115321 115336 CGAGATGGGATCTGAG 33 2664 2679 951 948810 115322 115337 CCGAGATGGGATCTGA 18 2665 2680 952 948811 115323 115338 GCCGAGATGGGATCTG 28 2666 2681 953 948812 115327 115342 ACTGGCCGAGATGGGA 13 2670 2685 954 948813 115328 115343 AACTGGCCGAGATGGG 20 2671 2686 955 948814 115330 115345 CGAACTGGCCGAGATG 27 2673 2688 956 948815 115331 115346 CCGAACTGGCCGAGAT 46 2674 2689 957 948816 115333 115348 ATCCGAACTGGCCGAG 35 2676 2691 958 948817 115334 115349 GATCCGAACTGGCCGA 105 2677 2692 959 948818 115991 116006 GCCGGCTGGGCGCAGC 124 2735 2750 960 948819 116000 116015 TAATGGTGGGCCGGCT 83 2744 2759 961 948820 116002 116017 GATAATGGTGGGCCGG 96 2746 2761 962 948821 116003 116018 GGATAATGGTGGGCCG 73 2747 2762 963 948822 116004 116019 CGGATAATGGTGGGCC 41 2748 2763 964 948823 116014 116029 CTCGGCTGGGCGGATA 109 2758 2773 965 948824 116023 116038 CAGGGATGGCTCGGCT 48 2767 2782 966 948825 116028 116043 TCGAGCAGGGATGGCT 84 2772 2787 967 948826 116029 116044 GTCGAGCAGGGATGGC 135 2773 2788 968 948827 116034 116049 GCCTAGTCGAGCAGGG 84 2778 2793 969 948828 116055 116070 CGAGAGCACGCCCCCC 37 2799 2814 970 948829 116058 116073 CCCCGAGAGCACGCCC 73 2802 2817 971 948830 116092 116107 ACTGAAGCTCCTGCGC 75 2836 2851 972 948831 116109 116124 GCGGAGGGCCCCAGAC 94 2853 2868 973 948832 116163 116178 GTTAAGGAAGAGGCCA 27 2907 2922 974 948833 116210 116225 TGCGGTGTCCAGCCAG 42 2954 2969 975 948834 116212 116227 AGTGCGGTGTCCAGCC 24 2956 2971 976 948835 116213 116228 CAGTGCGGTGTCCAGC 9 2957 2972 977 948836 116214 116229 GCAGTGCGGTGTCCAG 11 2958 2973 978 948837 116216 116231 GCGCAGTGCGGTGTCC 60 2960 2975 979 948838 116217 116232 TGCGCAGTGCGGTGTC 58 2961 2976 980 948839 116221 116236 CCTTTGCGCAGTGCGG 57 2965 2980 981 948840 116222 116237 CCCTTTGCGCAGTGCG 21 2966 2981 982 948841 116224 116239 GCCCCTTTGCGCAGTG 104 2968 2983 983 948842 116225 116240 GGCCCCTTTGCGCAGT 98 2969 2984 984 948843 116261 116276 GTGCAACACCCCAGCG 58 3005 3020 985 948844 116266 116281 CCAAAGTGCAACACCC 31 3010 3025 986 948845 116267 116282 CCCAAAGTGCAACACC 82 3011 3026 987 948846 116288 116303 TGCCACCCTGAGACTC 62 3032 3047 988 948847 116310 116325 TCAAGGGTTCTGGTCC 10 3054 3069 989 948848 116311 116326 GTCAAGGGTTCTGGTC 28 3055 3070 990 948849 116313 116328 GTGTCAAGGGTTCTGG 8 3057 3072 991 948850 116315 116330 TGGTGTCAAGGGTTCT 6 3059 3074 992 948851 116316 116331 ATGGTGTCAAGGGTTC 5 3060 3075 993 948852 116317 116332 GATGGTGTCAAGGGTT 6 3061 3076 994 948853 116319 116334 AGGATGGTGTCAAGGG 13 3063 3078 995 948854 116320 116335 CAGGATGGTGTCAAGG 11 3064 3079 996 948855 116321 116336 TCAGGATGGTGTCAAG 13 3065 3080 997 948856 116323 116338 ATTCAGGATGGTGTCA 13 3067 3082 998 948857 116325 116340 TCATTCAGGATGGTGT 20 3069 3084 999 948858 116327 116342 CCTCATTCAGGATGGT 82 3071 3086 1000 948859 116351 116366 GTAGAGTCCCCCCCAG 22 3095 3110 1001 948860 116353 116368 TGGTAGAGTCCCCCCC 44 3097 3112 1002 948861 116354 116369 TTGGTAGAGTCCCCCC 19 3098 3113 1003 948862 116355 116370 CTTGGTAGAGTCCCCC 9 3099 3114 1004 948863 116357 116372 ACCTTGGTAGAGTCCC 4 3101 3116 1005 948864 116358 116373 GACCTTGGTAGAGTCC 94 3102 3117 1006 948865 116361 116376 GAAGACCTTGGTAGAG 6 3105 3120 1007 948866 116363 116378 AAGAAGACCTTGGTAG 17 3107 3122 1008 948867 116364 116379 CAAGAAGACCTTGGTA 60 3108 3123 1009 948868 116365 116380 CCAAGAAGACCTTGGT 62 3109 3124 1010 948869 116366 116381 CCCAAGAAGACCTTGG 70 3110 3125 1011 948870 116367 116382 GCCCAAGAAGACCTTG 60 3111 3126 1012 948871 116384 116399 CTACATGGGCTTTCCC 85 3128 3143 1013 948872 116386 116401 CCCTACATGGGCTTTC 98 3130 3145 1014 948873 116399 116414 TATAGAAGGCCTGCCC 100 3143 3158 1015 948874 116401 116416 CTTATAGAAGGCCTGC 20 3145 3160 1016 948875 116402 116417 ACTTATAGAAGGCCTG 25 3146 3161 1017 948876 116403 116418 CACTTATAGAAGGCCT 34 3147 3162 1018 948877 116405 116420 CGCACTTATAGAAGGC 57 3149 3164 1019 948878 116406 116421 CCGCACTTATAGAAGG 83 3150 3165 1020 948879 116450 116465 CCCTGCACCCCAGCAA 128 3194 3209 1021 948880 116454 116469 ATACCCCTGCACCCCA 18 3198 3213 1022 948881 116456 116471 ATATACCCCTGCACCC 45 3200 3215 1023 948882 116457 116472 GATATACCCCTGCACC 11 3201 3216 1024 948883 116458 116473 TGATATACCCCTGCAC 13 3202 3217 1025 948884 116459 116474 TTGATATACCCCTGCA 9 3203 3218 1026 948885 116460 116475 GTTGATATACCCCTGC 4 3204 3219 1027 948886 116465 116480 GGGAAGTTGATATACC 14 3209 3224 1028 948887 116466 116481 TGGGAAGTTGATATAC 20 3210 3225 1029 948888 116468 116483 AATGGGAAGTTGATAT 59 3212 3227 1030 948889 116469 116484 TAATGGGAAGTTGATA 49 3213 3228 1031 948890 116470 116485 CTAATGGGAAGTTGAT 15 3214 3229 1032 948891 116472 116487 TGCTAATGGGAAGTTG 12 3216 3231 1033 948892 116473 116488 CTGCTAATGGGAAGTT 4 3217 3232 1034 948893 116475 116490 TCCTGCTAATGGGAAG 2 3219 3234 1035 948894 116476 116491 CTCCTGCTAATGGGAA 86 3220 3235 1036 948895 116479 116494 GAGCTCCTGCTAATGG 94 3223 3238 1037 948896 116498 116513 GGCCAGGCTTGCCGCT 99 3242 3257 1038 948897 116512 116527 TACCGAGCCCACTGGG 103 3256 3271 1039 948898 116515 116530 CACTACCGAGCCCACT 82 3259 3274 1040 948899 116517 116532 GGCACTACCGAGCCCA 64 3261 3276 1041 948900 116520 116535 CTGGGCACTACCGAGC 92 3264 3279 1042 948901 116525 116540 GCCAGCTGGGCACTAC 149 3269 3284 1043 948902 116526 116541 TGCCAGCTGGGCACTA 130 3270 3285 1044 948903 116539 116554 TACACCTCAGGCCTGC 28 3283 3298 1045 948904 116540 116555 GTACACCTCAGGCCTG 98 3284 3299 1046 948905 116542 116557 ATGTACACCTCAGGCC 77 3286 3301 1047 948906 116543 116558 TATGTACACCTCAGGC 9 3287 3302 1048 948907 116545 116560 ACTATGTACACCTCAG 5 3289 3304 1049 948908 116546 116561 GACTATGTACACCTCA 16 3290 3305 1050 948909 116548 116563 AGGACTATGTACACCT 125 3292 3307 1051 948910 116549 116564 AAGGACTATGTACACC 5 3293 3308 1052 948911 116551 116566 GGAAGGACTATGTACA 11 3295 3310 1053 948912 116552 116567 GGGAAGGACTATGTAC 28 3296 3311 1054 948913 116553 116568 CGGGAAGGACTATGTA 16 3297 3312 1055 948914 116554 116569 CCGGGAAGGACTATGT 60 3298 3313 1056 948915 116555 116570 GCCGGGAAGGACTATG 40 3299 3314 1057 948916 116560 116575 ATATGGCCGGGAAGGA 21 3304 3319 1058 948917 116562 116577 TAATATGGCCGGGAAG 2 3306 3321 1059 948918 116563 116578 TTAATATGGCCGGGAA 9 3307 3322 1060 948919 116564 116579 GTTAATATGGCCGGGA 16 3308 3323 1061 948920 116566 116581 TGGTTAATATGGCCGG 37 3310 3325 1062 948921 116567 116582 GTGGTTAATATGGCCG 45 3311 3326 1063 948922 116568 116583 TGTGGTTAATATGGCC 10 3312 3327 1064 948923 116570 116585 TGTGTGGTTAATATGG 3 3314 3329 1065 948924 116571 116586 CTGTGTGGTTAATATG 4 3315 3330 1066 948925 116572 116587 GCTGTGTGGTTAATAT 7 3316 3331 1067 948926 116574 116589 AGGCTGTGTGGTTAAT 3 3318 3333 1068 948927 116618 116633 GGCCTAGCAAAGGCAC 118 3362 3377 1069 948928 116631 116646 GCCAACGGCTCCGGGC 119 3375 3390 1070 948929 116637 116652 GCCCGGGCCAACGGCT 96 3381 3396 1071 948930 116645 116660 CAAGGCCGGCCCGGGC 131 3389 3404 1072 948931 116647 116662 GGCAAGGCCGGCCCGG 104 3391 3406 1073 948932 116652 116667 AATAGGGCAAGGCCGG 65 3396 3411 1074 948933 116653 116668 GAATAGGGCAAGGCCG 126 3397 3412 1075 948934 116654 116669 GGAATAGGGCAAGGCC 22 3398 3413 1076 948935 116656 116671 GAGGAATAGGGCAAGG 7 3400 3415 1077 948936 116657 116672 AGAGGAATAGGGCAAG 4 3401 3416 1078 948937 116658 116673 GAGAGGAATAGGGCAA 6 3402 3417 1079 948938 116660 116675 AGGAGAGGAATAGGGC 8 3404 3419 1080 948939 116705 116720 ACATAGCCCAAGCCCA 54 3449 3464 1081 948940 116706 116721 CACATAGCCCAAGCCC 72 3450 3465 1082 948941 116707 116722 CCACATAGCCCAAGCC 90 3451 3466 1083 948942 116709 116724 ACCCACATAGCCCAAG 71 3453 3468 1084 948943 116767 116782 ACCCATCAGGGAGGCA 93 3511 3526 1085 948944 116790 116805 CAGAGAGAGGCCGCCC 43 3534 3549 1086 948945 116793 116808 CCTCAGAGAGAGGCCG 134 3537 3552 1087 948946 116814 116829 AGCGAGGAGTGGGTGA 43 3558 3573 1088 948947 116817 116832 CTGAGCGAGGAGTGGG 57 3561 3576 1089 948948 116818 116833 ACTGAGCGAGGAGTGG 34 3562 3577 1090 948949 116820 116835 AAACTGAGCGAGGAGT 64 3564 3579 1091 948950 116821 116836 CAAACTGAGCGAGGAG 7 3565 3580 1092 948951 116823 116838 GTCAAACTGAGCGAGG 5 3567 3582 1093 948952 116824 116839 GGTCAAACTGAGCGAG 5 3568 3583 1094 948953 116825 116840 TGGTCAAACTGAGCGA 9 3569 3584 1095 948954 116827 116842 AGTGGTCAAACTGAGC 5 3571 3586 1096 948955 116828 116843 CAGTGGTCAAACTGAG 64 3572 3587 1097 948956 116829 116844 ACAGTGGTCAAACTGA 73 3573 3588 1098 948957 116830 116845 TACAGTGGTCAAACTG 69 3574 3589 1099 948958 116831 116846 TTACAGTGGTCAAACT 34 3575 3590 1100 948959 116833 116848 ACTTACAGTGGTCAAA 17 3577 3592 1101 948960 116834 116849 CACTTACAGTGGTCAA 11 3578 3593 1102 948961 116835 116850 GCACTTACAGTGGTCA 4 3579 3594 1103 948962 116836 116851 GGCACTTACAGTGGTC 45 3580 3595 1104 948963 116837 116852 AGGCACTTACAGTGGT 5 3581 3596 1105 948964 116841 116856 GTGCAGGCACTTACAG 43 3585 3600 1106 948965 116844 116859 AGAGTGCAGGCACTTA 7 3588 3603 1107 948966 116846 116861 ACAGAGTGCAGGCACT 8 3590 3605 1108 948967 116847 116862 TACAGAGTGCAGGCAC 12 3591 3606 1109 948968 116848 116863 ATACAGAGTGCAGGCA 6 3592 3607 1110 948969 116850 116865 GAATACAGAGTGCAGG 6 3594 3609 1111 948970 116851 116866 AGAATACAGAGTGCAG 2 3595 3610 1112 948971 116852 116867 TAGAATACAGAGTGCA 1 3596 3611 1113 948972 116854 116869 AATAGAATACAGAGTG 6 3598 3613 1114 948973 3394 3409 GCTCACCGGCCCACGA 72 N/A N/A 1115 948974 3500 3515 CGCGGGCACGCAAGCG 144 N/A N/A 1116 948975 3607 3622 CGTGACACCGCCCCTG 71 N/A N/A 1117 948976 3715 3730 ATCTACCCCAGACCCA 63 N/A N/A 1118 948977 3725 3740 CAGAAGAGGGATCTAC 99 N/A N/A 1119 948978 3776 3791 CAATAGATATCTAGAT 144 N/A N/A 1120 948979 3778 3793 CCCAATAGATATCTAG 59 N/A N/A 1121 948980 3815 3830 AGATACAAGAACAAGC 67 N/A N/A 1122 948981 3934 3949 AGCTAGCCAGACAGCA 146 N/A N/A 1123 948982 4010 4025 CAACAGAGGGACTGCT 85 N/A N/A 1124 948983 4035 4050 ACAGTAGAGGCCAGCT 96 N/A N/A 1125 948984 4130 4145 CGGAAGAGAGGAGCCA 84 N/A N/A 1126 948985 4135 4150 TCACACGGAAGAGAGG 63 N/A N/A 1127 948986 4142 4157 GAAGAATTCACACGGA 50 N/A N/A 1128 948987 4262 4277 GTCCAAACCTCCTCCT 63 N/A N/A 1129 948988 4315 4330 TCCTGAAGTAAGGTAC 96 N/A N/A 1130 948989 4326 4341 TCGGAAAGGAATCCTG 40 N/A N/A 1131 948990 4371 4386 AATTTGTAGGCTGTAG 21 N/A N/A 1132 948991 4388 4403 TCCAAAGGAGGGCCCC 140 N/A N/A 1133 948992 4476 4491 CACCGCGGCTTCTCAA 38 N/A N/A 1134 948993 4624 4639 GAGAAGTGGCCGCCCA 75 N/A N/A 1135 948994 4649 4664 CCACAAATGAGTAGTT 49 N/A N/A 1136 948995 4730 4745 CATTATCCCTTGACAA 115 N/A N/A 1137 948996 4742 4757 ATCAAGAAGGGACATT 85 N/A N/A 1138 948997 4838 4853 GGTGATCACAGTCCCT 72 N/A N/A 1139 948998 4938 4953 AGAGACAAGGTAGCAA 45 N/A N/A 1140 948999 4950 4965 AGGCAATGAGCTAGAG 39 N/A N/A 1141 949000 5049 5064 GAAGATGGTCACTCAA 47 N/A N/A 1142 949001 5051 5066 AGGAAGATGGTCACTC 32 N/A N/A 1143 949002 5162 5177 GTCAACCAAGACTTAG 48 N/A N/A 1144 949003 5545 5560 TAGAATGGCATCTTGT 28 N/A N/A 1145 949004 5710 5725 CCGGATCTGGTTCTGT 88 N/A N/A 1146 949005 5810 5825 AACCAGCCAGATAAAC 94 N/A N/A 1147 949006 5872 5887 GCTTAAGTGTGTAACG 8 N/A N/A 1148 949007 5873 5888 GGCTTAAGTGTGTAAC 10 N/A N/A 1149 949008 5898 5913 GATTATAGCAATGCCT 22 N/A N/A 1150 949009 5940 5955 GCTCAGCTATCTGAGC 107 N/A N/A 1151 949010 6074 6089 CCAGACACCATGGTAG 33 N/A N/A 1152 949011 6150 6165 ATATAATGAGCAACTC 47 N/A N/A 1153 949012 6174 6189 GTGAGACTCGGTGTAA 10 N/A N/A 1154 949013 6298 6313 GTGGTAACGCGCGCCT 41 N/A N/A 1155 949014 6455 6470 AATACTCTTAACGAGG 95 N/A N/A 1156 949015 6556 6571 ACCTTATCTCTTACAC 63 N/A N/A 1157 949016 6697 6712 TCCAGGCTCGGCGCAA 83 N/A N/A 1158 949017 6752 6767 AGCTATAGGGCTGAAC 129 N/A N/A 1159 949018 6816 6831 CGCAGGTAAAACAAAA 38 N/A N/A 1160 949019 6817 6832 ACGCAGGTAAAACAAA 56 N/A N/A 1161 949020 6821 6836 AGCTACGCAGGTAAAA 66 N/A N/A 1162 949021 6824 6839 AAAAGCTACGCAGGTA 27 N/A N/A 1163 949022 6870 6885 CCGGATATTGACTGGA 46 N/A N/A 1164 949023 6891 6906 TGTCTTAGAGCCACAA 131 N/A N/A 1165 949024 6906 6921 CTCTATAGATCTGAGT 123 N/A N/A 1166 949025 6918 6933 GACAACTCAGAACTCT 93 N/A N/A 1167 949026 7031 7046 TACCACCCTCAGCTTA 69 N/A N/A 1168 949027 7131 7146 CGCCAGGTGAAACTGA 86 N/A N/A 1169 949028 7155 7170 CCACAAGGGACAAAGG 89 N/A N/A 1170 949029 7170 7185 TCGAAGCCATTACTGC 89 N/A N/A 1171 949030 7248 7263 TGCTAGGGAGTAGTGG 47 N/A N/A 1172 949031 7273 7288 GCAAAATGATCTAGGC 26 N/A N/A 1173 949032 7328 7343 CCGCAGACAAGCCAGG 99 N/A N/A 1174 949033 7351 7366 CCAAAGTTCTATCTGC 15 N/A N/A 1175 949034 7395 7410 TGACAAGGGTCAAGAG 91 N/A N/A 1176 949035 7400 7415 CTAAATGACAAGGGTC 22 N/A N/A 1177 949036 7402 7417 GGCTAAATGACAAGGG 47 N/A N/A 1178 949037 7645 7660 GTATAAGACCCTATCT 83 N/A N/A 1179 949038 7849 7864 ATTTGAGGCGAGGAGG 58 N/A N/A 1180 949050 8567 8582 TTTTAAAGAAGACGGG 51 N/A N/A 1181 949051 8584 8599 TGCTATTATAACTCCT 15 N/A N/A 1182 949052 8671 8686 GAACAACACCTAATGT 47 N/A N/A 1183 949053 8675 8690 GAACGAACAACACCTA 8 N/A N/A 1184 949054 8678 8693 AATGAACGAACAACAC 22 N/A N/A 1185 949055 8705 8720 AGTAAAAGTACTCAGG 8 N/A N/A 1186 949056 8740 8755 TGGTAACTTGCTCAGG 16 N/A N/A 1187 949057 8773 8788 GCTGAAAGGCCAGCTC 83 N/A N/A 1188 949058 8949 8964 CTACAGGTGTCACCAT 100 N/A N/A 1189 949059 9093 9108 ACTTATCGCCTTTTTT 11 N/A N/A 1190 949061 9613 9628 CTCCACTGGCCTGCTA 4 N/A N/A 1191 949062 9724 9739 AGGGACAGCAGTAGCG 69 N/A N/A 1192 949063 9830 9845 AGAAAAATGGCACGGG 41 N/A N/A 1193 949064 9883 9898 TAAAAACGCAGCTGGA 79 N/A N/A 1194 949065 9971 9986 TGCACTGGTGCAGCAC 115 N/A N/A 1195 949066 10072 10087 GGCTCTAAACTAATAA 143 N/A N/A 1196 949067 10260 10275 TCGGGATTCACTATGT 28 N/A N/A 1197 949068 10379 10394 CGCTTACTGCAAGTTC 40 N/A N/A 1198 949069 10481 10496 CCTAACCGAGCCTTGC 78 N/A N/A 1199 949070 10675 10690 ACAACAATTTGCTACG 45 N/A N/A 1200 949071 10677 10692 TCACAACAATTTGCTA 23 N/A N/A 1201 949072 11266 11281 TGACACCAAACTGAGC 92 N/A N/A 1202 949073 11356 11371 AAAGAAACTAAGGCCG 87 N/A N/A 1203 949074 11384 11399 TAATGATGAGTTCCTT 14 N/A N/A 1204 949075 11392 11407 CAACAGAGTAATGATG 54 N/A N/A 1205 949076 11496 11511 CGATATTTCAGGATCT 88 N/A N/A 1206 949077 11597 11612 CTCATCACCGTACACA 9 N/A N/A 1207 949078 11881 11896 CCCTATCATTGGTTTT 55 N/A N/A 1208 949079 11984 11999 TAACAGGTCTTGTGCA 55 N/A N/A 1209 949080 12093 12108 ACGATTCACATGTGGG 11 N/A N/A 1210 949081 12141 12156 AACCTAATCCCCAAAC 104 N/A N/A 1211 949082 12195 12210 AGCACTTGGACAGCCT 36 N/A N/A 1212 949083 12200 12215 GAAAAAGCACTTGGAC 31 N/A N/A 1213 949084 12214 12229 CAATAAGTAACTCTGA 52 N/A N/A 1214 949085 12318 12333 ATCTACAACTGTCCCC 25 N/A N/A 1215 949086 12555 12570 AATAATGAGACCCCAC 145 N/A N/A 1216 949087 12667 12682 TAAATCTAACCTAGGC 126 N/A N/A 1217 949088 12778 12793 CAGAAGTTTGGCAGAT 5 N/A N/A 1218 949089 12788 12803 TCAAATCGGGCAGAAG 22 N/A N/A 1219 949090 12858 12873 AAATTACGGTTTACAT 71 N/A N/A 1220 949091 12859 12874 TAAATTACGGTTTACA 20 N/A N/A 1221 949092 12878 12893 TTGTAGTTGGCAATCC 12 N/A N/A 1222 949093 12892 12907 GGCTTAATTACAGCTT 86 N/A N/A 1223 949094 12901 12916 CACAATAAGGGCTTAA 10 N/A N/A 1224 949095 12902 12917 ACACAATAAGGGCTTA 10 N/A N/A 1225 949096 12947 12962 CCCTATAAATATCTCA 23 N/A N/A 1226 949097 13037 13052 ACGCACCCGGAAGCAG 71 N/A N/A 1227 949098 13140 13155 AAACAGTCATCCAGCT 105 N/A N/A 1228 949099 13208 13223 TGGCACACGGTGATTC 57 N/A N/A 1229 949100 13215 13230 GCACATGTGGCACACG 27 N/A N/A 1230 949101 13273 13288 AGGGATGCTAAGAGCA 69 N/A N/A 1231 949102 13281 13296 TATAAAGCAGGGATGC 117 N/A N/A 1232 949103 13391 13406 CCATATGTGTGGCTCT 21 N/A N/A 1233 949104 13520 13535 GCATATCCAAAGCCAC 38 N/A N/A 1234 949105 13635 13650 CATTTAACTGTTCACC 28 N/A N/A 1235 949106 13812 13827 CGACAGACAAGTACCA 46 N/A N/A 1236 949107 13952 13967 GCATACAGCCTTTTTT 38 N/A N/A 1237 949108 13953 13968 CGCATACAGCCTTTTT 15 N/A N/A 1238 949109 13955 13970 ACCGCATACAGCCTTT 9 N/A N/A 1239 949110 13956 13971 CACCGCATACAGCCTT 46 N/A N/A 1240 949111 13959 13974 AACCACCGCATACAGC 50 N/A N/A 1241 949112 13961 13976 TGAACCACCGCATACA 40 N/A N/A 1242 949113 14262 14277 TGCAACCTTCAAGTAA 94 N/A N/A 1243 949114 14390 14405 GCAAACCGCTTCTCAC 74 N/A N/A 1244 949115 14492 14507 CCCCAAGTCCTGGCGG 99 N/A N/A 1245 949116 14629 14644 GAAAAGTCGGCATTCC 74 N/A N/A 1246 949117 14757 14772 TGACAGTGGTGCTCCC 66 N/A N/A 1247 949118 15000 15015 TGGCATGTGGTTGTTG 26 N/A N/A 1248 949119 15165 15180 AACAAATATATGCACG 20 N/A N/A 1249 949120 15370 15385 TCGCACCTCGGGATTC 92 N/A N/A 1250 949121 15507 15522 GTGAAATTCACTCCAT 40 N/A N/A 1251 949122 15612 15627 GGAAGATGTCCTTGCT 49 N/A N/A 1252 949123 15643 15658 ATAGATGGAGCAAATC 77 N/A N/A 1253 949124 15647 15662 TTATATAGATGGAGCA 32 N/A N/A 1254 949125 15708 15723 ACGCAGATAGACACCC 53 N/A N/A 1255 949126 15712 15727 GCCAACGCAGATAGAC 93 N/A N/A 1256 949127 15777 15792 TGCCATACAGGGCCTC 116 N/A N/A 1257 949128 15859 15874 GAAAGAGCAGTGGTGC 73 N/A N/A 1258 949129 15973 15988 GGGCATGGAGGTGTCA 90 N/A N/A 1259 949130 16025 16040 CGCGAAAGTGTGTCAC 64 N/A N/A 1260 949131 16117 16132 TATCACCCAGCAGGCA 75 N/A N/A 1261 949132 16275 16290 GGCCAGCTGGTAGGCC 114 N/A N/A 1262 949134 16714 16729 GTCAAGCTGAGCCAGT 52 N/A N/A 1263 949135 16815 16830 ACAGAAGCCGGGCTTC 127 N/A N/A 1264 949136 16926 16941 ATCAATTTTCACCCAG 19 N/A N/A 1265 949137 16930 16945 GTGCATCAATTTTCAC 127 N/A N/A 1266 949138 17244 17259 AAAGAGTTTAAGGGCG 57 N/A N/A 1267 949139 17282 17297 CCACAACGAGTAAACA 15 N/A N/A 1268 949140 17615 17630 GGACAGGGTGAATTGT 62 N/A N/A 1269 949141 17723 17738 AGTCACACCTAGAAAT 32 N/A N/A 1270 949142 17758 17773 GACTTATAGGCTCACT 12 N/A N/A 1271 949143 17763 17778 TACTAGACTTATAGGC 26 N/A N/A 1272 949144 17765 17780 GTTACTAGACTTATAG 19 N/A N/A 1273 949145 17766 17781 TGTTACTAGACTTATA 40 N/A N/A 1274 949146 17834 17849 ATATAGCAGGGACCTG 70 N/A N/A 1275 949147 17838 17853 CTAAATATAGCAGGGA 36 N/A N/A 1276 949148 17840 17855 CACTAAATATAGCAGG 24 N/A N/A 1277 949149 18278 18293 TTTGAGCCCGAGAGGG 46 N/A N/A 1278 949150 18486 18501 TTATTTCTAGGCAGGG 13 N/A N/A 1279 949151 18524 18539 GTAAATTTGAAGCTTA 144 N/A N/A 1280 949152 18583 18598 AATTAGAGGACACTGG 19 N/A N/A 1281 949153 18665 18680 GCTTTAACTCCTAGAC 61 N/A N/A 1282 949154 19040 19055 GTATACCAAGGTTAAT 56 N/A N/A 1283 949155 19050 19065 CTTAATAGTAGTATAC 96 N/A N/A 1284 949156 19458 19473 CACACGAGGTCTCACT 44 N/A N/A 1285 949157 19461 19476 CTACACACGAGGTCTC 72 N/A N/A 1286 949158 19663 19678 TACATTCTGGCTTTGG 12 N/A N/A 1287 949159 19763 19778 TCTCAGTATGTATACT 12 N/A N/A 1288 949160 19814 19829 TGTCCAGTCCTAAGAC 101 N/A N/A 1289 949161 19816 19831 AATGTCCAGTCCTAAG 81 N/A N/A 1290 949162 19817 19832 CAATGTCCAGTCCTAA 19 N/A N/A 1291 949163 19818 19833 GCAATGTCCAGTCCTA 4 N/A N/A 1292 949164 19820 19835 ATGCAATGTCCAGTCC 13 N/A N/A 1293 949165 19821 19836 GATGCAATGTCCAGTC 70 N/A N/A 1294 949166 19822 19837 AGATGCAATGTCCAGT 13 N/A N/A 1295 949167 19824 19839 CTAGATGCAATGTCCA 12 N/A N/A 1296 949168 19843 19858 GCTTAAGGAGATCCGA 17 N/A N/A 1297 949169 19844 19859 GGCTTAAGGAGATCCG 85 N/A N/A 1298 949170 19872 19887 GGCTGAGTTGCTTCCC 79 N/A N/A 1299 949171 19935 19950 TTCCAGATAAGCCCTA 32 N/A N/A 1300 949172 19986 20001 CACCAATGGCCTTCTT 42 N/A N/A 1301 949173 20328 20343 GAAGATGGCTGGACGA 34 N/A N/A 1302 949174 20330 20345 CAGAAGATGGCTGGAC 34 N/A N/A 1303 949175 20378 20393 CAATAATTTATCAGTC 68 N/A N/A 1304 949176 20440 20455 GGGAAACCTAGCAAGC 80 N/A N/A 1305 949177 20487 20502 CCCAAAGGATAGAGTA 23 N/A N/A 1306 949178 20735 20750 TTACATGAGTCTAGGA 50 N/A N/A 1307 949179 20737 20752 TATTACATGAGTCTAG 68 N/A N/A 1308 949180 20740 20755 GATTATTACATGAGTC 49 N/A N/A 1309 949181 20748 20763 GGCAAGAGGATTATTA 53 N/A N/A 1310 949182 20844 20859 AGCAACTTTAGGGAGA 5 N/A N/A 1311 949183 20899 20914 GAACAGACAGTTCAGG 76 N/A N/A 1312 949184 20947 20962 AAGATATGTGGTTTTG 35 N/A N/A 1313 949185 21341 21356 GAGCATCACCAGCCCA 127 N/A N/A 1314 949186 21403 21418 TAGAAATGAGTGGGCG 116 N/A N/A 1315 949187 21416 21431 AGCTACAGCAATATAG 43 N/A N/A 1316 949188 21449 21464 ACTCACATGGCCTGAT 81 N/A N/A 1317 949189 21491 21506 CTAGACTAGACAAAAC 91 N/A N/A 1318 949190 21514 21529 ATATATATGTGGAGGC 4 N/A N/A 1319 949191 21561 21576 CTAATACACAATGATC 34 N/A N/A 1320 949192 21591 21606 CAAAAAACTAATACCG 105 N/A N/A 1321 949193 21698 21713 AACCAGTACCAGCTGG 98 N/A N/A 1322 949194 21758 21773 AGAAACTGTACTGGTC 25 N/A N/A 1323 949195 21845 21860 GGATATTCTTAACAGG 26 N/A N/A 1324 949196 21854 21869 AGCTAGGAAGGATATT 83 N/A N/A 1325 949197 22009 22024 AAGTATGCGCTGCCAT 38 N/A N/A 1326 949198 22018 22033 TGGGACTGTAAGTATG 63 N/A N/A 1327 949199 22133 22148 GGATATAGGGTCTCCC 138 N/A N/A 1328 949200 22243 22258 CATGAGGTAGGACAGC 54 N/A N/A 1329 949201 22251 22266 GAAAAAGCCATGAGGT 100 N/A N/A 1330 949202 22301 22316 CCACAGGGTTATCTGG 119 N/A N/A 1331 949203 22345 22360 AAGGAGGCTTTTAAGC 92 N/A N/A 1332 949204 22446 22461 AGGAATGACAAGTGGT 17 N/A N/A 1333 949205 22466 22481 CGCATAGGTGGAACAA 58 N/A N/A 1334 949206 22478 22493 CAAGAAACCAAACGCA 81 N/A N/A 1335 949207 22638 22653 AATATACGGGCATGTT 82 N/A N/A 1336 949208 22639 22654 AAATATACGGGCATGT 110 N/A N/A 1337 949209 22641 22656 AAAAATATACGGGCAT 104 N/A N/A 1338 949210 22643 22658 ACAAAAATATACGGGC 67 N/A N/A 1339 949211 22644 22659 TACAAAAATATACGGG 33 N/A N/A 1340 949212 22780 22795 TCAAACAAATAGGCCG 86 N/A N/A 1341 949213 22862 22877 ATGCAAGGGACTGCGC 66 N/A N/A 1342 949214 22883 22898 ACCTATCGCATGCCAG 17 N/A N/A 1343 949215 23000 23015 GTTCAGGTCAGAGCCT 51 N/A N/A 1344 949216 23297 23312 TCTCAATGAAAGTCTC 10 N/A N/A 1345 949217 23548 23563 GTAACAACCGCTGGGA 27 N/A N/A 1346 949218 23555 23570 TTAAAGAGTAACAACC 75 N/A N/A 1347 949219 23715 23730 GCCCAGCTAACTAACT 108 N/A N/A 1348 949220 24040 24055 GACTACAGTACAGGCG 74 N/A N/A 1349 949221 24201 24216 AGAACAAGGGAACACG 80 N/A N/A 1350 949222 24210 24225 CCCCATAGAAGAACAA 138 N/A N/A 1351 949223 24289 24304 GATTAGGTATTATGGT 12 N/A N/A 1352 949224 24296 24311 TCAAAAGGATTAGGTA 25 N/A N/A 1353 949225 24315 24330 ATCCACTGAATAGTAT 32 N/A N/A 1354 949226 24364 24379 CTACAAAATCAGATAG 91 N/A N/A 1355 949227 24438 24453 GACATTAGTGGCTTCC 35 N/A N/A 1356 949228 24561 24576 AACCAGCATGGATGAA 87 N/A N/A 1357 949229 24782 24797 TGCAACCTTGCCCCCC 11 N/A N/A 1358 949230 24934 24949 TAGTATTCAAAAAACG 80 N/A N/A 1359 949231 25044 25059 CAAATTAAATACACCC 62 N/A N/A 1360 949232 25058 25073 GAATACTATTCTAACA 118 N/A N/A 1361 949233 25210 25225 CACCACAATTTGCTCT 63 N/A N/A 1362 949234 25305 25320 TCAGAAAAGGAGGGTA 109 N/A N/A 1363 949235 25321 25336 TTCCACTTCAAGAACC 87 N/A N/A 1364 949236 25696 25711 TGTAAGCAACTGTATT 49 N/A N/A 1365 949237 25788 25803 TGAGAAGATATGCTGA 26 N/A N/A 1366 949238 25822 25837 AACCTATGTATCAAAG 87 N/A N/A 1367 949239 25925 25940 CAAAGTAGTTCCTCCA 34 N/A N/A 1368 949240 25927 25942 TACAAAGTAGTTCCTC 68 N/A N/A 1369 949241 26042 26057 CCCAAGAGTAAAATAC 105 N/A N/A 1370 949242 26084 26099 ACGAAACCAATAAGAC 104 N/A N/A 1371 949243 26090 26105 GAAAATACGAAACCAA 99 N/A N/A 1372 949244 26133 26148 TAATAATGGATGGAAC 84 N/A N/A 1373 949245 26155 26170 TGGTATCAGGCAAGAA 35 N/A N/A 1374 949246 27033 27048 CATGATGCTGCAATCA 97 N/A N/A 1375 949247 27177 27192 CACAAGCCTGCGGACC 110 N/A N/A 1376 949248 27191 27206 GAGCATAGCAGACACA 65 N/A N/A 1377 949249 27254 27269 GGCAACATCACTCTAA 62 N/A N/A 1378 949250 27289 27304 CAAAGAGCCTTGGCAC 111 N/A N/A 1379 949251 27390 27405 CAGGACTAGTTCACTA 78 N/A N/A 1380 949252 27473 27488 ATGAAATTGGGATAAC 60 N/A N/A 1381 949253 27509 27524 ATGAAGGCTGCCACTT 103 N/A N/A 1382 949254 27575 27590 AGCAAGATCATTGGGT 65 N/A N/A 1383 949255 27634 27649 GGAAACCTTGGACTCC 91 N/A N/A 1384 949256 27761 27776 GTCTATTGGCACACAG 38 N/A N/A 1385 949257 27775 27790 GATTAAGTCATCCGGT 70 N/A N/A 1386 949258 27872 27887 GGGCACTGCACAAAGC 86 N/A N/A 1387 949259 27975 27990 AGTCAGCGGAGACTGA 98 N/A N/A 1388 949260 28212 28227 CGGCAAAAGAAGCTGG 133 N/A N/A 1389 949261 28320 28335 AGCTAGAGCATCAGCT 122 N/A N/A 1390 949262 28971 28986 CTGGAAACAGTCTCGC 29 N/A N/A 1391 949263 29116 29131 AGCCGAAGTGTAGTGG 51 N/A N/A 1392 949264 29258 29273 GGCCAAGTCTCCCATC 117 N/A N/A 1393 949265 29370 29385 CCGGACCCGTTCTTGA 85 N/A N/A 1394 949266 29501 29516 AGGTAGTGACCTCCAG 114 N/A N/A 1395 949267 29557 29572 ACCCACAGTCTGCATT 97 N/A N/A 1396 949268 29591 29606 GCCCAAGTGAACTAGA 94 N/A N/A 1397 949269 29625 29640 ATGTATGGATTTCCAG 62 N/A N/A 1398 949270 29642 29657 TTACAGGGTGGTCAGC 82 N/A N/A 1399 949271 29721 29736 GTAAAACGGTTGTGGT 30 N/A N/A 1400 949272 29739 29754 CAACAGGTGTCCTGCT 64 N/A N/A 1401 949273 29842 29857 TGTCATCCTAACTGCT 57 N/A N/A 1402 949274 29943 29958 AGAAACTGGCCGGCCC 132 N/A N/A 1403 949275 30052 30067 TTTATAGTCTCCAACG 34 N/A N/A 1404 949276 30178 30193 ACGGACTGGATTATGC 27 N/A N/A 1405 949277 30248 30263 GGCTAAATCAATCTTG 60 N/A N/A 1406 949278 30282 30297 CGATAATGACCTAAAT 84 N/A N/A 1407 949279 30283 30298 CCGATAATGACCTAAA 8 N/A N/A 1408 949280 30406 30421 GAATATCAACACCTTG 35 N/A N/A 1409 949281 30508 30523 AGTGATATGCTGCCTA 39 N/A N/A 1410 949282 30705 30720 GGTTTATTTGCACCTC 39 N/A N/A 1411 949283 30830 30845 TACCAGGGACTCAACT 111 N/A N/A 1412 949284 30933 30948 GGCCAGACATTGCTGT 142 N/A N/A 1413 949285 31273 31288 CACATTGGTGGTCAAG 98 N/A N/A 1414 949286 31373 31388 CTCATAACATTTGACG 45 N/A N/A 1415 949287 31708 31723 AAAAAAGCCGGCACGG 120 N/A N/A 1416 949288 32027 32042 AAAATTGGTTGAGTGC 40 N/A N/A 1417 949289 32161 32176 GTAAAACTCAGGCTGA 81 N/A N/A 1418 949290 32192 32207 CAAAAGAGAACATTCG 64 N/A N/A 1419 949291 32264 32279 TGTTATGTGGGAATGA 35 N/A N/A 1420 949292 32420 32435 AGGGACACAACAGGCT 85 N/A N/A 1421 949293 32560 32575 CACAATCCACTCCTGG 100 N/A N/A 1422 949294 32561 32576 CCACAATCCACTCCTG 83 N/A N/A 1423 949295 32615 32630 TTGCAGAACAATGGGC 105 N/A N/A 1424 949296 32697 32712 GCGCAGGGTCCCGTAT 95 N/A N/A 1425 949297 32719 32734 TATTAGAGTGGCAGCC 86 N/A N/A 1426 949298 32799 32814 TGCCACTCACAACTGG 104 N/A N/A 1427 949299 32852 32867 CGCCATAGGAAGCTGC 111 N/A N/A 1428 949300 32895 32910 GAGCAGGCGGGCAGCT 82 N/A N/A 1429 949301 32899 32914 AACAGAGCAGGCGGGC 92 N/A N/A 1430 949302 32900 32915 TAACAGAGCAGGCGGG 103 N/A N/A 1431 949303 32903 32918 CATTAACAGAGCAGGC 119 N/A N/A 1432 949304 32904 32919 GCATTAACAGAGCAGG 46 N/A N/A 1433 949305 33006 33021 AGCCACATATGCCTCC 91 N/A N/A 1434 949306 33148 33163 TGTTATGGGCCCTCCT 82 N/A N/A 1435 949307 33277 33292 TCCAAGGCTGTCAGCG 106 N/A N/A 1436 949308 33391 33406 CACGAGGCTGCAGACC 40 N/A N/A 1437 949309 33454 33469 CCGCAGGTAGGTGCCA 56 N/A N/A 1438 949310 33488 33503 GCCCAAGCCTTACAGT 117 N/A N/A 1439 949311 33512 33527 AGCCATTGGTCACCCA 43 N/A N/A 1440 949312 33618 33633 CCGCACCCACCTCAGG 132 N/A N/A 1441 949313 33644 33659 CACCAATGAGGCAGAC 69 N/A N/A 1442 949314 33725 33740 GTGGACTGAGGTTCAG 101 N/A N/A 1443 949315 33826 33841 CTCTAACCCCATCTCG 81 N/A N/A 1444 949316 33927 33942 TCGGCAGGAGCCCACA 108 N/A N/A 1445 949317 34028 34043 CCATATGCTCAGCACA 30 N/A N/A 1446 949318 34029 34044 ACCATATGCTCAGCAC 45 N/A N/A 1447 949319 34159 34174 GATAAGCCCACAGAGG 107 N/A N/A 1448 949320 34164 34179 CAACAGATAAGCCCAC 83 N/A N/A 1449 949321 34281 34296 ACAGACCACAAGGCTC 65 N/A N/A 1450 949322 34283 34298 GAACAGACCACAAGGC 82 N/A N/A 1451 949323 34407 34422 CAGGAAGGCGGTAGGG 92 N/A N/A 1452 949324 34539 34554 TGGGAGGACACTTCCA 121 N/A N/A 1453 949325 34546 34561 CATGAAATGGGAGGAC 9 N/A N/A 1454 949326 34561 34576 ACTGACTTGGCCATCC 68 N/A N/A 1455 949327 34654 34669 CCAGACTGTGGAGCCA 35 N/A N/A 1456 949328 34763 34778 GCCAAGACTTCTGCAC 129 N/A N/A 1457 949329 34873 34888 GCCTACCTGGCCATGG 119 N/A N/A 1458 949330 34995 35010 GCTGACCGGGTTCCCC 148 N/A N/A 1459 949331 35150 35165 TCCTATCCATGGGCCC 93 N/A N/A 1460 949332 35178 35193 TACTATTGCATCATTT 33 N/A N/A 1461 949333 35385 35400 CCCTAGTGAACTTCCC 38 N/A N/A 1462 949334 35541 35556 GCAAACCTCAGTCTCG 39 N/A N/A 1463 949335 35921 35936 GCACAATTAAGTAGTT 36 N/A N/A 1464 949336 35950 35965 GCATAGAGTAGGGCTG 55 N/A N/A 1465 949337 35955 35970 CCAAAGCATAGAGTAG 57 N/A N/A 1466 949338 35956 35971 CCCAAAGCATAGAGTA 62 N/A N/A 1467 949339 36021 36036 CCCATCTGAGCTGTGT 79 N/A N/A 1468 949340 36170 36185 TCGAATGACATTTCCT 65 N/A N/A 1469 949341 36211 36226 AGTAAGACAGGGTAAC 136 N/A N/A 1470 949342 36311 36326 GTGCACCCAGGCTGCC 105 N/A N/A 1471 949343 36420 36435 TTCCAGCCTCCGTCAT 90 N/A N/A 1472 949344 36531 36546 CCTAAGGGTTTTCTGG 109 N/A N/A 1473 949345 36532 36547 CCCTAAGGGTTTTCTG 144 N/A N/A 1474 949346 36570 36585 CCAGAAGTCTCCTAGG 108 N/A N/A 1475 949347 36647 36662 CTAAAAGTTCCCAGAC 86 N/A N/A 1476 949348 36757 36772 GGAGACGCAGCTCTCA 103 N/A N/A 1477 949349 36892 36907 GGACAAGCACCCCTCT 26 N/A N/A 1478 949350 36996 37011 CCCGACCCCGGCCAAT 96 N/A N/A 1479 949351 37100 37115 GTTCACTACAGACATC 71 N/A N/A 1480 949352 37105 37120 TTCTAGTTCACTACAG 92 N/A N/A 1481 949353 37243 37258 CATAGTACCCCACACA 56 N/A N/A 1482 949354 37300 37315 TTGTAGTGTGGAATAT 40 N/A N/A 1483 949355 37364 37379 CGCCCAAGAGAACACA 104 N/A N/A 1484 949356 37481 37496 CTCCACTTTGTGTCTG 58 N/A N/A 1485 949357 37583 37598 GCCTTCTGAGCAAACA 90 N/A N/A 1486 949358 37726 37741 AAAATGGGTCTGCTGG 18 N/A N/A 1487 949359 37730 37745 CATTAAAATGGGTCTG 56 N/A N/A 1488 949360 37843 37858 ACCTTAAGTTTCTTGT 70 N/A N/A 1489 949361 37896 37911 TGCAATGGAGTCCAAA 65 N/A N/A 1490 949362 37970 37985 CCTTAAGTTTTTTGGT 132 N/A N/A 1491 949363 38144 38159 TCATGATTATTAACCT 29 N/A N/A 1492 949364 38160 38175 AGGCATTGAGAACTTT 77 N/A N/A 1493 949365 38190 38205 AGCTATTCAACACTGA 65 N/A N/A 1494 949366 38206 38221 CATTAGAGTAGCTAAT 141 N/A N/A 1495 949367 38246 38261 TTGAATTCCGCATCAT 86 N/A N/A 1496 949368 38313 38328 AACAAAACAGGACCCG 108 N/A N/A 1497 949369 38353 38368 GAAGAAAGTCTGTACT 86 N/A N/A 1498 949370 38488 38503 TTGTAGTGATCAGTTT 54 N/A N/A 1499 949371 38588 38603 ATCCATGCTGCTATGC 63 N/A N/A 1500 949372 38688 38703 TTGCACAACAAAGAGC 90 N/A N/A 1501 949373 38948 38963 GATATATTGCTGGGCA 72 N/A N/A 1502 949374 38949 38964 AGATATATTGCTGGGC 44 N/A N/A 1503 949375 39017 39032 ACCTAAGGAAGCTGAC 72 N/A N/A 1504 949376 39062 39077 TTAAAGCCCAGCAACA 93 N/A N/A 1505 949377 39088 39103 ACGAAAAATTCAGATC 104 N/A N/A 1506 949378 39089 39104 GACGAAAAATTCAGAT 83 N/A N/A 1507 949379 39124 39139 ACAGAATTGTTACAAC 104 N/A N/A 1508 949380 39156 39171 GTACAGGGTGGACATT 90 N/A N/A 1509 949381 39162 39177 ACAAAAGTACAGGGTG 66 N/A N/A 1510 949382 39163 39178 TACAAAAGTACAGGGT 86 N/A N/A 1511 949383 39164 39179 ATACAAAAGTACAGGG 54 N/A N/A 1512 949384 39195 39210 AGTCAAGGAGAACATG 63 N/A N/A 1513 949385 39529 39544 TTGTAGTGGGTCACGC 53 N/A N/A 1514 949386 39644 39659 CATGATTGCGCCGTTG 17 N/A N/A 1515 949387 39745 39760 GTAATTCACTGCGGAT 32 N/A N/A 1516 949388 39877 39892 AAACTTGCAGCAGTGG 67 N/A N/A 1517 949389 39981 39996 AAATGGACTAGAAGGG 59 N/A N/A 1518 949390 40014 40029 AGATAGAAATCAGGGC 47 N/A N/A 1519 949391 40058 40073 TCACAGGGTGGACTTG 53 N/A N/A 1520 949392 40089 40104 GTAGACACATGTCCTT 49 N/A N/A 1521 949393 40195 40210 GACTACAGTCTGTTCG 96 N/A N/A 1522 949394 40295 40310 AACACAGGAGCAGCAT 87 N/A N/A 1523 949395 40306 40321 AACGATAAAACAACAC 70 N/A N/A 1524 949396 40409 40424 ACTGAATCACCAGCAG 99 N/A N/A 1525 949397 40837 40852 GCCTTTACTTAAGATA 3 N/A N/A 1526 949398 40961 40976 ACGCAGTGTCTCAGGT 125 N/A N/A 1527 949399 41061 41076 CACAAGTAGCCTTGGC 107 N/A N/A 1528 949400 41107 41122 TCACAGTGGACACCAG 85 N/A N/A 1529 949401 41162 41177 TGACAGACCCCAAAGT 121 N/A N/A 1530 949402 41234 41249 GAACAAGCTACATCAA 100 N/A N/A 1531 949403 41266 41281 TGGAGAGGGTTCTCTG 94 N/A N/A 1532 949404 41272 41287 GATAATTGGAGAGGGT 84 N/A N/A 1533 949405 41393 41408 GCGAACCTTTCTCACT 57 N/A N/A 1534 949406 41447 41462 AAACAGGATACGAGAC 74 N/A N/A 1535 949407 41451 41466 GCACAAACAGGATACG 86 N/A N/A 1536 949408 41497 41512 TAATCCCTTTCCGTCA 92 N/A N/A 1537 949409 41604 41619 TGTCTTCGAGCCACAC 99 N/A N/A 1538 949410 41708 41723 CCCTACAGACACTTGC 101 N/A N/A 1539 949411 41814 41829 CCGTAGGCAGATTCCA 62 N/A N/A 1540 949412 41862 41877 GCGAAACCAGAGAGAT 88 N/A N/A 1541 949413 41863 41878 GGCGAAACCAGAGAGA 86 N/A N/A 1542 949414 41962 41977 AGCTTTTAAACCCCCC 87 N/A N/A 1543 949415 41984 41999 AGCCAGATTATTAACA 58 N/A N/A 1544 949416 42064 42079 GATGAGGAGGCTGGTC 78 N/A N/A 1545 949417 42169 42184 ACGAAGACCCCCCAGG 163 N/A N/A 1546 949418 42203 42218 CATGAGAAAAGGGATC 97 N/A N/A 1547 949419 42249 42264 CAACAAGTCAGCCCAA 100 N/A N/A 1548 949420 42252 42267 ACACAACAAGTCAGCC 78 N/A N/A 1549 949421 42254 42269 CTACACAACAAGTCAG 28 N/A N/A 1550 949422 42318 42333 TTCTAGCCCGTCAGCC 90 N/A N/A 1551 949423 42434 42449 TTCCAGAAGACCTGTT 143 N/A N/A 1552 949424 42507 42522 TAGCACTACAATCATT 71 N/A N/A 1553 949425 42544 42559 AACGAGACAGCATCCT 64 N/A N/A 1554 949426 42577 42592 GCAATTGGTACTGTAC 101 N/A N/A 1555 949427 42584 42599 ACACAGGGCAATTGGT 144 N/A N/A 1556 949428 42727 42742 TCGAACTCAACCTCAG 70 N/A N/A 1557 949429 42860 42875 TGCCTCGGGTTCAAGC 64 N/A N/A 1558 949430 42983 42998 TGAAAGGTTCTAGGCA 64 N/A N/A 1559 949431 42984 42999 GTGAAAGGTTCTAGGC 57 N/A N/A 1560 949432 43017 43032 TCGAAAGGAAATTCTG 89 N/A N/A 1561 949433 43028 43043 ACATTAAAGGCTCGAA 43 N/A N/A 1562 949434 43030 43045 GTACATTAAAGGCTCG 59 N/A N/A 1563 949435 43050 43065 GTAGAAACAGTGGGCT 61 N/A N/A 1564 949436 43094 43109 GTACACTCAGAAAGGA 91 N/A N/A 1565 949437 43141 43156 GTGAATACACCAGGAT 76 N/A N/A 1566 949438 43194 43209 ACTCAGGCACAACCAC 123 N/A N/A 1567 949439 43864 43879 CGACAGAGCTGTTTAA 47 N/A N/A 1568 949440 43884 43899 GCGGAATGTAAATTAC 40 N/A N/A 1569 949441 43918 43933 CTAAAGACCACTAATT 122 N/A N/A 1570 949442 43920 43935 GACTAAAGACCACTAA 53 N/A N/A 1571 949443 44005 44020 GTACAGAGCCATGACT 113 N/A N/A 1572 949444 44161 44176 TAAAAGCCTGGACAAG 77 N/A N/A 1573 949445 44199 44214 TACATCTGGACTATGG 23 N/A N/A 1574 949446 44271 44286 GATACCTGGATGTGGG 80 N/A N/A 1575 949447 44336 44351 GACAAAATAGGATGTG 88 N/A N/A 1576 949448 44351 44366 AGGAAAGTTATTGATG 63 N/A N/A 1577 949449 44356 44371 ATACGAGGAAAGTTAT 112 N/A N/A 1578 949450 44359 44374 AAAATACGAGGAAAGT 80 N/A N/A 1579 949451 44362 44377 GGTAAAATACGAGGAA 23 N/A N/A 1580 949452 44375 44390 CCACATGTATATGGGT 85 N/A N/A 1581 949453 44426 44441 CCATACCCAGGAGATC 57 N/A N/A 1582 949454 44509 44524 AACCATTTCCCTCTGG 58 N/A N/A 1583 949455 44624 44639 GGCGACCTCAGCAAAG 85 N/A N/A 1584 949456 44732 44747 AAGGAAGTCCCTGTGA 106 N/A N/A 1585 949457 44851 44866 GGCAACCACACATCCA 79 N/A N/A 1586 949458 44953 44968 ACTGAGCCGTTTTTCA 42 N/A N/A 1587 949459 45279 45294 CCGAAGTGAGAGGGTC 88 N/A N/A 1588 949460 45364 45379 CAAAATCGGGTTATCT 66 N/A N/A 1589 949461 45365 45380 GCAAAATCGGGTTATC 38 N/A N/A 1590 949462 45412 45427 AAGGATGGATGTGTCA 18 N/A N/A 1591 949463 45503 45518 TGACATGCGGGAATGA 40 N/A N/A 1592 949464 45523 45538 AGTAGAAACTGGGACG 43 N/A N/A 1593 949465 45570 45585 AGCTATAAAACCAGCC 106 N/A N/A 1594 949466 45603 45618 TACAAAAGAGTATAGC 70 N/A N/A 1595 949467 45705 45720 CACCACTGCACGGCCT 97 N/A N/A 1596 949468 45850 45865 AACATAACCCCCATCT 88 N/A N/A 1597 949469 45957 45972 AGCAATGGTAGAGGGC 113 N/A N/A 1598 949470 46279 46294 GCAATGGTGGCCGGGC 96 N/A N/A 1599 949471 46323 46338 TTCAACAGGCTGGGTC 44 N/A N/A 1600 949472 46330 46345 TACTATATTCAACAGG 18 N/A N/A 1601 949473 46344 46359 CCACACATAGGCCATA 35 N/A N/A 1602 949474 46382 46397 ATACACTGAGATCAGG 50 N/A N/A 1603 949475 46431 46446 GCTGGGATATACGCCC 98 N/A N/A 1604 949476 46505 46520 ACGGAGACCCTTACCT 129 N/A N/A 1605 949477 46528 46543 TTGCAGATTAGCAGGG 35 N/A N/A 1606 949478 46560 46575 ACAAACTGAGTGTTGA 73 N/A N/A 1607 949479 46562 46577 ACACAAACTGAGTGTT 78 N/A N/A 1608 949480 46577 46592 CGCAAGAAGACATTAA 54 N/A N/A 1609 949481 46666 46681 GGCAGCATGGCTAAGC 75 N/A N/A 1610 949482 46764 46779 ACGAAAGTGAGGAGTC 66 N/A N/A 1611 949483 46766 46781 GGACGAAAGTGAGGAG 15 N/A N/A 1612 949484 46863 46878 TACGAAATAGCAGAGC 17 N/A N/A 1613 949485 46885 46900 GCCCATTGGCCCATCG 154 N/A N/A 1614 949486 47094 47109 GATCACCCGCCACTGT 105 N/A N/A 1615 949487 47352 47367 CACCAGGGACTCATTA 124 N/A N/A 1616 949488 47466 47481 ACACAGTGGTGGTCCC 59 N/A N/A 1617 949489 47517 47532 TGCTTTAAGGCTAACA 82 N/A N/A 1618 949490 47599 47614 GGCCTGCGCTCTGTGC 87 N/A N/A 1619 949491 47700 47715 TGCCCTAAGGCAAGTG 91 N/A N/A 1620 949492 47797 47812 CAACAGCCACAGGATC 77 N/A N/A 1621 949493 47803 47818 TTCCACCAACAGCCAC 25 N/A N/A 1622 949494 47924 47939 AACTATGCATCCACCT 122 N/A N/A 1623 949495 47927 47942 TGCAACTATGCATCCA 130 N/A N/A 1624 949496 48220 48235 GGCTAGGTGGTGTGCG 116 N/A N/A 1625 949497 48501 48516 GAGATTGGAGCCTGGT 33 N/A N/A 1626 949498 48506 48521 AATAAGAGATTGGAGC 89 N/A N/A 1627 949499 48507 48522 CAATAAGAGATTGGAG 69 N/A N/A 1628 949500 48508 48523 GCAATAAGAGATTGGA 13 N/A N/A 1629 949501 48622 48637 GTGAATCCAACAGACA 70 N/A N/A 1630 949502 48748 48763 CAACATGCCTTCCAGT 124 N/A N/A 1631 949503 48869 48884 TGCCACTCCCTATCCC 79 N/A N/A 1632 949504 48972 48987 GCTTAATGCCTTGCCT 128 N/A N/A 1633 949505 49052 49067 CCGCAATGTGTTCATT 42 N/A N/A 1634 949506 49095 49110 GTATACCCCACAAGGC 73 N/A N/A 1635 949507 49171 49186 GTAAAGGGTGGCAGCC 84 N/A N/A 1636 949508 49196 49211 AGTCACTTTAACAAGT 57 N/A N/A 1637 949509 49218 49233 GCTACCAAGGCACAGA 72 N/A N/A 1638 949510 49265 49280 CATGGCCACGATGGCA 92 N/A N/A 1639 949511 49297 49312 GAAGAGACAGCATACC 69 N/A N/A 1640 949512 49403 49418 AGTTATGGTTCACTGG 29 N/A N/A 1641 949513 49511 49526 ACTCAGAGTTTACGGG 91 N/A N/A 1642 949514 49613 49628 TTCCGGTGAGCACACC 49 N/A N/A 1643 949515 49770 49785 GAATCAGGAGGGAGAT 101 N/A N/A 1644 949516 49888 49903 GGCAAGTGACCAGGTG 55 N/A N/A 1645 949517 49896 49911 ACGAAGGCGGCAAGTG 6 N/A N/A 1646 949518 50269 50284 GCAGAGAGAGTCCATT 38 N/A N/A 1647 949519 50271 50286 GCGCAGAGAGAGTCCA 116 N/A N/A 1648 949520 50402 50417 GCCCAGTAGGCAAGAA 117 N/A N/A 1649 949521 50423 50438 AAGTAACCCCCATCAC 94 N/A N/A 1650 949522 50491 50506 CTAGATACAAGGCTGC 62 N/A N/A 1651 949523 50510 50525 CGCCAGCTTGGTCTGC 70 N/A N/A 1652 949524 50597 50612 ACGCAAATATCTCCCA 41 N/A N/A 1653 949525 50612 50627 CTAATCCGAGGCAATA 59 N/A N/A 1654 949526 50654 50669 GCACACAACACTTCCC 41 N/A N/A 1655 949527 50713 50728 GGCAGGATCCACTCAT 111 N/A N/A 1656 949528 50818 50833 AGGAGAGGAGATCTGC 87 N/A N/A 1657 949529 50847 50862 ACACAATGACGAGGCT 27 N/A N/A 1658 949530 50945 50960 TGTTAGTCTCAGGGAA 54 N/A N/A 1659 949531 50961 50976 ACAAACACGGCTCAGC 77 N/A N/A 1660 949532 51078 51093 CGACACCCAGCTCCGG 95 N/A N/A 1661 949533 51207 51222 TTGAAATGCCCAGGTC 37 N/A N/A 1662 949534 51318 51333 TTCAAAGGAGCTTGTG 100 N/A N/A 1663 949535 51433 51448 TGCAAGCTGCCACCTT 79 N/A N/A 1664 949536 51496 51511 TGCTAAACAGTCAATC 62 N/A N/A 1665 949537 51544 51559 AACCTAGGAGGACATC 62 N/A N/A 1666 949538 51660 51675 CCCTACTGAAGCTGGA 71 N/A N/A 1667 949539 51787 51802 AATCACGCTGCCAAGG 112 N/A N/A 1668 949540 51890 51905 TCAGAGAGGTTCGCAG 57 N/A N/A 1669 949541 51993 52008 CGGCAAACTGCAAAGC 67 N/A N/A 1670 949542 52114 52129 CAACAAGCCACTGAGC 108 N/A N/A 1671 949543 52204 52219 TAACAATCCACTGGCC 116 N/A N/A 1672 949544 52243 52258 GCTCAAGTGCTGGAGA 89 N/A N/A 1673 949545 52494 52509 CAAGATCCTACATGTA 79 N/A N/A 1674 949546 52597 52612 TAAAAGCTTCCACCAG 119 N/A N/A 1675 949547 52610 52625 CCCAATAGAGGTTTAA 100 N/A N/A 1676 949548 52802 52817 TCTCATACTTCGGCCT 111 N/A N/A 1677 949549 52918 52933 CAACAGAGGTTTTTTG 67 N/A N/A 1678 949550 52944 52959 GTGAAAGTAAATGCTG 48 N/A N/A 1679 949551 53030 53045 AACAGAACCACACCAG 216 N/A N/A 1680 949552 53066 53081 CCAGAAAACCGTTTCT 93 N/A N/A 1681 949553 53509 53524 ATGCAGGCTGGGAACC 88 N/A N/A 1682 949554 53548 53563 TGCCAGACTTTGGAGC 92 N/A N/A 1683 949555 53611 53626 CCCAAGTCCGCCCAGT 90 N/A N/A 1684 949556 53712 53727 CTGAATCTAGGTGTCT 54 N/A N/A 1685 949557 53847 53862 CTTGAATGTCCATGCC 60 N/A N/A 1686 949558 53863 53878 ATATAGAGAGCTTTAC 104 N/A N/A 1687 949559 53866 53881 CTAATATAGAGAGCTT 51 N/A N/A 1688 949560 53867 53882 TCTAATATAGAGAGCT 78 N/A N/A 1689 949561 53909 53924 CCCCATAACACTTACT 98 N/A N/A 1690 949562 54006 54021 AGCTACTCTCTCAAGT 53 N/A N/A 1691 949563 54011 54026 GGGCAAGCTACTCTCT 126 N/A N/A 1692 949564 54127 54142 AGCTACGGTCTGAGCA 114 N/A N/A 1693 949565 54237 54252 AGTCAGAGGGCCTGCC 58 N/A N/A 1694 949566 54341 54356 GCTCACTTTGGATTGT 48 N/A N/A 1695 949567 54452 54467 GTCTACAAAGCCCAGC 67 N/A N/A 1696 949568 54562 54577 AAAGAGACCATCTCCC 91 N/A N/A 1697 949569 54673 54688 GGGAAACACTCGGCCG 142 N/A N/A 1698 949570 54784 54799 CAATGAGGACATCTGC 59 N/A N/A 1699 949571 54787 54802 GGGCAATGAGGACATC 54 N/A N/A 1700 949572 54890 54905 AGGAACTTCGCCTCTT 112 N/A N/A 1701 949573 54924 54939 TCCTAAGCCAGATAGC 49 N/A N/A 1702 949574 55043 55058 TCTAAGATCCCCATTT 106 N/A N/A 1703 949575 55144 55159 TTTCACCGTCCCATCA 72 N/A N/A 1704 949576 55247 55262 AATAACACAGCCATGC 84 N/A N/A 1705 949577 55348 55363 ACCCACCCCGGAGATG 100 N/A N/A 1706 949578 55383 55398 TAATAAGTCACACTGG 47 N/A N/A 1707 949579 55384 55399 GTAATAAGTCACACTG 107 N/A N/A 1708 949580 55469 55484 CTATGATCTATGATCA 115 N/A N/A 1709 949581 55678 55693 TCCGTATAAGATGTGA 34 N/A N/A 1710 949582 56054 56069 CTATTATCCAGCACTG 56 N/A N/A 1711 949583 56111 56126 AGCTACTGTAGTGATG 81 N/A N/A 1712 949584 56167 56182 TCGAATTTTCAGAGTA 26 N/A N/A 1713 949585 56229 56244 ACGGAAGGTGGCTGCC 61 N/A N/A 1714 949586 56251 56266 GCAAATATAAGGCATG 60 N/A N/A 1715 949587 56268 56283 CACAGATTGAGGACAA 47 N/A N/A 1716 949588 56319 56334 TGACAAGCAGTGTGGG 48 N/A N/A 1717 949589 56371 56386 GGTATCTGAAAGTCAC 9 N/A N/A 1718 949590 56530 56545 CCACAAGGTAGAGGGA 154 N/A N/A 1719 949591 56538 56553 CAAGGAGCCCACAAGG 114 N/A N/A 1720 949592 56633 56648 GCCCAAGTCCTTGTGG 105 N/A N/A 1721 949593 56691 56706 GATTAAGGTGATGCTG 61 N/A N/A 1722 949594 56692 56707 TGATTAAGGTGATGCT 41 N/A N/A 1723 949595 56734 56749 AGGAAGCACCAGGATA 23 N/A N/A 1724 949596 56860 56875 CATATTATGAATCCCC 66 N/A N/A 1725 949597 56863 56878 TGACATATTATGAATC 105 N/A N/A 1726 949598 56979 56994 ATGACAAGGGTCTTGG 17 N/A N/A 1727 949599 57373 57388 TAATGACCCAGGCTGG 121 N/A N/A 1728 949600 57619 57634 GCCTACCGTGTGGCGA 104 N/A N/A 1729 949601 57654 57669 CCAGAAACGGTCAGTG 132 N/A N/A 1730 949602 57722 57737 TGTGAATGGGCACATG 102 N/A N/A 1731 949603 57840 57855 CAAACAACTTCTTGGC 82 N/A N/A 1732 949604 57948 57963 GAAGACTGGTTCTGGC 60 N/A N/A 1733 949605 57953 57968 TTACAGAAGACTGGTT 91 N/A N/A 1734 949606 58891 58906 GGCAAGGTGGCTAAAA 123 N/A N/A 1735 949607 58993 59008 AGGAACCCATCATGGT 95 N/A N/A 1736 949608 59092 59107 TGACAAGGTAGGTTTT 57 N/A N/A 1737 949609 59093 59108 TTGACAAGGTAGGTTT 25 N/A N/A 1738 949610 59102 59117 CAAAACTGGTTGACAA 47 N/A N/A 1739 949611 59104 59119 TGCAAAACTGGTTGAC 58 N/A N/A 1740 949612 59272 59287 GTGAAGTGCAGTAGCT 88 N/A N/A 1741 949613 59302 59317 TAAGATAGAGGGTCTT 35 N/A N/A 1742 949614 59399 59414 GCTAACAATTTAAGGA 60 N/A N/A 1743 949615 59741 59756 CTGAGAGGCATACAAA 66 N/A N/A 1744 949616 59846 59861 GGAGAAGAAGTGAGCC 109 N/A N/A 1745 949617 60067 60082 ACAAATGGATGAGGCC 129 N/A N/A 1746 949618 60068 60083 GACAAATGGATGAGGC 54 N/A N/A 1747 949619 60379 60394 GACAAACAGATGAGGC 74 N/A N/A 1748 949620 60427 60442 GAATAAATTTCAGCCC 100 N/A N/A 1749 949621 60483 60498 TTCAATGGCACAGTTC 73 N/A N/A 1750 949622 60586 60601 TCAGACTTGAGGATGT 32 N/A N/A 1751 949623 60639 60654 GCACAAACAGGCCCGC 99 N/A N/A 1752 949624 60700 60715 GTCAAGTTCAACACTG 25 N/A N/A 1753 949625 60903 60918 GCTCAGGGTTACCTTG 81 N/A N/A 1754 949626 61033 61048 AGGAAGTGCCATGTTC 64 N/A N/A 1755 949627 61134 61149 TCCCACTCTGGCAACA 79 N/A N/A 1756 949628 61204 61219 AGCTAGATGGGACCTA 102 N/A N/A 1757 949629 61255 61270 GAAGTTCCCGTTCTGA 47 N/A N/A 1758 949630 61336 61351 AAATAGACGATCTCAC 87 N/A N/A 1759 949631 61340 61355 AGGGAAATAGACGATC 96 N/A N/A 1760 949632 61344 61359 TCGAAGGGAAATAGAC 101 N/A N/A 1761 949633 61382 61397 GTAGAAGGATCTGACT 114 N/A N/A 1762 949634 61384 61399 CAGTAGAAGGATCTGA 123 N/A N/A 1763 949635 61480 61495 GTGAAGATCTCTGGTG 88 N/A N/A 1764 949636 61485 61500 CCAGAGTGAAGATCTC 119 N/A N/A 1765 949637 61587 61602 CTGCAGATCAACTGCT 104 N/A N/A 1766 949638 61636 61651 CCACAAGTCATTCCAG 71 N/A N/A 1767 949639 61706 61721 TTCCAGGACTACCTCT 76 N/A N/A 1768 949640 61813 61828 GGCTTTGGGAAACCTC 48 N/A N/A 1769 949641 61839 61854 TATTAAGGACAACCTC 98 N/A N/A 1770 949642 61840 61855 TTATTAAGGACAACCT 81 N/A N/A 1771 949643 61842 61857 TGTTATTAAGGACAAC 125 N/A N/A 1772 949644 61889 61904 TGGCACACGGCAAATA 96 N/A N/A 1773 949645 61904 61919 TCATAAGGGTGAGCCT 70 N/A N/A 1774 949646 61915 61930 TCACAGGGTGGTCATA 68 N/A N/A 1775 949647 61937 61952 GAAGATGGTCACAGCC 51 N/A N/A 1776 949648 61944 61959 GTCGAATGAAGATGGT 38 N/A N/A 1777 949649 62105 62120 GGCCTGAAAGAGCCCA 112 N/A N/A 1778 949650 62252 62267 GATAAGGACCCCACCC 108 N/A N/A 1779 949651 62328 62343 AAAGAAGGAGTTACGG 88 N/A N/A 1780 949652 62378 62393 ACGAATGCATACAAAT 72 N/A N/A 1781 949653 62384 62399 TGAAAAACGAATGCAT 107 N/A N/A 1782 949654 62491 62506 CACCAGTGGCTGTCTG 63 N/A N/A 1783 949655 62887 62902 TCATAATAGGCCGGGT 61 N/A N/A 1784 949656 62969 62984 ATAATAACCACCGAAG 45 N/A N/A 1785 949657 62972 62987 ATAATAATAACCACCG 13 N/A N/A 1786 949658 63350 63365 CCTAGGATTTGTGTTA 101 N/A N/A 1787 949659 63667 63682 GCCTAGGATTTATAGA 96 N/A N/A 1788 949660 63759 63774 CCACAAATGAATGGTA 72 N/A N/A 1789 949661 63780 63795 TGGGATGTGGTCTGGT 98 N/A N/A 1790 949662 63826 63841 CTAATTACCAGCTAAC 46 N/A N/A 1791 949663 63880 63895 ACTTAGGTTACTCCTA 76 N/A N/A 1792 949664 64255 64270 AACTGCTGCTCCGATA 53 N/A N/A 1793 949665 64313 64328 GGCTATAGGGCTGATA 104 N/A N/A 1794 949666 64366 64381 AAATGCACCGCTCTGC 137 N/A N/A 1795 949667 64530 64545 ACAGAATAAGACATCG 55 N/A N/A 1796 949668 64650 64665 AGCAATCGCACATGCC 92 N/A N/A 1797 949669 64984 64999 AGTAGATGCCAGAGGG 54 N/A N/A 1798 949670 65026 65041 GGCTAAGCATGAAGGG 96 N/A N/A 1799 949671 65086 65101 ATCTATCTCAGACATC 110 N/A N/A 1800 949672 65109 65124 CCAAGGTCTGAACTTT 69 N/A N/A 1801 949673 65111 65126 AACCAAGGTCTGAACT 125 N/A N/A 1802 949674 65112 65127 CAACCAAGGTCTGAAC 110 N/A N/A 1803 949675 65113 65128 GCAACCAAGGTCTGAA 31 N/A N/A 1804 949676 65115 65130 TGGCAACCAAGGTCTG 67 N/A N/A 1805 949677 65116 65131 CTGGCAACCAAGGTCT 120 N/A N/A 1806 949678 65117 65132 GCTGGCAACCAAGGTC 156 N/A N/A 1807 949679 65119 65134 ATGCTGGCAACCAAGG 40 N/A N/A 1808 949680 65192 65207 GAATTTAGCCCTGACA 94 N/A N/A 1809 949681 65208 65223 AGCTAAACAGGGTTTT 78 N/A N/A 1810 949682 65343 65358 GTCCAAGGGCAGCCGG 100 N/A N/A 1811 949683 65383 65398 CCCCAAAGGCCCTTAG 97 N/A N/A 1812 949684 65458 65473 GTGGACATCAGTGAGT 53 N/A N/A 1813 949685 65527 65542 CTACAAGTGAGCTGAG 6 N/A N/A 1814 949686 65543 65558 CAAAACGGGAGCAGGC 83 N/A N/A 1815 949687 65544 65559 ACAAAACGGGAGCAGG 51 N/A N/A 1816 949688 65545 65560 CACAAAACGGGAGCAG 76 N/A N/A 1817 949689 65583 65598 AAAAAGGGTCCAGTGG 91 N/A N/A 1818 949690 65599 65614 TCATTAGTACGCCAGG 24 N/A N/A 1819 949691 65686 65701 CCCAACTGTGCTTTCC 26 N/A N/A 1820 949692 66037 66052 TCACACACGGATTTTT 73 N/A N/A 1821 949693 66148 66163 TTCTGCATTGCAGTGG 26 N/A N/A 1822 949694 66218 66233 GTAAAAAGCATCTGGC 83 N/A N/A 1823 949695 66272 66287 GCCAGAGTCACCATCA 73 N/A N/A 1824 949696 66327 66342 TGCCAAGGTGAGGTCA 91 N/A N/A 1825 949697 66373 66388 CGCCAGATCTCTCTTG 104 N/A N/A 1826 949698 66787 66802 TGCCTACCATTGCACT 86 N/A N/A 1827 949699 66882 66897 CGAGAAGGAGGTAGAA 82 N/A N/A 1828 949700 66890 66905 AACTACACCGAGAAGG 101 N/A N/A 1829 949701 66895 66910 TCCAAAACTACACCGA 72 N/A N/A 1830 949702 66973 66988 ATCAAACGAGTATATT 91 N/A N/A 1831 949703 66974 66989 TATCAAACGAGTATAT 101 N/A N/A 1832 949704 66987 67002 AGCTAAAATCCACTAT 110 N/A N/A 1833 949705 66998 67013 CAATAGGGAAGAGCTA 57 N/A N/A 1834 949706 66999 67014 GCAATAGGGAAGAGCT 117 N/A N/A 1835 949707 67000 67015 AGCAATAGGGAAGAGC 75 N/A N/A 1836 949708 67377 67392 ATCAAGACTCTGAATA 86 N/A N/A 1837 949709 67669 67684 TTCAAAGATAGGTGAG 32 N/A N/A 1838 949710 67762 67777 CATTAAGTATTTGGAG 77 N/A N/A 1839 949711 67770 67785 AAGAGCAACATTAAGT 111 N/A N/A 1840 949712 67773 67788 GCGAAGAGCAACATTA 120 N/A N/A 1841 949713 67793 67808 TGCGAATGCACATGGC 138 N/A N/A 1842 949714 67803 67818 ACACAGAGGGTGCGAA 153 N/A N/A 1843 949715 67805 67820 CAACACAGAGGGTGCG 47 N/A N/A 1844 949716 67823 67838 TAACATGTTACTCAGA 75 N/A N/A 1845 949717 67870 67885 TCAAGTATAGAGATGG 46 N/A N/A 1846 949718 68110 68125 AGTACCTGATTCAGCG 147 N/A N/A 1847 949719 68180 68195 TGCCAGTGAGGATTGC 56 N/A N/A 1848 949720 68210 68225 AAAACAAGTGCTGCTC 77 N/A N/A 1849 949721 68491 68506 GAATCAAGTACATTTC 77 N/A N/A 1850 949722 68541 68556 GTAATAGTAGCAGCAC 29 N/A N/A 1851 949723 68542 68557 TGTAATAGTAGCAGCA 20 N/A N/A 1852 949724 68610 68625 GTCTTCTGGGTAAATG 30 N/A N/A 1853 949725 68624 68639 AGGCAATGCATACAGT 25 N/A N/A 1854 949726 68992 69007 GAACGATAGGCCAGGC 90 N/A N/A 1855 949727 68999 69014 AAGAAGAGAACGATAG 67 N/A N/A 1856 949728 69029 69044 GTTTATGCACCATGTG 20 N/A N/A 1857 949729 69102 69117 AAAACAGCGAGGAGGA 90 N/A N/A 1858 949730 69108 69123 TGCTAGAAAACAGCGA 109 N/A N/A 1859 949731 69206 69221 CAGGAACCTACTCTCG 86 N/A N/A 1860 949732 69213 69228 ACAAGGACAGGAACCT 97 N/A N/A 1861 949733 69215 69230 CTACAAGGACAGGAAC 107 N/A N/A 1862 949734 69361 69376 CTAGACACTGACTTCC 89 N/A N/A 1863 949735 69486 69501 GGCCAGCTGGACTTTT 74 N/A N/A 1864 949736 69589 69604 TACTAGGGCACTTAAG 149 N/A N/A 1865 949737 69591 69606 GATACTAGGGCACTTA 69 N/A N/A 1866 949738 69692 69707 ACCAAGGGTCCCTGCC 113 N/A N/A 1867 949739 69781 69796 TACAAAGTGTCTGGCG 53 N/A N/A 1868 949740 69782 69797 ATACAAAGTGTCTGGC 41 N/A N/A 1869 949741 70034 70049 GATTAGGAGACAAGCC 87 N/A N/A 1870 949742 70467 70482 ATCCATTCTGGACAAC 62 N/A N/A 1871 949743 70664 70679 CACTAGAGGATAGGCG 118 N/A N/A 1872 949744 70759 70774 GTAAAGCAGAGTTTGG 25 N/A N/A 1873 949745 70760 70775 TGTAAAGCAGAGTTTG 46 N/A N/A 1874 949746 70766 70781 GCAAAGTGTAAAGCAG 53 N/A N/A 1875 949747 70787 70802 CCATAAAATCAGCCTA 71 N/A N/A 1876 949748 70897 70912 AAAGAACTCGGGAGGT 65 N/A N/A 1877 949749 71020 71035 TTAAGATCAAGAGATC 115 N/A N/A 1878 949750 71155 71170 TCAAGATGAGCTCCCC 65 N/A N/A 1879 949751 71255 71270 GTCCATCCAGACCACG 119 N/A N/A 1880 949752 71260 71275 GGACAGTCCATCCAGA 84 N/A N/A 1881 949753 71369 71384 GGAGACGGCACGGAGC 81 N/A N/A 1882 949754 71371 71386 ACGGAGACGGCACGGA 87 N/A N/A 1883 949755 71473 71488 ACCAAGGGCCAACACC 70 N/A N/A 1884 949756 71697 71712 ACATACTGCAGCAGGG 52 N/A N/A 1885 949757 71797 71812 AATCAATGAGTGGACG 29 N/A N/A 1886 949758 71827 71842 ACGCAGAAGGCTTGCA 87 N/A N/A 1887 949759 71908 71923 CCATTCTGAGCACTCC 41 N/A N/A 1888 949760 72021 72036 TCTAAAGGAGGCTGTT 82 N/A N/A 1889 949761 72175 72190 AGCCTAATTTTGCAAT 133 N/A N/A 1890 949762 72938 72953 GGCCAACACTCATCTT 128 N/A N/A 1891 949763 73188 73203 TGATATGCAGTGACAC 75 N/A N/A 1892 949764 73296 73311 TCCCACACGGCTCCTG 144 N/A N/A 1893 949765 73415 73430 GCACAACCTGCTCTAT 80 N/A N/A 1894 949766 73519 73534 GAGCACCTGAGTCAGT 91 N/A N/A 1895 949767 73639 73654 ACCAACCAAGTCATGG 137 N/A N/A 1896 949768 73653 73668 AGCTAAGCAGCTGCAC 133 N/A N/A 1897 949769 73742 73757 TTACAGGCCAAAAGCC 88 N/A N/A 1898 949770 73868 73883 GAGGAGGCGGTGTCCT 122 N/A N/A 1899 949771 73954 73969 CATAAAAGCACTCTGG 87 N/A N/A 1900 949772 73957 73972 GAGCATAAAAGCACTC 92 N/A N/A 1901 949773 73970 73985 GTCAAGGCTGTCTGAG 56 N/A N/A 1902 949774 74231 74246 GCTGAATCTTGTGTTT 47 N/A N/A 1903 949775 74259 74274 CACAACAACACTTCCT 73 N/A N/A 1904 949776 74351 74366 CTTTAGAGGTGCAGAA 53 N/A N/A 1905 949777 74592 74607 ATCCACTGAAGCCTCT 50 N/A N/A 1906 949778 74872 74887 CTTAACAAGTAGTATT 14 N/A N/A 1907 949779 74874 74889 GGCTTAACAAGTAGTA 38 N/A N/A 1908 949780 74962 74977 GGCAACTGGTTACAAA 58 N/A N/A 1909 949781 74967 74982 TGCAAGGCAACTGGTT 14 N/A N/A 1910 949782 75001 75016 CTCCATGGTGAGAGTG 73 N/A N/A 1911 949783 75055 75070 GCTAAAGCAAGAAGGC 87 N/A N/A 1912 949784 75104 75119 AGAAAGACCGCCCATG 97 N/A N/A 1913 949785 75219 75234 GCGGAGACAGAAGGCT 121 N/A N/A 1914 949786 75320 75335 AAGCATCGGTTAAGGC 142 N/A N/A 1915 949787 75846 75861 CCCAAGTGGTGAGGCT 74 N/A N/A 1916 949788 76007 76022 GTTCAGGCAGGCGGTT 53 N/A N/A 1917 949789 76107 76122 AACAAGAGACCTTGTC 47 N/A N/A 1918 949790 76211 76226 GATCAGGCTACTCAGG 116 N/A N/A 1919 949791 76415 76430 TCATAGCCAATATAAC 42 N/A N/A 1920 949792 76430 76445 TATCACAGGGTGTGCT 67 N/A N/A 1921 949793 76487 76502 TCGGAATGTACTCTTA 23 N/A N/A 1922 949794 76518 76533 GAATTCGGGTTGAATC 107 N/A N/A 1923 949795 76636 76651 GACAAAGCACACCTGG 81 N/A N/A 1924 949796 76637 76652 GGACAAAGCACACCTG 100 N/A N/A 1925 949797 76731 76746 CACTAAACTAATGACA 98 N/A N/A 1926 949798 76734 76749 TAGCACTAAACTAATG 88 N/A N/A 1927 949799 76737 76752 GCATAGCACTAAACTA 83 N/A N/A 1928 949800 76739 76754 AGGCATAGCACTAAAC 80 N/A N/A 1929 949801 76744 76759 AGCAAAGGCATAGCAC 91 N/A N/A 1930 949802 76764 76779 ACCAAACCAGGACCAA 57 N/A N/A 1931 949803 77124 77139 GTTAATGCTTCACCTG 25 N/A N/A 1932 949804 77125 77140 GGTTAATGCTTCACCT 104 N/A N/A 1933 949805 77175 77190 GTAAAGGGTGTGCACA 10 N/A N/A 1934 949806 77224 77239 AGGCAAGCACAAGCTG 115 N/A N/A 1935 949807 77245 77260 CCTTCATACCCCAACT 97 N/A N/A 1936 949808 77343 77358 TACTGAAGTACCTGGG 102 N/A N/A 1937 949809 77421 77436 TCCTAAGCATTCCTAA 113 N/A N/A 1938 949810 77450 77465 GTAGGATGATCTTGTT 27 N/A N/A 1939 949811 77458 77473 GTAAAAAAGTAGGATG 68 N/A N/A 1940 949812 77502 77517 CCTTAAAAAGAGTCTC 75 N/A N/A 1941 949813 77561 77576 GCTCATCTAATGGACA 46 N/A N/A 1942 949814 77634 77649 GGCGAGACAGAGTAAG 12 N/A N/A 1943 949815 77894 77909 TATACTGGACACGGTG 96 N/A N/A 1944 949816 77895 77910 ATATACTGGACACGGT 88 N/A N/A 1945 949817 77897 77912 ATATATACTGGACACG 36 N/A N/A 1946 949818 78035 78050 GTTTTATTGGCCGGGT 20 N/A N/A 1947 949819 78144 78159 AGTCACTGATCCTAAA 74 N/A N/A 1948 949820 78149 78164 CAAGAAGTCACTGATC 69 N/A N/A 1949 949821 78222 78237 ACAAAATGGGTTGAGG 38 N/A N/A 1950 949822 78223 78238 TACAAAATGGGTTGAG 50 N/A N/A 1951 949823 78262 78277 GGACAGGACTTTGCCC 119 N/A N/A 1952 949824 78348 78363 CCACAATTCAGGTGGC 122 N/A N/A 1953 949825 78366 78381 GGAAAGGTAGCCACTT 64 N/A N/A 1954 949826 78470 78485 GCCCACTTATTCCTCC 120 N/A N/A 1955 949827 78561 78576 CCAAATTCAAGAGCTC 45 N/A N/A 1956 949828 78611 78626 TACCATTTTTCAGCAG 25 N/A N/A 1957 949829 78678 78693 TCAAAACGGAGGTTTC 20 N/A N/A 1958 949830 78711 78726 GACCATCCTATGAGGA 106 N/A N/A 1959 949831 78878 78893 GACCAGAGACGGGAGG 58 N/A N/A 1960 949832 78949 78964 GCCTAGAGGTAGGAGC 64 N/A N/A 1961 949833 78961 78976 CCACAAGTTCAGGCCT 107 N/A N/A 1962 949834 79024 79039 TCAAAGCTGAGTGTCA 25 N/A N/A 1963 949835 79143 79158 TGCTAGGGACATCTTC 17 N/A N/A 1964 949836 79212 79227 GTATATATCAGCTCAG 30 N/A N/A 1965 949837 79225 79240 ACATAAGGATGTTGTA 126 N/A N/A 1966 949838 79243 79258 ATCCATGTTCAGTTTC 13 N/A N/A 1967 949839 79330 79345 CGGAAAAAGAAGTCCC 154 N/A N/A 1968 949840 79375 79390 TTCAAGCAAATCACAC 96 N/A N/A 1969 949841 79794 79809 TCAGTATGCACCACCA 6 N/A N/A 1970 949842 79870 79885 AAGCATGACATGACAC 16 N/A N/A 1971 949843 80250 80265 CAGAATATTTAACTCG 26 N/A N/A 1972 949844 80347 80362 GACAAACCAAGCACAT 107 N/A N/A 1973 949845 80435 80450 GTGGAACTTGCCTGAC 86 N/A N/A 1974 949846 80542 80557 TCCAAGAGCCCTCTTA 11 N/A N/A 1975 949847 80662 80677 CCTATTTGATCAGGAG 137 N/A N/A 1976 949848 80759 80774 TGATTCAGTGCCGCCC 7 N/A N/A 1977 949849 80769 80784 CCCAAAACCCTGATTC 17 N/A N/A 1978 949850 80805 80820 TCACGAGGAAGCCATG 54 N/A N/A 1979 949851 80870 80885 GGCGATGGAAGGGCAG 57 N/A N/A 1980 949852 80981 80996 TTTCATTGGCCCTGGC 62 N/A N/A 1981 949853 80987 81002 CAGCAATTTCATTGGC 63 N/A N/A 1982 949854 81187 81202 TACCTTACTGGTACAC 67 N/A N/A 1983 949855 81200 81215 GCCGAGGGAGCAATAC 102 N/A N/A 1984 949856 81201 81216 TGCCGAGGGAGCAATA 49 N/A N/A 1985 949857 81288 81303 GAAAAGGCACCAGTGG 39 N/A N/A 1986 949858 81306 81321 CACAAAGCGATATGGG 7 N/A N/A 1987 949859 81411 81426 GTGCATCTGTCTGGCC 79 N/A N/A 1988 949860 81445 81460 TGCTAGGCTTGGTATC 95 N/A N/A 1989 949861 81530 81545 CAGCAGTTGACGCGGG 127 N/A N/A 1990 949862 81635 81650 CCGGAGCTGAGGGACA 117 N/A N/A 1991 949863 81738 81753 AAAAATGGGCTGCCCC 103 N/A N/A 1992 949864 81740 81755 CCAAAAATGGGCTGCC 90 N/A N/A 1993 949865 81752 81767 GACTAAGTGGATCCAA 2 N/A N/A 1994 949866 81769 81784 GCGCATAGAGGCACTG 56 N/A N/A 1995 949867 81845 81860 AACCAGGCCCGCGGCG 90 N/A N/A 1996 949868 81909 81924 GCGCAAGCACAGACTG 109 N/A N/A 1997 949869 81953 81968 GCAGAAATTCCCTGGC 92 N/A N/A 1998 949870 82004 82019 AGCTTAAGCAGCAAAT 111 N/A N/A 1999 949871 82041 82056 TTTGGACTGTTTTCCC 8 N/A N/A 2000 949872 82043 82058 TGTTTGGACTGTTTTC 2 N/A N/A 2001 949873 82044 82059 CTGTTTGGACTGTTTT 1 N/A N/A 2002 949874 82045 82060 CCTGTTTGGACTGTTT 1 N/A N/A 2003 949875 82047 82062 AACCTGTTTGGACTGT 4 N/A N/A 2004 949876 82048 82063 CAACCTGTTTGGACTG 5 N/A N/A 2005 949877 82050 82065 TCCAACCTGTTTGGAC 27 N/A N/A 2006 949878 82052 82067 TTTCCAACCTGTTTGG 44 N/A N/A 2007 949879 82053 82068 TTTTCCAACCTGTTTG 17 N/A N/A 2008 949880 82054 82069 GTTTTCCAACCTGTTT 4 N/A N/A 2009 949881 82084 82099 ATGTCCATGACACCTG 17 N/A N/A 2010 949882 82085 82100 CATGTCCATGACACCT 39 N/A N/A 2011 949883 82087 82102 TTCATGTCCATGACAC 30 N/A N/A 2012 949884 82089 82104 CATTCATGTCCATGAC 13 N/A N/A 2013 949885 82091 82106 AACATTCATGTCCATG 51 N/A N/A 2014 949886 82154 82169 TACAGAAGGGCCACGG 6 N/A N/A 2015 949887 82155 82170 TTACAGAAGGGCCACG 10 N/A N/A 2016 949888 82259 82274 GATTAGTCCATGCATG 99 N/A N/A 2017 949889 82308 82323 ACACACGCAGGACAGG 85 N/A N/A 2018 949890 82361 82376 GGTCATGCGGAGGGCA 41 N/A N/A 2019 949891 82509 82524 TGTTACCTTCTCGGCA 19 N/A N/A 2020 949892 82529 82544 GCGGAGATGAGAACAA 13 N/A N/A 2021 949893 82619 82634 CTGGTAGGCGGAAGGG 77 N/A N/A 2022 949894 82632 82647 CTCTAAGTGACAACTG 18 N/A N/A 2023 949895 82720 82735 AACAAAGGCTGACCGC 85 N/A N/A 2024 949896 82827 82842 GATGATGTGTTTCCTG 1 N/A N/A 2025 949897 82836 82851 GGCTATACAGATGATG 7 N/A N/A 2026 949898 82948 82963 AACCAGACCTCATGCA 22 N/A N/A 2027 949899 82953 82968 AACTTAACCAGACCTC 12 N/A N/A 2028 949900 82994 83009 CGCCAAATGCCCCCAC 29 N/A N/A 2029 949901 83049 83064 GATAGGAACTCCTTGC 48 N/A N/A 2030 949902 83051 83066 TCGATAGGAACTCCTT 96 N/A N/A 2031 949903 83124 83139 CTGAAGGGCCTCGCCA 119 N/A N/A 2032 949904 83183 83198 TGCCATGCAGGGCTTC 74 N/A N/A 2033 949905 83283 83298 GTGGACCGGAGACAGC 125 N/A N/A 2034 949906 83399 83414 TAGAAAATGCGGAGGG 91 N/A N/A 2035 949907 83424 83439 CGGGAAGCAACATGAA 77 N/A N/A 2036 949908 83429 83444 TGGCACGGGAAGCAAC 87 N/A N/A 2037 949909 83464 83479 GAACAAGCAGAGTGGT 51 N/A N/A 2038 949910 83566 83581 GGCCAGTACCTGGTCC 103 N/A N/A 2039 949911 83622 83637 GAACAGTACACTTGAC 90 N/A N/A 2040 949912 83627 83642 GCACAGAACAGTACAC 100 N/A N/A 2041 949942 83908 83923 GGTTGACTACAAAGGG 5 N/A N/A 2042 949943 83909 83924 AGGTTGACTACAAAGG 3 N/A N/A 2043 949944 83911 83926 AGAGGTTGACTACAAA 4 N/A N/A 2044 949945 83912 83927 GAGAGGTTGACTACAA 2 N/A N/A 2045 949946 83914 83929 TTGAGAGGTTGACTAC 66 N/A N/A 2046 949947 83916 83931 TTTTGAGAGGTTGACT 21 N/A N/A 2047 949948 83918 83933 GTTTTTGAGAGGTTGA 2 N/A N/A 2048 949949 83919 83934 GGTTTTTGAGAGGTTG 3 N/A N/A 2049 949950 83920 83935 GGGTTTTTGAGAGGTT 5 N/A N/A 2050 949951 83922 83937 GTGGGTTTTTGAGAGG 17 N/A N/A 2051 949952 83923 83938 TGTGGGTTTTTGAGAG 25 N/A N/A 2052 949953 83924 83939 CTGTGGGTTTTTGAGA 38 N/A N/A 2053 949954 83926 83941 GCCTGTGGGTTTTTGA 24 N/A N/A 2054 949955 84164 84179 CCATAACTTACTGAAG 69 N/A N/A 2055 949956 84276 84291 GTAGGATAGGGAGCGG 31 N/A N/A 2056 949957 84379 84394 TCCCAAATGCAGACGC 38 N/A N/A 2057 949958 84397 84412 ACAAACAACACGCTTG 88 N/A N/A 2058 949959 84399 84414 CAACAAACAACACGCT 88 N/A N/A 2059 949960 84687 84702 AATTAGGTGGGTAAAG 64 N/A N/A 2060 949961 84860 84875 GCCTTTGCAAGAAAGC 94 N/A N/A 2061 949962 85204 85219 GGTTTCAACAAACAGT 11 N/A N/A 2062 949963 85243 85258 AACAAAGTGACATAGC 8 N/A N/A 2063 949964 85260 85275 GGAGAGGGACCATTTT 94 N/A N/A 2064 949965 85323 85338 AATCAAAACTGGGCGC 100 N/A N/A 2065 949966 85335 85350 AGCAATTGGCCAAATC 55 N/A N/A 2066 949967 85362 85377 GGCATAGGTGGACTGG 21 N/A N/A 2067 949968 85379 85394 AGCTACAGCAGCTATG 83 N/A N/A 2068 949969 85438 85453 CTTACCAACAGTAACA 67 N/A N/A 2069 949970 85541 85556 GGCTGGTTTAGTAAGG 75 N/A N/A 2070 949971 85608 85623 GGGCAAGGCACTCGGA 54 N/A N/A 2071 949972 85618 85633 GAATAAAGTAGGGCAA 44 N/A N/A 2072 949973 85681 85696 CGTCACTGGACTCCCC 75 N/A N/A 2073 949974 85784 85799 CCAGGATGAAGTTGGT 94 N/A N/A 2074 949975 85876 85891 ATCAAGCTAGAAAGGT 19 N/A N/A 2075 949976 85880 85895 AGCTATCAAGCTAGAA 82 N/A N/A 2076 949977 85884 85899 CTCAAGCTATCAAGCT 120 N/A N/A 2077 949978 85946 85961 CCAATTATGAACACTA 7 N/A N/A 2078 949979 85984 85999 GTTCAAAGTGTTGCAT 9 N/A N/A 2079 949980 86329 86344 AGCCACTGCCTTGTAT 74 N/A N/A 2080 949981 86547 86562 AATCATAGCCTCAAAC 85 N/A N/A 2081 949982 86551 86566 GAACAATCATAGCCTC 14 N/A N/A 2082 949983 86933 86948 AATAATGTGCAGTTGT 14 N/A N/A 2083 949984 87041 87056 CCCCAAGGTCTGGAGT 104 N/A N/A 2084 949985 87160 87175 TCCCAGACAGGAGAAC 80 N/A N/A 2085 949986 87349 87364 ACCTACTTGGCAAACC 128 N/A N/A 2086 949987 87359 87374 CTCTAAAAGTACCTAC 127 N/A N/A 2087 949988 87456 87471 CGACAGAGACTGTCTG 130 N/A N/A 2088 949989 87574 87589 CTAAACTAACCATGGG 79 N/A N/A 2089 949990 87595 87610 GAACATAGCACTGCCC 3 N/A N/A 2090 949991 87597 87612 CTGAACATAGCACTGC 3 N/A N/A 2091 949992 87598 87613 TCTGAACATAGCACTG 9 N/A N/A 2092 949993 87680 87695 GCACACTGGTCGCTAA 43 N/A N/A 2093 949994 87782 87797 TTGAAGCTAGGGAGAC 85 N/A N/A 2094 949995 87817 87832 ACGGAAGGTTCTGGTT 69 N/A N/A 2095 949996 87880 87895 GCACACTGAATCGACA 23 N/A N/A 2096 949997 87882 87897 ACGCACACTGAATCGA 43 N/A N/A 2097 949998 87893 87908 TGCCTGAGACCACGCA 152 N/A N/A 2098 949999 88002 88017 TACCAGCGGCACCACC 72 N/A N/A 2099 950000 88014 88029 AGCGAGAGGGCATACC 30 N/A N/A 2100 950001 88119 88134 CACTACACCTTAACGC 70 N/A N/A 2101 950002 88226 88241 CTCTAGAGGCCCTCCC 98 N/A N/A 2102 950003 88271 88286 CACCGATAAATGTTGT 27 N/A N/A 2103 950004 88308 88323 CAGCACGGAACAGATC 51 N/A N/A 2104 950005 88397 88412 AGGGACTTCGGCTCAT 120 N/A N/A 2105 950006 88497 88512 GCAAACCAAAGATGGG 47 N/A N/A 2106 950007 88619 88634 GGTAAGTGGGAAGGCC 73 N/A N/A 2107 950008 88766 88781 CCCCGTAGCTCTTCAG 24 N/A N/A 2108 950009 88878 88893 TTTAAGGACTCCACCT 86 N/A N/A 2109 950010 88992 89007 TGGCATCACCTGACTT 99 N/A N/A 2110 950011 89116 89131 ATCCAAAATCCTCCCC 43 N/A N/A 2111 950012 89192 89207 TCAAATAGCAGCCCAC 38 N/A N/A 2112 950013 89231 89246 CCTAAGGGCCTCCTGG 102 N/A N/A 2113 950014 89335 89350 CACAAGAAGGATTTTC 2 N/A N/A 2114 950015 89459 89474 CAGCAATCGACCCACC 31 N/A N/A 2115 950016 89560 89575 GCTGAGATTACGCACC 38 N/A N/A 2116 950017 89706 89721 CTTATCTGGGCTATTT 7 N/A N/A 2117 950018 89719 89734 TATTATAGGGCTTCTT 20 N/A N/A 2118 950019 89813 89828 GAAAGTAGGCTTCTGT 6 N/A N/A 2119 950020 89966 89981 TGTTACTTATCCATCA 7 N/A N/A 2120 950021 89980 89995 CAACATATATCTCCTG 8 N/A N/A 2121 950022 90075 90090 ACAAATCCCACTATAT 58 N/A N/A 2122 950023 90081 90096 GCATAGACAAATCCCA 3 N/A N/A 2123 950024 90175 90190 CGACAGGGTGTGTTTC 6 N/A N/A 2124 950025 90197 90212 AAATTTAGAGGACATC 38 N/A N/A 2125 950026 90276 90291 AGCCATCCAGTCTTAG 38 N/A N/A 2126 950027 90541 90556 CTCAAGTAGTTCCCCT 12 N/A N/A 2127 950028 90642 90657 CACTAGAATCCCGGAG 18 N/A N/A 2128 950029 90673 90688 ACTTACTAAAGCGCAG 24 N/A N/A 2129 950030 90722 90737 AGTAAATGTATCTGGT 3 N/A N/A 2130 950031 90754 90769 GCGCAAGGGAAACGGC 97 N/A N/A 2131 950032 90804 90819 TGAGCAGCCACAGGTA 31 N/A N/A 2132 950033 90806 90821 AGTGAGCAGCCACAGG 45 N/A N/A 2133 950034 90807 90822 AAGTGAGCAGCCACAG 83 N/A N/A 2134 950035 90808 90823 CAAGTGAGCAGCCACA 27 N/A N/A 2135 950036 90810 90825 ACCAAGTGAGCAGCCA 14 N/A N/A 2136 950037 90812 90827 GGACCAAGTGAGCAGC 54 N/A N/A 2137 950038 90837 90852 GCGAATGTGGCCGTTC 64 N/A N/A 2138 950039 90889 90904 GAACAGACAGGGTTCA 97 N/A N/A 2139 950040 90978 90993 CGGGAGACTGCAGAGG 44 N/A N/A 2140 950041 91083 91098 AGCAGATGGCCTGGTA 18 N/A N/A 2141 950042 91189 91204 ACATAGGGCCTTCTGG 38 N/A N/A 2142 950043 91226 91241 AGCCAAGAGTCAAGTT 36 N/A N/A 2143 950044 91384 91399 CATGAGCCCACCACTC 120 N/A N/A 2144 950045 91538 91553 CTCCTAACATGCTAGA 75 N/A N/A 2145 950046 91825 91840 CGCTCAAGGGAAAAAT 25 N/A N/A 2146 950047 91934 91949 TCCCAAGCTCCCCTGA 51 N/A N/A 2147 950048 92034 92049 GATACAGCCGTTCATA 11 N/A N/A 2148 950049 92059 92074 TAATAAGGTACTGAAG 54 N/A N/A 2149 950050 92634 92649 ACGAAGCTAGGAGGCG 108 N/A N/A 2150 950051 92635 92650 CACGAAGCTAGGAGGC 35 N/A N/A 2151 950052 92814 92829 GCATGATAATCCCAGC 98 N/A N/A 2152 950053 93110 93125 AGCCGCCCAGGCCAGA 96 N/A N/A 2153 950054 93183 93198 GCAGAAATTTTGCGAA 35 N/A N/A 2154 950055 93185 93200 AGGCAGAAATTTTGCG 48 N/A N/A 2155 950056 93235 93250 GGTGGAGTCCCCGCCC 165 N/A N/A 2156 950057 93248 93263 GTGCAAGGTACATGGT 11 N/A N/A 2157 950058 93303 93318 CGCAAAAATAAATCAT 83 N/A N/A 2158 950059 93304 93319 GCGCAAAAATAAATCA 105 N/A N/A 2159 950060 93322 93337 ATGTATTACCTACGGC 7 N/A N/A 2160 950061 93383 93398 CATATTCATGGTGTTA 10 N/A N/A 2161 950062 93496 93511 AGAGATGGAAGGGACG 89 N/A N/A 2162 950063 93586 93601 CCACACTAAGCATGTA 38 N/A N/A 2163 950064 93600 93615 TCTAATGTTTGCTACC 7 N/A N/A 2164 950065 93601 93616 CTCTAATGTTTGCTAC 4 N/A N/A 2165 950066 93612 93627 ACCACTAGATTCTCTA 56 N/A N/A 2166 950067 93648 93663 GAACAGGGAATATTAG 79 N/A N/A 2167 950068 93744 93759 TTATACCCAGGGCAAC 37 N/A N/A 2168 950069 93854 93869 TAAGTATTTGCCATCC 6 N/A N/A 2169 950070 93908 93923 GCTTAAGCGAGATCTT 42 N/A N/A 2170 950071 93921 93936 GAATTCTGGTCTGGCT 26 N/A N/A 2171 950072 93958 93973 CATAGGAGATAGAAGG 4 N/A N/A 2172 950073 93960 93975 TGCATAGGAGATAGAA 34 N/A N/A 2173 950074 94019 94034 CACAAGAGGGCAAGAT 36 N/A N/A 2174 950075 94050 94065 TGCTAGATCAACTAGC 7 N/A N/A 2175 950076 94058 94073 GCAAAGAGTGCTAGAT 89 N/A N/A 2176 950077 94060 94075 AGGCAAAGAGTGCTAG 78 N/A N/A 2177 950078 94065 94080 GCACAAGGCAAAGAGT 89 N/A N/A 2178 950079 94078 94093 TGCTAGAGGAGCGGCA 114 N/A N/A 2179 950080 94153 94168 CTATAGAACAGGAGTG 15 N/A N/A 2180 950081 94155 94170 TGCTATAGAACAGGAG 9 N/A N/A 2181 950082 94164 94179 AGCCACATCTGCTATA 89 N/A N/A 2182 950083 94176 94191 CCTTAATCACTTAGCC 7 N/A N/A 2183 950084 94200 94215 TATCATATAGGGAGAA 16 N/A N/A 2184 950085 94215 94230 GCATAGAGAAGAGGGT 6 N/A N/A 2185 950086 94270 94285 GACAAGAGGCAGCATC 7 N/A N/A 2186 950087 94333 94348 TCACAGGCCAAGGATA 81 N/A N/A 2187 950088 94371 94386 TGGCAGGAAACGGTGC 42 N/A N/A 2188 950089 94450 94465 GCAAATATGATTCATC 1 N/A N/A 2189 950090 94481 94496 AAGGAGGTGTTACCCA 60 N/A N/A 2190 950091 94581 94596 CTATGAGTAGCAGGCT 3 N/A N/A 2191 950092 94652 94667 GTCCAAGTGTAAGAGC 12 N/A N/A 2192 950093 94695 94710 GCAAAAGGGAGCCCCT 69 N/A N/A 2193 950094 94696 94711 AGCAAAAGGGAGCCCC 88 N/A N/A 2194 950095 94770 94785 TGCCAGAAGAGCCCCG 84 N/A N/A 2195 950096 94791 94806 CTACAAGAAAGACCCT 30 N/A N/A 2196 950097 94805 94820 TAGGATCGGCTCAGCT 18 N/A N/A 2197 950098 94810 94825 TGGCATAGGATCGGCT 54 N/A N/A 2198 950099 94920 94935 GAACACATGAGGAACC 24 N/A N/A 2199 950100 94977 94992 GTACAAGGGAGAAGCA 100 N/A N/A 2200 950101 95047 95062 GGCCACGCTCATGACG 97 N/A N/A 2201 950102 95086 95101 GTAGAGATGGGAACCA 4 N/A N/A 2202 950103 95155 95170 AAGCAGGGATCCTCTG 114 N/A N/A 2203 950104 95189 95204 GCGGTATGGGTGGCAG 106 N/A N/A 2204 950105 95227 95242 GGCTAGGGTGCACAGT 60 N/A N/A 2205 950106 95278 95293 CTTAGAAGGAAGTAGG 100 N/A N/A 2206 950107 95378 95393 CCGTTAGCCATCCACC 73 N/A N/A 2207 950108 95416 95431 CCCTAGGGAGCTGCAA 112 N/A N/A 2208 950109 95443 95458 CCACACGGGTTCAGAG 43 N/A N/A 2209 950110 95496 95511 GCACACCAAGCCTTGG 63 N/A N/A 2210 950111 95645 95660 AGGGATGTGCCCGCAC 87 N/A N/A 2211 950112 95745 95760 TGACAACCAGGTGAGG 24 N/A N/A 2212 950113 95854 95869 TGGGAATGCCTCCATT 95 N/A N/A 2213 950114 95954 95969 AGCCCCTGTGAGGTCA 66 N/A N/A 2214 950115 96079 96094 GTACAGACTTATCCCT 28 N/A N/A 2215 950116 96081 96096 GGGTACAGACTTATCC 95 N/A N/A 2216 950117 96178 96193 GGCTAAAGAGTACCCA 63 N/A N/A 2217 950118 96181 96196 GGTGGCTAAAGAGTAC 23 N/A N/A 2218 950119 96298 96313 GACTACCCCGACCCAC 71 N/A N/A 2219 950120 96399 96414 GCACGGCACGGCAGGA 24 N/A N/A 2220 950121 96523 96538 ACGCACAGGGCGGCCT 111 N/A N/A 2221 950122 96527 96542 AGGCACGCACAGGGCG 83 N/A N/A 2222 950123 96646 96661 CTAACGGCAGGCAGCC 71 N/A N/A 2223 950124 96752 96767 CATCAGGGTTTCAGGC 11 N/A N/A 2224 950125 96860 96875 GGCTAGGGTCAAAGGT 21 N/A N/A 2225 950126 96977 96992 GCCCATGGGAGGAGTC 80 N/A N/A 2226 950127 97078 97093 GAAACCAACATGAGGC 20 N/A N/A 2227 950128 97149 97164 CGCAATAGAGACACCT 32 N/A N/A 2228 950129 97221 97236 GAACCTCGCTCCGTGC 165 N/A N/A 2229 950130 97453 97468 AGTGACTGAGTTCTGC 22 N/A N/A 2230 950131 97809 97824 GGTTACGGTTGTTTTT 26 N/A N/A 2231 950132 97855 97870 GTACAATGTAAGCCTT 3 N/A N/A 2232 950133 97920 97935 TGCTAGTGACTCCATC 27 N/A N/A 2233 950134 98046 98061 AGTGATGGAACCCCGG 48 N/A N/A 2234 950135 98098 98113 CGCAGATAGAAAAACT 26 N/A N/A 2235 950136 98099 98114 TCGCAGATAGAAAAAC 60 N/A N/A 2236 950137 98150 98165 GCACACTGTGGCCAAG 70 N/A N/A 2237 950138 98259 98274 AGTGAACGAGTCCCTC 84 N/A N/A 2238 950139 98353 98368 TTCTACATAGGACCAT 13 N/A N/A 2239 950140 98399 98414 AAACATCACAGGGACC 43 N/A N/A 2240 950141 98508 98523 TCAGAAGAGAGGACCT 42 N/A N/A 2241 950142 98643 98658 AGACACAGGGTAATGC 35 N/A N/A 2242 950143 98866 98881 CAACAATGCAACAACG 15 N/A N/A 2243 950144 99310 99325 CGCCAGATTAATTTTG 46 N/A N/A 2244 950145 99477 99492 AACAATTGTCTGGTGT 85 N/A N/A 2245 950146 99478 99493 CAACAATTGTCTGGTG 63 N/A N/A 2246 950147 99481 99496 TAACAACAATTGTCTG 20 N/A N/A 2247 950148 99493 99508 TAAGACTATAGTTAAC 63 N/A N/A 2248 950149 99519 99534 CAACAGAAGAGTAGGG 26 N/A N/A 2249 950150 99522 99537 GTTCAACAGAAGAGTA 25 N/A N/A 2250 950151 99626 99641 GATAAATACTAGAGGC 45 N/A N/A 2251 950152 99810 99825 GATCAGGGCCATAGAA 79 N/A N/A 2252 950153 99823 99838 CAAGAAACGGGTTGAT 71 N/A N/A 2253 950154 99830 99845 AATTAAGCAAGAAACG 114 N/A N/A 2254 950155 99893 99908 CAACAAGCTATCACAC 92 N/A N/A 2255 950156 99912 99927 CTGGACCGCATCAGAG 92 N/A N/A 2256 950157 99924 99939 TTGAAAGCCAACCTGG 105 N/A N/A 2257 950158 100015 100030 TAACACAGCCATGGCT 123 N/A N/A 2258 950159 100020 100035 CCACATAACACAGCCA 28 N/A N/A 2259 950160 100125 100140 TTGCAGCACAGGGTCA 56 N/A N/A 2260 950161 100161 100176 GGCAACAGGAGACGCG 62 N/A N/A 2261 950162 100227 100242 AGAGGCTACATGGTGA 60 N/A N/A 2262 950163 100328 100343 GAAACAACCAATATCC 58 N/A N/A 2263 950164 100399 100414 CACGAAGGGTTGACAC 101 N/A N/A 2264 950165 100435 100450 GGCCAGAGTCCTGACT 98 N/A N/A 2265 950166 100535 100550 GTTACCAGGACAAAAC 126 N/A N/A 2266 950167 100670 100685 TGCCATCCCAGGGACC 105 N/A N/A 2267 950168 100782 100797 CTACAGAGCATTCCCC 89 N/A N/A 2268 950169 100811 100826 TGCCAGCAAGTCCCCA 80 N/A N/A 2269 950170 100929 100944 GCCAAGAGGCCCGCCT 171 N/A N/A 2270 950171 101038 101053 ACCCGAATAGCAAGCG 54 N/A N/A 2271 950172 101155 101170 GAGCATGGGCCCGCAG 139 N/A N/A 2272 950173 101255 101270 GATGATCCTTTCACCC 90 N/A N/A 2273 950174 101362 101377 CACCACCCTGGGTTTA 132 N/A N/A 2274 950175 101483 101498 GCAGACCACGCCTGGC 44 N/A N/A 2275 950176 101603 101618 TGCAAGGCGGAAAGAG 95 N/A N/A 2276 950177 101718 101733 GGCATTCCCACCCAGG 84 N/A N/A 2277 950178 101808 101823 GAAAACTAGACTTGCA 31 N/A N/A 2278 950179 101810 101825 CTGAAAACTAGACTTG 44 N/A N/A 2279 950180 101850 101865 GAAAAACACGAAGGGC 86 N/A N/A 2280 950181 101951 101966 TCATTACGGCCGGCGC 109 N/A N/A 2281 950182 102059 102074 CTAACTTGGGTGGTGG 43 N/A N/A 2282 950183 102159 102174 AGATATTGATGTCTTG 7 N/A N/A 2283 950184 102264 102279 GCAGAGGGAGCCCCGA 90 N/A N/A 2284 950185 102314 102329 TCGCATAGAAGATTCG 38 N/A N/A 2285 950186 102365 102380 CGGCAGGTGAGTGTCA 30 N/A N/A 2286 950187 102465 102480 GACTACCTGTTCAGGA 112 N/A N/A 2287 950188 102585 102600 GAAGAGTGGTGGTTTC 80 N/A N/A 2288 950189 102639 102654 TGCGAGCCGGCCCCAG 61 N/A N/A 2289 950190 102716 102731 CACGATCCCAAACCCT 79 N/A N/A 2290 950191 102830 102845 TGCCGGCACGCACGCG 135 N/A N/A 2291 950192 102935 102950 CAGCAGGGCCAAGTAA 61 N/A N/A 2292 950193 103102 103117 GGTAACACAGGGCCTG 119 N/A N/A 2293 950207 103286 103301 GAGCATAGGAAGAGGG 27 N/A N/A 2294 950208 103302 103317 GCAAAGAAGTAGGGCA 81 N/A N/A 2295 950209 103323 103338 GATTAGCCTGCCAGGC 20 N/A N/A 2296 950210 103425 103440 CCTCATCTATCCAAGG 99 N/A N/A 2297 950211 103552 103567 GGCACATGGGCTCAGC 119 N/A N/A 2298 950212 103672 103687 CTCCAAGTTCAGGAGC 119 N/A N/A 2299 950213 103832 103847 CGCAAGCCACAGCAGG 101 N/A N/A 2300 950214 103971 103986 ACTCACCCAGTGATGT 111 N/A N/A 2301 950215 104100 104115 GTTCAGGAAGCACCAA 20 N/A N/A 2302 950216 104276 104291 AGCCTTACTCCCTTTC 34 N/A N/A 2303 950217 104326 104341 CGCTTTAGGACATCTT 63 N/A N/A 2304 950218 104410 104425 TAGGAGTGAGTTACCT 102 N/A N/A 2305 950219 104458 104473 CACGAAGTGAATGGAA 13 N/A N/A 2306 950220 104486 104501 ACGCACAACACAACTG 63 N/A N/A 2307 950221 104560 104575 TGCCACTGGACTGACT 69 N/A N/A 2308 950222 104606 104621 GACCTAGGTGCCTGAC 27 N/A N/A 2309 950223 104678 104693 ACTCTACCCGCACCCT 96 N/A N/A 2310 950224 104783 104798 CTCCATGATGCTCCCT 63 N/A N/A 2311 950225 104895 104910 GTGTAGCATGCGCCAC 124 N/A N/A 2312 950226 104953 104968 GGGAAAAGAGTCACCC 113 N/A N/A 2313 950227 105113 105128 CTTCACCCCGAGCCAT 90 N/A N/A 2314 950228 105248 105263 CGGGAAGCATCCCTGG 114 N/A N/A 2315 950229 105253 105268 CAGCACGGGAAGCATC 53 N/A N/A 2316 950230 105366 105381 TGCAAGCACCTGAGCC 99 N/A N/A 2317 950231 105479 105494 CCCTATGGGTTCTGGC 78 N/A N/A 2318 950232 105561 105576 TCACAATTGGTGCCTT 16 N/A N/A 2319 950233 105622 105637 CCCCACCTCGGCCAAT 59 N/A N/A 2320 950234 105668 105683 CTAAATGGAGCTCTTG 64 N/A N/A 2321 950235 105671 105686 GGCCTAAATGGAGCTC 79 N/A N/A 2322 950236 105727 105742 CATCACACTCCTCGAT 96 N/A N/A 2323 950237 105864 105879 ATGTACTGTGAGCTTC 12 N/A N/A 2324 950238 106002 106017 GCTAATCCCTGACTCA 37 N/A N/A 2325 950239 106118 106133 ACTCAGCTGGAGTTGG 63 N/A N/A 2326 950240 106174 106189 GACAAATGGGTCTCGA 124 N/A N/A 2327 950241 106213 106228 GCCTAGAAGAGCTATG 97 N/A N/A 2328 950242 106218 106233 GGCAAGCCTAGAAGAG 95 N/A N/A 2329 950243 106269 106284 AGGCACACGGCTCAGG 55 N/A N/A 2330 950244 106276 106291 GTACAGGAGGCACACG 82 N/A N/A 2331 950245 106340 106355 TACTACTCTGGGTTTC 53 N/A N/A 2332 950246 106457 106472 GAACATGCAGGGCCTG 13 N/A N/A 2333 950247 106838 106853 AAGAAGTAGAAGTCGG 36 N/A N/A 2334 950248 106946 106961 GGATGAGGTTGTGTGG 82 N/A N/A 2335 950249 107060 107075 ACGCACATTTTCCTGT 59 N/A N/A 2336 950250 107115 107130 TGCTAAACAGTGCTTG 76 N/A N/A 2337 950251 107478 107493 AAAGTTTAGGCATGGT 22 N/A N/A 2338 950252 107673 107688 CGTCAATACTAAAATA 119 N/A N/A 2339 950253 108115 108130 GCCCGAATGTGTTTTG 72 N/A N/A 2340 950254 108434 108449 CACCAGAACTTTATTA 92 N/A N/A 2341 950255 108584 108599 GGCAAGTGTCTGAGTT 17 N/A N/A 2342 950256 108685 108700 TCTGACTGATCAGGAA 85 N/A N/A 2343 950257 108748 108763 GCACAAGCTTGACCCT 92 N/A N/A 2344 950258 108970 108985 GAAAATGACCTGTCCT 92 N/A N/A 2345 950259 109080 109095 CCGTGAGGGAACTTTC 69 N/A N/A 2346 950260 109124 109139 AAGCAAGTGGGACCCC 79 N/A N/A 2347 950261 109129 109144 GAACAAAGCAAGTGGG 62 N/A N/A 2348 950262 109183 109198 GGCCAAGGGTGGCCAT 143 N/A N/A 2349 950263 109205 109220 CGGCAAGGCATTTTAA 88 N/A N/A 2350 950264 109407 109422 TTTAAGCGATCTCCTG 31 N/A N/A 2351 950265 109408 109423 GTTTAAGCGATCTCCT 39 N/A N/A 2352 950266 109516 109531 ACCCAACCTTGGGACA 75 N/A N/A 2353 950267 109576 109591 CCCAAAGGATCTGCCC 101 N/A N/A 2354 950268 109649 109664 TGCCTGGGTATGTTTG 76 N/A N/A 2355 950269 109910 109925 AGATAGGCCTGCTTGC 70 N/A N/A 2356 950270 109914 109929 CACCAGATAGGCCTGC 74 N/A N/A 2357 950271 110212 110227 ACTCACATTGTTGATC 92 N/A N/A 2358 950272 110607 110622 CTCTAGGCTTACCACA 53 N/A N/A 2359 950273 110885 110900 GCCTAGGGTGCCTGGC 105 N/A N/A 2360 950274 110899 110914 TACAAACAGGTATGGC 20 N/A N/A 2361 950275 110900 110915 CTACAAACAGGTATGG 46 N/A N/A 2362 950276 111043 111058 TCAAATTTGTTGTTGC 14 N/A N/A 2363 950277 111093 111108 CCAAAGAGGATGGCCG 66 N/A N/A 2364 950278 111150 111165 AGTTAGTGGACTTGAT 37 N/A N/A 2365 950279 111166 111181 CTGCAGTGTTCACTCC 64 N/A N/A 2366 950280 111195 111210 GCCTAAGTTAATTCAG 88 N/A N/A 2367 950281 111339 111354 GCAACCAGGGTAAACG 94 N/A N/A 2368 950282 111471 111486 ACTGAAGAGGAGCCCA 57 N/A N/A 2369 950283 111548 111563 GCCAAAGGCCTGATAC 96 N/A N/A 2370 950284 111581 111596 GGTTTATAAAGCTTCC 35 N/A N/A 2371 950285 111781 111796 TCTTACCTCGGTCTTC 66 N/A N/A 2372 950286 111872 111887 TGAAAGAGGTTCCTGC 36 N/A N/A 2373 950287 111910 111925 GTTGACATTCATATAC 68 N/A N/A 2374 950288 112131 112146 TGAGAATGGGAGCAAC 39 N/A N/A 2375 950289 112147 112162 GAACACTGATCACTAC 32 N/A N/A 2376 950290 112174 112189 AAACATACCAGGACAC 39 N/A N/A 2377 950291 112192 112207 TCCTATCGGTATATGA 139 N/A N/A 2378 950292 112222 112237 TCATAGCAGAAGAACC 28 N/A N/A 2379 950293 112260 112275 TAAACTTGCAGGGTCA 9 N/A N/A 2380 950294 112267 112282 CTAAAAGTAAACTTGC 98 N/A N/A 2381 950295 112360 112375 TCCCATCTTTGGCTGC 37 N/A N/A 2382 950296 112902 112917 TCCTACTGGATACAGA 58 N/A N/A 2383 950299 113293 113308 GCCAATCCTGTTATAT 97 N/A N/A 2384 950300 113614 113629 GCAGAATAATCCTGTT 77 N/A N/A 2385 950301 113616 113631 TGGCAGAATAATCCTG 69 N/A N/A 2386 950302 113780 113795 GTTGACACCATGCTTG 14 N/A N/A 2387 950303 113923 113938 CCCCAGACTTTTTTGA 101 N/A N/A 2388 950304 114269 114284 AACCAGGCTTCCGGAC 83 N/A N/A 2389 950305 114450 114465 AGCTGTAGGGCTGGCT 61 N/A N/A 2390 950306 114637 114652 TCTGGCCACGCCTTGC 93 N/A N/A 2391 950307 114737 114752 CCTTAAGGAACTCCAT 109 N/A N/A 2392 950308 114843 114858 CCTAATATCTCTAGGG 82 N/A N/A 2393 950309 115000 115015 GCGCAGTGGGATCCTC 178 N/A N/A 2394 950310 115042 115057 TGCCAGAACCTGAGGT 96 N/A N/A 2395 950311 115081 115096 ATACAGATGGAGTAGG 63 N/A N/A 2396 950312 115423 115438 ACAGGAGGAGAGACCC 58 N/A N/A 2397 950313 115497 115512 CCAAATAGGGATGAGG 87 N/A N/A 2398 950314 115504 115519 TCGCAAGCCAAATAGG 29 N/A N/A 2399 950315 115538 115553 GAACAAGCCTCTTGGC 142 N/A N/A 2400 950316 115640 115655 GCCCAGTGTGAGGGTT 102 N/A N/A 2401 950317 115795 115810 CATCAACTCGCCTGCT 101 N/A N/A 2402 950318 115915 115930 CCGGGAGCAAGAGGCA 160 N/A N/A 2403 951323 3692 3707 CCAGATGGCAGACTTC 19 N/A N/A 2404 951324 3772 3787 AGATATCTAGATGGCC 111 N/A N/A 2405 951325 3773 3788 TAGATATCTAGATGGC 63 N/A N/A 2406 951326 3774 3789 ATAGATATCTAGATGG 52 N/A N/A 2407 951327 3884 3899 CCAAATGGTGGTGGCA 84 N/A N/A 2408 951328 4373 4388 CCAATTTGTAGGCTGT 9 N/A N/A 2409 951329 4487 4502 ACAGATGGGCACACCG 91 N/A N/A 2410 951330 4647 4662 ACAAATGAGTAGTTCC 6 N/A N/A 2411 951331 4668 4683 TCATTTGGCAGCCACA 41 N/A N/A 2412 951332 4670 4685 TATCATTTGGCAGCCA 77 N/A N/A 2413 951333 4673 4688 TGTTATCATTTGGCAG 13 N/A N/A 2414 951334 4767 4782 CCTTACTTGGGATTCA 64 N/A N/A 2415 951335 4792 4807 ATGATAACACAGCCTC 47 N/A N/A 2416 951336 4793 4808 GATGATAACACAGCCT 46 N/A N/A 2417 951337 4795 4810 GGGATGATAACACAGC 104 N/A N/A 2418 951338 4917 4932 GAGATTTGTGCTGCTT 16 N/A N/A 2419 951339 5744 5759 GTAAGTAAGCACTTTT 45 N/A N/A 2420 951340 5899 5914 GGATTATAGCAATGCC 12 N/A N/A 2421 951341 5970 5985 TCACTTTACAGCCTCC 9 N/A N/A 2422 951342 6124 6139 GGATTCTAGGAGGTCG 36 N/A N/A 2423 951343 6458 6473 ATTAATACTCTTAACG 57 N/A N/A 2424 951344 6738 6753 ACTAACTGGGCTGTTC 53 N/A N/A 2425 951345 6740 6755 GAACTAACTGGGCTGT 40 N/A N/A 2426 951346 6857 6872 GGAAATCTAACACTGG 7 N/A N/A 2427 951347 6908 6923 AACTCTATAGATCTGA 101 N/A N/A 2428 951348 6959 6974 AGACATGGTGGAACCA 81 N/A N/A 2429 951349 7117 7132 GATTACAACAACAGCC 76 N/A N/A 2430 951350 7175 7190 TGAAATCGAAGCCATT 95 N/A N/A 2431 951351 7399 7414 TAAATGACAAGGGTCA 83 N/A N/A 2432 951352 7942 7957 GCTATTATAACTTGTA 8 N/A N/A 2433 951353 8568 8583 ATTTTAAAGAAGACGG 42 N/A N/A 2434 951354 8583 8598 GCTATTATAACTCCTA 11 N/A N/A 2435 951355 8616 8631 CACTTAATCCCTATTC 74 N/A N/A 2436 951356 9095 9110 ATACTTATCGCCTTTT 5 N/A N/A 2437 951357 9099 9114 CATCATACTTATCGCC 6 N/A N/A 2438 951358 9144 9159 TCCAACTGTGATCTCT 8 N/A N/A 2439 951359 10032 10047 CCAAGGAACACATCAC 25 N/A N/A 2440 951360 10064 10079 ACTAATAAGATCTGTT 97 N/A N/A 2441 951361 10131 10146 TGCAATTTGTCTTTGC 78 N/A N/A 2442 951362 10136 10151 CAAGATGCAATTTGTC 3 N/A N/A 2443 951363 10700 10715 CGAGATCACAAATGCT 41 N/A N/A 2444 951364 11386 11401 AGTAATGATGAGTTCC 3 N/A N/A 2445 951365 11416 11431 CACTGATAGGCACTCC 8 N/A N/A 2446 951366 11553 11568 ATTACTTGTTTGCAGC 8 N/A N/A 2447 951367 11556 11571 CCAATTACTTGTTTGC 8 N/A N/A 2448 951368 11572 11587 TAAATAACTCTCACGG 25 N/A N/A 2449 951369 11573 11588 GTAAATAACTCTCACG 86 N/A N/A 2450 951370 11575 11590 GTGTAAATAACTCTCA 10 N/A N/A 2451 951371 11922 11937 GTTGATAGTCGGTTGT 4 N/A N/A 2452 951372 11960 11975 GGTCATTAAAGATTCT 4 N/A N/A 2453 951373 11990 12005 GGTACCTAACAGGTCT 93 N/A N/A 2454 951374 12062 12077 GTCTTTCCGGTCTTTT 4 N/A N/A 2455 951375 12148 12163 GATTATAAACCTAATC 121 N/A N/A 2456 951376 12215 12230 TCAATAAGTAACTCTG 11 N/A N/A 2457 951377 12216 12231 GTCAATAAGTAACTCT 140 N/A N/A 2458 951378 12237 12252 ACCTATCAAGGGCTGT 27 N/A N/A 2459 951379 12244 12259 GTTATGAACCTATCAA 20 N/A N/A 2460 951380 12245 12260 TGTTATGAACCTATCA 47 N/A N/A 2461 951381 12850 12865 GTTTACATGATGTTCT 7 N/A N/A 2462 951382 12860 12875 GTAAATTACGGTTTAC 122 N/A N/A 2463 951383 12861 12876 AGTAAATTACGGTTTA 14 N/A N/A 2464 951384 12890 12905 CTTAATTACAGCTTGT 6 N/A N/A 2465 951385 12934 12949 TCATTATTGGCTTGGA 41 N/A N/A 2466 951386 12935 12950 CTCATTATTGGCTTGG 4 N/A N/A 2467 951387 12971 12986 CCTTTATTCAGATTGT 3 N/A N/A 2468 951388 13136 13151 AGTCATCCAGCTCCCG 54 N/A N/A 2469 951389 13167 13182 ATAAATGTCCAGCAGC 44 N/A N/A 2470 951390 13169 13184 TCATAAATGTCCAGCA 63 N/A N/A 2471 951391 13170 13185 ATCATAAATGTCCAGC 32 N/A N/A 2472 951392 13392 13407 GCCATATGTGTGGCTC 65 N/A N/A 2473 951393 13487 13502 TGTAATCTTGGCCCAG 83 N/A N/A 2474 951394 13521 13536 TGCATATCCAAAGCCA 83 N/A N/A 2475 951395 14442 14457 CCACATGTGAAGCAGC 21 N/A N/A 2476 951396 14476 14491 GGCTATTCCACTGCAG 99 N/A N/A 2477 951397 14694 14709 TCTGTAATGGTTTCCC 5 N/A N/A 2478 951398 14808 14823 TGTACCTAAGTACAGA 97 N/A N/A 2479 951399 14824 14839 TCTATAGGTACCAGCA 50 N/A N/A 2480 951400 15508 15523 AGTGAAATTCACTCCA 47 N/A N/A 2481 951401 15651 15666 CTCTTTATATAGATGG 58 N/A N/A 2482 951402 16748 16763 AGAGATACATCAACCC 35 N/A N/A 2483 951403 17836 17851 AAATATAGCAGGGACC 51 N/A N/A 2484 951404 17839 17854 ACTAAATATAGCAGGG 30 N/A N/A 2485 951405 17842 17857 GGCACTAAATATAGCA 71 N/A N/A 2486 951406 19042 19057 TAGTATACCAAGGTTA 11 N/A N/A 2487 951407 19043 19058 GTAGTATACCAAGGTT 6 N/A N/A 2488 951408 19760 19775 CAGTATGTATACTTCC 2 N/A N/A 2489 951409 19761 19776 TCAGTATGTATACTTC 86 N/A N/A 2490 951410 20345 20360 TCCTGATAAGATTCAC 17 N/A N/A 2491 951411 20392 20407 TCAGTTATCACTGTCA 31 N/A N/A 2492 951412 20458 20473 ACTAGTAACTTTCCAG 37 N/A N/A 2493 951413 20741 20756 GGATTATTACATGAGT 11 N/A N/A 2494 951414 20743 20758 GAGGATTATTACATGA 29 N/A N/A 2495 951415 20864 20879 GCCAACTAATTCCAGA 46 N/A N/A 2496 951416 21512 21527 ATATATGTGGAGGCAA 10 N/A N/A 2497 951417 21513 21528 TATATATGTGGAGGCA 104 N/A N/A 2498 951418 21515 21530 AATATATATGTGGAGG 4 N/A N/A 2499 951419 21654 21669 CACTATTGGCACACCA 115 N/A N/A 2500 951420 21655 21670 ACACTATTGGCACACC 122 N/A N/A 2501 951421 21656 21671 AACACTATTGGCACAC 111 N/A N/A 2502 951422 21840 21855 TTCTTAACAGGCTCCC 41 N/A N/A 2503 951423 22010 22025 TAAGTATGCGCTGCCA 31 N/A N/A 2504 951424 22134 22149 AGGATATAGGGTCTCC 97 N/A N/A 2505 951425 22135 22150 AAGGATATAGGGTCTC 37 N/A N/A 2506 951426 22212 22227 GAACATCATGGAGCCT 33 N/A N/A 2507 951427 23308 23323 TTTGATACTGATCTCA 18 N/A N/A 2508 951428 24284 24299 GGTATTATGGTATGTG 2 N/A N/A 2509 951429 24285 24300 AGGTATTATGGTATGT 2 N/A N/A 2510 951430 24396 24411 TCATATGTATGGGTTT 4 N/A N/A 2511 951431 24398 24413 CTTCATATGTATGGGT 10 N/A N/A 2512 951432 25701 25716 ATAGATGTAAGCAACT 51 N/A N/A 2513 951433 25709 25724 GGAAATTCATAGATGT 113 N/A N/A 2514 951434 25740 25755 ACTTATGGATGCAGCT 52 N/A N/A 2515 951435 25741 25756 AACTTATGGATGCAGC 39 N/A N/A 2516 951436 26160 26175 AGCATTGGTATCAGGC 35 N/A N/A 2517 951437 26168 26183 TGGATATCAGCATTGG 17 N/A N/A 2518 951438 26173 26188 ATGGATGGATATCAGC 41 N/A N/A 2519 951439 26180 26195 TTCAATCATGGATGGA 72 N/A N/A 2520 951440 27070 27085 GGAATACTTGCAGCTA 41 N/A N/A 2521 951441 27071 27086 AGGAATACTTGCAGCT 11 N/A N/A 2522 951442 27224 27239 CAACATGGCACTCCCT 64 N/A N/A 2523 951443 27231 27246 TCTGATGCAACATGGC 12 N/A N/A 2524 951444 27569 27584 ATCATTGGGTGAAGAC 43 N/A N/A 2525 951445 27762 27777 GGTCTATTGGCACACA 32 N/A N/A 2526 951446 27776 27791 AGATTAAGTCATCCGG 90 N/A N/A 2527 951447 27777 27792 GAGATTAAGTCATCCG 61 N/A N/A 2528 951448 27778 27793 AGAGATTAAGTCATCC 73 N/A N/A 2529 951449 28228 28243 GCAAATGCTAGCTGCA 142 N/A N/A 2530 951450 29274 29289 CGCTCTAATGTCCTGA 11 N/A N/A 2531 951451 29308 29323 TGGATATCCAGACCCA 97 N/A N/A 2532 951452 29321 29336 GCAGATCCTGCCTTGG 92 N/A N/A 2533 951453 29584 29599 TGAACTAGAGGCAGGC 29 N/A N/A 2534 951454 29585 29600 GTGAACTAGAGGCAGG 19 N/A N/A 2535 951455 29974 29989 TGTAACTTTCAGCAGT 25 N/A N/A 2536 951456 29999 30014 TGTGATTGCAGGCCAG 13 N/A N/A 2537 951457 30053 30068 TTTTATAGTCTCCAAC 140 N/A N/A 2538 951458 30107 30122 TGTATGGACAGCAGGC 13 N/A N/A 2539 951459 30108 30123 GTGTATGGACAGCAGG 10 N/A N/A 2540 951460 30242 30257 ATCAATCTTGGGAGCT 39 N/A N/A 2541 951461 30246 30261 CTAAATCAATCTTGGG 40 N/A N/A 2542 951462 30348 30363 ATATTAATGCAGTGGT 4 N/A N/A 2543 951463 30349 30364 CATATTAATGCAGTGG 14 N/A N/A 2544 951464 30350 30365 ACATATTAATGCAGTG 66 N/A N/A 2545 951465 30407 30422 AGAATATCAACACCTT 69 N/A N/A 2546 951466 30408 30423 TAGAATATCAACACCT 61 N/A N/A 2547 951467 30426 30441 TTATCTAACAGTCCCA 45 N/A N/A 2548 951468 30429 30444 CATTTATCTAACAGTC 104 N/A N/A 2549 951469 30509 30524 TAGTGATATGCTGCCT 22 N/A N/A 2550 951470 30852 30867 CACAATCCTGGCTATC 56 N/A N/A 2551 951471 30931 30946 CCAGACATTGCTGTCG 108 N/A N/A 2552 951472 31367 31382 ACATTTGACGGTTTGA 15 N/A N/A 2553 951473 32256 32271 GGGAATGATGCCACCT 110 N/A N/A 2554 951474 32270 32285 CCAATCTGTTATGTGG 23 N/A N/A 2555 951475 32336 32351 TGGAATCCAGTATTTC 103 N/A N/A 2556 951476 32498 32513 AGGAATCCTGCAGCTC 108 N/A N/A 2557 951477 32722 32737 TCCTATTAGAGTGGCA 49 N/A N/A 2558 951478 32905 32920 AGCATTAACAGAGCAG 92 N/A N/A 2559 951479 33017 33032 GGCTTTACTCCAGCCA 104 N/A N/A 2560 951480 33518 33533 AACAATAGCCATTGGT 107 N/A N/A 2561 951481 34302 34317 TGTTTATTTACCGTTT 3 N/A N/A 2562 951482 35180 35195 AGTACTATTGCATCAT 28 N/A N/A 2563 951483 36041 36056 TCACATACAGACCCCA 59 N/A N/A 2564 951484 36073 36088 CTAAATGTCACTTAGC 40 N/A N/A 2565 951485 36087 36102 GGAACTAACACATGCT 23 N/A N/A 2566 951486 36362 36377 GAAATCTACCTACTCC 105 N/A N/A 2567 951487 36363 36378 TGAAATCTACCTACTC 121 N/A N/A 2568 951488 36617 36632 GGCACCAACATTCACC 96 N/A N/A 2569 951489 36660 36675 TCCGATTTTGCTTCTA 10 N/A N/A 2570 951490 36665 36680 ACTTATCCGATTTTGC 23 N/A N/A 2571 951491 36809 36824 TGTTATTCCGAACAGT 43 N/A N/A 2572 951492 36911 36926 TCTCATGGCGACTGGC 77 N/A N/A 2573 951493 36948 36963 GGAATAAAGGCTCTCG 22 N/A N/A 2574 951494 37009 37024 TTAGATTGTATGACCC 9 N/A N/A 2575 951495 37194 37209 GGCTTTGTTAGATGCC 107 N/A N/A 2576 951496 37246 37261 ATTCATAGTACCCCAC 62 N/A N/A 2577 951497 37304 37319 GTATTTGTAGTGTGGA 110 N/A N/A 2578 951498 37305 37320 GGTATTTGTAGTGTGG 10 N/A N/A 2579 951499 37446 37461 GACAATGGTGATGCCC 62 N/A N/A 2580 951500 37566 37581 ATCTTAGGCAGACCCT 42 N/A N/A 2581 951501 37570 37585 ACACATCTTAGGCAGA 14 N/A N/A 2582 951502 37729 37744 ATTAAAATGGGTCTGC 77 N/A N/A 2583 951503 37750 37765 CATTTAACCATGACAG 31 N/A N/A 2584 951504 37751 37766 CCATTTAACCATGACA 32 N/A N/A 2585 951505 37971 37986 ACCTTAAGTTTTTTGG 118 N/A N/A 2586 951506 38196 38211 GCTAATAGCTATTCAA 39 N/A N/A 2587 951507 38225 38240 CGCATTACTGAGTTCA 12 N/A N/A 2588 951508 38335 38350 GTGACTAAGACAACCA 40 N/A N/A 2589 951509 38538 38553 AGACATGTAACTCCCT 39 N/A N/A 2590 951510 38540 38555 CTAGACATGTAACTCC 72 N/A N/A 2591 951511 38592 38607 GCCTATCCATGCTGCT 105 N/A N/A 2592 951512 39123 39138 CAGAATTGTTACAACC 47 N/A N/A 2593 951513 39140 39155 CCATTAAAATTTGCCC 30 N/A N/A 2594 951514 39141 39156 TCCATTAAAATTTGCC 44 N/A N/A 2595 951515 39233 39248 TTAACTATATCTAACT 73 N/A N/A 2596 951516 39236 39251 CGATTAACTATATCTA 87 N/A N/A 2597 951517 39547 39562 ATTTATGCGATTGGCC 88 N/A N/A 2598 951518 39548 39563 GATTTATGCGATTGGC 17 N/A N/A 2599 951519 39549 39564 AGATTTATGCGATTGG 11 N/A N/A 2600 951520 39555 39570 TGTTTAAGATTTATGC 41 N/A N/A 2601 951521 39748 39763 AAAGTAATTCACTGCG 81 N/A N/A 2602 951522 40198 40213 ATGGACTACAGTCTGT 110 N/A N/A 2603 951523 40275 40290 TGCAATCACAGACATC 93 N/A N/A 2604 951524 41080 41095 GTATTAACCTCATGAA 93 N/A N/A 2605 951525 41081 41096 GGTATTAACCTCATGA 68 N/A N/A 2606 951526 41125 41140 GTCTTTCCGTCACAGT 40 N/A N/A 2607 951527 41273 41288 GGATAATTGGAGAGGG 94 N/A N/A 2608 951528 41274 41289 GGGATAATTGGAGAGG 68 N/A N/A 2609 951529 42072 42087 GGGATTATGATGAGGA 3 N/A N/A 2610 951530 42327 42342 GATGATGGGTTCTAGC 85 N/A N/A 2611 951531 42355 42370 GGGAGATGTGCTCTTT 49 N/A N/A 2612 951532 42381 42396 GTATTACCCAGTGGCT 62 N/A N/A 2613 951533 42382 42397 TGTATTACCCAGTGGC 15 N/A N/A 2614 951534 42387 42402 GGGAATGTATTACCCA 131 N/A N/A 2615 951535 42501 42516 TACAATCATTCCCAGC 89 N/A N/A 2616 951536 42506 42521 AGCACTACAATCATTC 82 N/A N/A 2617 951537 42569 42584 TACTGTACAGCTGTGC 8 N/A N/A 2618 951538 42578 42593 GGCAATTGGTACTGTA 121 N/A N/A 2619 951539 42599 42614 GAAAATTTGTACAGGA 55 N/A N/A 2620 951540 43029 43044 TACATTAAAGGCTCGA 44 N/A N/A 2621 951541 43843 43858 GTACATATCCTGGCCG 32 N/A N/A 2622 951542 43871 43886 TACTATTCGACAGAGC 31 N/A N/A 2623 951543 43873 43888 ATTACTATTCGACAGA 36 N/A N/A 2624 951544 43876 43891 TAAATTACTATTCGAC 45 N/A N/A 2625 951545 43877 43892 GTAAATTACTATTCGA 63 N/A N/A 2626 951546 43878 43893 TGTAAATTACTATTCG 19 N/A N/A 2627 951547 44416 44431 GAGATCAACACATTTC 57 N/A N/A 2628 951548 44701 44716 AGAAATTACTCTTGCG 116 N/A N/A 2629 951549 44902 44917 TCCAATGACAGCCCAG 26 N/A N/A 2630 951550 44914 44929 GTGAATTCAATGTCCA 11 N/A N/A 2631 951551 44929 44944 ACACATGTGGAACACG 80 N/A N/A 2632 951552 45353 45368 TATCTATAACACATGA 44 N/A N/A 2633 951553 45356 45371 GGTTATCTATAACACA 23 N/A N/A 2634 951554 45446 45461 GTCTTTATTGCATGGG 8 N/A N/A 2635 951555 45569 45584 GCTATAAAACCAGCCA 101 N/A N/A 2636 951556 45590 45605 AGCATTGGATTGAGCA 89 N/A N/A 2637 951557 46280 46295 AGCAATGGTGGCCGGG 109 N/A N/A 2638 951558 46328 46343 CTATATTCAACAGGCT 24 N/A N/A 2639 951559 46329 46344 ACTATATTCAACAGGC 61 N/A N/A 2640 951560 46335 46350 GGCCATACTATATTCA 102 N/A N/A 2641 951561 46428 46443 GGGATATACGCCCACC 8 N/A N/A 2642 951562 46590 46605 TATTTAAAAGGGCCGC 23 N/A N/A 2643 951563 46591 46606 GTATTTAAAAGGGCCG 97 N/A N/A 2644 951564 46861 46876 CGAAATAGCAGAGCTC 75 N/A N/A 2645 951565 46961 46976 TCTATAGTGACTCTCA 9 N/A N/A 2646 951566 46962 46977 TTCTATAGTGACTCTC 6 N/A N/A 2647 951567 47624 47639 GTTCATCCGGGTCAGG 36 N/A N/A 2648 951568 47926 47941 GCAACTATGCATCCAC 141 N/A N/A 2649 951569 48813 48828 GAACATGGCAGCCAGT 82 N/A N/A 2650 951570 48973 48988 TGCTTAATGCCTTGCC 82 N/A N/A 2651 951571 49051 49066 CGCAATGTGTTCATTT 27 N/A N/A 2652 951572 49192 49207 ACTTTAACAAGTCCCG 36 N/A N/A 2653 951573 49193 49208 CACTTTAACAAGTCCC 23 N/A N/A 2654 951574 49227 49242 ACAGATGAAGCTACCA 27 N/A N/A 2655 951575 49443 49458 GGTTATGGTCTTAGGT 16 N/A N/A 2656 951576 49674 49689 TCGATTTGATTCTGAG 84 N/A N/A 2657 951577 50575 50590 GACAAATTGCCACTGG 54 N/A N/A 2658 951578 50595 50610 GCAAATATCTCCCAGT 19 N/A N/A 2659 951579 50845 50860 ACAATGACGAGGCTGG 25 N/A N/A 2660 951580 50979 50994 TCAAATCCCATCAGGA 90 N/A N/A 2661 951581 51714 51729 TGTACTTGCGGGTTTT 42 N/A N/A 2662 951582 51790 51805 AGCAATCACGCTGCCA 99 N/A N/A 2663 951583 51798 51813 AGTCATCCAGCAATCA 43 N/A N/A 2664 951584 51810 51825 ATTAATCTGGGCAGTC 38 N/A N/A 2665 951585 51811 51826 GATTAATCTGGGCAGT 67 N/A N/A 2666 951586 51816 51831 TAAAGGATTAATCTGG 48 N/A N/A 2667 951587 51977 51992 ATTTTGATAGCTCCAC 33 N/A N/A 2668 951588 51979 51994 GCATTTTGATAGCTCC 17 N/A N/A 2669 951589 52601 52616 GGTTTAAAAGCTTCCA 98 N/A N/A 2670 951590 52938 52953 GTAAATGCTGAATGCC 34 N/A N/A 2671 951591 53084 53099 GGATATGGACAGCAGG 17 N/A N/A 2672 951592 53085 53100 AGGATATGGACAGCAG 15 N/A N/A 2673 951593 53553 53568 TCACATGCCAGACTTT 100 N/A N/A 2674 951594 53781 53796 CACACTCACGCATGTT 102 N/A N/A 2675 951595 53852 53867 TTTACCTTGAATGTCC 46 N/A N/A 2676 951596 54009 54024 GCAAGCTACTCTCTCA 88 N/A N/A 2677 951597 54160 54175 TCAATACCTGCACAGG 42 N/A N/A 2678 951598 54161 54176 GTCAATACCTGCACAG 80 N/A N/A 2679 951599 54177 54192 TGTATGAGGACTCAGA 42 N/A N/A 2680 951600 54189 54204 ATCATAACAGGCTGTA 28 N/A N/A 2681 951601 54190 54205 CATCATAACAGGCTGT 94 N/A N/A 2682 951602 54199 54214 TAAAATGCGCATCATA 51 N/A N/A 2683 951603 54255 54270 GTAATGAGCTCAGTCT 45 N/A N/A 2684 951604 55117 55132 GAAACTACGGCACTCT 121 N/A N/A 2685 951605 55385 55400 GGTAATAAGTCACACT 103 N/A N/A 2686 951606 55528 55543 GATTAATATCGGCTGA 44 N/A N/A 2687 951607 55530 55545 TGGATTAATATCGGCT 24 N/A N/A 2688 951608 55531 55546 ATGGATTAATATCGGC 9 N/A N/A 2689 951609 56236 56251 GTTCATCACGGAAGGT 120 N/A N/A 2690 951610 56274 56289 CCGAATCACAGATTGA 71 N/A N/A 2691 951611 56324 56339 GTAATTGACAAGCAGT 16 N/A N/A 2692 951612 56327 56342 TAAGTAATTGACAAGC 29 N/A N/A 2693 951613 56387 56402 GTATATAAGACCCGGG 65 N/A N/A 2694 951614 56388 56403 TGTATATAAGACCCGG 86 N/A N/A 2695 951615 56389 56404 GTGTATATAAGACCCG 53 N/A N/A 2696 951616 56390 56405 AGTGTATATAAGACCC 41 N/A N/A 2697 951617 56459 56474 GACTATTCAAGAGGGC 70 N/A N/A 2698 951618 56567 56582 TCTCATGGCACTCACT 42 N/A N/A 2699 951619 56617 56632 ATTCATGGTCCACCAG 101 N/A N/A 2700 951620 56685 56700 GGTGATGCTGCAGAGC 36 N/A N/A 2701 951621 56725 56740 CAGGATACATCACCCA 128 N/A N/A 2702 951622 56858 56873 TATTATGAATCCCCCT 90 N/A N/A 2703 951623 56859 56874 ATATTATGAATCCCCC 100 N/A N/A 2704 951624 56861 56876 ACATATTATGAATCCC 52 N/A N/A 2705 951625 57375 57390 AGTAATGACCCAGGCT 74 N/A N/A 2706 951626 57642 57657 AGTGATGGGTCCCCAC 94 N/A N/A 2707 951627 57738 57753 GTGAATATCAACTGTT 41 N/A N/A 2708 951628 57916 57931 GCAGATCTGGCTGCCT 71 N/A N/A 2709 951629 58905 58920 AGGATATTTGGCTGGG 70 N/A N/A 2710 951630 59003 59018 ACTTATCGCAAGGAAC 71 N/A N/A 2711 951631 59075 59090 GCGATATACCTTTCTG 26 N/A N/A 2712 951632 59076 59091 TGCGATATACCTTTCT 19 N/A N/A 2713 951633 59174 59189 TGAATGACAGGTGTGT 124 N/A N/A 2714 951634 59346 59361 TACAATCACAATTGCT 47 N/A N/A 2715 951635 60402 60417 GCCAATACCAAAGAAC 96 N/A N/A 2716 951636 60469 60484 TCTAAATCAGGACAGT 86 N/A N/A 2717 951637 61124 61139 GCAACATGGGCACTGC 100 N/A N/A 2718 951638 61190 61205 TAAGATCGCATCTGGG 93 N/A N/A 2719 951639 61274 61289 AGCTATCTGGGTTAGG 105 N/A N/A 2720 951640 61338 61353 GGAAATAGACGATCTC 68 N/A N/A 2721 951641 61460 61475 CCAATTTGGGCATCAA 102 N/A N/A 2722 951642 61461 61476 GCCAATTTGGGCATCA 102 N/A N/A 2723 951643 61530 61545 GTTATATGTGTGGCAT 35 N/A N/A 2724 951644 61531 61546 TGTTATATGTGTGGCA 40 N/A N/A 2725 951645 61532 61547 GTGTTATATGTGTGGC 9 N/A N/A 2726 951646 61680 61695 GCTAAAATTCCACTCT 96 N/A N/A 2727 951647 61796 61811 CGTAAACATGATTCCT 20 N/A N/A 2728 951648 61841 61856 GTTATTAAGGACAACC 120 N/A N/A 2729 951649 61857 61872 CGTTATTGTCATTTGT 46 N/A N/A 2730 951650 61943 61958 TCGAATGAAGATGGTC 30 N/A N/A 2731 951651 62255 62270 AATGATAAGGACCCCA 63 N/A N/A 2732 951652 62257 62272 GTAATGATAAGGACCC 66 N/A N/A 2733 951653 62258 62273 AGTAATGATAAGGACC 80 N/A N/A 2734 951654 62398 62413 GTTAATTGTGCACTTG 15 N/A N/A 2735 951655 62399 62414 TGTTAATTGTGCACTT 80 N/A N/A 2736 951656 62400 62415 GTGTTAATTGTGCACT 109 N/A N/A 2737 951657 62526 62541 AGTTATAAACCCTGGG 11 N/A N/A 2738 951658 63805 63820 ACAATAATTGGCCAAA 86 N/A N/A 2739 951659 63829 63844 GATCTAATTACCAGCT 128 N/A N/A 2740 951660 63881 63896 TACTTAGGTTACTCCT 49 N/A N/A 2741 951661 64400 64415 GACAATGGGTCAACGC 67 N/A N/A 2742 951662 65042 65057 TGCTCTAAATGACTGC 96 N/A N/A 2743 951663 65090 65105 CCACATCTATCTCAGA 112 N/A N/A 2744 951664 65141 65156 AATATCTCAGCAGTGC 54 N/A N/A 2745 951665 65142 65157 CAATATCTCAGCAGTG 126 N/A N/A 2746 951666 65354 65369 GGCCTAACAGTGTCCA 105 N/A N/A 2747 951667 65601 65616 AGTCATTAGTACGCCA 46 N/A N/A 2748 951668 66403 66418 GTCTTGTGGGATGTGA 66 N/A N/A 2749 951669 66821 66836 TCAATACACACTGTTG 85 N/A N/A 2750 951670 66828 66843 GGATAATTCAATACAC 41 N/A N/A 2751 951671 67824 67839 ATAACATGTTACTCAG 71 N/A N/A 2752 951672 67825 67840 CATAACATGTTACTCA 87 N/A N/A 2753 951673 67827 67842 GTCATAACATGTTACT 76 N/A N/A 2754 951674 67828 67843 TGTCATAACATGTTAC 102 N/A N/A 2755 951675 67840 67855 GGCACTCACAGCTGTC 119 N/A N/A 2756 951676 68164 68179 AGCTGTTGTGCAGTGC 73 N/A N/A 2757 951677 68238 68253 GCTAAATGTGGACTGA 28 N/A N/A 2758 951678 68623 68638 GGCAATGCATACAGTC 44 N/A N/A 2759 951679 68650 68665 GTTATTAACCCCCTGT 44 N/A N/A 2760 951680 69011 69026 TCAATTACTTACAAGA 62 N/A N/A 2761 951681 69030 69045 TGTTTATGCACCATGT 57 N/A N/A 2762 951682 69227 69242 GAATTATGCCTTCTAC 25 N/A N/A 2763 951683 69652 69667 GTCTATGTGGGCTGCC 80 N/A N/A 2764 951684 69735 69750 ATCTATGGCATGGAGC 82 N/A N/A 2765 951685 69737 69752 ACATCTATGGCATGGA 75 N/A N/A 2766 951686 71409 71424 ACAGATAAATCAAGCC 50 N/A N/A 2767 951687 71450 71465 CACTATGCGGCCACCA 93 N/A N/A 2768 951688 71699 71714 GTACATACTGCAGCAG 113 N/A N/A 2769 951689 71700 71715 GGTACATACTGCAGCA 107 N/A N/A 2770 951690 71857 71872 GCGAATGCCATGCTTA 82 N/A N/A 2771 951691 71968 71983 GACATTTAACACACTA 7 N/A N/A 2772 951692 73303 73318 GGCTTAATCCCACACG 97 N/A N/A 2773 951693 73694 73709 GAATTTGGGATTGTGG 21 N/A N/A 2774 951694 73828 73843 TCATGCATGGCACTGT 102 N/A N/A 2775 951695 73956 73971 AGCATAAAAGCACTCT 74 N/A N/A 2776 951696 74038 74053 GCTATGAATTTCCTCC 10 N/A N/A 2777 951697 74039 74054 GGCTATGAATTTCCTC 115 N/A N/A 2778 951698 74365 74380 TGCTATGACCCTCACT 82 N/A N/A 2779 951699 75020 75035 ACAGATAACAGTGGCG 24 N/A N/A 2780 951700 75136 75151 GTAATTCCCGTTCTCT 16 N/A N/A 2781 951701 75145 75160 TCTATTACCGTAATTC 23 N/A N/A 2782 951702 75247 75262 TACATGAACAGTCTGT 50 N/A N/A 2783 951703 75327 75342 AACTTACAAGCATCGG 91 N/A N/A 2784 951704 75329 75344 TGAACTTACAAGCATC 94 N/A N/A 2785 951705 75417 75432 ATCAATTTTAAACACG 31 N/A N/A 2786 951706 75765 75780 ACAAATACATGAGGTC 32 N/A N/A 2787 951707 75894 75909 GTATTATTCCCAGCTA 77 N/A N/A 2788 951708 75895 75910 TGTATTATTCCCAGCT 102 N/A N/A 2789 951709 76435 76450 GAGAATATCACAGGGT 10 N/A N/A 2790 951710 76448 76463 TGTAATCAGTCAAGAG 18 N/A N/A 2791 951711 76550 76565 GACAATTGTGACCGGC 88 N/A N/A 2792 951712 76568 76583 CACAATCAGAGCATTC 34 N/A N/A 2793 951713 76593 76608 TGATTTACAGGCCCAA 37 N/A N/A 2794 951714 76594 76609 GTGATTTACAGGCCCA 50 N/A N/A 2795 951715 76725 76740 ACTAATGACAGACAAC 27 N/A N/A 2796 951716 76728 76743 TAAACTAATGACAGAC 92 N/A N/A 2797 951717 76775 76790 TTGAATTGTGGACCAA 60 N/A N/A 2798 951718 77126 77141 AGGTTAATGCTTCACC 54 N/A N/A 2799 951719 77303 77318 TCAAATGGTGACCACT 112 N/A N/A 2800 951720 77432 77447 CGTTTTAGTTTTCCTA 14 N/A N/A 2801 951721 77538 77553 GTAATAACATGTGTCG 45 N/A N/A 2802 951722 77539 77554 GGTAATAACATGTGTC 27 N/A N/A 2803 951723 77570 77585 TAAACAATTGCTCATC 59 N/A N/A 2804 951724 78076 78091 GGTAATTCTGCAAAGA 29 N/A N/A 2805 951725 78080 78095 TAATGGTAATTCTGCA 43 N/A N/A 2806 951726 78082 78097 ACTAATGGTAATTCTG 50 N/A N/A 2807 951727 78166 78181 TTAGATCTCATTACCT 71 N/A N/A 2808 951728 78206 78221 GTAACAACATCTACCT 88 N/A N/A 2809 951729 78207 78222 GGTAACAACATCTACC 3 N/A N/A 2810 951730 78387 78402 TGATTTACAGGATGCT 15 N/A N/A 2811 951731 78388 78403 TTGATTTACAGGATGC 8 N/A N/A 2812 951732 78539 78554 GCAAATGCTGGCTACG 85 N/A N/A 2813 951733 78546 78561 CCCAATGGCAAATGCT 66 N/A N/A 2814 951734 78848 78863 GGCACTACCTTCACCA 109 N/A N/A 2815 951735 79046 79061 TCATATTGTTCTGCCC 15 N/A N/A 2816 951736 79047 79062 TTCATATTGTTCTGCC 11 N/A N/A 2817 951737 79077 79092 GGCTTTTGTCAGAGGA 8 N/A N/A 2818 951738 79153 79168 TTCAATGACATGCTAG 19 N/A N/A 2819 951739 79209 79224 TATATCAGCTCAGTGC 75 N/A N/A 2820 951740 79211 79226 TATATATCAGCTCAGT 66 N/A N/A 2821 951741 79214 79229 TTGTATATATCAGCTC 37 N/A N/A 2822 951742 79229 79244 TCATACATAAGGATGT 91 N/A N/A 2823 951743 79398 79413 GCTCATTGTAAACAGT 20 N/A N/A 2824 951744 79462 79477 TGCATTTGGTCTTGCT 118 N/A N/A 2825 951745 79799 79814 GACTATCAGTATGCAC 118 N/A N/A 2826 951746 79845 79860 CATCATATTGGTGGGA 11 N/A N/A 2827 951747 80265 80280 GCTATATTCACAAGGC 70 N/A N/A 2828 951748 80266 80281 GGCTATATTCACAAGG 39 N/A N/A 2829 951749 80520 80535 AACGATTAGGGACTCA 4 N/A N/A 2830 951750 80663 80678 CCCTATTTGATCAGGA 117 N/A N/A 2831 951751 80845 80860 GCAACTACCTTTGTTA 17 N/A N/A 2832 951752 80986 81001 AGCAATTTCATTGGCC 105 N/A N/A 2833 951753 81192 81207 AGCAATACCTTACTGG 46 N/A N/A 2834 951754 81436 81451 TGGTATCAGGGTCCCA 130 N/A N/A 2835 951755 81663 81678 CATGATGTCGCTGGCA 41 N/A N/A 2836 951756 81741 81756 TCCAAAAATGGGCTGC 28 N/A N/A 2837 951757 82016 82031 TCTAATCGAAGAAGCT 99 N/A N/A 2838 951758 82262 82277 TCTGATTAGTCCATGC 40 N/A N/A 2839 951759 82535 82550 ACAAATGCGGAGATGA 41 N/A N/A 2840 951761 82653 82668 GCCAATGCAAGGTGGC 119 N/A N/A 2841 951762 82803 82818 TGTTTTGGTGCTGGCT 99 N/A N/A 2842 951763 82880 82895 TGGAATGGTTACTCTC 3 N/A N/A 2843 951764 82920 82935 ATCTTCTGCAGTGTGG 2 N/A N/A 2844 951765 83070 83085 GGTATCTGGGCCATCA 101 N/A N/A 2845 951766 83419 83434 AGCAACATGAACCACA 26 N/A N/A 2846 951767 84425 84440 GTAATCAAGGCAGCAA 7 N/A N/A 2847 951768 85210 85225 AGCTCTGGTTTCAACA 82 N/A N/A 2848 951769 85217 85232 TTAATTAAGCTCTGGT 12 N/A N/A 2849 951770 85218 85233 CTTAATTAAGCTCTGG 22 N/A N/A 2850 951771 85220 85235 GGCTTAATTAAGCTCT 67 N/A N/A 2851 951772 85238 85253 AGTGACATAGCAAGCA 7 N/A N/A 2852 951773 85417 85432 AAGAATCAGACTCTTC 110 N/A N/A 2853 951774 85726 85741 CATTTATAACAGGCCA 82 N/A N/A 2854 951775 85727 85742 CCATTTATAACAGGCC 94 N/A N/A 2855 951776 85844 85859 GGCTTATGAGTCCACT 91 N/A N/A 2856 951777 85973 85988 TGCATTAAAACTGCGA 87 N/A N/A 2857 951778 86550 86565 AACAATCATAGCCTCA 114 N/A N/A 2858 951779 86582 86597 AACTTACTGTCTCCCA 37 N/A N/A 2859 951780 86937 86952 GTTTAATAATGTGCAG 40 N/A N/A 2860 951781 86938 86953 GGTTTAATAATGTGCA 11 N/A N/A 2861 951782 86939 86954 GGGTTTAATAATGTGC 27 N/A N/A 2862 951783 87671 87686 TCGCTAAAGGCTCTGA 10 N/A N/A 2863 951784 87858 87873 TGAAATCAGGGCTCCC 31 N/A N/A 2864 951785 88030 88045 CTCTATCACAGGGCCC 92 N/A N/A 2865 951786 88032 88047 TGCTCTATCACAGGGC 30 N/A N/A 2866 951787 88258 88273 TGTATCTGGTGACTCC 5 N/A N/A 2867 951788 88270 88285 ACCGATAAATGTTGTA 65 N/A N/A 2868 951789 88634 88649 TATAGTAACAGCTGGG 73 N/A N/A 2869 951790 88637 88652 CAGTATAGTAACAGCT 94 N/A N/A 2870 951791 88638 88653 TCAGTATAGTAACAGC 41 N/A N/A 2871 951792 88880 88895 TGTTTAAGGACTCCAC 28 N/A N/A 2872 951793 88887 88902 GACAATTTGTTTAAGG 5 N/A N/A 2873 951794 89152 89167 GATCTAATCAGAAGCA 29 N/A N/A 2874 951795 89558 89573 TGAGATTACGCACCAC 5 N/A N/A 2875 951796 89718 89733 ATTATAGGGCTTCTTA 30 N/A N/A 2876 951797 89720 89735 TTATTATAGGGCTTCT 8 N/A N/A 2877 951798 89721 89736 TTTATTATAGGGCTTC 1 N/A N/A 2878 951799 89722 89737 GTTTATTATAGGGCTT 1 N/A N/A 2879 951800 89746 89761 AGTGATATTCCCAACA 19 N/A N/A 2880 951801 89977 89992 CATATATCTCCTGTTA 20 N/A N/A 2881 951802 89999 90014 TCATATCACCACTTGC 29 N/A N/A 2882 951803 90003 90018 ACAATCATATCACCAC 6 N/A N/A 2883 951804 90004 90019 GACAATCATATCACCA 3 N/A N/A 2884 951805 90058 90073 TTATATGTGGACACCT 34 N/A N/A 2885 951806 90059 90074 TTTATATGTGGACACC 10 N/A N/A 2886 951807 90139 90154 CACAATCCCAGATCTC 7 N/A N/A 2887 951808 90161 90176 TCTATAAGGTTCCTTA 14 N/A N/A 2888 951809 90165 90180 TGTTTCTATAAGGTTC 3 N/A N/A 2889 951810 90199 90214 CCAAATTTAGAGGACA 46 N/A N/A 2890 951811 90222 90237 ACATATCTTGCATGAC 4 N/A N/A 2891 951812 90264 90279 TTAGACATCAGACTGT 76 N/A N/A 2892 951813 90267 90282 GTCTTAGACATCAGAC 115 N/A N/A 2893 951814 90706 90721 TCAATTGAGGCTTCTA 7 N/A N/A 2894 951815 90716 90731 TGTATCTGGTTCAATT 11 N/A N/A 2895 951816 90721 90736 GTAAATGTATCTGGTT 2 N/A N/A 2896 951817 91071 91086 GGTACTGAGGCTGTGG 28 N/A N/A 2897 951818 91117 91132 CAGAATTATCAATTCC 145 N/A N/A 2898 951819 91174 91189 GGTGGGTAAAATGTGC 63 N/A N/A 2899 951820 91191 91206 GCACATAGGGCCTTCT 79 N/A N/A 2900 951821 91909 91924 GACAATGTAGTTTCCA 2 N/A N/A 2901 951822 91939 91954 AACTATCCCAAGCTCC 10 N/A N/A 2902 951823 91945 91960 GGCTTCAACTATCCCA 39 N/A N/A 2903 951824 92037 92052 ATTGATACAGCCGTTC 8 N/A N/A 2904 951825 92827 92842 ATGATAAAGGCTGGCA 21 N/A N/A 2905 951826 92828 92843 AATGATAAAGGCTGGC 127 N/A N/A 2906 951827 93169 93184 AAGATTATGGTTTCCT 4 N/A N/A 2907 951828 93170 93185 GAAGATTATGGTTTCC 6 N/A N/A 2908 951829 93241 93256 GTACATGGTGGAGTCC 83 N/A N/A 2909 951830 93321 93336 TGTATTACCTACGGCA 6 N/A N/A 2910 951831 93392 93407 GCTATTAATCATATTC 18 N/A N/A 2911 951832 93572 93587 TACTTACCAGGATCTC 24 N/A N/A 2912 951833 93746 93761 ACTTATACCCAGGGCA 7 N/A N/A 2913 951834 93747 93762 GACTTATACCCAGGGC 81 N/A N/A 2914 951835 93923 93938 ATGAATTCTGGTCTGG 2 N/A N/A 2915 951836 94043 94058 TCAACTAGCCATGTCT 25 N/A N/A 2916 951837 94169 94184 CACTTAGCCACATCTG 5 N/A N/A 2917 951838 94174 94189 TTAATCACTTAGCCAC 8 N/A N/A 2918 951839 94177 94192 ACCTTAATCACTTAGC 5 N/A N/A 2919 951840 94182 94197 ACAATACCTTAATCAC 7 N/A N/A 2920 951841 94284 94299 CAATTTATCTGGAGGA 8 N/A N/A 2921 951842 94350 94365 TCAATTAGTGTTGCCT 119 N/A N/A 2922 951843 94351 94366 ATCAATTAGTGTTGCC 5 N/A N/A 2923 951844 94423 94438 GTCAATCGACTGGTAC 41 N/A N/A 2924 951845 94446 94461 ATATGATTCATCTCGG 2 N/A N/A 2925 951846 94447 94462 AATATGATTCATCTCG 2 N/A N/A 2926 951847 94583 94598 AGCTATGAGTAGCAGG 18 N/A N/A 2927 951848 94885 94900 GCCAACTAATTCCTCC 31 N/A N/A 2928 951849 96000 96015 GCCATTCACGGGCTGC 104 N/A N/A 2929 951850 96084 96099 CAAGGGTACAGACTTA 152 N/A N/A 2930 951851 96224 96239 GGCTGGATGTGAGTGC 63 N/A N/A 2931 951852 96650 96665 ACAACTAACGGCAGGC 17 N/A N/A 2932 951853 96755 96770 ACACATCAGGGTTTCA 56 N/A N/A 2933 951854 97483 97498 TCCTAATGGTGACTCA 40 N/A N/A 2934 951855 97854 97869 TACAATGTAAGCCTTT 7 N/A N/A 2935 951856 98522 98537 GTATTTCAAAGTAGTC 4 N/A N/A 2936 951857 98652 98667 GGTTTTAATAGACACA 6 N/A N/A 2937 951858 98653 98668 GGGTTTTAATAGACAC 53 N/A N/A 2938 951859 99483 99498 GTTAACAACAATTGTC 60 N/A N/A 2939 951860 99712 99727 ACAGATCTTGCATGTT 84 N/A N/A 2940 951861 99888 99903 AGCTATCACACAGAAG 95 N/A N/A 2941 951862 100033 100048 GCAAATCCATTGCCCA 78 N/A N/A 2942 951863 100171 100186 GTGTTAAGGTGGCAAC 43 N/A N/A 2943 951864 100222 100237 CTACATGGTGATGGGT 20 N/A N/A 2944 951865 100285 100300 GTTAGCTGGACTCACA 89 N/A N/A 2945 951866 100375 100390 CAATATCCTGGTGACT 36 N/A N/A 2946 951867 100514 100529 ACACATGCAGTGAGCC 60 N/A N/A 2947 951868 101384 101399 TGTATGGTGGCTCAGC 26 N/A N/A 2948 951869 101385 101400 TTGTATGGTGGCTCAG 44 N/A N/A 2949 951870 101796 101811 TGCAATGCTGCCAGGC 72 N/A N/A 2950 951871 102161 102176 AGAGATATTGATGTCT 51 N/A N/A 2951 951872 102425 102440 GCACATTGGTTAGGCT 93 N/A N/A 2952 951873 102445 102460 CTCAATGTGTACAGTA 22 N/A N/A 2953 951874 102885 102900 TGGAACTGTTTACAGT 10 N/A N/A 2954 951875 102926 102941 CAAGTAACTGAGTCAC 7 N/A N/A 2955 951876 103421 103436 ATCTATCCAAGGAGGA 93 N/A N/A 2956 951877 103897 103912 TCAGTTCACGGATCCC 42 N/A N/A 2957 951878 104120 104135 TGCTTTCTAAGGTTGG 14 N/A N/A 2958 951879 104441 104456 TTTTATCTGGGCTCCA 39 N/A N/A 2959 951880 104447 104462 TGGAACTTTTATCTGG 17 N/A N/A 2960 951881 104452 104467 GTGAATGGAACTTTTA 5 N/A N/A 2961 951882 104843 104858 TGTATATGAGCCCATC 99 N/A N/A 2962 951883 105539 105554 TCATATCCATGCCCAC 31 N/A N/A 2963 951884 105559 105574 ACAATTGGTGCCTTTC 14 N/A N/A 2964 951885 105560 105575 CACAATTGGTGCCTTT 20 N/A N/A 2965 951886 105730 105745 GGACATCACACTCCTC 100 N/A N/A 2966 951887 105777 105792 CGCAATGGTGACTGCC 114 N/A N/A 2967 951888 105791 105806 TGAAATACCATCCACG 40 N/A N/A 2968 951889 105793 105808 CTTGAAATACCATCCA 19 N/A N/A 2969 951890 106015 106030 GCCTTTACTGACAGCT 71 N/A N/A 2970 951891 106173 106188 ACAAATGGGTCTCGAG 101 N/A N/A 2971 951892 106195 106210 GGTTTTCACGGCCAGC 44 N/A N/A 2972 951893 106203 106218 GCTATGAAGGTTTTCA 10 N/A N/A 2973 951894 106204 106219 AGCTATGAAGGTTTTC 20 N/A N/A 2974 951895 106233 106248 TGTCATATGGCCAGGG 17 N/A N/A 2975 951896 106295 106310 TAATATTGTCACCCTC 93 N/A N/A 2976 951897 106296 106311 ATAATATTGTCACCCT 29 N/A N/A 2977 951898 106351 106366 GTTTTTGCAGCTACTA 9 N/A N/A 2978 951899 106371 106386 ACTATCAACCATCTTA 20 N/A N/A 2979 951900 106391 106406 GGACTTAATTTACACA 12 N/A N/A 2980 951901 106392 106407 TGGACTTAATTTACAC 30 N/A N/A 2981 951902 106404 106419 GATACTAAAGTCTGGA 11 N/A N/A 2982 951903 107100 107115 GCAGATGGTGGTCTAC 69 N/A N/A 2983 951904 109198 109213 GCATTTTAATATTGGG 31 N/A N/A 2984 951905 109409 109424 GGTTTAAGCGATCTCC 46 N/A N/A 2985 951906 109955 109970 CCAATAACTGACCTCA 72 N/A N/A 2986 951907 109956 109971 ACCAATAACTGACCTC 54 N/A N/A 2987 951908 111211 111226 AGTTATTCTGATGCCA 3 N/A N/A 2988 951909 111349 111364 GGGTATGGTTGCAACC 92 N/A N/A 2989 951910 111384 111399 TCATTAGGACACAGCG 20 N/A N/A 2990 951911 111385 111400 ATCATTAGGACACAGC 6 N/A N/A 2991 951912 111494 111509 TACTATCAGTACAGCT 83 N/A N/A 2992 951913 111496 111511 GATACTATCAGTACAG 42 N/A N/A 2993 951914 111499 111514 GGAGATACTATCAGTA 115 N/A N/A 2994 951915 111500 111515 TGGAGATACTATCAGT 27 N/A N/A 2995 951916 112149 112164 GTGAACACTGATCACT 86 N/A N/A 2996 951917 112185 112200 GGTATATGAGGAAACA 18 N/A N/A 2997 951918 112208 112223 CCGTATATGTCTCCGA 8 N/A N/A 2998 951919 112209 112224 ACCGTATATGTCTCCG 7 N/A N/A 2999 951920 112293 112308 GGCAATTGTCTCTCTT 47 N/A N/A 3000 951921 112316 112331 TGTATAAGCTCACTTT 40 N/A N/A 3001 951922 112318 112333 CATGTATAAGCTCACT 105 N/A N/A 3002 951923 112320 112335 AGCATGTATAAGCTCA 36 N/A N/A 3003 951924 112369 112384 ATAATTATGTCCCATC 24 N/A N/A 3004 951925 112370 112385 GATAATTATGTCCCAT 5 N/A N/A 3005 951926 112371 112386 GGATAATTATGTCCCA 61 N/A N/A 3006 951927 112372 112387 TGGATAATTATGTCCC 102 N/A N/A 3007 951928 112373 112388 ATGGATAATTATGTCC 105 N/A N/A 3008 951929 112950 112965 ACTACTAGTTTCTGTT 91 N/A N/A 3009 951930 112951 112966 CACTACTAGTTTCTGT 37 N/A N/A 3010 951931 113712 113727 GGTTATGAGATTCTTA 4 N/A N/A 3011 951932 113713 113728 TGGTTATGAGATTCTT 5 N/A N/A 3012 951933 114474 114489 TTTATTCACAGGGTCC 29 N/A N/A 3013 951934 114476 114491 TATTTATTCACAGGGT 28 N/A N/A 3014 951935 114477 114492 GTATTTATTCACAGGG 18 N/A N/A 3015 951936 114510 114525 GCCAATGGAAGGCACC 129 N/A N/A 3016 951937 114524 114539 TCCATTTGGGCTGTGC 86 N/A N/A 3017 951938 114750 114765 TGCGATATCCTCCCCT 15 N/A N/A 3018 951939 115717 115732 GAGAATAAAGCCTGGC 80 N/A N/A 3019 908415 83669 83684 GATTGAGGTAAGGGTT 20 N/A N/A 3020 83757 83772 N/A N/A 83845 83860 N/A N/A 908426 83689 83704 ACGGAACCGCTCTGTA 88 N/A N/A 509 83777 83792 N/A N/A 83865 83880 N/A N/A 908428 83691 83706 TGACGGAACCGCTCTG 73 N/A N/A 511 83779 83794 N/A N/A 83867 83882 N/A N/A 908507 103213 103228 AGCAGAGCATAGGAGA 20 N/A N/A 590 103251 103266 N/A N/A 949039 7946 7961 AAGTGCTATTATAACT 100 N/A N/A 3021 8587 8602 N/A N/A 949040 7947 7962 GAAGTGCTATTATAAC 8 N/A N/A 3022 8588 8603 N/A N/A 949041 7948 7963 AGAAGTGCTATTATAA 6 N/A N/A 3023 8589 8604 N/A N/A 949042 7949 7964 AAGAAGTGCTATTATA 15 N/A N/A 3024 8590 8605 N/A N/A 949043 7950 7965 AAAGAAGTGCTATTAT 37 N/A N/A 3025 8591 8606 N/A N/A 949044 7951 7966 GAAAGAAGTGCTATTA 19 N/A N/A 3026 8592 8607 N/A N/A 949045 7952 7967 GGAAAGAAGTGCTATT 20 N/A N/A 3027 8593 8608 N/A N/A 949046 7953 7968 GGGAAAGAAGTGCTAT 36 N/A N/A 3028 8594 8609 N/A N/A 949047 7954 7969 AGGGAAAGAAGTGCTA 64 N/A N/A 3029 8595 8610 N/A N/A 949048 7955 7970 AAGGGAAAGAAGTGCT 22 N/A N/A 3030 8596 8611 N/A N/A 949049 7956 7971 AAAGGGAAAGAAGTGC 21 N/A N/A 3031 8597 8612 N/A N/A 949060 9158 9173 TAAAATGTACCCCCTC 42 N/A N/A 3032 9478 9493 N/A N/A 949133 16330 16345 GAAAAGAACAACCTGG 21 N/A N/A 3033 16655 16670 N/A N/A 949913 83642 83657 TGCAGCTGTCAGCATG 61 N/A N/A 3034 83730 83745 N/A N/A 83818 83833 N/A N/A 949914 83643 83658 ATGCAGCTGTCAGCAT 113 N/A N/A 3035 83731 83746 N/A N/A 83819 83834 N/A N/A 949915 83644 83659 TATGCAGCTGTCAGCA 59 N/A N/A 3036 83732 83747 N/A N/A 83820 83835 N/A N/A 949916 83645 83660 ATATGCAGCTGTCAGC 16 N/A N/A 3037 83733 83748 N/A N/A 83821 83836 N/A N/A 949917 83648 83663 GCCATATGCAGCTGTC 13 N/A N/A 3038 83736 83751 N/A N/A 83824 83839 N/A N/A 949918 83652 83667 CTTTGCCATATGCAGC 8 N/A N/A 3039 83740 83755 N/A N/A 83828 83843 N/A N/A 949919 83653 83668 ACTTTGCCATATGCAG 15 N/A N/A 3040 83741 83756 N/A N/A 83829 83844 N/A N/A 949920 83654 83669 TACTTTGCCATATGCA 4 N/A N/A 3041 83742 83757 N/A N/A 83830 83845 N/A N/A 949921 83655 83670 TTACTTTGCCATATGC 1 N/A N/A 3042 83743 83758 N/A N/A 83831 83846 N/A N/A 949922 83656 83671 GTTACTTTGCCATATG 4 N/A N/A 3043 83744 83759 N/A N/A 83832 83847 N/A N/A 949923 83657 83672 GGTTACTTTGCCATAT 8 N/A N/A 3044 83745 83760 N/A N/A 83833 83848 N/A N/A 949924 83668 83683 ATTGAGGTAAGGGTTA 4 N/A N/A 3045 83756 83771 N/A N/A 83844 83859 N/A N/A 949925 83675 83690 TATCTTGATTGAGGTA 6 N/A N/A 3046 83763 83778 N/A N/A 83851 83866 N/A N/A 949926 83676 83691 GTATCTTGATTGAGGT 2 N/A N/A 3047 83764 83779 N/A N/A 83852 83867 N/A N/A 949927 83677 83692 TGTATCTTGATTGAGG 1 N/A N/A 3048 83765 83780 N/A N/A 83853 83868 N/A N/A 949928 83678 83693 CTGTATCTTGATTGAG 4 N/A N/A 3049 83766 83781 N/A N/A 83854 83869 N/A N/A 949929 83682 83697 CGCTCTGTATCTTGAT 2 N/A N/A 3050 83770 83785 N/A N/A 83858 83873 N/A N/A 949930 83683 83698 CCGCTCTGTATCTTGA 9 N/A N/A 3051 83771 83786 N/A N/A 83859 83874 N/A N/A 949931 83700 83715 TTTAGGAGGTGACGGA 6 N/A N/A 3052 83788 83803 N/A N/A 83876 83891 N/A N/A 949932 83701 83716 TTTTAGGAGGTGACGG 7 N/A N/A 3053 83789 83804 N/A N/A 83877 83892 N/A N/A 949933 83702 83717 ATTTTAGGAGGTGACG 17 N/A N/A 3054 83878 83893 N/A N/A 949934 83703 83718 GATTTTAGGAGGTGAC 15 N/A N/A 3055 83879 83894 N/A N/A 949935 83704 83719 GGATTTTAGGAGGTGA 6 N/A N/A 3056 83880 83895 N/A N/A 949936 83705 83720 GGGATTTTAGGAGGTG 15 N/A N/A 3057 83881 83896 N/A N/A 949937 83706 83721 AGGGATTTTAGGAGGT 8 N/A N/A 3058 83882 83897 N/A N/A 949938 83707 83722 CAGGGATTTTAGGAGG 12 N/A N/A 3059 83883 83898 N/A N/A 949939 83708 83723 ACAGGGATTTTAGGAG 18 N/A N/A 3060 83884 83899 N/A N/A 949940 83728 83743 CAGCTGTCAGCATGAT 63 N/A N/A 3061 83816 83831 N/A N/A 949941 83729 83744 GCAGCTGTCAGCATGA 67 N/A N/A 3062 83817 83832 N/A N/A 950194 103191 103206 CGGTGGCCATGGAGGG 67 N/A N/A 3063 103229 103244 N/A N/A 103267 103282 N/A N/A 950195 103192 103207 CCGGTGGCCATGGAGG 98 N/A N/A 3064 103230 103245 N/A N/A 103268 103283 N/A N/A 950196 103193 103208 CCCGGTGGCCATGGAG 91 N/A N/A 3065 103231 103246 N/A N/A 103269 103284 N/A N/A 950197 103194 103209 GCCCGGTGGCCATGGA 122 N/A N/A 3066 103232 103247 N/A N/A 103270 103285 N/A N/A 950198 103195 103210 GGCCCGGTGGCCATGG 106 N/A N/A 3067 103233 103248 N/A N/A 103271 103286 N/A N/A 950199 103196 103211 GGGCCCGGTGGCCATG 125 N/A N/A 3068 103234 103249 N/A N/A 103272 103287 N/A N/A 950200 103210 103225 AGAGCATAGGAGAGGG 20 N/A N/A 3069 103248 103263 N/A N/A 950201 103212 103227 GCAGAGCATAGGAGAG 21 N/A N/A 3070 103250 103265 N/A N/A 950202 103214 103229 GAGCAGAGCATAGGAG 23 N/A N/A 3071 103252 103267 N/A N/A 950203 103215 103230 GGAGCAGAGCATAGGA 22 N/A N/A 3072 103253 103268 N/A N/A 950204 103217 103232 AGGGAGCAGAGCATAG 53 N/A N/A 3073 103255 103270 N/A N/A 950205 103219 103234 GGAGGGAGCAGAGCAT 50 N/A N/A 3074 103257 103272 N/A N/A 950206 103221 103236 ATGGAGGGAGCAGAGC 53 N/A N/A 3075 103259 103274 N/A N/A 950297 113289 113304 ATCCTGTTATATCTTT 3 N/A N/A 3076 113606 113621 N/A N/A 950298 113290 113305 AATCCTGTTATATCTT 2 N/A N/A 3077 113607 113622 N/A N/A

Each modified oligonucleotide listed in the table below is 100% complementary to human DNM2 nucleic acid sequence GENBANK Number NM_001005361.2. (SEQ ID No: 3). As shown below, modified oligonucleotides complementary to human DNM2 inhibited human DNM2 mRNA expression.

TABLE 4 DNM2 mRNA Expression SEQ SEQ ID: 3 ID: 3 Sequence Dynamin2 SEQ Compound Start Stop (% ID Number Site Site Control) NO 948482 1735 1750 CACCAGGATCTCCCCC 30 3078 948483 1738 1753 GATCACCAGGATCTCC 101 3079 948509 1511 1526 GCTTCTCGGCACACTT 27 3080 948510 1512 1527 AGCTTCTCGGCACACT 48 3081 948511 1514 1529 TGAGCTTCTCGGCACA 111 3082 948512 1520 1535 AGGAACTGAGCTTCTC 39 3083 948513 1521 1536 TAGGAACTGAGCTTCT 37 3084

Example 3: Effect of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Modified oligonucleotides complementary to dynamin 2 (DNM2) nucleic acid were designed and tested for their effect on dynamin 2 mRNA in vitro. The modified oligonucleotides were tested in a series of experiments that had similar culture conditions.

A431 cells cultured at a density of 10,000 cells per well were treated with only 500 nM of modified oligonucleotide via free uptake or no modified oligonucleotide for untreated controls. After approximately 24 hours, RNA was isolated from the cells and DNM2 mRNA levels were measured by quantitative real-time PCR as described in Example 1.

The modified oligonucleotides described in the tables below each have a 3-10-3 cEt gapmer motif, wherein the central gap segment contains ten 2′-deoxynucleosides and is flanked by wing segments on the 3′ and 5′ ends, each containing three cEt nucleosides. Each modified oligonucleotide listed in the tables below is 100% complementary to human DNM2 nucleic acid sequence GENBANK Number NC_000019.10, truncated from 10715001 to 1083500 (SEQ ID NO:1) and/or GENBANK Number NM_004945.3 (SEQ ID NO: 2). As shown below, modified oligonucleotides complementary to human DNM2 inhibited human DNM2 mRNA expression.

TABLE 5 DNM2 mRNA Expression SEQ SEQ SEQ ID: SEQ ID: ID: 2 ID 2: SEQ Compound 1 Start 1 Stop DNM2 Start Stop ID Number Site Site Sequence (% Control) Site Site NO 694824 57496 57511 TTTTGGACTTGCAGTG 25 443 458 3085 695171 82451 82466 ACACACTTCAAACTCG 30 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 26 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 28 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 31 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 27 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 42 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 37 N/A N/A 13 695171 82451 82466 ACACACTTCAAACTCG 29 N/A N/A 13 951371 11922 11937 GTTGATAGTCGGTTGT 9 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 8 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 7 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 7 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 7 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 10 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 19 N/A N/A 2452 951371 11922 11937 GTTGATAGTCGGTTGT 9 N/A N/A 2452 988378 82447 82462 ACTTCAAACTCGGCTC 24 N/A N/A 3086 988379 81166 81181 AACTGTATTGATTAGC 20 1492 1507 3087 988380 116569 116584 GTGTGGTTAATATGGC 2 3313 3328 3088 988381 116853 116868 ATAGAATACAGAGTGC 19 3597 3612 3089 988382 11917 11932 TAGTCGGTTGTCTGGA 21 N/A N/A 3090 988383 11919 11934 GATAGTCGGTTGTCTG 37 N/A N/A 3091 988384 11920 11935 TGATAGTCGGTTGTCT 67 N/A N/A 3092 988385 11921 11936 TTGATAGTCGGTTGTC 26 N/A N/A 3093 988386 11923 11938 AGTTGATAGTCGGTTG 3 N/A N/A 3094 988387 11924 11939 GAGTTGATAGTCGGTT 5 N/A N/A 3095 988388 11925 11940 CGAGTTGATAGTCGGT 9 N/A N/A 3096 988389 11927 11942 AGCGAGTTGATAGTCG 42 N/A N/A 3097 988390 24283 24298 GTATTATGGTATGTGA 14 N/A N/A 3098 988391 24286 24301 TAGGTATTATGGTATG 20 N/A N/A 3099 988392 24287 24302 TTAGGTATTATGGTAT 31 N/A N/A 3100 988393 24288 24303 ATTAGGTATTATGGTA 29 N/A N/A 3101 988394 24290 24305 GGATTAGGTATTATGG 6 N/A N/A 3102 988395 82040 82055 TTGGACTGTTTTCCCC 39 N/A N/A 3103 988396 82042 82057 GTTTGGACTGTTTTCC 7 N/A N/A 3104 988397 82824 82839 GATGTGTTTCCTGTGT 2 N/A N/A 3105 988398 82825 82840 TGATGTGTTTCCTGTG 3 N/A N/A 3106 988399 82826 82841 ATGATGTGTTTCCTGT 5 N/A N/A 3107 988400 82828 82843 AGATGATGTGTTTCCT 4 N/A N/A 3108 988401 82829 82844 CAGATGATGTGTTTCC 4 N/A N/A 3109 988402 82830 82845 ACAGATGATGTGTTTC 7 N/A N/A 3110 988403 82832 82847 ATACAGATGATGTGTT 99 N/A N/A 3111 988404 83917 83932 TTTTTGAGAGGTTGAC 19 N/A N/A 3112 988405 89716 89731 TATAGGGCTTCTTATC 61 N/A N/A 3113 988406 89717 89732 TTATAGGGCTTCTTAT 64 N/A N/A 3114 988407 89723 89738 AGTTTATTATAGGGCT 8 N/A N/A 3115 988408 89724 89739 AAGTTTATTATAGGGC 13 N/A N/A 3116 988409 89725 89740 TAAGTTTATTATAGGG 25 N/A N/A 3117 988410 89726 89741 GTAAGTTTATTATAGG 24 N/A N/A 3118 988411 89727 89742 AGTAAGTTTATTATAG 96 N/A N/A 3119 988412 90717 90732 ATGTATCTGGTTCAAT 34 N/A N/A 3120 988413 90718 90733 AATGTATCTGGTTCAA 11 N/A N/A 3121 988414 90719 90734 AAATGTATCTGGTTCA 8 N/A N/A 3122 988415 90720 90735 TAAATGTATCTGGTTC 11 N/A N/A 3123 988416 90723 90738 AAGTAAATGTATCTGG 15 N/A N/A 3124 988417 90724 90739 CAAGTAAATGTATCTG 51 N/A N/A 3125 988418 90725 90740 ACAAGTAAATGTATCT 45 N/A N/A 3126 988419 90726 90741 AACAAGTAAATGTATC 109 N/A N/A 3127 988420 93918 93933 TTCTGGTCTGGCTTAA 16 N/A N/A 3128 988421 93920 93935 AATTCTGGTCTGGCTT 45 N/A N/A 3129 988422 93922 93937 TGAATTCTGGTCTGGC 7 N/A N/A 3130 988423 93924 93939 AATGAATTCTGGTCTG 30 N/A N/A 3131 988424 93925 93940 GAATGAATTCTGGTCT 80 N/A N/A 3132 988425 93926 93941 AGAATGAATTCTGGTC 20 N/A N/A 3133 988426 93928 93943 CAAGAATGAATTCTGG 74 N/A N/A 3134

Example 4: Dose Response of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Selected oligonucleotides listed in the Examples above were tested at various doses via free uptake in A431 cells. Cells were cultured at a density of 10,000 cells per well and treated with 62.5, 250, 1,000, or 4,000 nM of modified oligonucleotide, as specified in the table below. After a treatment period of approximately 48 hours, total RNA was isolated and analyzed by RT-PCR with primer probe set RTS36027 (described in Example 1), normalized with ribogreen. As illustrated in the tables below, DNM2 mRNA expression was inhibited in a dose-dependent manner by modified oligonucleotides complementary to DNM2.

TABLE 6 DNM2 mRNA Expression Compound DNM2 expression (% control) Number 62.5 nM 250 nM 1,000 nM 4,000 nM IC₅₀ (μM) 694838 31 12 5 3 <0.1 695171 74 28 11 4 0.1 695171 83 33 11 5 0.2 695171 57 25 7 3 0.1 695171 59 24 9 4 0.1 695171 51 17 9 4 <0.1 695171 57 28 10 4 0.1 907945 38 10 5 3 <0.1 907946 70 36 17 11 0.2 907947 48 28 9 6 <0.1 907948 51 22 9 5 <0.1 907949 77 43 16 6 0.2 907966 53 30 15 8 <0.1 907967 32 10 6 4 <0.1 907968 65 30 14 8 0.1 907969 19 6 3 2 <0.1 907970 20 5 3 2 <0.1 907971 59 30 17 12 0.1 907972 72 36 18 17 0.2 907975 35 15 7 4 <0.1 907979 55 26 14 10 <0.1 907983 39 16 9 8 <0.1 907998 40 13 6 4 <0.1 908000 71 42 19 11 0.2 908011 53 24 13 9 <0.1 908013 52 25 13 7 <0.1 908025 69 31 13 6 0.1 908027 38 13 5 2 <0.1 908028 80 51 22 9 0.3 908029 83 43 19 9 0.3 908031 44 13 4 2 <0.1 908033 52 18 8 5 <0.1 908034 63 29 13 8 0.1 908035 26 6 2 1 <0.1 908036 71 39 20 11 0.2 908037 26 9 3 1 <0.1 908041 49 19 6 3 <0.1 908043 28 15 10 8 <0.1 908044 43 17 7 3 <0.1 908047 54 28 15 9 <0.1 908049 49 15 6 3 <0.1 908052 53 21 7 4 <0.1 908055 69 36 19 12 0.2 908056 54 23 9 6 <0.1 908059 35 11 3 2 <0.1 908061 27 7 2 1 <0.1 908068 72 41 21 10 0.2 908070 64 35 15 9 0.1 908085 68 33 18 11 0.1 908098 61 28 12 10 0.1 908102 42 28 17 11 <0.1 908104 44 23 12 8 <0.1 908107 51 25 11 7 <0.1 908135 46 23 14 14 <0.1 908138 50 24 11 6 <0.1 908146 58 33 19 15 0.1 908147 37 18 10 6 <0.1 908148 42 15 7 5 <0.1 908154 28 9 3 2 <0.1 908164 65 31 16 10 0.1 908166 44 18 9 5 <0.1 908167 62 28 16 12 0.1 908177 69 37 15 7 0.2 908178 52 22 6 4 <0.1 908179 47 18 7 4 <0.1 908183 58 34 15 11 0.1 908184 56 24 11 8 <0.1 908201 26 13 5 4 <0.1 908213 37 13 5 3 <0.1 908214 57 37 17 12 0.1 908215 63 30 12 6 0.1 908217 32 10 3 2 <0.1 908232 58 26 6 3 0.1 908255 64 28 13 9 0.1 908267 48 28 12 8 <0.1 908355 83 62 42 26 0.6 908389 43 16 5 3 <0.1 908392 12 3 1 1 <0.1 908396 57 19 6 3 <0.1 908401 26 6 2 1 <0.1 908404 58 29 15 8 0.1 908405 49 26 9 4 <0.1 908407 70 30 12 5 0.1 908408 18 2 1 1 <0.1 908409 67 33 13 5 0.1 908410 71 36 15 7 0.2 908412 58 24 10 6 0.1 908413 33 8 2 1 <0.1 908414 25 6 3 2 <0.1 908415 40 11 4 3 <0.1 908416 42 13 4 1 <0.1 908417 26 5 2 1 <0.1 908418 63 33 11 4 0.1 908419 50 11 4 2 <0.1 908420 17 3 1 1 <0.1 908421 23 4 1 1 <0.1 908422 51 16 5 3 <0.1 908424 57 22 9 7 <0.1 908425 57 38 20 12 0.1 908434 54 20 8 3 <0.1 908436 71 40 17 8 0.2 908439 38 9 2 2 <0.1 908440 25 6 3 3 <0.1 908441 33 6 2 1 <0.1 908442 32 9 3 1 <0.1 908443 56 17 5 2 <0.1 908444 31 7 2 1 <0.1 908448 78 44 13 8 0.2 908449 47 20 7 4 <0.1 908451 45 14 6 5 <0.1 908475 66 29 12 5 0.1 908506 34 9 4 3 <0.1 908507 67 39 16 10 0.1 908508 52 30 14 10 <0.1

Example 5: Dose Response of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Selected oligonucleotides listed in the Examples above were tested via free uptake at various doses in A431 cells. Cells were cultured at a density of 10,000 cells per well and treated with 31.25, 125, 500, or 2,000 nM of modified oligonucleotide, as specified in the tables below. After approximately 48 hours, total RNA was isolated and analyzed by RT-PCR with primer probe set RTS36027 (described in Example 1), normalized with ribogreen. As illustrated in the tables below, DNM2 mRNA expression was inhibited in a dose-dependent manner by modified oligonucleotides complementary to DNM2.

TABLE 7 DNM2 mRNA Expression Compound DNM2 expression (% control) Number 31.25 nM 125 nM 500 nM 2,000 nM IC50 (μM) 695015 105 94 89 94 >2.0 695170 62 30 13 5 0.05 695171 72 33 11 4 0.07 695171 70 33 10 3 0.1 695171 70 35 14 6 0.1 695171 58 22 9 2 <0.03 695171 71 36 12 4 0.08 695171 70 32 11 4 0.07 695171 74 36 12 4 0.08 695171 71 31 10 3 0.07 695171 73 36 14 4 0.08 695171 73 36 17 7 0.09 695171 54 27 10 3 <0.03 695171 69 33 10 5 0.06 695171 74 35 12 4 0.08 695171 81 40 14 4 0.11 695171 79 40 14 5 0.11 695171 77 38 14 5 0.10 695171 72 37 13 5 0.08 695171 71 34 11 4 0.07 695171 66 43 11 5 0.08 695171 68 33 11 4 0.06 695171 63 29 12 5 0.05 948488 79 33 12 4 0.09 948489 53 17 5 1 <0.03 948490 25 5 1 0 <0.03 948492 67 32 9 4 0.06 948496 72 43 15 6 0.09 948505 67 36 12 5 0.07 948506 58 16 5 2 <0.03 948507 80 30 9 3 0.1 948508 63 26 7 3 0.0 948521 79 35 19 13 0.11 948524 70 43 19 9 0.09 948525 75 47 19 7 0.12 948526 73 35 12 7 0.08 948527 62 31 14 9 0.05 948528 64 29 11 20 0.04 948538 104 95 96 91 >2.0 948549 71 38 16 11 0.08 948556 36 11 4 3 <0.03 948557 23 8 4 3 <0.03 948558 68 29 14 10 0.06 948559 48 16 7 5 <0.03 948560 24 7 3 2 <0.03 948562 69 26 10 5 0.06 948568 57 26 11 7 <0.03 948575 73 39 20 10 0.1 948587 43 14 7 4 <0.03 948589 66 21 11 9 0.04 948590 53 35 16 10 0.03 948602 39 15 7 5 <0.03 948604 42 17 7 4 <0.03 948608 54 18 6 4 <0.03 948622 79 47 22 10 0.13 948629 51 13 6 2 <0.03 948630 67 33 13 5 0.06 948631 46 14 5 3 <0.03 948632 42 12 5 2 <0.03 948633 57 21 8 6 <0.03 948646 63 58 23 10 0.11 948654 68 40 13 4 0.08 948656 69 40 22 13 0.09 948660 47 11 2 1 <0.03 948661 80 41 14 4 0.11 948662 63 38 16 8 0.06 948664 45 12 2 1 <0.03 948665 64 25 7 3 0.04 948666 82 37 12 4 0.11 948673 33 9 3 2 <0.03 948674 75 39 12 5 0.1 948675 43 8 2 0 <0.03 948676 40 10 2 0 <0.03 948677 53 11 2 1 <0.03 948678 69 27 9 4 0.06 948684 61 29 11 4 0.04 948685 52 15 5 2 <0.03 948686 24 8 2 1 <0.03 948687 58 19 5 2 <0.03 948689 73 26 17 8 0.07 948692 49 20 8 6 <0.03 948693 71 40 18 10 0.09 948695 75 38 20 7 0.1 948700 63 25 7 3 0.04 948701 64 24 9 4 0.04 948702 60 25 6 1 0.04 948703 66 29 7 2 0.05 948707 69 24 7 3 0.05 948729 47 12 2 1 <0.03 948731 67 33 11 4 0.06 948732 68 40 14 7 0.08 948735 22 9 2 2 <0.03 948741 49 55 24 15 0.06 948752 64 31 12 5 0.05 948765 61 20 7 3 0.03 948766 78 43 18 7 0.11 948767 76 40 19 12 0.1 948768 67 35 17 12 0.1 948769 60 24 10 5 0.0 948788 57 27 13 10 0.03 948794 51 26 5 2 <0.03 948804 42 18 8 5 <0.03 948805 34 13 5 3 <0.03 948806 16 18 7 5 <0.03 948807 56 35 18 11 0.04 948812 77 40 20 11 0.11 948835 66 28 7 3 0.05 948836 52 27 11 6 <0.03 948847 68 32 12 7 0.06 948849 43 13 6 5 <0.03 948850 43 15 7 5 <0.03 948851 45 16 5 3 <0.03 948852 51 16 4 2 <0.03 948853 84 32 9 5 0.10 948854 58 21 7 3 <0.03 948855 56 30 12 6 0.03 948856 70 38 14 8 0.08 948862 55 26 10 4 <0.03 948863 43 8 2 2 <0.03 948865 57 24 10 6 <0.03 948880 84 46 26 14 0.16 948882 66 36 19 8 0.07 948883 81 62 29 16 0.21 948884 59 25 9 4 0.03 948885 53 18 6 4 <0.03 948891 96 52 24 12 0.20 948892 54 24 7 4 <0.03 948893 93 84 59 44 1.24 948906 81 46 19 9 0.13 948907 65 25 8 4 0.05 948910 62 22 8 4 0.0 948911 48 16 10 4 <0.03 948917 81 57 30 19 0.20 948918 69 36 14 6 0.07 948922 64 32 12 6 0.05 948923 30 8 4 3 <0.03 948924 32 11 3 2 <0.03 948925 58 27 9 6 0.03 948926 109 94 105 111 >2.0 948935 38 17 6 3 <0.03 948936 47 12 4 2 <0.03 948937 48 21 7 3 <0.03 948938 49 19 8 5 <0.03 948950 54 27 8 3 <0.03 948951 32 13 5 3 <0.03 948952 46 13 4 2 <0.03 948953 69 41 14 7 0.08 948954 43 15 8 4 <0.03 948960 41 14 8 7 <0.03 948961 48 17 6 3 <0.03 948963 51 23 8 4 <0.03 948965 96 77 53 28 0.57 948966 63 32 11 4 0.05 948967 71 38 13 6 0.08 948968 60 29 9 3 0.04 948969 47 18 6 4 <0.03 948970 31 9 3 2 <0.03 948971 34 9 2 2 <0.03 948972 72 32 9 3 0.07 949006 79 53 19 8 0.1 949007 84 37 9 6 0.1 949012 81 38 17 10 0.11 949040 80 36 11 4 0.10 949041 101 50 14 5 0.18 949051 74 45 16 8 0.10 949053 89 54 18 5 0.2 949055 68 24 8 4 0.0 949059 73 40 15 5 0.09 949061 109 99 83 73 >2.0 949077 82 47 15 5 0.1 949080 48 20 7 5 <0.03 949088 73 24 8 3 0.06 949092 66 24 13 14 0.05 949094 79 48 17 6 0.13 949095 90 66 19 6 0.20 949109 95 55 26 13 0.22 949139 72 47 24 11 0.12 949158 54 20 10 8 <0.03 949159 75 40 15 25 0.10 949163 52 15 4 2 <0.03 949164 42 30 15 10 <0.03 949167 78 39 17 21 0.11 949168 67 36 19 12 0.07 949182 65 27 8 4 0.05 949190 57 15 3 2 <0.03 949216 74 42 14 5 0.10 949223 87 28 16 6 0.1 949229 125 101 92 78 >2.0 949279 85 41 15 5 0.12 949325 98 112 86 75 >2.0 949397 94 96 100 106 >2.0 949483 71 43 21 11 0.10 949500 78 56 24 10 0.16 949517 103 98 97 80 >2.0 949589 111 89 57 42 1.06 949685 101 82 58 40 0.99 949778 90 55 20 9 0.18 949805 106 88 66 48 1.73 949814 59 51 22 8 0.08 949841 87 46 11 4 0.13 949846 48 30 11 7 <0.03 949848 57 18 4 2 <0.03 949858 66 23 10 6 0.04 949865 61 11 3 1 <0.03 949871 70 26 7 3 0.1 949872 47 13 3 1 <0.03 949873 45 10 2 1 <0.03 949874 14 3 1 0 <0.03 949875 54 23 5 2 <0.03 949876 79 32 10 5 0.09 949880 52 20 6 3 <0.03 949884 87 41 16 7 0.13 949886 62 22 6 3 0.04 949887 87 64 21 8 0.19 949892 83 49 22 13 0.2 949896 13 1 1 0 <0.03 949897 67 32 15 7 0.06 949899 80 49 20 6 0.14 949917 80 48 22 10 0.1 949918 84 46 15 4 0.1 949920 59 20 3 2 <0.03 949921 67 19 2 1 0.04 949922 56 21 6 2 <0.03 949923 70 34 15 7 0.07 949924 112 106 5 2 0.31 949925 59 27 6 2 0.04 949926 44 7 1 1 <0.03 949927 37 4 1 1 <0.03 949928 68 20 4 2 0.04 949929 66 18 3 1 0.04 949930 61 30 10 4 0.04 949931 68 27 6 2 0.05 949932 72 31 6 2 0.07 949934 66 42 22 12 0.08 949935 52 20 8 6 <0.03 949937 69 27 7 5 0.06 949938 66 35 14 5 0.06 949942 69 30 8 3 0.06 949943 52 21 6 2 <0.03 949944 60 20 4 3 0.03 949945 54 16 5 3 <0.03 949948 34 5 1 1 <0.03 949949 46 10 2 1 <0.03 949950 46 12 3 2 <0.03 949962 70 34 16 9 0.1 949963 71 43 15 6 0.1 949978 65 35 9 2 0.06 949979 72 35 11 5 0.08 949983 89 66 25 12 0.23 949990 61 23 5 2 0.04 949991 55 21 5 1 <0.03 949992 56 29 11 6 0.03 950014 60 28 8 3 0.04 950017 68 38 11 5 0.07 950019 52 20 8 5 <0.03 950020 84 43 13 5 0.12 950021 80 46 15 6 0.12 950023 57 17 5 2 <0.03 950024 51 17 7 5 <0.03 950030 37 7 1 0 <0.03 950048 57 40 16 6 0.05 950057 65 38 21 9 0.07 950060 26 16 3 2 <0.03 950061 55 34 10 5 0.04 950064 74 32 11 4 0.08 950065 72 30 8 2 0.07 950069 68 31 8 4 0.06 950072 49 20 6 3 <0.03 950075 87 38 13 5 0.12 950080 69 40 15 7 0.08 950081 60 28 8 4 0.04 950083 65 29 12 4 0.1 950085 53 14 6 4 <0.03 950086 76 43 15 4 0.10 950089 46 10 2 1 <0.03 950091 45 12 2 1 <0.03 950092 80 42 14 8 0.11 950102 81 37 9 3 0.10 950124 69 31 14 8 0.06 950132 55 14 4 1 <0.03 950139 87 59 24 9 0.19 950183 44 23 5 2 <0.03 950219 84 37 18 11 0.12 950237 83 48 17 8 0.14 950246 76 33 15 7 0.09 951328 76 37 12 4 0.09 951330 76 40 13 5 0.10 951333 89 45 22 9 0.16 951340 74 42 15 6 0.10 951341 92 58 21 4 0.19 951346 49 22 4 3 <0.03 951352 67 19 7 3 0.04 951354 67 36 12 6 0.07 951356 57 23 6 2 <0.03 951357 62 35 10 4 0.05 951358 76 36 12 5 0.09 951362 53 15 3 1 <0.03 951364 58 18 4 2 <0.03 951365 78 47 16 6 0.12 951366 61 34 12 6 0.05 951367 69 28 8 4 0.06 951370 74 41 16 7 0.10 951371 30 7 2 2 <0.03 951372 61 21 6 4 0.03 951374 62 17 4 2 0.03 951376 67 47 15 5 0.09 951381 63 28 11 6 0.05 951384 63 27 6 2 0.05 951386 66 22 6 3 0.04 951387 68 20 3 1 0.04 951397 69 35 8 4 0.07 951406 73 52 19 9 0.12 951407 56 21 6 3 <0.03 951408 47 15 3 1 <0.03 951413 68 46 20 9 0.09 951416 63 42 17 7 0.07 951418 60 22 6 3 0.03 951428 28 4 1 1 <0.03 951429 32 6 2 2 <0.03 951430 59 25 6 2 0.03 951431 46 32 9 5 <0.03 951441 100 82 67 42 1.33 951450 71 36 12 6 0.08 951458 63 32 15 10 0.05 951459 77 44 17 9 0.11 951462 74 28 6 2 0.07 951463 74 35 15 6 0.09 951481 91 47 26 13 0.18 951489 59 17 8 3 <0.03 951494 64 32 10 5 0.05 951498 58 27 10 7 0.03 951519 60 32 8 3 0.05 951529 90 35 24 18 0.15 951537 103 101 105 168 >2.0 951550 66 42 15 6 0.08 951554 83 36 10 5 0.10 951561 88 59 74 100 >2.0 951565 65 38 13 4 0.07 951566 77 36 9 3 0.09 951608 73 25 8 4 0.06 951645 64 29 12 7 0.05 951657 107 91 64 62 >2.0 951691 58 28 9 3 0.04 951696 58 19 9 5 <0.03 951700 76 40 16 9 0.10 951709 52 25 9 6 <0.03 951729 73 74 88 89 >2.0 951731 70 34 10 4 0.07 951737 57 24 5 4 <0.03 951746 68 31 17 11 0.06 951749 71 27 4 2 0.06 951763 44 11 4 2 <0.03 951764 40 9 2 1 <0.03 951767 87 48 16 5 0.14 951772 62 30 10 7 0.05 951781 95 42 15 7 0.15 951783 56 31 12 5 0.04 951787 53 20 7 4 <0.03 951793 44 11 4 2 <0.03 951795 64 24 7 3 0.04 951797 40 15 6 4 <0.03 951798 31 5 1 1 <0.03 951799 27 5 1 1 <0.03 951803 67 29 9 4 0.06 951804 45 13 3 1 <0.03 951806 65 43 15 7 0.07 951807 59 30 10 4 0.04 951808 69 46 18 6 0.10 951809 47 13 3 1 <0.03 951811 57 22 7 3 <0.03 951814 60 25 10 7 0.04 951815 58 37 15 7 0.05 951816 46 10 2 1 <0.03 951821 41 14 4 2 <0.03 951822 86 44 15 7 0.13 951824 67 23 5 3 0.05 951827 51 17 5 2 <0.03 951828 63 23 9 4 0.04 951830 61 26 10 5 0.04 951833 59 39 9 4 0.05 951835 23 4 1 0 <0.03 951837 53 16 4 1 <0.03 951838 80 51 22 8 0.14 951839 56 25 8 2 <0.03 951840 76 37 12 4 0.09 951841 69 27 11 2 0.06 951843 63 29 8 4 0.05 951845 39 9 3 1 <0.03 951846 45 14 3 1 <0.03 951855 87 65 19 5 0.19 951856 61 18 4 2 <0.03 951857 57 27 7 2 0.03 951874 74 73 68 47 >2.0 951875 66 33 10 4 0.06 951881 49 22 3 2 <0.03 951893 53 26 10 5 <0.03 951898 46 18 5 2 <0.03 951902 61 34 13 7 0.05 951938 85 51 20 11 0.16

Example 6: Dose Response of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Selected oligonucleotides listed in the Examples above were tested at various doses via free uptake in A431 cells. Cells were cultured at a density of 10,000 cells per well and treated with 8, 40, 200, or 1,000 nM of modified oligonucleotide, as specified in the table below. After approximately 48 hours, total RNA was isolated and analyzed by RT-PCR with primer probe set RTS36027 (described in Example 1), normalized with GADPH. As illustrated in the tables below, DNM2 mRNA expression was inhibited in a dose-dependent manner by modified oligonucleotides complementary to DNM2.

TABLE 8 DNM2 mRNA Expression Compound DNM2 expression (% control) Number 8 nM 40 nM 200 nM 1,000 nM IC50 (μM) 695171  90 84 54 26 0.24 951371 105 67 25  9 0.10 951371 101 70 27 11 0.10 951371 109 63 16  4 0.08 951371  91 61 23  8 0.07 951371  94 78 25  9 0.10 951371  91 63 23  8 0.07 951371  59 66 23  8 0.04 951371  94 56 20  7 0.07 951371  88 67 26 10 0.08 988380  77 33  5  1 0.02 988386  93 70 21  6 0.08 988387 101 46  5  1 0.05 988388  97 80 39 11 0.13 988394 120 81 23  5 0.12 988396 113 87 30  9 0.14 988397  77 29  7  2 0.02 988398  86 46 11  3 0.04 988399  81 47 13  3 0.04 988400  88 54 15  3 0.05 988401  98 65 16  6 0.07 988402  94 48 11  2 0.05 988407  99 77 30  8 0.11 988413  84 58 23  7 0.06 988414  95 73 23  6 0.09 988415  82 62 25  7 0.06 988422  91 60 17  7 0.06

Example 7: Dose Response of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Selected oligonucleotides listed in the Examples above were tested at various doses via free uptake in A431 cells. Cells were cultured at a density of 10,000 cells per well treated with 7.8, 31.25, 125, 500, or 2,000 nM of modified oligonucleotide, as specified in the tables below. After approximately 48 hours, total RNA was isolated and analyzed by RT-PCR with primer probe set RTS36027 (described in Example 1), normalized with GADPH. As illustrated in the tables below, DNM2 expression was inhibited in a dose-dependent manner by modified oligonucleotides complementary to DNM2.

TABLE 9 DNM2 mRNA Expression DNM2 expression (% control) 7.8 nM 31.25 125 500 2,000 IC50 Compound Number nM nM nM nM nM (μM) 908166 106 97 57 28 16 0.22 908213 139 85 56 30 16 0.21 908408 98 80 33 7 2 0.08 908420 91 86 45 13 4 0.11 948660 105 90 51 13 2 0.14 948677 101 101 61 23 8 0.21 948951 97 79 35 14 8 0.09 949190 107 101 54 22 8 0.18 949865 94 80 40 16 7 0.10 949935 88 84 58 31 19 0.20 950023 89 75 45 13 4 0.09 950060 81 79 48 29 11 0.13 950089 84 79 53 18 5 0.12 950132 87 83 44 19 9 0.11 950183 88 83 58 35 15 0.21

TABLE 10 DNM2 mRNA Expression DNM2 expression (% control) 7.8 nM 31.25 125 500 2,000 IC50 Compound Number nM nM nM nM nM (μM) 908408 98 80 34 10 2 0.08 951356 190 79 60 28 10 0.23 951362 97 85 63 30 11 0.21 951372 87 80 55 23 10 0.14 951431 100 90 68 38 21 0.31 951797 89 77 42 19 10 0.10 951798 89 58 23 6 1 0.04 951799 90 68 23 6 2 0.05 951816 100 77 38 10 3 0.09 951821 87 57 45 16 6 0.07 951827 94 79 45 17 5 0.11 951839 95 90 69 38 14 0.29 951845 92 71 31 8 2 0.06 951846 91 85 50 19 5 0.13 951856 97 86 54 22 7 0.15

Example 8: Dose Response of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Selected oligonucleotides listed in the Examples above were tested at various doses in HSMM cells (human myoblast, Lonza CC-2580). Cells were cultured at a density of 20,000 cells per well and transfected via electroporation with 7.8, 31.25, 125, 500, or 2,000 nM of modified oligonucleotide, as specified in the tables below. After approximately 16 hours, total RNA was isolated and analyzed by RT-PCR with primer probe set RTS36027 (described in Example 1), normalized with ribogreen. As illustrated in the tables below, DNM2 mRNA expression was inhibited in a dose-dependent manner by modified oligonucleotides complementary to DNM2.

TABLE 11 DNM2 mRNA Expression DNM2 expression (% control) 7.8 nM 31.25 125 500 2,000 IC50 Compound Number nM nM nM nM nM (μM) 908166 104 95 98 66 42 1.29 908213 93 82 70 42 19 0.33 908408 111 100 74 38 17 0.36 908420 91 93 67 39 17 0.30 948660 88 86 83 42 15 0.40 948677 90 80 87 51 22 0.54 948951 88 74 57 31 12 0.16 949190 99 88 82 47 23 0.49 949865 132 106 92 39 19 0.50 949935 90 92 94 60 25 0.77 950023 113 97 86 40 15 0.43 950060 109 105 78 69 32 0.95 950089 111 102 80 54 21 0.58 950132 117 98 79 51 19 0.51 950183 95 110 84 59 23 0.70

TABLE 12 DNM2 mRNA Expression DNM2 expression (% control) 7.8 nM 31.25 125 500 2,000 IC50 Compound Number nM nM nM nM nM (μM) 908408 98 102 81 55 20 0.58 951356 95 102 94 74 41 1.45 951362 95 67 85 56 29 0.62 951372 95 91 86 60 27 0.75 951431 87 90 89 55 35 0.77 951797 94 94 98 72 41 1.40 951798 103 95 79 40 21 0.40 951799 104 100 81 47 20 0.50 951816 106 91 89 53 30 0.70 951821 122 106 66 32 22 0.32 951827 100 87 51 38 20 0.21 951839 123 94 99 72 31 1.17 951845 104 94 75 51 20 0.48 951846 112 91 80 59 27 0.69 951856 113 101 77 50 22 0.52

Example 9: Dose Response of Modified Oligonucleotides Complementary to Dynamin 2 In Vitro

Selected oligonucleotides listed in the Examples above were tested at various doses in SkMC cells (human skeletal muscle, Lonza CC-2561). Cells were cultured at a density of 20,000 cells per well and transfected via electroporation with 7.8, 31.25, 125, 500, or 2,000 nM of modified oligonucleotide, as specified in the tables below. After approximately 16 hours, total RNA was isolated and analyzed by RT-PCR with primer probe set RTS36027 (described in Example 1), normalized with ribogreen. As illustrated in the tables below, DNM2 mRNA expression was inhibited in a dose-dependent manner by modified oligonucleotides complementary to DNM2.

TABLE 13 DNM2 mRNA Expression DNM2 expression (% control) 7.8 nM 31.25 125 500 2,000 IC50 Compound Number nM nM nM nM nM (μM) 908166 90 84 87 43 13 0.41 908213 101 79 59 21 5 0.15 908408 94 72 57 21 3 0.13 908420 84 72 53 9 4 0.10 948660 95 90 64 12 2 0.16 948677 88 77 58 15 4 0.13 948951 83 67 41 12 5 0.07 949190 103 84 61 16 4 0.16 949865 130 106 55 10 4 0.17 949935 118 100 86 33 7 0.36 950023 129 98 57 11 3 0.17 950060 101 103 72 26 5 0.26 950089 112 78 65 20 4 0.17 950132 115 93 53 14 3 0.15 950183 114 92 70 24 5 0.23

TABLE 14 DNM2 mRNA Expression DNM2 expression (% control) 7.8 nM 31.25 125 500 2,000 IC50 Compound Number nM nM nM nM nM (μM) 908408 91 80 46 10 3 0.10 951356 103 98 90 52 15 0.55 951362 90 88 65 22 4 0.19 951372 99 88 65 16 4 0.18 951431 103 97 70 25 6 0.24 951797 102 94 69 25 7 0.23 951798 99 90 46 8 3 0.12 951799 101 90 49 12 3 0.13 951816 96 78 63 13 4 0.14 951821 104 79 47 12 3 0.11 951827 94 71 44 8 3 0.08 951839 114 103 76 32 6 0.32 951845 97 88 55 12 4 0.14 951846 90 86 41 18 4 0.11 951856 102 91 62 15 4 0.17

Example 10: Administration of Modified Oligonucleotides Complementary to Human Dynamin 2 to CD1 Mice

CD1® mice (Charles River, Mass.) were treated with modified oligonucleotides selected from Examples above and evaluated for changes in the levels of various plasma chemistry markers. Groups of 6 week old male CD1 mice were injected subcutaneously once a week for 6 weeks with 50 mg/kg of a modified oligonucleotide listed in the tables below (50 mg/kg/week dose). Each group contained 4 mice. One control group of male CD1 mice was injected subcutaneously once a week for 6 weeks with PBS. Mice were sacrificed 48 hours after the last dose, and organs and plasma were harvested for further analysis.

Levels of transaminases, albumin, BUN, and billirubin were measured using an automated clinical chemistry analyzer (Hitachi Olympus AU400e, Melville, N.Y.). Kidney, liver, and spleen weights were also measured. The results, presented in the tables below, show that many of the modified oligonucleotides complementary to DNM2 were well tolerated in vivo.

TABLE 15 Levels of plasma markers ALT AST Albumin BUN Creatine T. Bil. (U/L) (U/L) (mg/dL) (mg/d) (mg/dL) (g/dL) PBS 48 82 3.36 27.2 0.12 0.66 549144 72 68 3.23 23.6 0.12 0.47 908166 259 108 3.16 20.4 0.11 0.38 908213 93 85 2.95 23.9 0.10 0.34 908389 1073 636 3.17 22.7 0.09 0.55 908408 67 70 2.97 26.2 0.11 0.32 908415 286 209 2.60 26.2 0.10 0.28 908416 425 336 2.35 26.4 0.07 0.19 908420 105 144 2.50 26.5 0.06 0.38 948660 112 165 2.59 21.8 0.08 0.26 948673 225 263 2.15 27.2 0.04 0.82 948675 100 132 2.25 21.4 0.06 0.22 948677 65 91 2.32 17.7 0.05 0.21 948951 107 126 2.46 21.4 0.07 0.22 949158 713 608 2.99 18.6 0.01 0.27 949190 64 62 2.52 22.1 0.07 0.20 949865 45 58 2.62 23.2 0.06 0.22 949873 89 163 2.33 20.7 0.04 0.21 949874 1079 853 2.77 20.7 0.05 0.46 949935 98 81 2.63 22.9 0.07 0.20 950023 42 57 2.52 22.2 0.04 0.20 950030 59 77 2.44 20.6 0.05 0.21

TABLE 16 Levels of plasma markers Compound ALT AST Albumin BUN Creatine T. Bil. No. (U/L) (U/L) (mg/dL) (mg/d) (mg/dL) (g/dL) PBS 37 62 2.78 22.0 0.08 0.46 549144 64 79 2.64 24.0 0.08 0.29 950060 47 63 2.47 22.0 0.09 0.33 950089 40 56 2.65 21.0 0.10 0.22 950132 58 58 2.58 20.0 0.07 0.24 950183 49 62 2.38 21.0 0.06 0.29 951356 64 80 2.39 23.0 0.10 0.25 951362 60 63 2.74 22.0 0.09 0.18 951371 312 209 2.32 20.0 0.09 0.18 951372 59 99 2.54 25.0 0.07 0.21 951407 172 200 2.72 24.0 0.07 0.24 951431 64 80 2.48 23.0 0.08 0.22 951793 319 238 2.5 19.0 0.10 0.20 951797 41 63 2.6 24.0 0.11 0.26 951798 53 97 2.57 26.0 0.10 0.19 951799 44 97 2.44 25.0 0.08 0.19 951816 121 113 2.63 19.0 0.10 0.20 951821 79 80 2.39 23.0 0.07 0.17 951827 56 88 2.46 25.0 0.10 0.21 951839 45 50 2.52 23.0 0.08 0.20 951845 117 132 2.51 21.0 0.08 0.25 951846 35 47 2.59 21.0 0.10 0.21 951856 112 412 2.25 20.0 0.09 0.17

TABLE 17 Organ weights kidney liver spleen (g) (g) (g) PBS 0.55 1.9 0.09 549144 0.52 1.9 0.10 908166 0.48 2.0 0.08 908213 0.52 2.0 0.12 908389 0.54 2.6 0.14 908408 0.49 2.2 0.13 908415 0.51 2.2 0.12 908416 0.51 2.1 0.16 908420 0.52 2.0 0.13 948660 0.44 1.8 0.14 948673 0.51 3.9 0.62 948675 0.48 2.1 0.21 948677 0.54 2.0 0.15 948951 0.45 1.9 0.11 949158 0.59 2.3 0.18 949190 0.53 2.2 0.14 949865 0.53 2.1 0.14 949873 0.47 1.8 0.20 949874 0.52 2.3 0.16 949935 0.57 2.0 0.13 950023 0.53 1.9 0.16 950030 0.59 2.1 0.20

TABLE 18 Organ weights Compound kidney liver spleen No. (g) (g) (g) PBS 0.57 2.1 0.11 549144 0.57 2.0 0.09 950060 0.57 2.3 0.12 950089 0.60 2.4 0.15 950132 0.59 2.3 0.16 950183 0.60 2.4 0.14 951356 0.57 2.4 0.19 951362 0.58 2.3 0.16 951371 0.51 2.7 0.16 951372 0.55 2.5 0.17 951407 0.53 2.2 0.17 951431 0.54 2.2 0.18 951793 0.55 2.6 0.17 951797 0.52 2.1 0.15 951798 0.57 2.4 0.18 951799 0.54 2.4 0.16 951816 0.50 2.4 0.16 951821 0.50 2.0 0.13 951827 0.47 1.8 0.13 951839 0.51 2.2 0.15 951845 0.55 2.0 0.17 951846 0.57 2.2 0.17 951856 0.60 2.5 0.19 

1. A compound comprising a modified oligonucleotide 14 to 30 linked nucleosides in length having i) a nucleobase sequence comprising at least 14 contiguous nucleobases of SEQ ID NO: 2879; ii) a nucleobase sequence comprising a portion of at least 14 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 87,359-90,915; 90,968-97,263; 83,573-87,287; 3,404-44,737; 97,378-104,979; 81,061-81,199; or 116,048-116,903 of SEQ ID NO: 1, iii) a nucleobase sequence complementary to intron 12, intron 13, intron 11, intron 1, intron 14, exon 10, or the 3′-UTR of a human DNM2 pre-mRNA or human DNM2 mRNA, or iv) a nucleobase sequence comprising at least 12, at least 13, at least 14, or at least 15 contiguous nucleobases of any one of the nucleobase sequences of SEQ ID NOs: 7-3134, or a pharmaceutically acceptable salt thereof.
 2. The compound according to claim 1, wherein the modified oligonucleotide has a nucleobase sequence consisting of any one of SEQ ID NOs: 2879, 2123, 2189, 2160, 3056, 2453, or
 2232. 3. The compound according to claim 1, wherein the modified oligonucleotide comprises: a gap segment consisting of 8-12 linked 2′-deoxynucleosides; a 5′ wing segment consisting of 1-7 linked nucleosides; and a 3′ wing segment consisting of 1-7 linked nucleosides; wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each terminal wing nucleoside comprises a modified sugar.
 4. The compound according to claim 1, wherein the modified oligonucleotide is at least 80%, 85%, 90%, 95% or 100% complementary to any of SEQ ID NOs: 1, 2, 3, or
 3135. 5. The compound according to claim 1, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.
 6. The compound according to claim 1, wherein the modified oligonucleotide comprises at least one bicyclic sugar.
 7. The compound according to claim 1, wherein the modified oligonucleotide comprises at least one 5-methylcytosine.
 8. The compound according to claim 1, wherein the compound is single-stranded.
 9. The compound according to claim 1, wherein the compound is double-stranded.
 10. The compound according to claim 1, wherein the modified oligonucleotide consists of 16 to 20 linked nucleosides.
 11. A compound comprising a modified oligonucleotide according to the following formula: Gks Tks Tks Tds Ads Tds Tds Ads Tds Ads Gds Gds Gds mCks Tks Tk; wherein, A=an adenine, mC=a 5-methylcytosine G=a guanine, T=a thymine, k=a cEt sugar moiety, d=a 2′-deoxyribosyl sugar moiety, and s=a phosphorothioate internucleoside linkage.
 12. (canceled)
 13. A compound according to the following formula:

or a salt thereof.
 14. (canceled)
 15. A chirally enriched population of the compound according to claim 1, wherein the population is enriched for modified oligonucleotides comprising at least one particular phosphorothioate internucleoside linkage having a particular stereochemical configuration.
 16. A pharmaceutical composition comprising the compound according to claim 1 and at least one pharmaceutically acceptable diluent or carrier.
 17. (canceled)
 18. A method of treating, preventing, or ameliorating a disease associated with DNM2 in an individual, comprising administering to the individual the compound according to claim
 1. 19. An in vitro method of inhibiting expression of DNM2 in a cell comprising contacting the cell with a single-stranded compound comprising a modified oligonucleotide 100% complementary to exon 10, an intron, or the 3′-UTR of a DNM2 nucleic acid transcript, thereby inhibiting expression of DNM2 in the cell.
 20. The compound according to claim 5, wherein the at least one modified internucleoside is a phosphorothioate internucleoside linkage.
 21. The compound according to claim 6, wherein the at least one bicyclic sugar is selected from the group consisting of LNA, ENA, and cEt.
 22. The compound according to claim 1, comprising a conjugate group.
 23. The compound according to claim 22, wherein the compound consists of the modified oligonucleotide and the conjugate group.
 24. The compound according to claim 1, wherein the pharmaceutically acceptable salt is a sodium salt or a potassium salt.
 25. The method according to claim 18, wherein the disease is centronuclear myopathy, Duchenne Muscular Dystrophy, Charcot-Marie Tooth disease, X-linked myotubular myopathy, autosomal recessive centronuclear myopathy, or autosomal dominant centronuclear myopathy.
 26. The method according to claim 18, wherein the disease is associated with a mutation in at least one gene selected from among MTM1, BIN1, and DNM2. 